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General introduction and 
outline of the thesis
Chapter 1
10
Every individual differs in the way it reacts to harmful threats such as 
pathogenic microorganisms that surround or try to invade the human body 
every day. Although the overall host defense mechanisms are generally very 
robust and efficient, yet subtle differences between individuals may lead to 
differences in susceptibility to infections. These inter-individual variations 
emerge from specific genetic information itself  or from environmental 
factors that on their turn may alter the response to different pathogens.
 Millions of  years of  evolution through selective pressure have tailored 
a powerful and tightly regulated complex (defense) system that controls 
and initiates a suitable immune response whenever potential harmful 
microorganisms such as bacteria, fungi, viruses or parasites breach the 
physical barriers of  human skin and mucosae. The immune system of  
vertebrates is divided into two distinct arms with different properties: the 
innate and the adaptive immune system. Those two components are in close 
interplay with each other and communicate using soluble mediators called 
cytokines and chemokines.
 In the present thesis, I focused on the innate immune system that is 
rapidly activated during infection, is generally highly effective in eliminating 
the invading pathogen, but is rather unspecific and till recently it was 
believed that lacks immune memory. This last assumption has been recently 
challenged by studies demonstrating adaptation within innate immune 
mechanisms through epigenetic reprogramming, a process termed “trained 
immunity” [1]. The second arm of  this system, the adaptive immune system, 
depends on T- and B-lymphocytes and is activated only if  the infection has 
not been eliminated by the innate immune responses. Although the adaptive 
immune response is rapidly induced, it takes 1-2 weeks for it to expand 
pathogen specific T and B cell clones. However, this investment is rewarded 
by high specificity and induction of  long-lasting memory for protection 
against pathogens
 The innate immune system is activated through the recognition of  
pathogenic microorganisms by pattern recognition receptors (PRRs) 
present on the surface or cytoplasm of  immune cells such as monocytes, 
macrophages, dendritic cells or neutrophils [2]. PRRs recognize conserved 
structures present on pathogens termed pathogen-associated molecular 
patterns (PAMPs). Subsequently these receptors activate the innate 
immune response by induction of  effector molecules such as cytokines 
and chemokines, which play a major role in recruitment and activation of  
innate and adaptive immune cells. A schematic overview of  the components 
involved in the innate immune response are shown in Figure 1.
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Figure 1. Schematic overview of  the pattern recognition repertoire of  innate immune 
cells. Soluble receptors such as MBL and PTX3, membrane bound receptors as TLRs and 
CLRs family members as well as intracellular receptors as NOD1 and NOD2 together 
with numerous signaling molecules are responsible in the recognition and initiation of  
transcriptional pathways leading to effector molecules such as cytokine and chemokines.
Although the immune system does have plasticity, the blueprint for all 
components is the genetic information fixed within the DNA. Alterations 
in this blueprint may disrupt parts of  the building plan and ultimately lead 
to differences in function and efficiency. Single nucleotide polymorphisms 
(SNPs) are small variations in the DNA code that, among others, may lead 
to differences in function or transcription of  the protein. Additionally, these 
commonly occurring variations may also indirectly affect other regions of  
the DNA, making them valuable markers for different diseases. 
The dimorphic fungus Candida albicans
Candida species are commensal yeasts that colonize the skin and mucosal 
membranes of  healthy individuals. The GI tract is the largest reservoir of  
Candida species in the human body [3]. Among the Candida species found in 
and on the human body, C. albicans is the most abundant [4]. C. albicans has 
a dimorphic character, which means that it exists in the colonizing yeast 
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form, but can, under certain circumstances, grow as filamentous hyphae 
that can invade tissues. The colonization by Candida species is tightly 
regulated and tolerated by the host immune system, however disturbances 
of  this regulation may lead to invasion of  the fungus into the blood stream 
and dissemination into vital organs. This is characterized by high mortality 
despite the application of  (novel) antifungal therapies [4, 5]. Patients who 
are immunocompromised, for example due to organ transplantation 
or chemotherapy, are most prone to these invasive infections. A rough 
estimate accounts 50000 death to invasive Candida infections on an annual 
basis. These infections are known to account for the fourth most common 
bloodstream infection in intensive care units, and for the seventh to tenth 
most common bloodstream infection in population based studies [6]. 
 In addition to the invasive and disseminated infections caused by Candida 
species, an emerging number of  individuals suffer from skin and mucosal 
infections with different Candida species. Vaginal Candida infections are 
frequently observed in women of  the childbearing age and it is estimated 
that 75% of  all women will experience at least one vaginal Candida infection 
(vaginal candidiasis) during their lifetime [7-9]. From these woman, around 
6-9% will experience recurrent infection episodes, a condition called 
recurrent vulvovaginal candidiasis (RVVC) which is characterized by at least 
3-4 episodes per year [10]. Although several risk factors, have been reported 
that favor (recurrent) vaginal Candida infections most RVVC patients are not 
exposed to those risk factors, making a strong genetic component in RVVC 
pathogenesis most likely [11].
Immune response against Candida albicans
The C. albicans cell wall is composed of  different layers of  polysaccharides 
and glycoproteins such as a– and b–glucans, mannans, mannoproteins, and 
chitin [12, 13]. Different pattern recognition receptors (PRR) recognize these 
structures and initiate the immune response [2]. 
 Among the PRR families, Toll-like receptors (TLRs) and C-type lectin 
receptors (CLRs) are most important for initiating the anti-Candida immune 
response [14, 15]. The CLRs Dectin-1 (CLEC7A; recognizing b-(1,3),(1,6)-
glucans) and Detin-2 (CLEC6A; recognizing a-mannans), as well as the TLRs 
TLR2 (alpha-1,4-glucans) and TLR4 (O-linked mannans) are some of  the 
most important Candida-recognizing receptors [16]. Monocytes, neutrophils, 
macrophages and dendritic cells are the first cells to encounter and recognize 
C. albicans and express several TLRs and CLRs [15]. Engagement of  fungal 
PAMPs with their corresponding PRRs leads to a cascade of  signaling 
13
1
F
ig
ur
e 
2.
 O
ve
rv
ie
w
 o
f 
th
e 
C
an
di
da
 i
m
m
un
e 
re
sp
on
se
14
pathways and ultimately to the production of  cytokines (e.g. TNFa, IL-1b, 
IL-6) and chemokines (e.g. IL-8, MCP-1) that in their turn recruit other 
immune cells and initiate several immune pathways and mechanisms to 
eliminate the fungus. 
 In addition to the pro-inflammatory cytokines produced by macrophages 
and monocytes, T-cells produce cytokines such as IL-17, IL-22 and  IFN-γ 
that are crucial for the anti-Candida immune response, especially at the 
surface of  the mucosa. The importance of  these cytokines becomes clear 
when looking at patients with defects in pathways leading to the production 
of  these mediators. Patients with excessive production of  IL-17 suffer 
from auto immune like diseases as systemic lupus erythematosus (SLE) or 
rheumatoid arthritis (RA) [17-19]. On the contrary, patients with lower numbers 
of  Th17 cells or defects in either the IL-17 receptor or IL-17 itself  suffer from 
chronic mucocutaneous candidiasis [20-23]. Figure 2 gives a schematic overview 
of  the components involved in the anti-Candida immune response. 
The aim of  this thesis is to identify novel genes and pathways that are 
involved in the immune response against different pathogens in general, and 
against the fungus C. albicans in particular. Furthermore, a comprehensive 
assessment of  the genetic and non-genetic factors that influence the immune 
response is investigated, with the aim to understand the sources of  variation 
in individual host defense efficacy. Identification and characterization of  
these novel components of  the immune response, and understanding the 
factors which lead to the heterogeneity of  these responses in the population, 
is needed in order to take the step towards novel personalized treatment 
strategies in the future.
Outline of the thesis
Part I of  this thesis concentrates on inter-individual differences in the 
immune response in the healthy host. Genetic as well as non-genetic factors 
such as age, gender or life style influence the immune response to different 
pathogens.
 Chapter 2 provides a comprehensive overview of  genetic variants in 
genes that encode for members of  the 5 pattern recognition receptor families 
(Toll-like receptors (TLRs), C- type lectin receptors (CLRs), NOD-like 
receptors (NLRs), RIG-I like receptors (RLRs) and AIM2-like receptors. By 
interfering with either recognition or downstream signaling events, genetic 
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variation in these genes may lead to an increase in susceptibility to various 
infectious diseases and inflammatory conditions described in this review.
 By integrating data from the Human Functional Genomics Project 
(HFGP), Chapter 3 identifies novel genetic loci that influence the in vitro 
cytokine production by monocytes and lymphocytes after stimulation with 
bacterial, fungal and viral stimuli. We investigated whether a specific cytokine 
response is built towards responding to specific pathogens or to modulate specific 
immune pathways, without making a precise difference between pathogens. 
Using systems biology approaches I demonstrate that human immune responses 
are organized towards specific responses to pathogens.
Next to the individual genetic makeup, environmental and non-genetic 
factors as life style, age and even gender influence the specific immune 
response against many pathogens. Chapter 4 investigates non-genetic 
factors in this large cohort of  healthy volunteers with Western-European 
ancestry. Age and gender, as well as annual seasonality, were shown to have 
a significant influence on both in vitro cytokine production capacity after 
stimulation with different pathogens, and baseline cytokine levels measured 
in serum and plasma. 
 The second part of  this thesis concentrates on novel genes that are 
dysregulated in Candida related malignancies such as (recurrent) vaginal 
infections as well as systemic Candida infections.
 Alterations and defects in components of  the PRR complexes may lead 
to impairment in recognition, signaling and effector mechanisms which 
ultimately leads to reduced capacity to clear the pathogen. Impaired 
clearance of  the pathogen may in turn lead uncontrolled (invasive) growth 
and even dissemination to vital organs, followed by death. 
 Chapter 5 provides an overview of  components that are involved in the 
immune response against Candida and that are dysregulated in patients 
suffering from recurrent vulvovaginal candidiasis. Next to the pattern 
recognition receptors (PRR) responsible for Candida recognition on immune 
as well as vaginal epithelial cell, genetic alterations in cytokines and 
components of  the complements system have been shown to be more often 
dysregulated in RVVC patients compared to healthy controls. Chapter 6 
investigates the role of  CX3CR1, a chemokine receptor that has previously 
been shown to be a susceptibility factor for systemic Candida infections in 
humans and mice. The aim of  this study was to assess whether CX3CR1 is 
also involved in the mucosal immune response against Candida.
 Cytokines play a crucial role in the (innate) immune response against 
pathogens. The Candida-specific cytokine response includes several cytokines 
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from different cellular sources such as monocytes, macrophages and T cells. 
IL-1b is crucial in fungal infections as it is involved in the recruitment and 
activation of  different immune cells such as PMNs. Furthermore, it has 
been shown that IL-1b-/- mice were highly susceptible to Candida infections 
[24, 25] , and IL-1b injection can protect mice from lethal Candida infection [26]. 
Chapter 7 focusses on a specific genetic variation in the inflammasome 
component NLRP3 gene, which is responsible for activation of  IL-1b. This 
gene is important in the processing of  the inactive pro-form of  IL-1b into 
its bioactive form, and loss of  function or reduced activity of  this protein is 
associated with numerous pathogenic conditions ranging from autoimmune 
diseases to different inflammatory diseases. 
 Next to the know non-genetic risk factors that favor (recurrent) vaginal 
Candida colonization and infection, such as hormone therapy, pregnancy 
and usage of  birth control, a strong genetic component is believed to be 
very important for RVVC susceptibility. In Chapter 8 a comprehensive 
systems genetic approach was applied to compare healthy controls with 
woman suffering from RVVC. Through this approach followed by functional 
validation, novel pathways, cellular processes, as well as specific target genes 
were identified that are dysregulated in RVVC. 
 In addition to mucosal Candida infections such as (R)VVC, systemic 
Candida infections are an important cause of  morbidity and mortality, 
especially in immunocompromised patients. Dissemination of  Candida 
into the bloodstream may lead to invasion of  vital organs such as liver 
and kidney, and may ultimately lead to organ failure followed by death. 
Chapter 9 identifies MDA5 (IFIH1) as the first member of  the RIG-I 
helicases family of  PRRs that is involved in the immune response against 
C. albicans. Although previously solely known for its role in anti-viral 
immune responses, MDA5 showed a clear expression signature after 
C. albicans stimulation, and patients suffering from severe invasive Candida 
infections were more often affected by a missense mutation in the IFIH1 
gene, which encodes for MDA5.
 Numerous pathways have been shown to crucial in host responses to 
Candida. The induction of  different chemokines and cytokines remains a 
very important event that is needed to attract and activate other immune cells 
and cellular processes needed at the site of  infection. Chapter 10 identifies 
IL-32 as novel component involved in the anti-Candida immune response 
in both human and mice. IL-32 seems to have a protective role against 
C. albicans by increasing the production of  T cell cytokines, especially 
IFN-γ. Genetic analysis of  patients suffering from candidemia validates the 
17
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role of  IL-32 for antifungal host defense, as a specific genetic variant in the 
intronic region of  this gene influences baseline levels of   IFN-γ, known to 
be crucial for fungal host defense.
 Deep knowledge about the exact mechanisms in fungal (innate) immune 
responses are crucial to understand the pathogenesis of  different fungal 
related diseases. The combination of  genetic data from case – control studies 
as well as functional in vitro assays in different cell systems and their gene 
expression patterns after fungal stimulation is missing. Chapter 11, for the 
first time, makes an attempt to combine these different datasets to identify 
novel host pathways and gene candidates important for the antifungal 
immune response.
 Chapter 12 summarizes the findings from each chapter within this thesis 
and gives an outlook to the future and the possible applications of  the findings.
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Abstract
 
Cells of  the innate immune system are equipped with surface and cytoplasmic 
receptors for microorganisms called pattern recognition receptors (PRRs). 
PRRs recognize specific pathogen-associated molecular patterns and as 
such are crucial for the activation of  the immune system. Currently, five 
different classes of  PRRs have been described: Toll-like receptors, C-type 
lectin receptors, nucleotide-binding oligomerization domain-like receptors, 
retinoic acid-inducible gene I-like receptors and absent in melanoma 2-like 
receptors. Following their discovery, many sequence variants in PRR genes 
have been uncovered and shown to be implicated in human infectious 
diseases. In this review, we will discuss the effect of  genetic variation in 
PRRs and their signalling pathways on susceptibility to infectious diseases 
in humans.
23
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Introduction
Infectious diseases are a major cause of  morbidity and mortality worldwide 
[1]. The genetic makeup of  an individual has a strong influence on the risk 
of  death from infection, as demonstrated by studies correlating the cause of  
death in adopted children with biological or adoptive parents [2]. To defend 
the host against infections, components of  the innate and adaptive immune 
system collaborate to eliminate intruding pathogens. Genetic variation 
in both components of  the immune system influences the susceptibility 
to infectious disease. For example, individuals with severe combined 
immunodeficiency suffer from recalcitrant opportunistic infections due to 
deficiencies in T and B cells of  the adaptive immune system [3], and defects 
in the innate interferon-γ pathway are associated with recurrent infections 
with mycobacteria and Salmonella spp. [4].
 In this review, we will discuss the major findings concerning genetic 
variation in pattern recognition receptors of  the innate immune system 
and molecules involved in their signalling pathways. We will focus on the 
relation between genetic variation and susceptibility to infectious disease 
and review the functional consequences induced by these genetic variants.
Pattern recognition of the innate immune system
The human body is constantly exposed to potential harmful threats such 
as bacteria, fungi, viruses, parasites and protozoa. Upon intrusion of  a 
pathogen in a normally sterile environment, the innate immune system is 
the first line of  defense against these invaders. Cells of  the innate immune 
system are equipped with membrane and cytoplasmic receptors called pattern 
recognition receptors (PRRs), a concept first proposed by Charles Janeway 
Jr. [5]. These highly conserved, germ-line encoded receptors are able to 
recognize specific pathogen-associated molecular patterns (PAMPs) that are 
essential structures of  microorganisms [6, 7]. Although highly conserved, 
small interspecies variation in PAMPs have been shown to result in altered 
immune responses mediated by the same PRR. One relevant example in that 
respect is that of  bacterial muramyl dipeptide (MDP): it has been shown the 
glycolyl-MDP from mycobacteria and other Actinomycetes is much more 
active for stimulation of  immune responses compared to acetyl-MDP from 
other bacterial species [8-10]. Recognition of  PAMPs by PRRs activates 
intracellular signal transduction cascades followed by gene transcription, 
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secretion of  distinctive effector molecules and generation of  an adaptive 
immune response. Depending on the structure and composition of  the 
microbe, different combinations of  PRRs are activated, inducing specific 
signaling pathways, which results in tailored responses to infectious agents 
[6, 7]. At present, five main classes of  PRRs have been described: Toll-
like receptors (TLRs), C-type lectin receptors (CLRs), nucleotide-binding 
domain (NOD)-like receptors (NLRs), retinoic acid-inducible gene I (RIG-
I)-like receptors (RLRs) and absent in melanoma 2 (AIM2)-like receptors 
(ALRs) (Figure 1) [7, 11]. Most PRRs recognize cell wall components of  
microorganisms, but DNA, RNA or metabolites of  microbial origin can 
also act as PAMPs [7]. Table 1 summarizes important PRRs of  the innate 
immune system with corresponding PAMPs and their microbial sources.
Genetic variation in pattern recognition receptors
Changes in the nucleotide sequence of  genes encoding pattern recognition 
receptors can affect the susceptibility to infectious disease. Most often, the 
susceptibility to infections is multifactorial, with the odds of  developing the 
disease increasing with every risk sequence variant. In a minority of  cases, 
single sequence variants are able to induce a strong increase in susceptibility 
to certain infections. The presence of  such a mutation thus results in a 
monogenetic or primary immunodeficiency. 
 The majority of  genetic variation is represented by variants such as 
substitutions (single nucleotide polymorphisms), insertions, deletions, 
inversions and duplications and micro- and minisatellites, in which only one 
or a few nucleotides are affected. Less often, large-scale variants in which 
whole chromosomes or regions are altered can also be encountered [12].
 Depending on the type of  sequence variant and its location in the gene, 
it can have different functional consequences. Variants in the coding region 
can affect the amino acid sequence, and as such, the potential to influence 
the function of  the protein. By contrast, variation in the noncoding region 
of  the gene can still affect the functionality of  the gene by alterations in 
promoter binding sites, splicing of  the gene, stability and degradation of  the 
messenger RNA.
 As a result, one may expect that genetic variation in genes encoding for 
pattern recognition receptors, key mediators in innate immune recognition, 
affects susceptibility to infectious disease, a hypothesis confirmed in recent years. 
Here we will discuss the major genetic polymorphisms in TLR, CLR, NLR, 
25
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Table 1. Overview of  pattern recognition receptors and corresponding pathogen-
associated molecular patterns.
Toll-like receptors 
TLRs PAMP Source
TLR2/TLR1 Triacyl lipopeptides Bacteria
TLR2 Peptidoglycans
Glycolipids
Envelope proteins
Bacteria
Bacteria, fungi
Viruses
TLR2/TLR6 Diacyl lipopeptides
Lipoteichoic acid
Zymosan
Bacteria
Bacteria
Fungi
TLR2/TLR10 Unknown Unknown
TLR3 Single-stranded RNA
Double-stranded RNA
Viruses
Viruses
TLR4 Lipopolysaccharide
Mannans
Envelope proteins
Bacteria
Fungi 
Viruses
TLR5 Flagellin Bacteria
TLR7 Single-stranded RNA Viruses
TLR8 Single-stranded RNA Viruses
TLR9 Unmethylated CpG motifs
Double-stranded DNA
Bacteria, fungi, viruses
Viruses
C-type lectin receptors 
CLRs PAMP Source 
Dectin-1 Beta (linked)-glucans Fungi, bacteria
Dectin-2 High mannose structures Fungi, bacteria
Mannose receptor Mannose, fucose, Fungi, bacteria, viruses
DC-SIGN Mannan, high mannose structures Fungi, bacteria, viruses 
Mannose-binding lectin High mannose, N-acetylglucosamine 
structures
Fungi, bacteria, viruses
NOD-like receptors 
NLRs PAMP Source 
NOD1 Muramyl tripeptide Bacteria
NOD2 Muramyl dipeptide Bacteria
NLRP3 Uric acid crystals, silica, different PAMPs Bacteria, fungi, viruses
RIG-I-like receptors 
RLRs PAMP Source 
RIG-I Short double-stranded RNA Viruses
MDA5 Long double-stranded RNA Viruses
AIM2-like receptors 
ALRs PAMP Source
AIM2 Double-stranded DNA Bacteria, viruses, host
26
RLR and ALR genes, their association in susceptibility to infectious disease and 
functional consequences for activation of  the innate immune response.
Figure 1. Overview of  pattern-recognition receptors and downstream signalling pathways
Toll-like receptors 
Following the discovery of  the Toll signaling pathway in Drosophila, 
implicated in the host defense against fungal infections [13], ten Toll 
homologues termed TLRs (TLR1-10) have been characterized in humans. 
TLRs are primarily expressed in cells of  the immune system such as 
monocytes, neutrophils, basophils, eosinophils and NK cells, but also cells 
of  epithelial, endothelial and stromal origin [14]. TLRs recognize a variety 
of  different microbes based on the presence of  specific PAMPs (Table 1). 
A broad division can be made between TLRs primarily expressed on the 
surface of  cells (TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10), mainly 
targeting microbial lipids and proteins; and those located in intracellular 
compartments of  the endocytic pathway (TLR3, TLR7, TLR8 and TLR9), 
mainly involved in the recognition of  microbial nucleic acids (Table 1).
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All TLRs consist of  an extracellular domain with varying amounts of  
leucine-rich repeats for recognition of  PAMPs, a transmembrane region, 
and a cytoplasmic Toll/Interleukin-1R (TIR) homology domain involved 
in signal transduction. Recognition of  its ligand induces the formation 
of  homo- or heterodimers between TLRs and subsequent recruitment of  
downstream adaptor proteins, activation of  transcription factors, resulting 
in the production of  cytokines and interferons and induction of  an adaptive 
immune response. Most TLRs depend on the activation of  adaptor protein 
myeloid differentiation primary response gene 88 (MyD88), which via 
Interleukin-1 receptor-associated kinase (IRAK) induces activation of  
transcription factors such as nuclear factor kappa-light-chain-enhancer 
of  activated B-cells (NF-kB) and activating protein-1 (AP1). In contrast, 
TLR3 signals via the TIR domain containing adaptor protein inducing 
IFN-β (TRIF). TLR4 has, besides MyD88, a second signalling pathway via 
TRIF-related adaptor molecule (TRAM). Both TRIF and TRAM pathways 
activate TNF receptor associated factor (TRAF)3, resulting in the activation 
of  IFN-stimulated response elements (ISRE) [15]. For the last discovered 
member, TLR10, the exact signaling pathway remains to be elucidated. 
Table 2 summarizes the sequence variants in TLRs and their association in 
susceptibility to infectious diseases.
Toll-like receptor 2 subfamily
TLR1, TLR2, TLR6 and TLR10 are located in a cluster on chromosome 
4, and for convenience are termed the TLR2 subfamily. Besides significant 
sequence similarity [16], members of  the TLR2 subfamily form heterodimers 
that cooperate for the recognition of  microbes. TLR2 is the key receptor in 
this process, due to its ability to form homodimers as well as heterodimers 
with TLR1 and TLR6 for the recognition of  various ligands from bacterial, 
fungal and viral origin (Table 1). Until recently, TLR10 was the only 
TLR without known ligand and function. However, molecular modelling 
indicated Pam3Cys as a possible ligand for the TLR10/2 heterodimer and 
PamCysPam for the TLR10/1 heterodimer and TLR10 homodimer [17]. 
Recent studies have suggested that the function of  TLR10 differs from other 
TLRs, as it was shown to inhibit TLR2-driven innate immune activation [18-
20]. By contrast, TLR10 has also been described as a stimulatory receptor in 
the innate immune recognition [21, 22]. 
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Table 2. Overview of  genetic variation in Toll-like receptors and susceptibility to 
infectious diseases.
Gene Sequence variant Disease Risk
allele
Reference
rs-number Nucleotide
change#
Amino acid 
change#
TLR1 rs5743618 T > G Ile602Ser Tuberculosis T [25]
Leprosy T [23, 26]
Candidemia G [27]
Malaria G [28]
TLR1 rs4833095 C > T Ser248Asn Tuberculosis C [25]
Leprosy C [31]
Complicated skin and skin 
structure infection
T [29]
Aspergillosis C [32]
Candidemia T [27]
TLR2 rs5743708 G > A Arg753Gln Tuberculosis A [35, 36]
Lyme disease G [37]
CMV infection A [38, 39]
TLR2 rs5743704 C > A Pro631His Tuberculosis A [40]
Complicated skin and skin 
structure infection
A [29]
Recurrent vulvo vaginal 
candidiasis
A [41]
TLR6 rs5743810 C > T Pro249Ser Tuberculosis T [25]
Complicated skin and skin 
structure infection
T [29]
Aspergillosis T [32]
Malaria T [28]
TLR10 rs4129009& 
rs11096955
A > C and
A > C
Ile775Leu 
and
Ile369Leu
Complicated skin and skin 
structure infection
A & 
A
[44]
TLR4 rs4986790& 
rs4986791
A > G
C > T
Asp299Gly 
and 
Thr399Ile 
Sepsis G & 
T
[57-59]
Urinary tract infection A & 
C
[60]
Brucellosis G & 
T
[61]
Legionnaire’s disease A & 
C
[62]
Meningococcal disease G & 
T
[63, 64]
Tuberculosis G & 
T
[65, 66]
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Toll-like receptor 1
TLR1 sequence variant rs5743618 (Ile602Ser) leads to the substitution of  
isoleucine for serine at amino-acid position 602 of  the TLR1 protein. Presence 
of  the 602Ser variant results in aberrant trafficking of  TLR1 to the cell surface 
and results in decreased NF-kB activation and proinflammatory cytokine 
responses to TLR1 agonists [23, 24]. TLR1 sequence variant rs5743618 is 
associated with susceptibility to tuberculosis [25], leprosy [23, 26], candidemia 
[27] and malaria [28]. 
Leprosy A & 
C
[67]
Aspergillosis G & 
T
[68-71]
Candidiasis G & 
T
[72]
RSV infection G & 
T
[75]
Malaria G & 
T
[73, 74]
TLR5 rs5744168 C > T Arg392Ter Legionnaires’ disease T [76]
Urinary tract infection T [60]
TLR3 rs3775291 G > A Leu412Phe HCV infection A [82]
HSV infection G [83]
HIV infection G [81]
Tick-borne encephalitis 
virus infection 
G [84]
TLR7 rs179008 A > T Gln11Leu HCV T [86]
HIV infection T [85]
TLR8 rs3764880 G > A Val1Met Tuberculosis A [90, 91]
Crimean-Congo 
hemorrhagic fever 
G [93]
HCV infection A [89, 92]
TLR9 rs5743836 C > T N/A Tuberculosis T [96]
Aspergillosis C [69]
Malaria C [97, 98]
# The first nucleotide (and corresponding amino acid) is the ancestral nucleotide and 
therefore is considered the wild-type allele. N/A, not applicable; CMV, cytomegalovirus; 
RSV, respiratory syncytial virus; HCV, hepatitis C virus; HSV, herpes simplex virus; HIV, 
human immunodeficiency virus. 
Table 2. Continued
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TLR1 sequence variant rs4833095 (Ser248Asn) leads to the substitution of  
serine for asparagine at amino-acid position 248 of  the TLR1 protein. TLR1 
rs4833095 is in strong linkage with the above described TLR1 rs5743618 
in populations of  European descent [24, 27], which may partially explain 
why the 248Asn variant is associated with reduced cytokine responses after 
exposure to TLR2 ligand Pam3Cys and Staphylococcus aureus [27, 29]. 
However, slight reduction of  NF-kB activation was detected in the presence 
of  248Asn, irrespective of  the presence of  TLR1 rs5743618 [30]. TLR1 
sequence variant rs4833095 is associated with susceptibility to tuberculosis 
[25], leprosy [31], complicated skin and skin structure infections [29], 
aspergillosis [32] and candidemia [27]. 
Toll-like receptor 2
TLR2 sequence variant rs5743708 (Arg753Gln) leads to the substitution 
of  arginine for glutamine at amino-acid position 753 of  the TLR2 protein. 
Presence of  the 753Gln variant does not influence the expression of  TLR2, but 
instead causes deficient tyrosine phosphorylation, compromises the assembly 
of  the TLR2-TLR6 complex and impairs recruitment of  transcription 
factors MyD88 and Mal [33]. Engagement of  a receptor encoded by TLR2 
753Gln results in decreased NF-kB activation and proinflammatory cytokine 
secretion after exposure to specific TLR2 ligands (Pam3Cys, lipoteichoic 
acid and macrophage-activating lipopetide-2) and whole cell stimuli such as 
Mycobacterium tuberculosis or S. aureus [33, 34]. TLR2 sequence variant 
rs5743708 is associated with susceptibility to tuberculosis [35, 36], Lyme 
disease [37] and cytomegalovirus infection [38, 39]. 
 TLR2 sequence variant rs5743704 (Pro631His) leads to the substitution 
of  proline for histidine at amino-acid position 631 of  the TLR2 protein. 
Presence of  the 631His variant is associated with decreased internalization 
of  the TLR2 complex after recognition of  its ligand [40], attenuated NF-kB 
activation and proinflammatory cytokine secretion after exposure to specific 
TLR2 ligands (Pam3Cys, lipoteichoic acid, lipomannan and follistatin-like 
1) and Mycobacterium avium [30, 40]. TLR2 sequence variant rs5743704 
is associated with susceptibility to tuberculosis [40], complicated skin and 
skin structure infections [29], and recurrent vulvovaginal infections with C. 
albicans (RVVC) [41].
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Toll-like receptor 6
TLR6 sequence variant rs5743810 (Pro249Ser) leads to the substitution of  
proline for serine at amino-acid position 249 of  the TLR6 protein. Presence 
of  the 249Ser variant resulted in decreased NF-kB activation and cytokine 
secretion after exposure to TLR6/2 ligands and Mycobacterium tuberculosis 
[42]. The Pro249Ser variant is located in the extracellular domain of  TLR6. 
Therefore, this variant may influence ligand recognition or affect assembly of  
a TLR6/2 heterodimer, but the exact mechanism remains unknown. TLR6 
sequence variant rs5743810 is associated with susceptibility to tuberculosis 
[25], complicated skin and skin structure infections [29], aspergillosis [32] 
and malaria [28].
Toll-like receptor 10
TLR10 sequence variant rs4129009 (Ile775Leu) leads to the substitution 
of  isoleucine to leucine at amino-acid position 775 of  the TLR10 protein. 
TLR10 sequence variant rs11096955 (Ile369Leu) also leads to the substitution 
of  isoleucine to leucine at amino-acid position 369 of  the TLR10 protein. 
Presence of  the 775Leu or 369Leu variant is associated with increased 
cytokine secretion in the presence of  TLR1/2 ligand Pam3Cys, TLR6/2 
ligand follistatin-like 1 and various pathogens [19, 20, 43]. How these 
TLR10 sequence variants precisely exert their effect remains unknown, 
but the location of  rs4129009 in the LRR region and rs11096955 in the 
TIR domain could indicate involvement in the recognition of  PAMPs or 
signal transduction, respectively. Both these TLR10 sequence variants have 
been associated with susceptibility to complicated skin and skin structure 
infections [44].
Toll-like receptor 4
TLR4 forms homodimers for the recognition of  various ligands of  bacterial, 
fungal and viral origin (Table 1). The TLR4 gene is located on chromosome 
9. TLR4 sequence variant rs4986790 (Asp299Gly) leads to the substitution of  
aspartic acid for glycine at amino-acid position 299 of  the TLR4 protein. TLR4 
sequence variant rs4986791 (Thr399Ile) leads to the substitution of  threonine 
for isoleucine at amino-acid position 399 of  the TLR4 protein. Both TLR4 
sequence variants lead to alterations in the leucine-rich repeat region of  the 
protein, and as such, possible influence ligand recognition [45]. The presence 
of  both TLR4 variants differs between populations [46]. In populations from 
European descent, TLR4 rs4986790 and rs4986791 are found to be present in 
cosegregation, whereas in African populations mainly presence of  299Gly and 
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almost no 399Ile is observed. In Asian populations both 299Gly and 399Ile 
are practically absent [46]. Several studies have investigated the functional 
consequences of  TLR4 sequence variants rs4986790 and/or rs4986791. 
Presence of  the TLR4 299Gly allele, but not the 399Ile allele, is associated 
with diminished recruitment of  MyD88 and TRIF, decreased NF-kB activation 
and cytokine responses after exposure to LPS in transfection experiments 
with different cell lines [47-49]. On the other hand, most studies investigating 
the effect of  TLR4 299Gly and/or 399Ile on LPS-stimulated whole-blood or 
isolated primary cells, showed no differences [50-55]. These contrasting results 
are possibly due to type of  stimulation used or the fact that the cosegregated 
nature of  these variants in different populations was not taken into account 
[56]. TLR4 sequence variants rs4986790 and rs4986791 are associated with 
susceptibility to sepsis [57-59], urinary tract infections [60], brucellosis [61], 
Legionnaires’ disease [62], meningococcal disease [63, 64], tuberculosis [65, 
66], leprosy [67], aspergillosis [68-71], candidiasis [72], malaria [73, 74], 
respiratory syncytial virus infection [75].
Toll-like receptor 5
TLR5 forms homodimers for the recognition of  bacterial flagellin (Table 1). 
The TLR5 gene is located on chromosome 1. TLR5 sequence variant 
rs5744168 (Arg392Ter) leads to the substitution of  arginine to a stop codon 
at amino-acid position 392 of  the TLR5 protein. Presence of  the 392Ter 
variant results in premature truncation in the extracellular domain of  the 
TLR5 protein with complete loss of  the transmembrane and cytoplasmic 
region. Cells expressing the 392Ter variant were not able to induce NF-kB 
activation and reduced cytokine secretion was observed in response to TLR5 
ligand flagellin [76]. TLR5 sequence variant rs5744168 is associated with 
susceptibility to Legionnaires’ disease [76] and urinary tract infections [60]. 
TLRs recognizing nucleic acids
TLR3, TLR7, TLR8 and TLR9 are all located in intracellular compartments 
of  the cell where they recognize different microbial nucleic acids structures 
(Table 1). TLR3, TLR7 and TLR8, as homodimers, recognize single-
stranded RNA of  viral origin. In addition, TLR3 is also involved in the 
recognition of  viral double-stranded RNA. TLR9 forms homodimers for 
the recognition of  DNA motifs of  bacterial, fungal or viral origin. The 
TLR3 gene is located on chromosome 4, and the TLR9 gene is located on 
chromosome 3. The TLR7 and TLR8 genes are located in close proximity 
of  one other on chromosome X.
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Toll-like receptor 3
TLR3 sequence variant rs3775291 (Leu412Phe) leads to the substitution 
of  leucine for phenylalanine at amino-acid position 412 of  the TLR3 
protein. Presence of  the 412Phe variant is associated with decreased NF-kB 
activation and proinflammatory cytokine secretion after exposure to TLR3 
ligand Poly I:C [77-79]. Decreased intracellular expression of  TLR3 [79], 
deficient cell surface expression and receptor shedding [77, 80] have all been 
suggested as possible mechanisms for the described functional consequences 
of  the 412Phe variant. By contrast, one study reported increased cytokine 
responses after exposure to Poly I:C in the presence of  the 412Phe variant 
[81]. TLR3 sequence variant rs3775291 is associated with susceptibility 
to hepatitis C virus (HCV) infection [82], human immunodeficiency virus 
(HIV) infection [81], herpes simplex virus (HSV) infection [83] and tick-
borne encephalitis virus infection [84].
Toll-like receptor 7
TLR7 sequence variant rs179008 (Gln11Leu) leads to the substitution 
of  glutamine for leucine at amino-acid position 11 of  the TLR7 protein. 
Presence of  the 11Leu variant is associated with decreased IFNα secretion 
after exposure to TLR7 ligand Imiquimod, whereas IL-6 remained unaltered 
[85]. Although the exact mechanism remains unknown, it is speculated that 
due to its location in the signal sequence region, sequence variant rs179008 
could influence post-translational modification, localization, quantity and 
therefore functionality of  TLR7 [85]. TLR7 sequence variant rs179008 is 
associated with susceptibility to HCV infection [86] and HIV infection [85].
Toll-like receptor 8
The TLR8 gene encodes two different splice variants, TLR8v1 and TLR8v2, 
which share a similar sequence, with the exception of  the longer N-terminal 
section of  TLR8v1 [87]. TLR8 sequence variant rs3764880 (Val1Met) 
influences TLR8v2, but not TLR8v1, and leads to the substitution of  
valine for methionine at amino-acid position 1, resulting in alteration of  
the start codon and truncation of  the TLR8 protein. Different functional 
consequences have been described for TLR8 sequence variant rs3764880. 
Presence of  the variant 1Val is associated with decreased NF-kB activation, 
but increased cytokine secretion, after exposure to TLR8 ligands CL075 and 
R848 [88, 89]. By contrast, another study reported no differences in TLR8 
function and cellular distribution for TLR8 sequence variant rs3764880 [87]. 
This study suggested that the TLR8 sequence variant rs3764880 influences 
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fine-tuning of  translation of  both TLR8 isoforms, indicated by decreased 
TLR8v2 and increased TLR8v1 [87]. TLR8 sequence variant rs3764880 is 
associated with susceptibility to tuberculosis [90, 91], HCV infection [89, 
92], and Crimean-Congo hemorrhagic fever [93].
Toll-like receptor 9
TLR9 sequence variant rs5743836 (-1237C/T) is located in the promoter 
region of  the TLR9 gene. Presence of  the -1237C variant is associated with 
increased transcription of  the TLR9 gene after exposure to proinflammatory 
cytokines or TLR ligands [94, 95]. The incorporation of  cytosine is suggested 
to create a novel NF-kB transcriptional binding site [94] or IL-6 binding 
site [95] in the promoter region of  the TLR9 gene. TLR9 sequence variant 
rs5743836 is associated with susceptibility to tuberculosis [96], aspergillosis 
[69] and malaria [97, 98].
Primary immunodeficiencies in the TLR pathway
Primary immunodeficiencies in the TLR signaling pathway are rare, but 
novel genetic variants are continuously discovered. Some of  the most 
important examples are the deficiencies in MyD88 and IRAK4 of  the TLR 
signaling pathway [99, 100]. Different sequence variants have been described 
in both genes including deletions, insertions and substitutions resulting 
in loss-of-expression or loss-of-function phenotypes [99]. Deficiencies in 
the MyD88/IRAK4 pathway result in defective downstream signaling of  
most TLRs and failure to induce proinflammatory cytokines in response to 
known TLR ligands and whole organisms [101, 102]. Patients with MyD88 
or IRAK4 deficiency are predisposed to life-threatening infections with 
invasive pyogenic bacteria, such as Streptococcus pneumoniae, S. aureus 
and Pseudomonas aeruginosa [99]. Despite antibiotic treatment, these 
infections lead to a mortality up to 30-40% during infancy and childhood, 
but decrease in frequency and severity of  infections after adolescence [103].
 Another cluster of  primary immunodeficiencies discovered over the last 
decade are the defects in the TLR3/TRIF/TRAF3/UNC93B pathway [104-
107]. The TLR3 pathway is important for the recognition of  single- and 
double stranded RNA of  viral origin (Table 1), and patients with primary 
immunodeficiencies in this pathway have loss-of-expression or loss-of-
function phenotypes, due to sequence variations such as deletions and 
substitutions. TLR3 pathway deficiencies are characterized by a failure 
to induce interferons after stimulation with HSV-1. Patients with TLR3 
pathway deficiencies are predisposed to development of  recurrent herpes 
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simplex encephalitis, a rare complication of  the common viral infection 
HSV-1.
C-type lectin receptors
A prominent role in host immunity in general and antifungal immunity in 
particular has been attributed to CLRs, as they are able to recognize fungal 
cell wall components as β-glucans or mannans [108]. Most, but not all, CLRs 
are Ca2+ dependent and recognize carbohydrate-containing PAMPs through 
a C-type-lectin-like-domain. Recognition leads to subsequent signaling 
via Src and spleen tyrosine kinase (Syk), which in turn signal downstream 
adaptor molecules to induce a NF-kB dependent immune response through 
secretion of  cytokines such as (pro-)IL-1β, IL-6, IL-10 and TNF-α [109-111]. 
Moreover, signaling leads to reactive oxygen species (ROS) production and 
subsequent activation of  inflammasomes, which in turn process the inactive 
pro-IL-1β and pro-IL-18 into their biologically active forms [112]. Although 
most CLRs are membrane-bound, there are also soluble CLRs such as the 
complement activating mannose-binding-lectin (MBL) and pentraxin-3. 
Table 3 summarizes the sequence variants in CLRs and their association in 
susceptibility to infectious diseases.
Dectin-1
The β-glucan receptor Dectin-1 (C-type lectin domain family 7 member A, 
CLEC7A) is a prominent member of  the CLR family. By recognizing its 
ligand, different adaptor proteins such as CARD9 (Caspase recruitment 
domain-containing protein 9), Syk, as well as Bcl-10 and Malt-1 are recruited 
which leads to the activation of  NF-kB and subsequent transcription of  
proinflammatory cytokines. In addition, Dectin-1 is known to synergize 
with TLRs to amplify cytokine production after pathogen recognition in 
both human and mice [108, 113-115].
 Dectin-1’s importance in β-glucan recognition was shown in different 
mice knock out studies as well as in patients with fungal infections who 
carried a specific mutation in the CLEC7A gene [116, 117]. The sequence 
variant responsible for the altered phenotypes is rs16910526 (Tyr238Ter) 
in the CLEC7A gene, located in exon 6 of  chromosome 12. The sequence 
variant leads to a change from tyrosine into a stop codon resulting in the 
loss of  amino acids within the carbohydrate-recognition domain [118]. 
Subsequently, this sequence variant results in decreased surface expression of  
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Table 3. Overview of  genetic variation in C-type lectin receptors and susceptibility to 
infectious diseases.
Gene Sequence variant Disease Risk allele Reference
rs-number Nucleotide
change#
Amino acid 
change#
CLEC7A rs16910526 T > G Tyr238Ter Candida 
colonization 
G [119] 
Recurrent 
vulvovaginal 
candidiasis
G [118]
Onychomycosis G [118]
CLEC7A rs16910527 A > C Ile223Ser Oropharyngeal 
candidiasis 
A [124]
Aspergillosis C [121, 122]
CLEC7A rs7309123 G > C N/A Aspergillosis G [123]
CLEC7A rs3901533 G > T N/A Aspergillosis T [123]
CD209 rs4804803 G > A N/A Tuberculosis G [127]
HIV infection G [128]
Dengue fever G [129]
CD209 rs735239 A > G N/A Tuberculosis A [127]
CD209 rs4804800 A > G Unknown Aspergillosis G [123]
CD209 rs11465384 C > T Unknown Aspergillosis T [123]
CD209 rs7248637 G > A Unknown Aspergillosis A [123]
CD209 rs7252229 G > C Unknown Aspergillosis C [123]
CD206 rs1926736 C > T Gly396Ser Tuberculosis C [133]
Leprosy T [132, 134]
CD206 rs692527 T > C Unknown Leprosy C [134]
CD206 rs34856358 C > T Unknown Leprosy T [134]
PTX3 h2/h2 
(G-A/G-A)
Aspergillosis h2/h2 
haplotype
[140]
PTX3 rs2305619 A > G Tuberculosis Haplotype 
(GAG)
[142]
PTX3 rs1840680 G > A Tuberculosis Haplotype 
(GAG)
[142]
Pseudomonas 
aeruginosa 
colonization
Haplotype 
(GAG)
[143]
 MBL rs1800450,
rs5030737,
rs1800451
Arg52Cys, 
Gly54Asp, 
Gly57Glu 
Recurrent 
vulvovaginal 
candidiasis
Haplotype [149-152]
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the receptor accompanied by low levels of  IL-17 and IL-23 after stimulation 
with either β-glucan or C. albicans [118].
 Contradictory results regarding susceptibility to different infectious 
diseases have been observed for CLEC7A sequence variant Y238X. However, 
independent studies show an increase in mucosal and gastrointestinal 
fungal colonization as a consequence of  the sequence variant [118-120]. In 
addition, several studies show a correlation between this sequence variant 
and invasive as well as pulmonary aspergillosis [121-123]. Finally, Sainz 
et al. observe a correlation with susceptibility to aspergillosis in two other 
intronic CLEC7A sequence variants (rs7309123 and rs3901533). Presence 
of  the GG genotype for sequence variant rs7309123 leads to decreased 
Dectin-1 mRNA expression, whereas the functional consequences of  
rs3901533 remains unknown [123]. Plantinga et al. observed an association 
of  rs16910527 (Ile223Ser) and oropharyngeal candidiasis in HIV patients 
which is accompanied with lower IFN-γ levels as well as a reduced capacity 
to bind zymosan [124]. 
DC-SIGN
DC-SIGN (CD209) is mainly present in dendritic cells and macrophages 
and recognizes mannose glycoproteins. In addition, it has an important 
function in the process of  adhesion and was shown to modulate TLR 
function [125]. Several studies link genetic variation in DC-SIGN to various 
infectious diseases. DC-SIGN sequence variant rs4804803 (336A/G), 
CARD9 rs121918338 C > T Gln295Ter Chronic 
mucocutaneous 
candidiasis
T [116]
CARD9 rs398122363 C > T Gln289Ter Dermatophytic
disease
T [157]
CARD9 rs398122364 C > T Arg101Cys Dermatophytic
disease
T [157]
CARD9 Unknown T > C Tyr91His C. albicans 
meningoencephalitis
C [158]
# The first nucleotide (and corresponding amino acid) is the ancestral nucleotide and 
therefore is considered the wild-type allele. Abbreviations: N/A, not applicable; HIV, 
human immunodeficiency virus.
Table 3. Continued
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located in the promoter region is linked with susceptibility to tuberculosis, 
HIV and dengue fever [126-129]. By contrast, both -336A as well as -871G 
(rs735239) have been shown to have a protective effect in the development of  
tuberculosis [130]. These sequence variants most likely affect transcription 
levels leading to lower expression of  CD209 [127, 129]. However, one meta-
analysis of  the -336A/G polymorphism of  DC-SIGN did not show any 
association with susceptibility to tuberculosis [131]. Sainz et al. observed 
four sequence variants in DC-SIGN (rs4804800, rs11465384, rs7248637, 
rs7252229) that are associated with increased risk to develop invasive 
pulmonary aspergillosis [123]. 
Mannose receptor 
The mannose receptor (CD206) recognizes different high mannose 
structures present on the surface of  various pathogens. After recognition and 
subsequent internalization, the pathogen is degraded in the lysosome and an 
immune response is initiated. Very little is known about sequence variants 
in CD206 and susceptibility to infectious disease in humans. Nevertheless, 
sequence variant rs1926736 (Gly396Ser) in exon 7 of  the MRC1 gene on 
chromosome 10 is suggested to be associated in susceptibility to leprosy and 
tuberculosis [132-134].
Soluble C-type lectin receptors 
Pentraxin-3 
The soluble and circular pentraxin-3 (PTX3) belongs to the pentraxin 
superfamily that also includes C reactive protein as well as serum amyloid 
P component. It is released by several immune and nonimmune cells, 
such as dendritic cells and endothelial cells. By forming complexes with 
different pathogenic antigens and components of  the complement system 
it enhances cellular processes as antigen recognition and phagocytosis. 
Interaction of  PTX3 with Aspergillus fumigatus and Candida albicans 
has been reported [135-139]. In a cohort of  patients with hematopoietic 
stem-cell transplantation Cunha et al. showed that the h2/h2 haplotype 
(G-A/G-A) in PTX3 is associated with invasive aspergillosis [140], whereas 
another study did not find an association for PTX3 with susceptibility to 
aspergillosis [141]. The increased risk for aspergillosis is most likely due to 
a reduced expression of  PTX3 in neutrophils, which might therefore lead to 
reduced phagocytosis of  the fungus [140]. In a study of  African tuberculosis 
39
2
cases and controls, Olesen et al. found an association between sequence 
variants rs2305619 and rs1840680 in PTX3 and pulmonary tuberculosis 
[142]. In addition, a haplotype containing these two sequence variants has 
been shown to be associated with P. aeruginosa colonization in patients 
suffering from cystic fibrosis [143].
Mannose-binding-lectin 
Mannose-binding-lectin (MBL) is able to recognize carbohydrate patterns 
present on the surface of  different microorganisms. Upon binding to its ligand, 
MBL activates the lectin pathway of  the complement system, initiating a 
cascade of  complement activation [144, 145]. Three polymorphisms located 
in exon 1 of  the MBL2 gene rs5030737 (Arg52Cys), rs1800450 (Gly54Asp) 
and rs1800451 (Gly57Glu) have been shown to decrease circulating levels 
of  MBL2 [146, 147]. All three polymorphisms are linked to recurrent 
vulvovaginal infections with C. albicans (RVVC), although there is still some 
debate for the role of  MBL2 as a marker for this disease since genotype 
distribution strongly depends on ethnic background [148-153]. Decreased 
levels of  MBL and complete MBL deficiency are associated with invasive 
and pulmonary aspergillosis [154, 155]. Moreover, Hibberd et al. showed 
that homo and/or heterozygous combinations of  MBL2 genotypes are more 
frequently present in patients suffering from meningococcal disease [156].
Caspase recruitment domain-containing protein 9
Caspase recruitment domain-containing protein 9 (CARD9) functions as 
adapter protein downstream of  most CLRs, for example, Dectin-1, Dectin-2 and 
Mincle. Upon engagement of  these CLRs with their ligands typically present 
on the cell walls of  various fungi, signaling via CARD9 leads to the production 
of  proinflammatory cytokines. Several sequence variants in the CARD9 
gene are associated with fungal infections in humans [116, 157]. Sequence 
variants rs121918338 (Gln295Ter) and rs398122363 (Gln289Ter) lead to the 
incorporation of  a stop codon, whereas rs398122364 (Arg101Cys) leads to the 
substitution of  arginine for cysteine. Homozygosity for these variants results 
in absence (289Ter, 295Ter) or decreased levels of  CARD9 protein (101Cys), 
and it is associated with reduced numbers of  Th17 cells and altered cytokine 
profiles, essential for the antifungal defense [116, 157]. Gavino et al. recently 
reported a novel mutation in the CARD domain of  CARD9 (Tyr91His) in a 
patient with relapsing C. albicans meningoencephalitis. Interestingly, presence 
of  91His is associated with decreased levels of  CARD9 protein and impaired 
GM-CSF expression but not reduced numbers of  Th17 cells [158].
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Nod-like receptors
NOD-like receptors are intracellular receptors that recognize mainly 
bacterial PAMPs, and they are able to induce proinflammatory cytokines 
and activation of  host defense. Interestingly, it has also been shown that 
NLRs also participate in the antiviral immune response [159]. Moreover, a 
central role in the induction of  autophagy was ascribed to members of  this 
receptor family. Although NLRs form a heterozygous group of  receptors, 
in general they contain a C terminal leucine rich repeat (LRR) domain, a 
NACHT (and NACHT associated domain, NAD) and an effector domain. 
Based on the N terminal effector domain, which can be either PYD, CARD 
or BIR2, several subfamilies can be distinguished [160]. However, regarding 
phylogenetic aspects of  NLRs, 3 subfamilies (NALPs, IPAF/NAIP and 
NODs) have been proposed [161, 162].
 Besides their role in the direct signaling and stimulation of  cytokine 
production, some family members form molecular complexes known as 
inflammasomes that are able to recruit inflammatory caspases. The classical 
example is the recruitment of  caspase-1 into the NLRP3 inflammasome that 
processes the inactive pro-IL-1β and pro-IL-18 into their bioactive forms. 
Two well-known cytosolic NLRs are NOD1 (CARD4) and NOD2 
(CARD15). Both recognize different parts of  the bacterial cell wall 
component peptidoglycan [163, 164]. Table 4 summarizes the sequence 
variants in NLRs and their association in susceptibility to infectious diseases.
NOD2
Frameshift variant rs2066847 (Leu1007fsinsC) in CARD15 encoding the 
leucine rich repeat of  NOD2, as well as two sequence variants in CARD15 
rs2066844 (Arg702Trp) and rs2066845 (Gly908Arg) are associated with 
susceptibility to Crohn’s disease and sepsis [163, 165-168]. These sequence 
variants most likely affect antigen binding at the site of  the LRR and, 
therefore, downstream signaling via NF-kB. This, in turn, may lead to a 
diminished production of  proinflammatory cytokines. Genome-wide 
association studies suggest that genetic variants in CARD15 (also CARD4) 
may affect autophagy function and thereby contribute to the development 
and severity of  various diseases, such as Crohn’s disease [169, 170].
 In addition, sequence variants in CARD15 (NOD2) are linked to 
susceptibility to leprosy and tuberculosis. Using a genome-wide association 
study approach, a couple of  sequence variants in CARD15 (rs9302752, 
rs7194886, rs8057341, rs3135499) and downstream genes were identified 
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to be associated with the susceptibility to leprosy [171, 172]. In addition, 
Berrington et al. identified an intronic sequence variant rs5743289 that 
is also associated with susceptibility to leprosy [173]. Finally, rs5743278 
(Ala725Gly) is shown to increase the risk for tuberculosis, whereas 
Table 4. Overview of  genetic variation in NOD-like receptors and susceptibility to 
infectious diseases.
Gene Sequence variant Disease Risk 
allele
Reference
rs-number Nucleotide
change#
Amino acid 
change#
CARD15 rs2066845 G > C Gly908Arg Crohn’s disease C [165, 166] 
CARD15 rs2066844 C > T Arg702Trp Sepsis T [167]
Tuberculosis C [168]
CARD15 rs2066847 insC Leu1007fsinsC Crohn’s disease 1007C [165, 166] 
CARD15 rs9302752 A > G Unknown Leprosy G [171] , 
[172]
CARD15 rs7194886 G > A Unknown Leprosy A [171]
CARD15 rs8057341 A > G Unknown Leprosy G [171]
CARD15 rs3135499 A > C Unknown Leprosy C [171]
CARD15 rs5743289 C > T Unknown Leprosy T [173]
CARD15 rs2066842 C > T Pro268Ser Tuberculosis C [168]
CARD15 rs5743278 C > G Ala725Gly Tuberculosis G [168]
CARD4 rs2075820 
(E266K) 
 G > A Glu796Lys H. pylori 
gastric 
inflammation
A [180]
CIAS1 rs74163773 12,9,7,6 Tandem repeat Mycoplasma 
infection-
associated 
infertility
Allele 
7
[184]
Recurrent 
vulvovaginal 
candidiasis
Allele 
7
[183]
CIAS1 rs4925663 C > T Gly223Asp Chlamydia 
trachomatis 
infection
T [185]
# The first nucleotide (and corresponding amino acid) is the ancestral nucleotide and 
therefore is considered the wild-type allele. N/A, not applicable.
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rs2066842 (Pro268Ser) as well as rs2066844 (Arg702Trp) are shown to have 
a protective effect [168]. The protective effect is most likely due to a more 
stable NOD2 protein with increased functionality [168]. 
NOD1
Two different sequence variants rs2075820 (G796A) and +32656 (rs number 
unknown) have linked CARD4 (NOD1) to various inflammatory diseases 
such as inflammatory bowel disease, Crohn’s disease and asthma [174-179]. 
In addition, Kim et al. found an association with sequence variant rs2075820 
(Gly796Ala) and H. pylori associated gastric mucosal inflammation [180]. 
NACHT, LRR and PYD domains-containing protein 3
NLRP3 is encoded by the CIAS1 gene and was extensively studied due to its 
capacity to form active inflammasomes. Several danger signals can activate 
the NLRP3 inflammasome, leading to activation of  caspase-1, which in turn 
processes the inactive forms of  pro-IL-1β and pro-IL-18 into their biologically 
active forms [160, 181]. Numerous genetic variations have been described 
within the CIAS1 locus that lead to various different diseases, commonly 
summarized as cryopyrin-associated periodic syndrome. Depending on the 
genetic variant, most (but not all) share an increased inflammasome activity 
that leads to excessive IL-1β production and tissue damage [181, 182]. 
 A few genetic variants in NLRP3 have been described that are associated 
with bacterial or fungal infections. Lev-Sagie et al. showed that presence 
of  allele 7 of  tandem repeat rs74163773 in intron 4 of  the CIAS1 gene is 
increased in patients suffering from recurrent vulvovaginal infections with C. 
albicans. Furthermore, the risk genotype is associated with reduced levels of  
IL-1β, pointing toward a reduced inflammasome activity [183]. In addition, 
the same variant was described by Witkin et al. who showed a significant 
correlation with mycoplasma infection-associated infertility [184]. Wang et 
al. proposed a negative correlation between rs4925663 in NLRP3 and the 
course of  Chlamydia trachomatis infections [185].
Rig-I-like receptors 
RLRs are intracellular DEAD box containing RNA helicases that 
are important for antiviral defense [186, 187]. RIG-I and melanoma 
differentiation-associated protein 5 (MDA5) recognize double stranded 
RNA (dsRNA) of  viral origin. RIG-I is known to recognize relatively short 
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dsRNA strands, whereas MDA5 recognizes longer dsRNA strands [188]. 
Recognition and downstream signaling through mitochondrial antiviral-
signaling protein followed by interferon regulatory factors leads to the 
production of  type 1 interferons. Laboratory of  genetics and physiology 
2 (LGP2), the third member of  the RLR family, is thought to have a 
regulatory function on RIG-I and MDA5, as it misses the N-terminal CARD 
domain essential for downstream signaling [189, 190]. Table 5 summarizes 
the sequence variants in RLRs and their association in susceptibility to 
infectious diseases.
Table 5. Overview of  genetic variation in RIG-1-like receptors and susceptibility to 
infectious diseases.
Gene Sequence variant Disease Risk 
allele
Reference
rs-number Nucleotide
change#
Amino acid 
change#
DDX58 rs10813831 G > A Arg7Cys IgG antibody 
levels
A [191]
DDX58 rs669260 A > G Unkown IgG antibody 
levels
G [192]
DDX58 rs36055726 Frameshift p229fs Immune 
response against 
viruses
[193]
DDX58 rs11795404 G > T Ser183Ile Immune 
response against 
viruses
T [193]
IFIH1 rs1990760 C > T Ala946Thr Candidemia T [199]
IFIH1 rs3747517 T > C His843Arg Candidemia C [199]
# The first nucleotide (and corresponding amino acid) is the ancestral nucleotide and 
therefore is considered the wild-type allele. N/A, not applicable.
RIG-I
RIG-I is encoded by DDX58 (DEAD (Asp-Glu-Ala-Asp) box polypeptide 58) 
which is located on chromosome 9. A sequence variant in the CARD 
domain of  RIG-I rs10813831 (Arg7Cys) has been shown to increase 
transcription of  IFNB1 and DDX58 [191]. In addition, Ovsyannikova et 
al. showed that the same variant and RIG-1 sequence variant rs669260 is 
associated with differences in rubella antibody levels [192]. A frameshift 
mutation in DDX58 rs36055726 (p229fs) was reported to lead to a truncated 
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and constitutively active protein, resulting in excessive cytokine production. 
In addition, sequence variant rs11795404 (Ser183Ile) leads to impaired 
antiviral signaling due to disrupted interactions of  RIG-I with downstream 
molecules. Both sequence variants most likely lead to an altered immune 
response against dsRNA viruses [193]. 
MDA5
MDA is encoded by the IFIH1 gene located on chromosome 2. MDA5 
polymorphisms have been mainly associated with autoimmune diseases 
such as Type-1 diabetes mellitus and SLE, or with IgA deficiency [194-197]. 
In this context, the sequence variant rs1990760 (Ala946Thr) is proposed to 
have a major contribution to disease development and progression, due to 
increased (baseline) expression levels of  MDA5 [198]. Recently, two MDA5 
variants rs1990760 (Ala946Thr) and rs3747517 (His843Arg) have been 
associated with susceptibility to candidemia [199]. However, it remains to 
be investigated which PAMP of  C. albicans is recognized by MDA5.
Aim2-like receptors 
The AIM2 protein is encoded by the AIM2 gene located on chromosome 
1. It recognizes cytosolic DNA derived from the host, bacterial and viral 
origin [200, 201]. Antigen recognition by a specific C-terminal domain of  
AIM2 is followed by formation of  an inflammasome platform. The pyrin 
domain of  AIM2 interacts with ASC, which contains a CARD domain that 
subsequently recruits caspase-1 to the complex responsible for processing 
of  pro-IL-1β and pro-IL-18 [11, 202]. Although no specific polymorphisms 
have been found that link AIM2 to infectious diseases so far, it is likely 
that more research on this recently discovered receptor will identify genetic 
variants that contribute to infectious disease susceptibility. 
Conclusion 
Since the discovery of  pattern recognition receptors, sequence variants in 
the genes encoding them have been recorded, and evidence regarding their 
associations with susceptibility to infectious disease has mounted. In this 
review, we have discussed major examples of  genetic variation in PRRs, 
their association with susceptibility to infectious diseases, with a specific 
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focus on their functional consequences. As such, this review provides 
strong arguments that genetic variation in PRRs has a profound impact on 
innate immune responses to infectious stimuli and affects infectious disease 
susceptibility.
 However, this review is subject to several limitations. Although very 
important for the understanding of  the consequences of  sequence variants, 
negative associations and numerous attempts to validate sequence variants 
received less prominence. In addition, generalization of  the results of  
individual studies is difficult and reproducibility often fails in independent 
validation studies. At least part of  the differences between studies may be 
due to variations in ethnic background of  the populations, often the small 
sample sizes of  patient cohorts, the type of  analyses performed, as well as 
possible confounding factors such as age, gender and co-morbidities which 
were not always taken into account. 
 Nonetheless, the study of  genetic variation in PRRs has been of  crucial 
importance for several reasons. First, genetic variation in PRRs has increased 
our understanding of  the role that these receptors play in infectious diseases. 
Second, this information may represent a first step in an approach toward 
personalized diagnosis and treatment. Finally, this type of  research provides 
a human model to study PRR pathways to complement experimental animal 
models of  infection.
Future perspective
Within the last decades extensive research in the field of  immunogenetics 
has led to a better understanding of  the functional immune pathways and 
interactions underlying infectious diseases. Studying the genetic background 
of  patients with infections has allowed us to pinpoint components of  the 
immune system that contribute to disease susceptibility, as well as the 
influence on disease progression and outcome. Advances in technology, 
such as next generation sequencing, will enable the extensive study of  large-
scale genomic information rather than single sequence variants. Moreover, 
structural variation as well as gene-gene interactions and gene expression 
changes will be more easily detected and may be linked to different diseases. 
Finally, technical improvement will allow the study of  the epigenetic changes, 
and add an additional layer of  complexity to the field of  immunogenetics. 
Understanding the multiple pathways and factors that underlie susceptibility 
to infectious disease may lead to personalized diagnosis and treatment 
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in the future. Such personalized treatment might involve patient-adjusted 
prophylaxis in those deemed at high risk of  developing a severe infection 
due to a combination of  genetic risk factors, or inhibition of  an overactive 
immune system due to genetic variants in order to restore a normal cytokine 
balance.
Executive summary
Pattern-recognition receptors (PRRs) recognize specific pathogen-
associated molecular patterns (PAMPs) and are involved in the initiation of  
the immune response against microorganisms.
Five different classes of  PRRs have been described: Toll-like receptors, 
C-type lectin receptors, NOD-like receptors, RIG-1-like receptors and 
AIM2-like receptors.
Sequence variants are changes in the nucleotide sequence of  DNA.
Depending on the type of  sequence variant and its location in the gene, it 
can have different functional consequences. 
Genetic variation in PRRs influences susceptibility to infectious disease.
Genetic variation in PRRs has increased our understanding in the 
pathological mechanism of  infectious diseases and may lead toward 
personalized diagnosis and treatment in the future.
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Summary
As part of  the Human Functional Genomics Project, that aims to 
understand the factors that determine the variability of  immune responses, 
we investigated genetic variants affecting cytokine production in response 
to ex vivo stimulation in two independent cohorts of  500 and 200 healthy 
individuals. We demonstrate a strong impact of  genetic heritability on 
cytokine production capacity after challenge with bacterial, fungal, viral, 
and non-microbial stimuli. In addition to 17 novel genome-wide significant 
cytokine production QTLs (cQTLs), our study provides a comprehensive 
picture of  the genetic variants that influence six different cytokines in whole 
blood, blood mononuclear cells, and macrophages. Important biological 
pathways that contain cytokine QTLs map to pattern recognition receptors 
(TLR1-6-10 cluster), cytokine and complement inhibitors, and the kallikrein 
system. The cytokine QTLs show enrichment for monocyte-specific 
enhancers, are more often located in regions under positive selection, and 
are significantly enriched among SNPs associated with infections and 
immune-mediated diseases. 
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Introduction
The Human Functional Genomics Project (HFGP) is an initiative that aims 
to identify the factors responsible for the variability of  immune responses 
in health and disease (www.humanfunctionalgenomics.org). Within HFGP, 
the 500-Human Functional Genomics (500FG) cohort focuses on gaining 
a broader understanding of  the variability in human cytokine responses. 
In a first study reported in this issue of  Cell we investigated the role of  
environmental and non-genetic host factors for cytokine responses(ter Horst 
et al., 2016). In the present study we investigate the role of  genetic variation 
for individuals human cytokine responses, while a third complementary 
study assessed the impact of  microbiome factors(Schirmer et al., 2016).
 Many targeted candidate gene studies have demonstrated the impact 
of  specific genetic variants on immune responses, while a recent study 
that assessed the genetics of  lipopolysaccharide (LPS)-induced cytokine 
responses by dendritic cells identified several candidate genes (Lee et 
al., 2014). Furthermore, genome-wide genetic studies have found genetic 
variants that impact transcript abundance for immune genes (so-called 
eQTLs)(Kumar et al., 2014a; Fairfax et al., 2014; Lee et al., 2014), while 
genome-wide association studies (GWAS) have identified hundreds of  
genetic variants predisposing to the susceptibility to immune-mediated 
diseases and/or their severity (Welter et al., 2014). However, there have been 
no comprehensive genome-wide association studies to investigate variation 
in cytokine production in humans so far. As a proof-of-concept, we assessed 
the genetics of  three monocyte-derived cytokines (TNF-α, IL-1β, IL-6) after 
stimulation with a few microbial stimuli: we identified four genome-wide loci 
that influence cytokine release (Li et al., 2016). This clearly demonstrated 
the importance of  genetic variation for cytokine production in humans, and 
we decided to pursue a more comprehensive approach to reveal the most 
important genetic factors that influence cytokine responses.
 Here we describe the stimulation of  three different cellular systems (whole-
blood, peripheral blood mononuclear cells (PBMC), and macrophages) 
with a broad panel of  bacterial, fungal, viral, and non-microbial stimuli to 
induce cytokine production, which was analyzed with approximately 8.0 
million genetic variants (SNPs). The discovery was performed in the 500FG 
cohort and validation in the 200FG cohort. We were able to validate 17 
new genome-wide significant loci that represent cytokine quantitative trait 
loci (cQTLs) and we describe new pathways for the modulation of  cytokine 
responses in humans. 
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Overview of cytokine response architecture
We assessed cytokine production capacity in the 500FG discovery cohort in 
three cellular systems: whole-blood stimulations, PBMC stimulations, and 
stimulation of  monocyte-derived macrophages. We used a comprehensive 
range of  seven bacterial, three fungal, one viral, four Toll-like receptor 
(TLR) ligands, and two non-microbial metabolic stimuli to assess three 
monocyte-derived and three lymphocyte-derived cytokines (see Figure 1 for 
overview).
 Significant increases in the levels of  all cytokines were observed in all 
stimulation systems compared to steady-state levels (see also the related 
manuscript by Schirmer et al for the main bacterial and fungal stimuli, 
as well as Figure S1 for a full description of  all stimuli). Cytokines IL-6 
and TNF-α from whole blood and PBMCs showed higher inter-individual 
variation than production by macrophages (Figure S2), suggesting that the 
in vitro differentiation of  macrophages is a process that partly overrides 
individual variation. In general, IL-6 showed a much stronger inter-
individual variation than any other cytokines (p < 0.001), suggesting a much 
stronger impact of  cell types and/or genetic variation on IL-6 production 
than other cytokines. These results were consistent with those we obtained 
from the 200FG cohort (data not shown).
 Unsupervised clustering of  the cytokine responses showed a clear 
distinction between stimulations with bacteria, fungi, or viruses (Figure 2A). 
Correlations between the production of  various cytokines were found mainly 
for stimulation with a certain microbe rather than between cytokine production 
induced by different microbes, which suggests that immune responses are 
organized to respond to a specific pathogen rather than through a specific 
immune pathway. The clustering also revealed a poor correlation between 
monocyte-derived- and T-helper-derived cytokine responses (Figure 2A). 
This is surprising as the differentiation of  naive T-cells into Th1- or Th17-
effector lymphocytes is controlled by monocyte-derived cytokines. However, 
this conclusion is also supported by our clustering analyses of  whole-blood 
stimulations (Figure 2B). An exception to these patterns was the fungal 
Cryptococcus-induced cytokine responses, in which the distinction between 
monocyte-derived- and T-cell-derived cytokines was weak. In addition, the 
Cryptococcus-induced cytokines were more similar to cytokine responses 
induced by influenza virus than to other fungi (Figure 2A).
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To assess whether cell-based factors are the only factor determining 
variation in cytokine responses, or whether plasma-derived factors can 
qualitatively modulate the responses, we correlated specific responses in 
purified PBMC vs whole-blood stimulations (Figure 2B). Unsupervised 
clustering demonstrated stronger correlations of  responses in the two 
stimulation systems, but we also found positive correlations between them 
(Figure 2B). These findings suggest that although intrinsic factors in the 
mononuclear cells mainly determine the cytokine response, additional 
variation in cytokine production may also be induced by other whole-blood 
components, such as neutrophils or plasma factors.
Figure 1. Study overview. We collected blood samples from 500 healthy individuals in the 
500FG cohort and isolated their DNA. This was hybridized on the HumanCoreExome 
SNP Chip to provide genotype information on approximately 8 million SNPs. The blood 
was also used to perform a series of  stimulation experiments with major human pathogens 
and to profile the cytokines released in the serum (see Methods). See also Figure S1-2.
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Contribution of genetic variation to how cytokines respond 
to pathogens
We observed that cytokines show higher inter-individual variation upon 
stimulation (Figure S2). Since a difference in cell count proportions can 
be an important factor influencing the amount of  cytokines produced, we 
tested whether cell count differences determine inter-individual variation 
in cytokine levels. For this, we obtained immune cell count data measured 
by fluorescence-activated cell sorting (FACS) for total lymphocytes, T-cells, 
B-cells, monocytes and NK-cells from all 500FG individuals (see Aguirre-
Gamboa et al., Cell Reports, in revision). We observed weak correlations 
between cell counts and cytokine levels (Figure S3A) suggesting a minor 
effect of  cell-count differences on cytokine production capacity. We then 
estimated the proportion of  cytokine variance explained by genome-wide 
SNPs for all cytokine measurements before and after correcting for age, 
gender and cell counts (Figure 3, Figure S3B and Table S1) using the 
GREML method (Yang et al., 2010).
 In total, for around 70% of  all the cytokine responses in PBMCs, the 
genetic influence was considerably larger than previously reported (>25% of  
explained variance) (Brodin et al., 2015). We found similar results when we 
estimated heritability without correcting age, gender and cell counts (Table 
S1). In general, we found a higher explained variance for monocyte-derived 
cytokines from genetic factors (>50% of  explained variance especially 
for IL-6 and IL1-β) than for T-cell-derived cytokines (Figure 3). Finding 
the strongest inter-individual variation in IL-6 levels upon stimulation, in 
addition to the highest heritability for IL-6 levels, indicates there may be 
many genome-wide significant QTLs for IL-6 in the context of  infectious 
pressure. In T-cell-derived cytokines, we found a higher explained variance 
for IL-17 from genetic factors. Although it may be expected that the 
cytokine production capacity is affected by genetic factors, we observed 
that the estimated explained variance due to genetic factors differed for the 
stimulation by the various microorganisms and for the individual cytokines 
studied. This finding indicates there are genetic variations that may be 
strongly regulating the cytokine production in response to certain pathogens.
Identifying genome-wide genetic variations affecting 
cytokine production in response to pathogens
To identify the most significant genetic loci that determine cytokine levels 
upon stimulation, we mapped cytokine production quantitative trait loci 
(cQTLs) using genome-wide SNP genotypes. After correcting for age, gender 
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and cell counts, we identified 18 genome-wide (p < 5×10-8) significant lead 
SNPs in 17 independent loci (Figures 4A and 4B). These include seven 
independent QTLs for IL-6, three independent QTLs for IL-1β, and three 
independent QTL for TNF-α levels (Table 1). Of  the 17 loci, all but one 
were identified for cytokines measured after PBMC stimulations, while one 
locus on chromosome 19 came from the whole-blood stimulation system 
(Table 1). We identified cQTLs for both monocyte- and T-cell-derived 
cytokines upon bacterial and fungal stimulations, whereas stimulation with 
purified TLR-ligands only yielded cQTLs for monocyte-derived cytokines 
(Figure S3B). The validity of  the 17 loci was further corroborated for the 12 
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Figure 2. The cytokine responses are organized around the physiological response 
towards specific pathogens. (A) The results from unsupervised hierarchical clustering of  
the cytokine responses in PBMCs induced by various pathogens and microbial ligands 
are shown. Clustering was performed using Spearman’s correlation as the measure of  
similarity. Red indicates a strong positive correlation, whereas blue indicates a strong 
negative correlation. Cluster 1 depicts the positive correlation between monocyte-
induced cytokines (IL-6, IL-1β and TNF-α) on stimulation of  PBMCs for 24 hours. 
Cluster 2 depicts the positive correlation among cytokines derived from T-helper cells 
(IL-17, IL-22 and IFN-γ) on stimulation of  PBMCs for 7 days. Cluster 3 depicts the 
strong correlation between influenza- and Cryptococcus-induced cytokines for both 
T-cell- and monocyte-derived cytokines. (B) The results from unsupervised hierarchical 
clustering of  the cytokine responses in blood were compared with responses in PBMCs. 
The stimulation-cytokine pairs that were available for both cell-systems were chosen 
to perform unsupervised hierarchical clustering. Four different clusters indicate the 
pathogen-specific clustering of  cytokines.
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cytokine-microbial stimulations that were performed in the 200FG cohort. 
Of  the cQTLs 9/12 (75%) were replicated (p < 0.05) and, in all cases, the 
effects were in the same direction (Table S2). We could not replicate five of  
the cQTLs, as these stimulus-cytokine measurements were not tested in the 
200FG cohort. No genome-wide significant cQTLs were identified for the 
macrophage production of  cytokines, which agrees with the conclusion that 
the process of  in vitro differentiation erases many of  the differences between 
individuals. This conclusion has important consequences as it suggests that 
in vitro differentiated cell systems (such as monocyte-derived macrophages 
or dendritic cells) may not be suitable for studying the genetics of  cytokine 
responses.
Prioritizing cQTL-affected genes indicates microbial-sensing 
and processing molecules as putative causal genes
We used three approaches to identify the causal genes at the 17 significant 
cQTL loci. Firstly, we tested whether the cQTLs were strongly correlated with 
other SNPs that alter the protein structure of  any genes. Using HaploReg SNP 
annotation tool (Ward and Kellis, 2012), we extracted all SNPs in linkage 
disequilibrium (LD) (R2 > 0.8; using CEU population as a reference) with 
the cQTLs. We found two loci that were in strong LD with missense 
variants (Table S3): SNPs rs28393318 and rs6834581 on chromosome 4 
were in strong LD (R2 = 0.97, D prime = 0.99) with a missense variant, 
rs4833095, on the TLR1 gene. SNP rs7256586 on chromosome 19 was in 
strong LD with a missense variant rs198977 (R2 = 0.82, D prime = 0.92) 
on the KLK2 gene. These observations suggest that TLR1 and KLK2 could 
be causal genes at these cQTL loci. The other 15 cQTLs and their proxies 
are all located in non-coding regions of  the genome, suggesting a possible 
regulatory function of  cQTL loci.
 As a second approach, we performed cis-eQTL mapping using RNA 
sequencing data and genotype data from 629 healthy-donor blood samples 
(LifeLines-Deep cohort) (Ricaño-Ponce et al., 2016; Tigchelaar et al., 2015) 
as well as eQTL results obtained from publicly available datasets provided 
by HaploReg (Ward and Kellis, 2012).
 As a third approach, we hypothesized that the genes that are differentially 
regulated in response to different microbial stimuli are the potential causal 
genes at our cQTL loci. To test this, we extracted all the genes, including 
the non-coding genes, located in a 500 kb cis-window of  the 17 cQTLs 
and tested their expression in PBMCs stimulated with different microbial 
antigens (Figure S3C). By combining these three approaches, we identified 
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21 putative causal genes in 12 of  the loci (Table 1). In the remaining 
five loci, the gene nearest to the cQTL SNP is shown. Intriguingly, the 
genes we identified by these three approaches were all regulatory genes 
modulating cytokine production, rather than eQTLs directly modulating the 
transcription of  cytokine genes and the production of  cytokines themselves. 
The identified genes were mainly involved in microbial sensing (TLR1, 
TLR6, TLR10, CSMD1, CD63, CR2 and CD55), processing molecules 
(SLC36A4, SLC37A2), endoplasmic reticulum organization, and cytokine 
signaling (IL1F10, IL1RN, STAM2).
TLR1-TLR6-TLR10 locus is associated with cytokine 
production capacity for diverse stimulations
The strongest association among the 17 cQTL loci was at the TLR1-
TLR6-TLR10 locus (Figures 5A and 5B) on chromosome 4, influencing 
Poly-IC induced IL-6 (p = 3.93×10-25) and IL-1β levels (p = 2.47×10-10) 
in PBMCs. This locus also showed significant association with Coxiella 
burnetii-induced IL-1β (p = 4.62×10-13) and TNF-β (p = 7.59×10-8) levels, 
and moderate association with 20 different cytokine levels (FDR corrected 
p < 0.05) in response to multiple other microbial stimulations (Figure 4B). 
This locus was also found to be under strong evolutionary selection (see 
below). Since we also had full transcriptomics data obtained by RNA-seq on 
PBMCs from 70 healthy individuals in the Lifelines-Deep cohort (Tigchelaar 
et al., 2015) stimulated with Candida albicans, we were able to construct co-
expression networks for the various alleles of  the TLR1-TLR6-TLR10 locus. 
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Figure 4. Genome-wide significant cytokine QTLs and their shared association. (A) 
A circular Manhattan plot showing the 17 independent genome-wide significant loci 
associated with different cytokine levels. The cytokine name, type of  stimuli, and the 
top SNP rs ID is given. Loci that affect fungal-induced cytokines are shown in pink; loci 
that affect bacterial-induced cytokines are in blue; loci that affect TLR-ligand-induced 
cytokines are in green. (B) The association results of  all 17 genome-wide significant 
cQTLs with all the available cytokine measurements are shown. The color legend 
indicates the range of  cQTL p values (shown as –log10p value) ranging from p < 0.01 to p 
< 5×10-23. Red indicates the minor allele associated with higher levels of  cytokines, while 
blue indicates the minor allele associated with lower levels of  cytokines. The x-axis shows 
all 17 genome-wide significant loci and the y-axis shows the cytokine-stimuli pairs. See 
also Figure S3 and Table S2-3.
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Our pathway analysis showed an interesting differential induction of  genes 
that are important for cytokine regulation and dependent on the cytokine-
inducing allele (rs6834581*C) or the alternative allele (rs6834581*T) 
(Figure S4). Many of  these differentially regulated genes have been shown 
to be important for cytokine regulation, for example, TREML4 encodes for 
a protein crucial for TLR7 signaling and antiviral defense (Ramirez-Ortiz 
et al., 2015), and SCGB3A1 encodes for the cytokine-like secretoglobin 
family 3A member 1 (or HIN-1), which plays an important role in lung 
inflammation (Yamada et al., 2009).
IL1F10-IL1RN locus is a shared QTL for Cryptococcus- and 
influenza-induced cytokines
We found a significant cQTL for TNF-α levels in response to Cryptococcus 
(Figures 5C and 5D) on chromosome 2 (P = 4.22×10-9). The same SNP 
(rs4496335) also has an effect on the expression of  genes in the IL-1F10-
IL1RN locus that encodes the IL-1 receptor antagonist. This locus also showed 
moderate association with IL-6 (3.38×10-6) and IL-1β levels (5.51×10-6) 
in response to Cryptococcus. IL-1Ra is a known natural antagonist of  the 
IL-1 receptor pathway, but it was not known whether this also influences 
Cryptococcus-induced cytokine production. In order to validate this finding, 
we performed a series of  experiments in which we show that pre-incubation 
of  PBMCs with IL-1Ra significantly inhibits the induction of  cytokines 
by Cryptococcus (Figure S5A). This is the only locus in our 17 cQTL loci 
that was also moderately associated with influenza-induced TNF-α, IL-1β 
and IL-6 levels (Figure 4A). Unsupervised clustering analysis of  cytokines 
(Figure 2A) showed much stronger similarities between influenza- and 
Cryptococcus-induced responses than between Cryptococcus and other 
fungi-induced responses, suggesting that these two pathogens activate similar 
inflammatory pathways. This association warrants further study.
CSMD1 and SLC36A4 loci specifically regulate T-cell-derived 
cytokines
We quantified three T-cell-derived cytokines (IL-22, IL-17 and IFN-γ) after 
stimulating PBMCs for 7 days with various stimuli. We found three genome-
wide significant loci for IFN-γ and two for IL-22 levels (Table 1). The strongest 
association in these five loci was at SLC36A4 locus on chromosome 
11 (Figures S5B-C) with Staphylococcus aureus-induced IL-22 levels 
(p = 2.42×10-9). SLC36A4 encodes for an amino acid transporter with a 
high affinity for glutamine, tryptophan and proline (Pillai and Meredith, 
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Figure 5. Regional association plots and boxplots for cytokine QTLs. Regional association 
plots at (A) the TLR10-TLR1-TLR6 locus associated with poly:IC-induced IL-6 levels, 
and (C) the IL1F10-IL1RN locus associated with Cryptococcus-induced TNF-α levels. The 
corresponding p-values (as –log10 values) of  all SNPs in the region were plotted against 
their chromosomal position. Estimated recombination rates are shown in blue to reflect 
the local LD structure (based on the CEU population) around the associated top SNP and 
its correlated proxies (with bright red indicating highly correlated, and pale red indicating 
weakly correlated). Boxplots (B) and (C) show the genotype-stratified cytokine levels for 
the TLR and IL1RN loci, respectively. See also Figure S4-5.
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Figure 6. Cytokine QTLs are enriched for human diseases. (A) A Q-Q plot showing 
the enrichment of  cytokine QTLs is under positive selection. The cytokine QTLs were 
intersected with loci under positive selection and tested for their inflation compared to 
a randomly selected set of  SNPs. (B) Impact of  genome-wide significant cytokine QTLs 
on human diseases. All 17 cQTL loci and their proxies (R2 > 0.8) were intersected with 
cell-type-specific enhancers from the ENCODE project. The x-axis depicts the –log10 
binomial uncorrected p-values; the y-axis shows the different cell types. The dotted gray 
line indicates the significance threshold after Bonferroni correction for the number of  
cell types tested. Different colors indicate the two sets of  background SNPs included for 
testing enrichment of  cQTLs located in any cell-type-specific enhancers. The percentages 
of  SNPs associated with (C) infectious disease, and (D) immune-mediated diseases that 
affect either monocyte-derived or T-cell-derived cytokines levels are shown. (E) The 
percentage of  disease-associated SNPs showing suggestive cytokine QTLs. GWAS SNPs 
and their proxies from each disease were compared to SNPs associated with “height”, a 
trait serving as a reference (null) set. P-values of  enrichment analysis from Fisher exact 
tests are shown by red asterisks (** p < 10-4; * p < 0.05).
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2011). Amino acid metabolism (especially tryptophan and glutamine) 
has been reported to modulate cytokine production (Bosco et al., 2000; 
Coëffier et al., 2001; Harden et al., 2015). We validated this pathway in 
our study by showing that blocking glutaminolysis with BPTES (bis-2-(5-
phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide) significantly inhibits 
S. aureus-induced IL-22 production (Figure S5D). The other cQTL for C. 
albicans-induced IL-22 levels was found on chromosome 8 (p = 2.42×10-9) on the 
CSMD1 gene. CSMD1 encodes a protein which functions as a complement 
inhibitor (Escudero-Esparza et al., 2013) and recent studies have shown 
that IL-22 and the complement pathway influence each other and synergize 
during host defense against pathogens (Yamamoto and Kemper, 2014). The 
importance of  the complement pathway for modulating cytokine production 
is underscored by the presence of  CR2 and CD55 among the genes whose 
genetic variation regulates cytokine production (Table 1).
 Finally, we tested whether the five independent T-cell cytokine QTLs were also 
associated with other cytokines. Although they were moderately associated with 
cytokines produced in response to other types of  stimuli (e.g. Mycobacterium 
tuberculosis, Cryptococcus, see Table 1), CSMD1 and SLC36A4 loci were 
specifically associated with IL-22 and IFN-γ production capacity.
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KLK2-KLK4 locus is significantly associated with IL-6 levels 
in whole blood stimulation
We quantified IL-6, IL-1β, TNF-α and IFN-γ after stimulating whole blood 
for 48 h with various stimuli. We identified one locus on chromosome 19 
as significantly associated (p = 8.50×10-9) with C. albicans-induced IL-6 
levels. This locus encodes for kallicrein-related peptidases 2 and 4 (KLK2 
and KLK4); the latter has been described as inducing IL-6 production 
through activation of  protease-activated receptor 1(PAR-1), a well-known 
immune-activated receptor (Wang et al., 2010). This locus is also moderately 
associated with both monocyte- and T-cell-derived cytokines in response to 
multiple microbial stimulations (Figure 4A).
cQTLs are enriched for regions under positive selection 
and monocyte-specific enhancers, and are associated with 
complex human diseases
Some of  the cQTL loci were common to several stimuli, but many were 
stimulus-specific (Figure 4B). This finding supports the conclusion that the 
cytokine response is evolutionarily built around the response to specific 
pathogens, a process most likely shaped by the selective evolutionary 
processes exerted by local infections in certain geographical locations. This 
is also supported by our observation that the cQTL genes are under strong 
selective pressure. We intersected our 17 cQTLs with the regions in the 
human genome catalogued as ‘loci under positive selection’ in 230 ancient 
Eurasian genomes (Mathieson et al., 2015). Our cQTLs were significantly 
enriched (Kolmogorov-Smirnov test, P value < 0.01) for ‘genes under 
positive selection’ in the Eurasian genomes (Figure 6A), including the well-
known TLR1-TLR6-TLR10 and LCT loci.
 The fact that the majority of  the cQTL loci were in linkage disequilibrium 
with SNPs in non-coding regions means they could have regulatory 
functions. We therefore intersected these 17 top cQTLs and their proxies (r2 
≤ 0.8) with the ENCODE-defined cell-type-specific enhancers. This showed 
a significant enrichment of  these cQTLs in monocyte-specific enhancers 
(Figure 6B), suggesting that many of  the cQTLs influence gene expression 
in monocytes and thereby alter cytokine production. We also tested whether 
the 17 cQTLs are associated with human diseases. We intersected the cQTLs 
with GWAS-SNPs known to influence susceptibility to various immune-
mediated diseases. Interestingly, SNPs that affect monocyte-derived 
cytokines are also enriched for SNPs associated to infectious diseases (Figure 
6C). In contrast, cQTLs that affect T-cell-derived cytokines are enriched 
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for SNPs associated with autoimmune diseases (Figure 6D). In addition, 
we identified a trend for association of  cQTLs with SNPs associated with 
other complex human phenotypes, such as blood-related traits and cancer 
(Figure 6E). These results suggest that proinflammatory cytokines have an 
important role as underlying mediators in many complex human diseases.
Discussion
In three complementary studies in this issue of  Cell, we report on the impact 
of  genetic (this study), environmental (ter Horst et al., 2016) and microbiome 
(Schirmer et al., 2016) factors on the cytokine production capacity in a 
large cohort of  healthy individuals of  Western European background. The 
present study is broad both at the genomic level (8 million SNPs), as well as 
at a functional level: we assessed three types of  cellular stimulations models 
(whole-blood, PBMCs, and monocyte-derived macrophages) challenged 
with a comprehensive panel of  bacterial, fungal, viral and non-microbial 
metabolic stimuli. The data presented here supports the hypothesis that 
genetic variation is one of  the main factors influencing cytokine responses, 
with variation of  several cytokines, especially the IL-1b/IL-6 pathway, being 
mainly regulated by genetic factors (Figure S6). In line with this, we identify 
17 new genome-wide significant loci that influence cytokine production and 
we provide genetic and functional validation for their biological importance. 
 The conclusion that there is a high genetic heritability of  cytokine 
production capacity in the context of  microbial stimulation is supported 
by a recent study showing a strong genetic component in the regulation 
of  multiple immune traits in twins (Roederer et al., 2015). The genes we 
identify as cytokine regulators can be grouped into two processes: (a) innate 
immune genes such as the pattern recognition receptors (e.g the TLR1/6/10 
cluster), and complement modulators; and (b) genes important for antigen 
processing in the endoplasmic reticulum. Among this last groups of  genes, 
one of  them (SLC36A4) is also an amino acid transporter, in particular for 
tryptophan, proline and glutamine (Pillai and Meredith, 2011), and we have 
here validated the role of  glutamine metabolism in the induction of  IL-22 
responses. 
 The identification of  cell-type-dependent cQTLs and their potential 
relevance for infectious and autoimmune diseases in humans is of  
considerable interest. Our results imply that monocyte-derived cQTLs are 
associated to a susceptibility to infections, while T-cell-derived cQTLs overlap 
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with loci associated to autoimmune diseases. This result has important 
implications as it provides a model to gain insight into the mechanistic 
basis of  disease associations in a cell-type-specific manner. This important 
finding is underpinned by another HFGP study by Aguirre-Gamboa et al, 
which describes cell-count QTLs that influence lymphocyte numbers being 
associated with susceptibility to autoimmune diseases (Aguirre-Gamboa et 
al, Cell Reports, in revision). We were also able to further dissect the impact 
of  the various cQTLs for different pathologies, and have, for example, 
gained important new insight into the preferential impact of  monocyte-
derived cQTLs for blood-related (hematological) diseases, while these are 
seen to be less strongly involved in autoimmune diseases or cancer.
 We also extracted additional important biological properties characterizing 
cytokine responses. Firstly, we observed a surprisingly small impact of  cell 
numbers on cytokine production capacity, even in the case of  whole blood 
stimulation, with only a few exceptions showing a moderate impact. This 
conclusion is supported by the results of  a previous study published by our 
group(Li et al., 2016) and demonstrates that the most important impact 
on cytokine secretion is determined by the intrinsic cellular characteristics. 
Secondly, we identified an important pattern in the architecture of  
cytokine responses: the production capacity of  various monocyte-derived 
or lymphocyte-derived cytokines correlated strongly when cells were 
stimulated with a specific pathogen, whereas the correlation was poor when 
comparing bacterial stimuli with fungal and viral stimuli. This makes sense 
from an evolutionary point of  view, as immune responses mainly need 
to have plasticity to respond to specific infectious pressures in any given 
geographic area (Netea et al., 2012) This conclusion is supported by the 
enrichment of  cQTL genes among the genes recently reported to be under 
selection in Eurasian populations (Mathieson et al., 2015). Finally, nearly 
all the cQTLs described here are trans-QTLs and they were significantly 
enriched in monocyte-specific enhancers. This suggests that many cQTLs 
influence the expression of  target genes in monocytes to alter cytokine 
production indirectly. 
 There are also a number of  limitations to the present study. It is possible 
that we may have underestimated the heritability of  cytokine responses 
by performing a SNP-based analysis. To address this aspect, it will be 
interesting in the future to assess the heritability of  cytokine responses 
using longitudinal data, as this will allow us to take other factors (such as 
seasonal variation) into account. Moreover, future twin-based studies could 
take the stimulation aspect into account when performing the heritability 
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estimation of  immune parameters. In addition, although this is the most 
comprehensive study on cytokine production in humans so far, the number 
of  cytokines measured is still relatively limited. We have chosen to study the 
most important proinflammatory cytokines produced by monocytes, Th1 
and Th17 cells: however, future studies should also include other classes of  
cytokines, such as anti-inflammatory cytokines, interferons or chemokines. 
 In conclusion, we present a comprehensive analysis of  how genetic 
variation affects cytokine production capacity in humans. Our study 
should be considered in the broader framework of  the Human Functional 
Genomics Project, in which environmental, non-genetic host factors and 
the microbiome have also been shown to influence immune responses (see 
accompanying studies by ter Horst et al and Schirmer et al in this issue). 
In a first study we show that age is an important factor, with a specific 
defect of  IFN-γ and IL-22 production in the elderly (ter Horst et al., 2016): 
future studies in a population of  elderly individuals should assess whether 
the genetic factors identified here also play a role in this process. Similarly, 
gender and seasonality also influence immune responses. In addition, 
the accompanying study by Schirmer et al demonstrates the impact of  
microbiome variability on cytokine responses. Although it is important to 
note that the microbiome has an important role, it does seem to have a 
smaller impact on cytokine production than host genetic factors: while we 
observe here a 25% to 75% genetic heritability for most of  the cytokines 
mentioned, the microbiome variation explains up to 10% of  the cytokine 
production capacity (Schirmer et al., 2016).
 However, the genomic variation may act either directly, or indirectly through 
impacting on other factors, e.g. the microbiome. In this respect, recent studies 
have reported host genetic factors that influence the microbiome (Bonder et 
al., 2016; Davenport et al., 2015; Goodrich et al., 2016; Knights et al., 2014): 
future studies in the Human Functional Genomics Project plan to integrate 
the complex patient-related and omics databases into comprehensive models 
to explain cytokine production and other complex immune traits. These 
complementary studies will be important in understanding the influences on 
human cytokine responses and their variation, and can be used to pinpoint 
factors that can be modified and targeted for the personalized treatment 
of  immune-mediated diseases. Finally, the HFGP in general, and these 
three studies reported in this issue of  Cell in particular, offer an important 
methodology beyond the analyses of  cytokine responses, because they 
provide a framework for future functional genomics studies looking to assess 
immune and non-immune biological processes.
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Figure S1. Related to Figure 1. Increased levels of  cytokines upon stimulation
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Figure S2! Log(2) cytokine levels!
Figure S2. Related to Figure 1. Increased inter-individual variation upon stimulation
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Figure S3. Related to Figure 4. (A) Correlation between PBMC-derived cytokines and cell 
counts; (B) Summary of  all genome-wide significant cytokine QTLs; (C) Prioritized causal 
genes by differential expression analysis for genome-wide significant cytokine QTLs.
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Figure S4. Related to Figure 5. TLR1-6-10 locus genotype stratified gene regulation upon 
Candida stimulation.
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Figure S5. Related to Figure 5. (A) Validation of  Cryptococcus induced cytokine TNFα 
production; (B) Regional plot of  the association of  SLC36A4 locus with S. aureus induced 
IL-22 levels in PBMCs; (C) Boxplot of  S. aureus induced IL-22 levels in PBMCs at 
SLC36A4 locus. (D) Validation of  S. aureus induced cytokine IL22 production 
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Figure S6. Related to Figure 3. Proportion of  explained variance of  cytokine levels by 
genetics: across all the measurements
Figure S7. Related to the STAR Method section. Multidimensional scale analysis of  
genotype data from 500FG cohort.
Figure S7!
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https://www.sciencedirect.com/science/article/pii/
S0092867416314003?via%3Dihub#app2
STAR Method
Methods and resources 
Contact for reagent and resource sharing
Request should be directed and will be fulfilled by lead author Y.L. (y.li01@
umcg.nl). 
Experimental model and subject details
Ethics statement
The HFGP study was approved by the Ethical Committee of  Radboud 
University Nijmegen, the Netherlands (no. 42561.091.12). Experiments 
were conducted according to the principles expressed in the Declaration of  
Helsinki. Samples of  venous blood were drawn after informed consent was 
obtained.
Population cohorts
The study was performed in two independent cohorts of  ~500 and ~200 
healthy individuals of  Western European ancestry from the Human 
Functional Genomics Project (500FG and 200FG cohorts, see www.
humanfunctionalgenomics.org). The 500FG cohort comprises 534 adults 
from Nijmegen, the Netherlands (237 males and 296 females, age range 
18–75 years). The 200FG cohort comprises Individuals from the ‘Geldersch 
Landschap’, ‘Hoge Veluwe’, ‘Twickel’, and ‘Kroondomein het Loo’ in the 
Netherlands (77% males and 23% females, age range 23-73 years old).
Stimuli
Bacteria. Bacteroides fragilis (NCTC 10584) grown anaerobically overnight 
at 37°C on blood agar plates (BD Biosciences, Franklin Lakes, NJ, USA) 
was inoculated in 20 mL pre-warmed and pre-reduced Brain Heart Infusion 
broth (BD Diagnostics, Basel, Switzerland) and again grown anaerobically 
overnight at 37°C until reaching a stationary growth phase mimicking 
growth conditions in abscesses. Bacterial suspensions were washed three 
times in phosphate-buffered saline (PBS; B. Braun Medical B.V., Melsungen, 
Germany) and heat-killed at 95°C for 30 min. Before heat-killing, aliquots 
of  bacterial suspensions were taken to determine colony-forming unit (CFU) 
counts. Heat-killed bacteria were washed again and after adjusting the 
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concentration in PBS to 1×108 CFU/mL, stored at –80°C. B. fragilis was 
used in the stimulation experiments as 1×106/mL.
 E. coli ATCC 25922 was grown overnight in culture medium, washed 
three times with PBS, and heat-killed for 60 min at 80°C. Staphylococcus 
aureus strain ATCC 29213 was grown overnight in culture medium, washed 
twice with cold PBS, and heat-killed for 30 min at 100°C; both E. coli and 
S. aureus were used in a final concentration of  1×106/mL. Success of  heat-
inactivation was confirmed by cultures.
 LPS (E. coli serotype 055:B5), a TLR4 ligand, was purchased from Sigma-
Aldrich (St. Louis, MO, USA) and an extra purification step was performed 
as described previously (Hirschfeld et al., 2000). Purified LPS was tested in 
TLR4−/− mice for the presence of  contaminants and did not show any TLR4-
independent activity. CpG (ODN M362) was purchased from InvivoGen (San 
Diego, CA, USA) and used at a final concentration of  10 mg/mL.
 Cultures of  H37Rv Mycobacterium tuberculosis (MTB) were grown to 
mid-log phase in Middlebrook 7H9 liquid medium (Difco, Becton-Dickinson, 
East-Rutherford, NJ, USA) supplemented with oleic acid/albumin/
dextrose/catalase (OADC) (BBL, Becton-Dickinson), washed three times 
in sterile saline solution, heat-killed and then disrupted using a bead beater, 
after which the concentration was measured using a bicinchoninic acid 
(BCA) assay (Pierce, Thermo Scientific, Rockville, MD, USA).
 C. burnetii Nine Mile RSA493 (NM) phase I (a gift from the Bundeswehr 
Institute for Microbiology, Munich, Germany) was cultured on buffalo green 
monkey cells, and the numbers of  Coxiella DNA copies were determined 
using TaqMan real-time polymerase chain reaction as described (Roest et 
al., 2012). Lipopolysaccharide (LPS) phase determination was performed 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis and silver 
staining, using purified phase I (RSA493) and phase II (RSA439) C. burnetii 
NM LPS (kindly provided by R. Toman) as controls (Hitchcock and Brown, 
1983; Schramek and Galanos, 1981). C. burnetii was inactivated by heating 
for 30 mins at 99°C.
 B. burgdorferi, ATCC strain 35210, was cultured at 33°C in Barbour-
Stoenner-Kelley (BSK)-H medium (Sigma-Aldrich) supplemented with 6% 
rabbit serum. Spirochetes were grown to late-logarithmic phase and examined 
for motility by dark-field microscopy. Organisms were counted using a 
Petroff-Hauser counting chamber. Bacteria were harvested by centrifugation 
of  the culture at 3000 g for 30 mins, washed twice with sterile PBS (pH 7.4), 
and diluted in the specified medium to the required concentrations of  1×106 
spirochetes per mL. The serum-resistant Salmonella typhimurium strain 
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(phage type 510) was grown at 37°C for 12 h in nutrient broth (BHI Oxoid, 
Nepean, Canada). Bacteria were collected and centrifuged and then washed 
three times in PBS. Aliquots were stored at –20°C throughout the study.
 Fungi. Heat-killed C. albicans blastoconidia (strain ATCC MYA-3573, UC 
820) in a concentration of  106 CFU/mL were used throughout this study. A 
clinical isolate of  Aspergillus fumigatus V05-27 was used for stimulations. 
Isolates were grown on YAG agar plates for 3 days at 37°C. Fungal spores 
in the presence of  sterile 0.1% Tween 20 in PBS were harvested by gentle 
shaking, washed twice with PBS, filtered through a 40-mm pore size cell 
strainer (Falcon, Vienna, VA, USA) to separate conidia from contaminating 
mycelium. They were then counted by a hemacytometer, suspended at a 
concentration of  108 spores/mL and heat-killed. A final concentration of  
1×107/mL was used in the experiments. A clinical isolate of  Cryptococcus 
gattii (A1M-R265, AFLP type 6) was freshly grown on Sabouraud dextrose 
agar plates. Afterwards a suspension in PBS was heat-killed at 56°C for 24 
h and then quantified at a wavelength of  530 nm on a spectrophotometer. 
Killing efficiency as well as bacterial and fungal contamination was checked 
using Sabouraud dextrose and blood agar plates, respectively. Aliquots were 
stored at –20°C throughout the study.
 Influenza virus culture and inactivation. Influenza virus strain pH1N1 
A/Netherlands/602/09 (kindly provided by Prof. Ron Fouchier, Erasmus 
MC, Rotterdam, the Netherlands) was grown in the allantoic fluid of  
embryonated chicken eggs. Viral titers were determined by three independent 
plaque assays performed on Madin-Darby canine kidney (MDCK) cells. To 
inactivate the pH1N1 strain, β-propiolactone (BPL) (Acros Organics, Morris 
Plans, NJ, USA) in citrate buffer (125 mM sodium citrate, 150 mM sodium 
chloride, pH 8.2) was added to the pH1N1 virus to a final concentration 
of  0.1% and incubated for 24 h at 4°C under continuous slow shaking. 
Inactivated virus was subsequently snap-frozen and stored at –80°C. Virus 
inactivation was confirmed by three passages in MDCKs where no virus 
could be detected by plaque assay following the third passage.
 TLR ligands and non-microbial stimuli. Pam3Cys, a TLR1/2 ligand, 
was purchased at EMC microcollections (L-2000) and used in a final 
concentration of  10 µg/mL.
 PolyI:C, a TLR3 ligand, was purchased from InvivoGen and used at a 
final concentration of  100 mg/mL. PHA was purchased from Sigma and 
used at a final concentration of  10 mg/mL. Palmitic acid was purchased 
from Sigma-Aldrich. Human albumin (Albuman) was purchased from 
Sanquin (Amsterdam, the Netherlands). Stock palmitic acid was dissolved 
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in 100% ethanol. Palmitic acid (C16.0) and human albumin were conjugated 
by warming to 37°C in a water bath before adding together in a 1:5 ratio. 
The mixture was sonicated for 20–25 min and kept at 37°C until use. The 
vehicle control for 50µM C16.0 consisted of  0.025% albumin and 0.025% 
ethanol. MSU crystals were formed by dissolving 1.0 g of  uric acid and 
0.48 g sodium hydroxide in 400 mL of  sterile water. The pH was adjusted 
to 7.2 and the solution was sterilized by heating it for 6 h at 120°C. No LPS 
contamination was detected by Limulus amoebocyte lysate assay.
Method details
PBMC collection and stimulation experiments
After obtaining informed consent, venous blood was drawn from the cubital 
vein of  volunteers into 10 mL EDTA Monoject tubes (Medtronic, Dublin, 
Ireland). The PBMC fraction was obtained by density centrifugation of  
EDTA blood diluted 1:1 in pyrogen-free saline over Ficoll-Paque (Pharmacia 
Biotech, Uppsala, Sweden). Cells were washed twice in saline and suspended 
in medium (RPMI 1640) supplemented with gentamicin (10 mg/mL), 
L-glutamine (10 mM) and pyruvate (10 mM). Addition of  antibiotics such as 
gentamycin is a standard method used to avoid contamination of  cultures, and 
it does not influence the ability to induce cytokine production by PBMCs or 
macrophages (data not shown). The cells were counted in a Coulter counter 
(Beckman Coulter, Pasadena, CA, USA) and the number was adjusted to 
5×106 cells/mL. A total of  5×105 PBMCs in a total volume of  200 µL per 
well were incubated at 37°C in round-bottom 96-well plates with the different 
stimuli, as indicated above. After 24 h (for early cytokines IL-1β, TNF-β, IL-6, 
IL-8, and IL-10), or 7 days of  incubation (for IFN-γ and IL-17), supernatants 
were collected and stored at –20°C until assayed. The stimulation periods were 
chosen based on extensive studies that showed that 24 h stimulation was best 
suited for assessing monocyte-derived cytokines. When cells were cultured for 
7 days, this was done in the presence of  10% human pooled serum.
For validation experiments, PBMCs were incubated with recombinant IL-
1Ra (R&D Systems, Minneapolis, MN, USA) 10 mg/ml, 30 mins before 
stimulation with C. neoformans. The cytokine production capacity in 
the absence or presence of  IL-1Ra was measured in the supernatants as 
described above.
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Macrophage differentiation and stimulation
We cultured > 5×105 monocytes in flat-bottom plates with 10% human 
serum at 37°C and 5%CO2 for 6 days. After differentiation, the medium 
was removed and the differentiated macrophages were stimulated for 24 h. 
Supernatants were collected and stored in –20°C until used for ELISA.
Whole-blood stimulation experiments
100 ml of  heparin blood was added to a 48-well plate and then stimulated 
with 400 ml stimulus (final volume 500 ml) for 48 h at 37°C and 5%CO2. 
Supernatants were collected and stored in –20°C until used for ELISA.
Cytokine measurements
Concentrations of  human IL-1β, IL-6, IL-10, TNF-α, IL-17, or IFN-γ were 
determined using specific commercial ELISA kits (PeliKine Compact, 
Amsterdam, the Netherlands, or R&D Systems), in accordance with 
the manufacturer’s instructions. Detection limits were 31 pg/mL (IL-6 
(macrophages), 39 pg/mL (IL-1b and  IFN-γ), 156 pg/mL (IL-6 (whole 
blood), IL-22) or 78 pg/mL (TNF-α and IL-17).
Cytokine clustering and variance analysis
Raw cytokine levels were first log-transformed, and cytokine measurements 
showing little/no variation across individuals were filtered out for the 
follow-up analysis. We excluded 17 stimulation-cytokine measurements that 
did not pass our quality control. Unsupervised hierarchical clustering was 
performed using Spearman’s correlation as the measure of  similarity. We 
used Levene’s test to check the equality of  variance of  cytokine levels before 
and after stimulation.
Genotyping, quality control and imputation
DNA samples of  500 individuals were genotyped using the commercially 
available SNP chip, Illumina HumanOmniExpressExome-8 v1.0. The 
genotype calling was performed using Opticall 0.7.0 (Shah et al., 2012) 
using default settings. Samples with a call rate ≤ 0.99 were excluded from 
the dataset, as were variants with a Hardy-Weinburg equilibrium (HWE) 
≤ 0.0001, call rate ≤ 0.99 and minor allele frequency (MAF) ≤ 0.001. We 
identified 17 ethnic outliers by merging multi-dimensional scaling plots of  
samples with 1000 Genomes data and these were excluded from further 
analysis (Figure S7). This resulted in a dataset of  483 samples containing 
genotype information on 518,980 variants for further imputation. The 
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strands and variant-identifiers were aligned to the reference Genome of  
The Netherlands (GoNL, Genome of  the Netherlands Consortium, 2014) 
dataset using Genotype Harmonizer (Deelen et al., 2014a). The data was 
phased using SHAPEIT2 v2 (Delaneau et al., 2013) using GoNL as a 
reference panel. Finally, this data was imputed using IMPUTE2 (Howie 
et al., 2011) with GoNL as the reference panel (Deelen et al., 2014b). We 
selected SNPs that showed an INFO score ≥ 0.8 upon imputation for further 
cytokine QTL mapping.
Cytokine QTL mapping
Both genotype and cytokine data could be generated for a total of  442 
individuals. We obtained cell count data measured by FACS for total 
lymphocytes, T-cells, B-cells, monocytes and NK-cells from 487 individuals 
from the 500FG cohort. In total, there were 409 samples with genotype, 
cytokine and cell-count data. We excluded 17 samples due to genetic 
differences. We coded gender information either 0 for females or 1 for 
males. The actual age, gender and cell-count information were included 
as covariables in the linear model to correct the cytokine distributions for 
QTL mapping. Raw cytokine levels were first log-transformed then mapped 
to genotype data using a linear regression model with age and gender as 
covariates. Since the stimulation-cytokine combinations cannot be regarded 
as completely independent (we observed strong correlations in the cytokine 
clustering analysis we performed), the total number of  independent tests 
among all phenotypes will be much less than the number of  phenotypes 
measured, and therefore correcting for the number of  SNPs tested for each 
trait should be sufficient. We considered a p-value of  < 5×10-8 to be the 
threshold for significant cytokine QTLs.
Cytokine heritability estimation
Using the GCTA tool (Yang et al., 2010), we fitted a linear mixed model 
to each of  the 112 cytokine phenotypes and used restricted maximum 
likelihood to estimate the variance explained by the approximately 8 
million SNPs. Following our method for cQTL mapping, we also included 
age, gender and cell counts as covariates for estimating the proportions of  
phenotypic variance explained by the SNPs. It should be noted that the 95% 
confidence intervals for the heritability estimate are wide due to the sample 
size (N < 1000) in this study (Zaitlen and Kraft, 2012).
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Expression QTL analysis to prioritize causal genes
RNA sequencing of  629 peripheral blood samples from the LifeLines-Deep 
cohort (Tigchelaar et al., 2015) were investigated to map cis-eQTLs. The 
eQTL mapping strategy and data have been described in detail (Ricaño-
Ponce et al., 2016). Briefly, cis-eQTL analysis was performed on transcript-
SNP combinations for which the distance from the center of  the transcript 
to the genomic location of  the SNP was ≤ 500 kb. Associations were tested 
by non-parametric Spearman’s rank correlation test and a p value < 0.05 
was considered significant. We also employed HaploReg database v4.1 
(Ward and Kellis, 2012) (www.broadinstitute.org/mammals/haploreg/
haploreg.php) to extract publicly available eQTL results from blood tissue 
for cytokine QTL SNPs.
Genotype-dependent gene expression analysis at rs6834581
The PBMCs from 70 individuals in the Lifelines-Deep cohort (Tigchelaar et al., 
2015) were stimulated with or without Candida albicans as previously described 
( Smeekens et al., 2013; Kumar et al., 2014b). The RNA sequencing analysis 
of  this dataset has been described by previously (Li et al., 2016). There were 
7 CC, 25 CT and 38 TT individuals carrying these genotypes at rs6834581. 
We combined CC and CT in one group and compared the median expression-
fold changes of  genome-wide transcripts between two genotype groups 
(CC+CT vs. TT). We focused on the absolute fold changes between these 
two groups and show the expression levels of  the top 30 genes in Figure S4.
 Candidate genes located within a cis-window of  approximately 500 kb of  
all significant cytokine QTL loci were further tested to see if  they responded to 
any of  the pathogens using RNA-seq data from PBMCs of  eight individuals, 
which were stimulated by Pseudomonas aeruginosa, Streptococcus pneumoniae, 
Mycobacterium tuberculosis, Candida albicans, Aspergillus fumigatus, and IL-1a 
( Li et al., 2016).
Intersection of ENCODE enhancers and regions under 
positive selection
To perform enhancer enrichment analysis on cytokine QTL SNPs, we extracted 
all proxies for the 17 cQTLs (R2 ≥ 0.8; CEU population as a reference) to 
have 186 variants. We then intersected these variants with enhancer data of  
127 different cell lines available in HaploReg tool v4.1 (www.broadinstitute.
org/mammals/haploreg/haploreg.php). HaploReg calculates a background 
frequency of  enhancer overlap in each cell type using two background sets of  
SNPs. It compares the data with all independent GWAS loci associated in the 
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European population, and with a second set of  background SNPs consisting 
of  all 1000 Genomes variants with a frequency >5%. Initial enrichment of  
enhancers is calculated using the Binomial test and we applied the Bonferroni 
correction for multiple testing to define significance levels (0.05/127 cell lines).
Extraction of infectious disease associated SNPs
SNPs associated with a number of  infectious diseases that showed a p value 
< 9.99×10-6 were extracted using the GWAS catalogue (http:/www.genome.
gov/gwasstudies). As of  December 2014, there were two studies on leprosy, 
two studies on malaria, four studies on tuberculosis, four studies on chronic 
hepatitis C infection, one study on HPV seropositivity, one study on Dengue 
shock syndrome, and one study on meningococcal susceptibility. From 
a systematic search of  the literature, we extracted SNPs associated with 
susceptibility to other infectious diseases but not reported in the GWAS 
catalogue. We found three studies on invasive aspergillosis and two studies 
on pneumococcal disease (see the list published in Li et al. (2016).
GWAS SNP extraction and enrichment analysis
GWAS SNPs from the GWAS catalogue and their proxies (r2 ≥ 0.8 from a 500 
kb window) were first extracted, which provided a list of  SNPs associated 
to 122 different human traits and diseases. We selected diseases/traits for 
which at least 10 independent SNPs were reported to be associated. We then 
binned these GWAS SNPs into eight categories based on their association 
to closely related human phenotypes (cancer, immune-mediated diseases, 
infectious disease, heart-related traits, blood-related traits, metabolic traits, 
height, and Type 2 diabetes-related traits). Duplicated SNPs were removed 
from further analysis. We then intersected the SNPs of  each category with 
cQTLs that showed p < 0.05 in our study. The Fisher exact test was applied 
to test the over-representation of  cQTL SNPs in infectious disease SNPs 
using the height-associated SNPs as reference.
Enrichment for positive selection
The cytokine QTLs at different thresholds (1×10-7, 1×10-6, 1×10-5, 1×10-4) 
were intersected with loci under positive selection (Mathieson et al., 2015). 
The distribution of  positive selection p values on cQTL SNPs were compared 
with a randomly selected set of  non-significant cQTL SNPs ( p > 0.01) by 
using Kolmogorov–Smirnov test.
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Quantification and statistical analysis
Statistical analyses were performed in R. Unsupervised hierarchical 
clustering was performed using Spearman’s correlation as the measure of  
similarity. The Levene’s test to check the equality of  variance of  cytokine 
levels before and after stimulation. R-package Matrix-eQTL, was used for 
cytokine QTL mapping, where linear model was applied with age, gender 
and cell-count information included as covariables. The Fisher exact test 
was applied to test the over-representation of  cQTL SNPs in infectious 
disease SNPs using the height-associated SNPs as reference.
Data and software availability
Online database
All data used in this project have been meticulously catalogued and archived 
in the BBMRI-NL data infrastructure (https://bbmri.nl/molgenis/500FG) 
using the MOLGENIS open source platform for scientific data (Swertz 
et al., 2010). This allows flexible data querying and download, including 
sufficiently rich metadata and interfaces for machine processing (R statistics, 
REST API) and using FAIR principles to optimize Findability, Accessibility, 
Interoperability and Reusability (Wilkinson et al., 2016).
Acknowledgements
We thank all volunteers in the 500FG and 200FG cohorts of  the Human 
Functional Genomics Project for their participation. We thank Kate 
McIntyre and Jackie Senior for editing the text. The HFGP is supported by 
an ERC Consolidator Grant (3310372), an IN-CONTROL CVON grant, 
and a Spinoza Prize (NWO SPI 94-212) to MGN; an ERC Advanced Grant 
(FP/2007-2013/ERC grant 2012-322698) and a Spinoza Prize (NWO SPI 
92-266) to CW; a Dutch Digestive Diseases Foundation grant (MLDS WO11-
30) to CW and VK; an European Union’s Seventh Framework Programme 
grant (EU FP7) TANDEM project (HEALTH-F3-2012-305279) to CW and 
VK, and a Netherlands Organization for Scientific Research (NWO) VENI 
grant (863.13.011) to YL. The creation and hosting of  the online database 
has been supported by BBMRI-NL, a research infrastructure financed 
by the Netherlands Organization for Scientific Research (NWO), grant 
number 184.021.007. We thank Edith Adriaanse, Marije van der Geest, and 
Marieke Bijlsma for structuring the data into the online database, and the 
96
MOLGENIS open source team (Dennis Hendriksen, Erwin Winder†, Bart 
Charbon, Fleur Kelpin, Jonathan Jetten, Mark de Haan, Tommy de Boer, 
David van Enckevort, Chao Pang, and Joeri van der Velde) for designing 
and implementing the database software.
Author contributions
M.G.N. and C.W. coordinated the recruitment of  cohorts and data 
generation. M.G.N., V.K., L.A.B.J. and C.W. conceived and directed the 
study with input from all authors. Y.L. analysed and interpreted the data. 
M.O., S.S. and M.J. conducted the stimulation experiments and cytokine 
quantification. R.A.G., K.T.T.L., P.D., I.R.-P., and V.K. performed 
genotyping and imputation. R.A.G. performed the analysis of  variance 
explained by genetics. T.S, A.F.M.J., E.V., M.D., F.V., and J.W.M.M. 
assisted the lab experiments. M.A.S., S.W., R.J.X., A.Z., and L.F. provided 
the computational framework for the study and critical inputs to the study 
design. M.G.N., V.K., C.W., Y.L., M.O., S.S. and M.J. wrote the manuscript 
with input from all authors.
97
3
98
99
4
Host and environmental factors 
influencing individual human 
cytokine responses
Cell 2016 
Chapter 4
Martin Jaeger
Rob ter Horst
Sanne P Smeekens
Marije Oosting
Morris A Swertz
Yang Li
Vinod Kumar
Dimitri A Diavatopoulos
Anne FM Jansen
Heidi Lemmers
Helga Toenhake-Dijkstra
Antonius E van Herwaarden
Matthijs Janssen
Renate G van der Molen
Irma Joosten
Fred CGJ Sweep
Jan W Smit
Romana T Netea-Maier
Mieke MJF Koenders
Ramnik J Xavier
Jos WM van der Meer
Charles A Dinarello
Norman Pavelka
Cisca Wijmenga
Richard A Notebaart
Leo AB Joosten
Mihai G Netea
100
Summary
Differences in susceptibility to immune-mediated diseases are determined 
by variability in immune responses. In three studies within the Human 
Functional Genomics Project we assessed the effect of  environmental and 
non-genetic host factors, of  the genetic make-up of  the host, and of  the 
intestinal microbiome, on the cytokine responses in humans. We analyzed 
the association of  these factors with circulating mediators and with six 
cytokines after stimulation with 19 bacterial, fungal, viral and non-microbial 
metabolic stimuli in 534 healthy subjects. In this first study we show a 
strong impact of  non-genetic host factors (e.g. age and gender) on cytokine 
production and circulating mediators. Additionally, annual seasonality 
is found to be an important environmental factor influencing cytokine 
production. Alpha-1-antitrypsin concentrations are shown to partially 
mediate the seasonality of  cytokine responses, whereas the effect of  vitamin 
D levels is limited. Data are provided at https://bbmri.nl/molgenis/500FG 
as a comprehensive resource for future studies.
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Introduction
Host defense mechanisms mediated by the immune system protect the 
host from the invading pathogens that continuously attempt to breach the 
mucosal and skin barriers. Individuals with diminished immune responses 
from inborn or acquired causes have an increased susceptibility to infections 
(Blot et al., 2002; Clark and Hajjeh, 2002; Fishman, 2007; Fishman and 
Rubin, 1998; McNeil et al., 2001). Conversely, individuals with an overactive 
immune system are more susceptible to autoimmune diseases such as 
rheumatoid arthritis, type 1 diabetes and multiple sclerosis, and inflammatory 
diseases such as gout, Crohn’s disease, and atherosclerosis (Gandhi et 
al., 2010; Martinon, 2010; Szablewski, 2014). Variability in the immune 
responses also influences susceptibility to other important pathologies 
such as malignant processes (de Visser et al., 2006) and neurodegenerative 
diseases like Parkinson’s disease and Alzheimer disease (Heneka et al., 
2015; Mosley et al., 2012). This variability in immune responses is likely 
affected by factors already known to influence disease prevalence such as 
age, gender and seasonality. For instance, women are more likely to suffer 
from autoimmune diseases, it gets more difficult to fight off  infections with 
age, and influenza infections peak in winter. However, the differences in 
susceptibility to immune-mediated diseases between individuals cannot be 
fully accounted for by what is currently known, and a systems biology-based 
approach to comprehensively asses the environmental and host-related 
factors that influence immune responses is needed. 
 Production and release of  proinflammatory cytokines is one of  the 
most important components of  host defense mechanisms, representing the 
communication network within the immune system. So far, variation of  
cytokine production capacity in the general population has been investigated 
only in small studies, and this limitation resulted in conflicting conclusions 
(Aulock et al., 2006; Bernstein and Murasko, 1998; Grandgirard et al., 
2013; Hwang et al., 2015; Nielsen et al., 2013; Scott et al., 2013). The only 
large scale studies of  the immune system published to date are genome-wide 
studies focussed on the regulatory effect of  genetic variation on cytokine 
gene transcription levels (eQTLs) rather than on protein expression levels 
(Berry et al., 2010; Fairfax et al., 2014; Lee et al., 2014; Raj et al., 2014; Ye 
et al., 2014). These studies were based on a limited number of  stimulations 
or used unstimulated cells. The few studies assessing variability of  cytokine 
production are all based on responses to standard immune stimuli such 
as lipopolysaccharide (LPS) (Fairfax et al., 2014; Lee et al., 2014). A 
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comprehensive assessment of  environmental and host factors influencing 
cytokine responses to a wide range of  pathological and physiological stimuli 
is still lacking. 
 The Human Functional Genomics Project (HFGP; www.humanfunction 
algenomics.org) aims to fill this gap. Within HFGP, the first major study 
that intends to assess the variability of  human cytokine responses is the 
500 Functional Genomics (500FG) study, comprising of  a group of  
approximately 500 healthy volunteers of  Western-European ancestry. 
The specific aim of  500FG cohort is to assess and integrate the various 
factors influencing individual human cytokine responses. The 500FG 
study has two important advantages compared to previous studies: firstly, 
it comprises the largest cohort of  healthy individuals studied to date, and 
secondly, the cytokine production was assessed in response to a large panel 
of  microbial and metabolic stimuli and in three different cellular systems. 
The current manuscript is the first in a series of  three studies presented in 
this issue of  Cell, that aim to provide a systematic assessment of  the impact 
of  various intrinsic and environmental factors (this manuscript), the host 
genome (Li et al., 2016), and the gut microbiome (Schirmer et al., 2016), on 
baseline immune status and cytokine production in a systems biology-based 
approach. A schematic overview of  these three studies on the 500FG cohort 
is presented in Figure 1. 
 In this first study we focus on environmental and non-genetic host factors 
that have been described to influence the immune response and/or disease 
prevalence (e.g. age, gender, BMI, oral contraceptive usage, smoking, 
vitamin D and seasonality), but for which a comprehensive assessment of  
their effect on cytokine responses is missing. We observe that several of  
the studied factors directly influence immune parameters and host defense 
and we describe a novel vitamin D-independent/alpha-1-antitrypsin (AAT)-
dependent effect of  seasonality on inflammation.
Results
Measurement of circulating immune parameters
To study variation in baseline immune status, we measured circulating 
concentrations of  some of  the most important families of  parameters 
responsible for host defense in the circulation: acute phase proteins (CRP 
and AAT), immunoglobulins (IgA, IgM, IgG and 4 IgG+ sub-classes), 
adipokines (leptin, adiponectin, and resistin), IL-6, IL-18, IL-18-binding 
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Figure 1. Schematic overview of  the three studies on the 500FG cohort. The cohort 
consists of  534 volunteers with varying characteristics. The current manuscript is the 
first in a series of  three studies presented in this issue of  Cell, that aim to provide a 
systematic assessment of  the impact of  various intrinsic and environmental factors (this 
manuscript), the host genome (Li et al., 2016), and the gut microbiome (Schirmer et al., 
2016), on cytokine production and baseline immune parameters in a systems biology-
based approach. See also Table S1, S2 and Figure S1.
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protein (IL-18BP), IL-1β, and interleukin-1 receptor antagonist (IL-1Ra). 
Measurement of  resting levels of  low abundance cytokines such as IL-
1β, IL-6, IL-18 and VEGF are below the lower limit of  quantification by 
standard ELISAs in a healthy cohort; therefore, the Ella™ microfluidic 
analyzer was used to assess cytokine concentrations in the fg/ml to low 
pg/ml range. For instance, the mean level of  IL-6 concentrations of  the 
cohort was 1.25±0.06 pg/ml (range 0.15-8.1 pg/ml; see Methods for levels 
of  all circulating mediators). The assessment of  these parameters provides 
a comprehensive view of  baseline immune characteristics, most importantly 
of  inflammatory status and humoral immunity.
 The immune parameters were analyzed as a function of  a set of  
environmental and intrinsic non-genetic host factors (age, gender, BMI, oral 
contraceptive usage, smoking, vitamin D concentrations and seasonality) 
(Figure 2). 
Correlations between circulating cytokine concentrations 
indicate co-regulation
As displayed in Figure 3A,B and Figure S2E, some cytokine levels show 
positive correlations with other cytokine levels. IL-1β concentrations show a 
strong correlation with IL-6 (p<0.0001), a particularly relevant observation 
since treatment of  patients with IL-1β blocking therapies reveals a consistent 
fall in circulating IL-6 levels (Dinarello et al., 2012). IL-1Ra and IL-6 
concentrations also correlate significantly, since these are both markers of  
inflammation (Figure 3B). IL-1β circulating concentrations also correlated 
with IL-1Ra (p<0.05), and this is in agreement with in vitro and human trial 
data demonstrating that IL-1β induces its own receptor antagonist. In line 
with the well-known anti-inflammatory effects of  AAT (Bergin et al., 2012; 
Lewis, 2012), the only strong negative correlation was found between AAT 
and IL-1β concentrations (Figure 3B).
Age and gender have a significant impact on circulating 
mediators
The concentrations of  IL-6 and IL-1Ra are increased in the circulation of  
older individuals (Figure 3C, with relevant examples in Figure 3D). An 
increased low-level inflammation during the aging process (inflammaging) 
has been proposed as a culprit for metabolic syndrome and cardiovascular 
diseases (Kovacic et al., 2011a; Kovacic et al., 2011b; Veronica and Esther, 
2012), and the higher IL-6 and IL-1Ra concentrations with age in our 
study gives weight to this hypothesis. The effect of  age on IL-6 levels is 
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Figure 2. Schematic depiction of  the study parameters. (A) Stimuli and measurements 
in this study. (B-E) Different factors studied in our cohort. The blue dots in E are the 
individual vitamin-D measurements and the red line is the LOESS fit through these 
points. See also Table S1, S2 and Figure S1.
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Figure 3. Correlations of  circulating mediators with non-genetic host characteristics. (A) 
P-values (FDR corrected) of  the correlations of  mediators with each other. For color 
codes of  the FDR, see legend. (B) Scatterplots of  highly signficant correlations from 
A. (C) Significance of  the relation between host characeristics/environmental factors 
(x-axis) to circulating mediators and immunoglobulins (y-axis). (D) Scatterplots showing 
the effect of  age, gender, oral contraceptive and BMI. The lines indicate the Local 
Regression (LOESS) fit. See also Figure S2 and Table S3.
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also supported by the validation of  these findings in a second independent 
cohort of  300 individuals from the HFGP (p=1.12e-03, Figure S2A). With 
regard to gender, we find significantly higher circulating concentrations 
of  IL-1Ra in women. This was previously observed in a cohort of  type II 
diabetes patients (Ybarra et al., 2008), and which we now confirm in healthy 
individuals.
 We also observe an increase in IL-18BP concentrations in older individuals 
(Figure 3C) and IL-18BP levels were also significantly higher in men than in 
women, whilst total IL-18 concentrations remained unaffected by both age 
and gender. However, in patients with cardiovascular disease, IL-18 levels 
are higher in men than in women (Opstad et al., 2011). 
 IgA immunoglobulin concentrations also increase with age (Figure 3C), 
as was previously detected in saliva (Gonzalez-Quintela et al., 2008; 
Jafarzadeh et al., 2010). IgA has been implicated with several age-related 
diseases such as macular degeneration and diabetes, which makes IgA a 
potential therapeutic agent for prophylaxis and/or treatment (Rodriguez-
Segade et al., 1996; Yu et al., 2016). Higher IgA was also detected in men 
compared to women, as supported by earlier studies, while circulating 
concentrations of  IgM were higher in women (Cassidy et al., 1974; Obiandu 
et al., 2013; Weber-Mzell et al., 2004). In another study from the HFGP 
(Aguirre-Gamboa et al., 2016), IgG2 and IgG4 are shown to significantly 
interact with age and gender, respectively. Due to the larger number of  
factors corrected for and stronger multiple testing correction applied in this 
manuscript, we observe only a borderline significant effect. However, using 
similar corrections we find false discovery rates (FDRs) of  4.06e-3 and 
2.20e-3 for IgG2 and IgG4, respectively.
 Concentrations of  leptin and adiponectin are higher in women than in 
men (Figure 3C). This is due to the higher percentage of  adipose tissue in 
females compared to males, as well as a higher secretion rate of  leptin in 
females compared to males as previously shown by others (Bottner et al., 
2004; Considine et al., 1996; Hellstrom et al., 2000). Adiponectin levels 
were also raised in older individuals. Elevated levels of  CRP positively 
correlate with the use of  oral contraceptives, as shown by several earlier 
studies (Buchbinder et al., 2008; Cauci et al., 2008; van Rooijen et al., 2006). 
In addition, plasma VEGF was higher in women using oral contraceptives 
(Charnock-Jones et al., 2000; Macpherson et al., 1999) (Figure 3C), whereas 
circulating IL-18BP were lower. These findings provide clinical validation 
that biomarkers such as circulating low abundance cytokines reflect 
fundamental physiologic parameters in the absence of  disease.
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Stimulation of proinflammatory cytokines in three ex-vivo 
systems
To comprehensively capture cytokine responses of  immune cells, we 
measured the production of  both monocyte-derived (IL-1β, TNFα, IL-6) and 
lymphocyte-derived cytokines (IFN-γ, IL-17, IL-22) after stimulation in three 
ex-vivo systems (whole blood, peripheral blood mononuclear cells-PBMCs, 
and monocyte-derived macrophages) with one of  19 stimuli (8 bacterial, 
4 fungal, 1 virus, 4 purified microbial ligands, and 2 metabolic stimuli). 
We used these complex cellular systems with 24h (monocyte-derived 
cytokines) and 7 days (lymphocyte-derived cytokines) stimulation times 
in order to mimic real-life situations, as opposed to artificial systems 
using purified cell populations. This resulted in a total of  128 cytokine 
measurements for each of  the 534 individuals included in this study. This is 
by far the largest set of  stimuli-cytokine combinations measured to date, with 
previous studies generally studying one or two stimuli in one experimental 
setting. In addition, the choice was made to focus on protein levels (which 
confer biological activity) rather than gene expression (as in earlier eQTL 
studies), since protein levels are a better representation of  an individual’s 
immune state. Gene expression and protein expression levels of  cytokines 
are not always correlated to one another, since post-transcriptional processes 
play a crucial role in determining the rate of  cytokine synthesis and release 
(Anderson, 2008). A complete list of  measurements is provided in Table 
S1, and example distributions are shown in Figure S1. The data for each 
participant (including all measurements of  circulating immune parameters) 
can be found at https://bbmri.nl/molgenis/500FG (database is described 
in detail in the STAR Methods).
IFN-γ and IL-22 responses decrease with age
Production of  monocyte-derived cytokines (IL-1β, TNFα and IL-6) after 
stimulation was similar across the ages of  the volunteers, with the exception 
of  S. aureus-induced IL-1β and C. albicans hyphae-induced IL-6, that 
showed a moderately higher production in the elderly. In contrast, there 
was a consistent effect of  age on lymphocyte function, with the production 
of  IFN-γ and IL-22 being significantly lower in elderly individuals after 
stimulation with most pathogens, in line with the concept of  immune-
senescence (Baylis et al., 2013). Interestingly, no such impairment with age 
was observed for the production of  IL-17, an important product of  Th17 
cells. The strongest decrease of  cytokine production in the older participants 
was observed after stimulation with Borrelia spp., as detailed and analyzed in 
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the HFGP manuscript by Oosting et al. (Cell Host Microbe, submitted). The 
impact of  age on cytokine production capacity induced by various microbial 
and metabolic stimuli is schematically depicted in Figure 4A, with relevant 
examples provided in Figure 4C. 
Monocyte-derived cytokine responses are increased in men, 
whereas women have increased Th17 responses to Candida
The production of  proinflammatory cytokines released from monocytes 
was higher in men after stimulation with several stimuli. In the whole-blood 
system these cytokines were increased in men after LPS stimulation, while 
in PBMCs this effect was apparent especially after stimulation of  C. albicans 
conidia. Figure 4B presents an overview of  the gender effects on cytokine 
production, with examples shown in Figure 4E. Although the use of  oral 
contraceptives did not have strong effects on cytokine production capacity in 
vitro, women using oral contraceptives did show an even further decreased 
IFN-γ and TNFα response after LPS stimulation (Figure 4D,E). Th17 
responses were mostly similar between men and women, although IL-17 
and IL-22 production was higher in women after stimulation with C. albicans 
hyphae (Figure 4B). 
Hormonal differences do not explain gender-specific immune 
differences
To investigate whether differences in circulating hormone levels may have 
a role in the above-described gender effects, we assessed the correlation of  
inflammatory markers with the levels of  progesterone and testosterone in 
men and women separately. The majority of  the cytokines and mediators 
identified to differ between men and women showed no correlation with 
progesterone and testosterone concentrations, excluding a potential role 
of  hormones in explaining the gender differences. However, we identified 
several notable exceptions, with the significant correlations displayed in 
Figure 4F (all correlations in Figure S2C). One of  the most important 
findings is that leptin concentrations show a clear negative correlation 
with testosterone levels within the male subgroup of  the 500FG cohort 
(R = -0.36, FDR = 6.78e-06, see Figure 4G) supported by previous reports 
(Behre et al., 1997). Surprisingly, however, no such effect is observed in 
women. In fact, if  anything, there is a positive correlation between leptin 
levels and testosterone (FDR = .07; Figure S2D), in line with a study that 
observed a similar effect for non-obese women (Soderberg et al., 2001). 
Moreover, there was a significant positive correlation and a significant 
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negative correlation of  testosterone and progesterone levels, respectively, 
with circulating IL-18BP concentrations in men, which was partially able to 
explain the gender difference.
Smoking and BMI do not affect in vitro cytokine production, 
but BMI influences several circulating mediators
We have analyzed two sets of  parameters in relation with non-genetic host 
factors: resting circulating concentrations of  the immune mediators, and in-
vitro cytokine production capacity after microbial stimulation. Surprisingly, 
with the exception of  a few spurious effects, BMI and smoking had no 
detectable effect on in vitro cytokine production (Figure S3A,B), even though 
they are thought to be important modulators of  immune responses (McCrea 
et al., 1994; Sopori, 2002). In contrast, some of  the circulating mediators 
measured were significantly related to BMI (Figure 3C). As expected, leptin 
and CRP correlated positively with BMI (Buchbinder et al., 2008; Cauci et 
al., 2008; van Rooijen et al., 2006). BMI also showed a small but significant 
association with circulating levels of  both IL-6 and IL-18, which is in 
accordance with the concept of  an increased inflammatory status when BMI 
increases (Kantor et al., 2013; Khaodhiar et al., 2004; Siervo et al., 2012). 
This finding was confirmed in an independent cohort of  volunteers (p=4.3e-5, 
Figure S2B). The same increased inflammation is likely the cause of  the 
increased IL-1Ra concentrations in individuals with high BMI: the levels of  
the cytokine are probably reactively up-regulated. The only effect we observe 
for smoking is a reduction in IgG levels, which confirms the findings of  a study 
by Gonzalez-Quintela et al. (Gonzalez-Quintela et al., 2008).
Seasonality has a major impact on cytokine responses and 
inflammation 
It was recently suggested that gene expression in human immune cells shows 
annual seasonality (De Jong et al., 2014; Dopico et al., 2015). We therefore 
checked immune responses for the presence of  annual seasonal patterns 
using linear regression. This analysis provided both the significance of  the 
seasonality pattern and the month at which the immune responses were 
at their highest (Table S3). Results were confirmed using an independent 
nonlinear fitting method (Table S4). The results show that the production 
of  several cytokines (TNFα, IL-1b and IL-6) shows a significant peak in 
summer (Figure 5A), while circulating AAT concentrations were highest in 
the winter. The clearest effects of  seasonality are apparent for monocyte-
derived cytokines after stimulation with influenza virus, Coxiella burnetti, or 
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Cryptococcus neoformans (Figure 5D). As influenza incidence displays a very 
clear seasonality pattern, with increased transmission in the winter months 
(Lipsitch and Viboud, 2009; Lofgren et al., 2007), it is tempting to speculate 
that the lower cytokine responses to influenza in the winter months may 
represent an important pathophysiological factor in this phenomenon. 
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Figure 5. Seasonal changes in cytokine levels. (A) Heatmap showing the cytokines having 
seasonal responses. Three letter abbreviation indicate the month at which the production 
of  the cytokine (x-axis) is highest. A few stimulus-cytokine combinations were excluded 
(see legend), because the time profile showed clear storage degradation effects which 
interfere with the seasonality analysis. (B) Effects of  vitamin D levels shown in a heatmap 
to Figure 3A, red indicates a positive relation. (C) Heatmap showing the signifiance of  the 
seasonality of  the circulating cytokines. (D) Examples of  some of  the seasonal responses, 
where each blue dot is an individual measurement and the red line depicts LOESS. See 
also Figure S2, S3 and S4 and Table S3, S4, S5, S6 and S7.
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The extent to which seasonal variation in baseline gene expression could 
contribute to seasonal variation in cytokine responses remains to be fully 
tested. To get an estimation of  this contribution, we performed RNA-
sequencing in a subset of  88 volunteers and first analyzed the seasonality 
patterns of  AAT and the three cytokines showing seasonal responses (IL-
1β, TNFα, IL-6; figure 4B). Only TNFα mRNA showed a seasonal pattern 
of  expression, peaking in summer, which matches protein secretion (Table 
S5). Additionally, we checked the same genes in a large pediatric cohort 
from Germany, which shares a very similar climate with the Netherlands 
(Dopico et al., 2015). PBMC expression of  SERPINA1 (the gene encoding 
AAT) was found to be seasonal in that cohort. It is important to note that 
AAT seasonality is amongst the weaker seasonal genes in the German 
cohort of  Dopico et al., in which 5136 genes were found to be seasonal 
(corresponding to ~1/4 of  protein-coding genes in the human genome). 
Second, we assessed seasonality of  mRNA expression of  genes known to 
be involved in regulating cytokine production: PRRs, signaling molecules, 
transcription factors (for details see STAR Methods). Expression analysis 
of  these genes in our cohort showed no individual seasonal patterns after 
multiple-testing correction (Table S6). Interestingly, in the genes significant 
before correction, there was an enrichment of  seasonal genes peaking in 
summer (19 out of  30 genes, chi-square p<0.01), the same season at which 
concentrations are highest for most seasonal cytokines. Inspection of  this 
same regulatory set of  genes in the larger German pediatric cohort revealed a 
larger set of  seasonal genes involved in the regulation of  cytokine expression 
(Table S7). Seasonality of  these regulatory genes, combined with marginal 
seasonal gene expression of  AAT and one out of  three seasonal cytokines, 
does point towards some transcriptional regulation. However, this also 
suggests that post-transcriptional processes, rather than gene transcription, 
are influenced strongly by seasonal variations. Additionally, the biological 
relevance of  RNA levels is less direct, and more difficult to interpret, than 
protein expression levels. This strengthens our choice to investigate cytokine 
expression as a more direct measure of  immune regulation.
Variations in vitamin D concentrations have limited effect on cytokine 
production capacity
Vitamin D has been repeatedly reported to have important immunomodulatory 
effects (Bikle, 2009; Correale et al., 2009), and based on this we expected 
to observe important effects on cytokine production capacity. Surprisingly, 
vitamin D circulating concentrations did not have a significant effect on 
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seasonal response of  AAT, showing a decrease in summer. The line indicate the LOESS 
fit. (B) Combined plots of  AAT and IL-1b after influenza stimulation, showing their 
opposite seasonal periodicity. (C) Bar plots showing decreased joint inflammation in 
mice injected with uric acid crystals after being injected AAT. Data are represented as 
mean +/- SEM. (D) Bar plots showing decreased IL-1β production in mice injected with 
uric acid crystals after being injected AAT. Data are represented as mean +/- SEM. 
(E) Number of  patients presenting with gout at a primary physician in the Netherlands 
(n~800), with a clear increase in spring/summer. (F,G) Histopathology of  an inflamed 
knee joint of  an vehicle (BSA, 100 µg/kg)-treated mouse, 4h after induction of  gouty 
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original magnification 200x. See also Figure S5 and Table S5, S6 and S7.
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any of  the cytokine production systems investigated here (Figure 5B). The 
seasonality of  vitamin D has been suggested to influence inflammatory 
markers (Prietl et al., 2013): however, when we separated out the general 
periodicity over time and the residual variation of  vitamin D at each time-
point, it was only the periodicity that was significantly correlated with 
cytokine outcomes and not the season-independent vitamin D variations 
(Figure S3C,D). This is not due to a lack of  residual variation around the 
periodic signal, since the residuals have an amplitude similar to the periodic 
signal (Figure 2E). With inter- and intra-assay coefficients of  variation of  
less than 5%, the residuals can also not be ascribed to measurement noise. 
There are a number of  environmental factors that show seasonal variations, 
which explains why vitamin D concentrations alone are not a strong 
predictor of  cytokine responses. Examples of  factors that peaked in summer 
include temperature, atmospheric NH3 and O2 levels, whereas humidity, and 
SO2, NO, NO2 and CO concentrations peaked in winter (Figure S4). Pollen, 
which is a known allergen, peaked in concentration at different times during 
our study depending on the species, and could also have contributed to 
seasonal immune responses (examples in Figure S4). It is thus likely that 
vitamin D is only one of  many other factors with a seasonal pattern that 
influence the immune response. 
Alpha-1-antitrypsin (AAT) is partially responsible for 
seasonality of cytokine responses: impact on gouty 
inflammation
In contrast to in vitro cytokine production, most circulating markers were 
not influenced by the season, with the notable exception of  plasma AAT 
concentrations, which was highest in February and lowest in the summer 
months (Figure 5C, Figure 6A). Thus the periodicity of  AAT is opposite 
to the periodicity of  the cytokines that are highest in summer (displayed in 
Figure 6B for IL-1β for MSU + C16 stimulations and Figure S5 for others). 
AAT is a known anti-inflammatory mediator (Bergin et al., 2012; Joosten 
et al., 2016), but nothing was known about its seasonal variation. Because 
of  the opposite seasonality of  AAT with cytokine induction by uric acid 
crystals and fatty acids (C16) (Figure 6B), we validated the impact of  AAT 
on cytokine response in sterile inflammation in an experimental model of  
gout, a condition caused by the deposition of  MSU crystals in the joints. 
When a plasma-derived form of  AAT (Prolastin C) was injected in mice 
challenged with uric acid crystals and fatty acids intra-articularly, joint 
swelling was strongly reduced (Figure 6C), the synovial IL-1β production 
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was significantly inhibited (Figure 6D), and histology showed lower cellular 
infiltration in the joint cavity after AAT treatment (Figure 6F,G). 
 To demonstrate the clinical relevance of  these findings, we thereafter 
assessed whether the seasonal periodicity of  MSU-induced cytokine 
responses may impact the clinical picture of  gout. Indeed, retrospective 
assessment of  the incidence and prevalence of  inflammatory exacerbations 
in a cohort of  more than 800 patients with gout identified a clear seasonality 
profile, with the peak in spring/summer when the cytokine production 
of  IL1b was highest and plasma AAT is the lowest level (Figure 6E). It 
is also important to note the highly negative correlation of  plasma AAT 
with plasma IL1b in the same plasma sample, which is consistent with AAT 
negatively regulating IL1b production in vivo. All in all, this suggests that 
AAT is not only anti-inflammatory, but that it specifically decreases IL-1β 
production in a seasonal fashion, and that this has a clear clinical relevance 
to at least one very important autoinflammatory disorder.
Discussion
The HFGP aims to understand the individual sources of  variability in 
immune responses by studying human cytokine production capacity in 
response to a comprehensive panel of  microbial and metabolic stimuli. We 
systematically investigated the factors that influence the human cytokine 
responses in the 500 Functional Genomics (500FG) cohort of  healthy 
volunteers within HFGP, after stimulation of  their leukocytes with bacterial, 
fungal, viral and non-microbial metabolic stimuli; while the present study 
assessed the impact of  environmental and non-genetic host factors on 
cytokine responses, complementary studies investigated the impact of  the 
genetic (Li et al., 2016) and microbiome (Schirmer et al., 2016) variability 
on cytokine production. 
 An important conclusion of  the present study is that non-genetic host 
factors such as age or gender have a clear effect on cytokine responses, 
and that most of  these effects are cytokine and/or stimulus dependent. 
For example, old age is associated with clear defects in the production of  
the T-helper cytokine products IL-22 and IFN-γ, while the production of  
monocyte-derived cytokines and IL-17 does not change with age. Changes 
in immune responses due to old age are well documented, but have been 
performed in smaller cohorts, resulting in conflicting data: while some 
have reported defective TLR-induced cytokine responses in dendritic cells 
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of  elderly individuals (Panda et al., 2010), others have not identified such 
effects (Janssen et al., 2015). Lymphocyte defects in the elderly have been 
previously described (Ferrando-Martinez et al., 2011; Swain et al., 2005), 
and our data presents an important biological correlate to this defect. The 
defective adaptive lymphocyte responses may thus at least partly explain 
the poor response to vaccination in the elderly (Weinberger et al., 2008). 
In contrast, the intact innate immune responses (production of  monocyte-
derived cytokines) can present an opportunity to initiate a new strategy 
of  vaccination in the elderly based on trained immunity (innate immune 
memory) (van der Meer et al., 2015). Additionally, the presence of  higher 
concentrations of  several circulating inflammatory mediators in the elderly 
(such as IL-6, IL-1Ra) may be a mirror of  the low-grade inflammatory 
condition described as ‘inflammaging’ (Baylis et al., 2013), and that has 
been hypothesized to be responsible for some of  the age-related chronic 
diseases associated with inflammation.
 Another important host factor that influences immune responses is gender 
(Oertelt-Prigione, 2012), resulting in a differential susceptibility of  men and 
women to infectious, autoimmune and inflammatory diseases (Libert et al., 
2010). Understanding the gender-related aspects of  cytokine biology was 
therefore an important aim of  our study. We found that monocyte-derived 
cytokine production was higher in men in several stimulation assays, which 
may contribute to the increased susceptibility of  men to inflammatory 
diseases such as insulin resistance or atherosclerosis ((Geer and Shen, 2009; 
Towfighi et al., 2009). In contrast, Th17 responses were higher in women 
using Candida albicans hyphae as a model stimulation system. High IL-17 
production could be a driver for a higher incidence of  several autoimmune 
diseases such as multiple sclerosis or rheumatoid arthritis in women 
(Gaffen, 2004; Gold and Luhder, 2008; Kotake et al., 1999; Lock et al., 
2002), although this remains to be demonstrated in future studies. On the 
other hand, the higher Candida-induced IL-17 production in women may 
just be a mirror of  more prevalent Candida colonization, e.g. at the level of  
vaginal mucosa. In contrast to age and gender, other important host-related 
factors such as BMI or smoking did not exert a sizeable effect on cytokine 
production capacity.
 In addition to host factors, the immune responses of  an individual are 
also likely to be affected by the environment, and this study aimed to 
comprehensively assess the role of  both environmental and host factors in 
cytokine responses. One of  the most interesting observations is the role of  
seasonality as a factor influencing cytokine production variability. This is 
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biologically very relevant especially given the seasonality of  many infectious 
diseases (Bonsall et al., 2015). A separate HFGP manuscript that assessed 
variation of  cell counts in the 500FG cohort supports the importance 
of  seasonality on immune parameters (Aguirre-Gamboa et al., 2016). 
Importantly, while previous smaller studies suggested seasonal fluctuations 
of  vitamin D levels as the main explanation for seasonal effects (Khoo et al., 
2012; Khoo et al., 2011a; Khoo et al., 2011b), this hypothesis is not supported 
by our study. The absence of  direct effects on vitamin D concentrations on 
human cytokine responses is a crucial finding that needs further investigation: 
because vitamin D is seen as a possible target for health policy intervention, 
its true impact on biological processes in large cohorts of  individuals needs 
to be thoroughly assessed before such policies are implemented. In contrast, 
our study unravels an unknown effect of  seasonality on the circulating 
concentration of  AAT, one of  the most important acute phase proteins. 
AAT shows an inverse correlation with the production of  cytokines after 
several stimulations, amongst them MSU, suggesting an anti-inflammatory 
effect of  AAT. The biological importance of  our findings is validated in 
an experimental model of  gouty arthritis in mice (a disease caused by the 
formation of  uric acid crystals). Even more significantly, the peak of  uric 
acid-induced IL-1β production in summer is also validated by an increased 
incidence and prevalence of  gout attacks during summer in a large cohort 
of  patients. This demonstrates both the validity of  the hypotheses extracted 
from the HFGP database, as well as the clinical impact of  these processes.
 All in all, the findings of  this study define the main environmental 
and non-genetic host factors that impact immune responses. In order to 
comprehensively investigate the factors that influence cytokine production, 
complementary studies presented in this issue of  Cell investigate the impact 
of  genetic variation and of  the gut microbial flora on the same responses. 
The accompanying study by Yang et al. demonstrates that genetic variability 
of  the host has a strong effect on cytokine responses, again with the impact 
depending on the type of  pathogen and cytokine studied (Li et al., 2016). In 
addition, a role of  non-genetic factors for the modulation of  cytokine responses 
is supported by the identification of  important microbiome components that 
modulate cytokine responses, as described in the accompanying manuscript 
by Schirmer et al. (Schirmer et al., 2016). These effects are likely mediated 
by microbial components, or through diverse metabolites released by 
microbiota-diet interaction. These three complementary studies within 
HFGP that assess the host/environmental, genetic and microbiome factors 
influencing cytokine responses provide a comprehensive picture of  cytokine 
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response variability in humans, potentially opening up new avenues for 
personalized medicine. Future studies and analyses of  the cohorts from the 
HFGP will focus on the assessment of  the effect of  other factors (e.g. diet, 
metabolome), as well as on integrating these different datasets to be even 
more accurate in predicting and understanding the immune response against 
various pathogens.
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Figure S1 - Collection of  plots showing several distributions of  cytokine expression and 
circulating mediator concentrations, Related to Figure 1 and Figure 2. All values were 
log10 transformed, as depicted on the x-axis. If  cytokine concentrations were measured 
after stimulation, the title indicates: which stimulation, in what sample type and at what 
time point. Also, for these samples the detection limits of  the ELISA are indicated with 
red vertical lines. Normality of  the distribution was tested using Anderson-Darling test 
for normality with a cut-off  of  p<=.05. All concentrations were measured in pg/ml.
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Figure S2 – Plots showing the effect of  different parameters on cytokine production 
and circulating mediators, Related to Figure 3, Figure 4 and Figure 5. (A) Scatter plot 
validating the influence of  age on IL-6 levels in a healthy subset of  about 100 individuals 
in another cohort of  the Human Functional Genomics Project (HPGP). Line shows the 
LOESS fit to the data. (B) Scatter plot validating the influence of  BMI on IL-6 levels in 
the same cohort as in A. Line shows the LOESS fit to the data. (C) Correlations between 
the hormones progesterone and testosterone and immunological parameters, performed 
separately for men and women. Tests were performed for all immunological responses 
showing a significant relation to gender. All correlations are shown in this plot. (D) 
Scatterplot showing the relation between testosterone in men and leptin concentrations. 
Line shows the LOESS fit to the data. (E) Graph showing the distribution of  normalized 
amplitudes of  the seasonality signal for all cytokines. The arrow shows the cut-off  value 
below which the amplitude of  seasonality was not considered significant. (F) Heatmap 
showing the Pearson correlations between circulating cytokines.
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Figure S3 - Heatmaps showing the relation between several factors and cytokine 
production, Related to Figure 4 and Figure 5. The factors are: (A) smoking, (B) BMI, (C) 
periodicity of  vitamin D, and (D) non-periodic signal of  vitamin D.
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Figure S4 - Scatterplots showing the seasonality of  different parameters with a possible 
influence on the immune system, Related to Figure 5. Red lines indicate the LOESS fit 
to the data. These data were collected in the timeframe our study was conducted. (A)-(C) 
climatological parameters (D)-(H) examples of  several pollen peaking at different times 
of  year. Pollen were counted as number of  pollen from a certain species per m3 of  air. 
(I)-(N) Atmospheric concentrations of  several compounds in the city where the study was 
performed. (O) Location of  the measuring stations for the parameters displayed in D-H. 
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Figure S5 - Scatterplots showing the opposed seasonality of  AAT with several cytokine 
responses after stimulation, Related to Figure 6.
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STAR Methods
Contact for reagent and resource sharing
Further information and requests for reagents may be directed to, and will 
be fulfilled by the Lead contact and corresponding author Mihai G. Netea 
at the Radboud University Medical Center, Nijmegen, The Netherlands 
(mihai.netea@radboudumc.nl).
Experimental model and subject details
Main cohort
The 500FG cohort consists of  534 healthy individuals of  Caucasian 
origin and is part of  the Human Functional Genomics Project (HFGP). 
The inclusion of  the volunteers took place between 8/2013 until 12/2014 
in the Radboud University Medical Center, the Netherlands. Baseline 
characteristics of  the cohort are shown in Figure 2 and Table S1. Out of  the 
534 individuals, 45 were excluded in the final analysis after examining the 
answers of  their questionnaire and genetic results (see “Methods Details”), 
leaving 489 individuals.
 The study was approved by the Ethical Committee of  Radboud University 
Medical Center Nijmegen (NL42561.091.12, 2012/550). Inclusion of  
volunteers and experiments were conducted according to the principles 
expressed in the Declaration of  Helsinki. All volunteers gave written 
informed consent before any material was taken.
Validation cohorts
Gout patient cohorts 
Patients from 7 general practices (from 1971-2002), 3 practices from general 
health centers (1994-2002) as well as Dutch institute of  primary care (2001-
2002) were included in this validation study. Information about gout attacks and 
morbidity was assessed using available databases provided by these institutions. 
Prior to the statistical analysis we categorized the seasons into: 1/1-31/3 
(winter); 1/4-30/6 (spring); 1/7-30/9; (summer); 1/10-31/12 (autumn).
300 Functional Genomics (300FG) cohort. 
As a part of  the HFGP a cohort of  300 individuals with a BMI higher 
than 27 was also recruited. Out of  these 300 individuals, a sub-cohort of  
individuals with no diagnosed health problem was selected (N~100). For 
these individuals circulating IL-6 levels were measured, and these levels 
were used to validate the relation between age and BMI with IL-6. The study 
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was approved by the Ethical Committee of  Radboud University Medical 
Center Nijmegen (N146846.091.13, 2013/505). Inclusion of  volunteers 
and experiments were conducted according to the principles expressed in 
the Declaration of  Helsinki. All volunteers gave written informed consent 
before any material was taken.
Animal model of gout arthritis
Joint inflammation was induced by intra-articular injection (i.a.) MSU 
crystals mixed with C16.0 into the right knee joint of  naïve male C57BL/6 
mice. The mice were between 20-25 grams, housed in standard housing, 5 
mice per cage. All procedures performed were in accordance with the ethical 
standards of, and approved by, the Ethical review board of  University of  
Colorado Denver, USA.
Methods details
Demographic data collection
After visiting the hospital to donate blood, the volunteers received an 
extensive online questionnaire about lifestyle, diet and disease history. Based 
on the results of  this questionnaire we had to exclude 45 volunteers for 
various reasons, e.g. they were under medication, non-European ancestry, 
or had a chronic disease. By excluding these individuals from the analysis 
we minimized false positive effects on the cytokine production capacity in 
vitro and in vivo. 
In vitro cytokine stimulation assays in the three systems 
After obtaining informed consent, venous blood was drawn from a cubital 
vein of  volunteers into sterile 10 mL EDTA tubes, 8 ml serum tubes as well 
as 8ml heparine tubes (Monoject).
 
PBMC stimulation experiments
Isolation of  PBMCs was performed as described in Oosting et al. (Oosting 
et al., 2015). Cells were washed twice in saline and suspended in medium 
(RPMI 1640) supplemented with gentamicin 10 mg/mL, L-glutamine 10 mM 
and pyruvate 10 mM. PBMC stimulations were performed with 5x105 cells/
well in round-bottom 96-wells plates (Greiner) for either 24 hours or 7 days 
in the presence of  10% human pool serum at 37°C and 5% CO2. Additional 
details are available in the Supplemental Information. Supernatants were 
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collected and stored in -20oC until used for ELISA. The stimulations used 
for the 24 hour and 7 day experiments are shown in Table S1.
 
Macrophage stimulation experiments
In order to perform macrophage stimulation experiments we plated 5x105 
cells in flat-bottom plates (Greiner) with 10% human serum at 37°C and 
5% CO2 which was refreshed after 3 days. After another 3 days the medium 
was removed and cells adherent macrophages were stimulated for 24 hours. 
Supernatants were collected and stored in -20oC until used for ELISA. The 
stimulations used for the 24 hour macrophage experiment are shown in 
Table 1.
 
Whole blood stimulation experiments
100µl of  heparin blood was added to a 48 well plate and subsequently 
stimulated with 400ul stimulus (final volume 500ul) for 48 hours at 37°C 
and 5% CO2. Supernatants were collected and stored in -20
oC until used for 
ELISA. The stimulations used for the 48 hours whole blood experiment are 
shown in Table S1.
Influenza culture and inactivation
Influenza virus strain pH1N1 A/Netherlands/602/09 (kindly provided 
by Prof. Ron Fouchier, Erasmus MC) was grown in the allantoic fluid of  
embryonated chicken eggs as described previously (Diavatopoulos et al., 
2010). Viral titers were determined by three independent plaque assays 
performed on Madin-Darby canine kidney (MDCK) cells (Hoffmann et 
al., 2001). To inactivate the pH1N1 strain, β -propiolactone (BPL) (Acros 
Organics, Morris Plans, NJ) in citrate buffer (125 mM sodium citrate, 150 
mM sodium chloride, pH 8.2) was added to the pH1N1 virus to a final 
concentration of  0.1% and incubated for 24h at 4°C under continuous slow 
shaking. Inactivated virus was subsequently snap-frozen and stored at -80°C. 
Virus inactivation was confirmed by three passages in MDCKs where no 
virus could be detected by plaque assay following the third passage.
ELISA analysis
Samples of  all experiments were measured at once using the following 
ELISA kits: In the 24-hour PBMC stimulation experiments we measured 
concentrations of  human IL-1β, IL-6 as well as TNFα (PeliKine Compact 
or R&D Systems). Supernatants of  the 7 days stimulation assays were used 
to measure IL-22, IL-17 or IFN-γ (PeliKine Compact or R&D Systems). 
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For the whole blood samples IL-6, TNFα, IL-1β as well as IFN-γ levels 
were determined (PeliKine Compact or R&D Systems). Supernatants from 
the macrophage stimulation experiment were used for IL-6 and TNFα 
measurements (PeliKine Compact or R&D Systems).
Measurements of circulating mediators
The circulating mediators resistin, leptin, adiponectin, CRP and alpha-1 
antitrypsin (AAT) were measured in EDTA plasma using the R&D Systems 
DuoSet ELISA kits following the Manufacturer’s protocol. The plasma 
cytokines IL-1Ra and IL-18 binding protein (IL-18BP) were measured 
using R&D Quantikine kits following the manufacturer’s standard protocol. 
Plasma IL-1β, IL-6, IL-18 and VEGF were measure in Simple Plex cartridges 
using the Ella apparatus (Protein Simple, San Jose, CA). The IL-6 levels for 
the 300FG validation cohort were measured similarly. The data generated 
using Simple Plex cartridges correlated with physiological, environmental 
and other circulating factors. Resting mean level of  IL-1β in the cohort was 
0.33 ±0.37 pg/mL (range 0.04-11 pg/mL), mean total IL-18 was 163 ± 3.5 
pg/mL (range 0.4-838), mean AAT levels were 1.54 ± 1.16 mg/mL and in 
the peak season (Feb) levels were 2.93 ± 1.81 mg/mL, mean VEGF was 
35.91 ± 1.04 (range 1.15-186) and mean IL-6, 1.25 ± 0.06 pg/mL (range 
0.15-8.1). These levels IL-6 levels correlated with age, BMI, CRP, IL-1β and 
IL-1Ra, total IL-18 and VEGF (see Figure 3A and C). 
Vitamin D measurements
25-hydroxy vitamin D3 (25OH-vitamin D3) was analyzed by LCMSMS 
after protein precipitation and solid-phase extraction. Internal standard 
[2H3] 25OH-vitamin D3 (Bioconnect) was added to 100 uL serum. 50 µL 
NaOH (2M) was added to release protein-bound 25OH-vitamin D3 and 
subsequently 500 µL Acetonitrile/Methanol (9:1) was added for protein 
precipitation. 700 µL H2O was added to 400 µL supernatant followed by 
solid phase extraction (Oasis HLB 1cc, Waters). Columns were conditioned 
with 1 mL methanol/isopropanol (95:5) and subsequently washed with 1 
mL H2O. After application of  the sample, columns were washed with 1 
mL H2O and 1 mL methanol/H2O (60:40). The eluate (300 µL methanol/
isopropanol 95:5) was diluted with H2O (3:1) and injected (10 µL) into 
an Agilent Technologies 1290 Infinity VL UHPLC-system (Agilent 
Technologies, Santa Clara, CA), equipped with a BEH C18 (1.7µm 2.1 
X 50mm) analytical column (Waters Corp.) at 45°C. Mobile phase A 
(methanol:water 20:80 + 2 mM NH4CH3COO + 0.1% formic acid) and 
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B (methanol:water 98:2 + 2 mM NH4CH3COO + 0.1% formic acid) were 
run in a gradient (0.4 mL/min). The gradient program was as follows: Start 
gradient 30:70 A:B to 5:95 A:B in 3.5 min and return to 30:70 A:B in 0.5 
min. Retention time was 2.73 min, total run time was 4 minutes. An Agilent 
6490 tandem mass spectrometer (Agilent Technologies) was operated in the 
electrospray positive ion mode, with a capillary voltage 3.5 kV, fragmentor 
voltage 380 V, sheath gas temperature 350°C and gas temperature 100 °C 
with N2 collision gas. Both 25OH-vitamin D3 and 25OH-vitamin D3 
[-H2O] (in-source fragmentation) were used for quantification (results were 
averaged) with both two transitions (qualitative and quantitative) monitored. 
Transitions (Q1>Q3) were m/z 401.4 > 159.1 (27 kEV) and m/z 401.4 > 
107.1 (27 kEV) for 25OH-vitamin D3; m/z 404.4 > 109.1 (27 kEV) and m/z 
404.4 > 162.1(30 kEV) for [2H3] 25OH-vitamin D3; m/z 383.4 > 107.1 (36 
kEV) and m/z 383.4 > 257.2 (16 kEV) for 25OH-vitamin D3 [-H2O]; m/z 
386.4 > 109.1 (27 kEV) and m/z 386.4 > 162.1 (27 kEV) for [2H3] 25OH-
vitamin D3 [-H2O]. Dwell time 25 ms. An 8-point calibration curve was used 
and absolute concentration of  the calibrator (Sigma-Aldrich) was assessed 
by spectrophotometry (264nm). The method was linear assessed by CLSI 
EP6 protocol. Recovery was within 90 – 109%. Within-run and between-run 
CV is 6.4% and 6.1% at 23 nmol/L) and 5.1% and 5.5% at 81 nmol/L as 
assessed by adapted CLSI EP5 protocol. LOQ was 7 nM (10% CV).
Immunoglobulin measurements
Serum levels of  IgG, IgM and IgA were determined by immunonephelometry 
using a Beckman Coulter Immage (Beckman Coulter, Fullerton, CA, USA) 
and Beckman Coulter reagents. Measurements were standardized using 
certified european reference material 470 (ERMÒ-DA470). Reference values 
for serum Ig are: total IgG 7.0 -16g/l, IgM 0.4-2.3g/l and IgA 0.7-4.0g/l. 
IgG subclass measurements in serum were performed on a BNTM II 
immunonephelometer (Siemens Healthcare, Erlangen, Germany) using the 
Binding Site© (Birmingham, UK) Human IgG Subklass BN II Combi Kit. 
Values were standardized using the N protein standard SL (OQIM, Siemens 
Healthcare), which is based on the Sanquin (Amsterdam, Netherlands) 
nephelometric standard M1590. Reference values are: IgG1 4.9 – 11.4g/l, 
IgG2 1.5-6.4g/l, IgG3 0.2-1.1g/l and IgG4 0.08-1.4g/l.
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Hormone measurements
Testosterone and progesterone were analyzed by LCMSMS after protein 
precipitation and solid-phase extraction. Internal standard [13C3]-
testosterone (Isoscience, King of  Prussia, PA) and [2H9]-progesterone (CDN 
isotopes) was added to 100 µL serum. Subsequently 300 µL Acetonitrile + 
0.1% formic acid was added for protein precipitation. 300 µL H2O was added 
to 200 µL supernatant followed by solid phase extraction (Oasis HLB 1cc, 
Waters). Columns were pre-equilibrated with 1 mL methanol/isopropanol 
(95:5) and subsequently washed with 1 mL H2O. After application of  the 
sample, columns were washed with 1 mL H2O and 1 mL methanol/H2O 
(30:70). The 300 µL eluate (methanol/isopropanol 95:5) was dried under 
a stream of  N2 gas, reconstituted in methanol: water (30:70) and injected 
(10 µL) into an Agilent Technologies 1290 Infinity VL UHPLC-system 
(Agilent Technologies, Santa Clara, CA) equipped with a BEH C18 (1.7µm 
2.1 X 50mm) analytical column (Waters Corp.) at 60°C. Mobile phase A 
(methanol:water 20:80 + 2 mM NH4CH3COO + 0.1% formic acid) and 
B (methanol:water 98:2 + 2 mM NH4CH3COO + 0.1% formic acid) were 
run in a gradient (0.4 mL/min). The gradient program was as follows: Start 
gradient 70:30 A:B for 2.5 min; then to 40:60 A:B in 3.5 min; followed by a 
gradient in 0.5 min to 2:98 to remain such for 0.5 min and thereafter to 70:30 
A:B in 0.5 min and remain such for 0.5 min. Retention time was 4.37 min and 
6.04 min for testosterone and progesterone respectively. Total run time was 
8 minutes. An 9-point calibration curve was used (testosterone (Steraloids); 
progesterone (Sigma)). An Agilent 6490 tandem mass spectrometer (Agilent 
Technologies) was operated in the electrospray positive ion mode, with a 
capillary voltage 3.5 kV, fragmentor voltage 380 V, sheath gas temperature 
350°C and gas temperature 150 °C with N2 collision gas. Two transitions 
(qualitative and quantitative) were monitored. Transitions (Q1>Q3) were 
m/z 289.2 > 109.1 (30 kEV) and m/z 289.2> 97.1 (30 kEV) for testosterone; 
m/z 292.3 > 112.1 (30 kEV) and m/z 292.3 > 100.1(30 kEV) for [13C3]-
testosterone; m/z 315.3 > 109.1 (29 kEV) and m/z 315.3 > 97.1 (29 kEV) 
for progesterone; m/z 324.3 > 113.1 (29 kEV) and m/z 324.3 > 100.1 
(29 kEV) for [2H9]-progesterone. Dwell time was 50 ms and 100 ms for 
testosterone and progesterone respectively. The method was linear assessed 
by CLSI EP6 protocol. Recovery was within 98.4 – 103% (testosterone) and 
99.8 – 102% (progesterone). For testosterone within-run and between-run 
CV is 4.1% and 6.0% at 0.9 nmol/L and 3.3% and 5.3 at 19 nmol/L as 
assessed by adapted CLSI EP5 protocol. For progesterone within-run and 
between-run CV is 2.8% and 5.1% at 4.9 nmol/L and 3.4% and 6.1 at 28 
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nmol/L as assessed by adapted CLSI EP5 protocol. LOQ was 0.05 nmol/L 
and 0.25 nmol/ L (15% CV) for testosterone and progesterone respectively.
Animal model of gout arthritis
Joint inflammation was induced by intra-articular injection (i.a.) of  300µg 
highly pure MSU crystals mixed with 200µM C16.0 in 10 µl of  PBS into the 
right knee joint of  naïve C57BL/6 mice. Four hours after i.a. injection, joint 
swelling was determined, synovial tissue was isolated and knee joints were 
removed for histology. The mice were pre-treated with plasma derived AAT 
(Prolastin C) in a dose of  4 mg per mouse or BSA (vehicle) 2 hours before 
gouty arthritis was induced (n=10 mice per group). Joint inflammation 
was measured by macroscopic scoring (Joosten et al., 2010 A&R), 0= no 
swelling, 1= mild swelling, 2 = moderated and 3 = severe swelling. After 
the skin was removed the joint swelling was scored, 0= no swelling, 1= mild 
swelling, 2 = moderated and 3 = severe swelling. All values exceeding 0.25 
were considered joint swelling. Joint swelling scoring was performed without 
knowledge of  the experimental groups. For total IL-1β levels, patellae with 
surrounding tissue were directly transferred to 200µl 0.5% Triton-X 100 in 
PBS. After repeated freeze-thawing IL-1β was determined by ELISA (R&D 
systems).
RNA sequencing
RNA was extracted from Paxgene tubes and RNA quantity and quality were 
checked on a Bioanalyzer. Total RNA from whole blood was deprived of  
globin using Life Technologies Globin Clear kit. RNAseq libraries were 
prepared from 1 µg RNA of  each cell population using the TruSeq RNA 
sample preparation kit v2 (Illumina) according to the manufacturer’s 
instructions, and these libraries were subsequently sequenced on a HiSeq 
2500 sequencer (Illumina) using paired-end sequencing of  2 x 50 bp, upon 
pooling of  10 samples per lane. 
Environmental parameters
Pollen counts were performed at the Elkerliek Hospital, Helmond, The 
Netherlands. Pollen were collected using a Burkard pollen sampler (http://
www.burkardscientific.co.uk/) and were counted using a microscope as 
number of  pollen from a certain species per m3 of  air. All counts were 
performed by a trained technician.
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Daily levels of  atmospheric NH3, O2, SO2, NO, NO2 and CO were obtained 
from the National Institute for Public Health and the Environment 
(RIVM), Ministry of  Health, Welfare and Sport (http://www.lml.rivm.nl/
gevalideerd/).
 Climate data (temperature, humidity, sunshine duration) were obtained 
from The Royal Netherlands Meteorological Institute (KNMI) (http://
projects.knmi.nl/klimatologie/daggegevens/selectie.cgi).
Quantification and statistical analysis
Data pretreatment
All cytokine and circulating mediator data were log-transformed. In the cases 
where the response fell outside of  the range of  the ELISA measurement, the 
threshold value of  the ELISA plate was used as the measured value. The rank-
based regression method used for most analysis should not be affected by the 
non-normality of  some of  the data (and is unaffected by the log-transformation)
 Measurements for which one of  the detection limits contained >50% of  the 
measurements were filtered out of  any further analysis. Missing values were 
handled on a pairwise basis (for each comparison separately): given the limited 
number of  missing values and large number of  people in our study, this was 
found preferable over imputing the data.
Circulating cytokine correlations
For the circulating cytokine correlations the linear Pearson correlation was 
used as implemented in the “stats” package of  the programming language “R”.
Statistical regression analysis
Rank based regression results (for all regression analysis except for the 
seasonality) were obtained using “Rfit” (Kloke and Mckean, 2012). With 
this method, a regression value and standard error are calculated for each 
factor in the model, and these are used to calculate a p-value. The t-statistic 
is defined as the ratio of  these two values and a p-value for each vector is 
calculated based on a t distribution with n-p-1 degrees of  freedom where p 
is the number of  regression parameters. The following regression formula 
was used (including an offset term):
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 (1)
where sin(2 * pi * numDaysFromJan2013 / 366) and cos( 2 * pi * 
numDaysFromJan2013 / 366) are periodic signals together capturing 
seasonality patterns with a periodicity of  one year. The linear term 
numDaysFromJan2013 was added to partially correct for sample storage 
degradation. In this analysis these terms are added as correction factors, 
calculation of  the significance of  the seasonality is described below. The 
other factors were included as follows: age was added to the model as 
numerical (float) values, gender was added as a categorical value, with 
categories ‘male’ and ‘female’, BMI was added to the model as numerical 
(float) values, smoking was added as a binary value to indicate if  somebody 
smokes (on a regular basis), vitD was added as a numerical (float) value, 
indicating someone’s vitamin D levels and oralContraceptive was added as a 
binary factor, indicating oral contraceptive usage.
Seasonality analysis
Seasonality analysis was performed using a linear regression analysis. A 
linear combination of  a sine and cosine term with the same frequency allows 
for the formation of  a sine wave with any phase of  that particular frequency. 
This property can be mathematically described as:
 (2)
 (3)
 (4)
(for proof see: http://dspguru.com/sites/dspguru/files/Sum_of_Two_Sinusoids.
pdf, http://math.stackexchange.com/questions/535600/sum-of-sinusoids-with-
same-frequency-sinusoid-proof)
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We used a sine and cosine wave with a period of  one year. By fitting a linear 
model to each cytokine/measurement using the “lm” function part of  the “stats” 
package in R, it is possible to estimate the amplitude and phase of  a periodic 
signal present in the data. To achieve this we use the same regression formula 
(1) as was used for the rank-based model. By comparing the regression analysis 
with the cosine and sine term to an alternative regression model lacking these 
terms we obtained P-values for the seasonality. The comparison between the two 
models was performed using analysis of  variance (“anova” function in R). 
Seasonality filtering
The seasonality analysis tends to pick up spurious effects caused by sample 
storage (samples stored in the freezer tend to degrade over). To remove these 
false positives, the results were filtered on a stricter p-value threshold than 
the other factors (P<= 0.0001) and a threshold was set on the (relative) 
amplitude of  the seasonal term.
 The amplitude of  the seasonality term was calculated as defined in (3). 
To normalize this amplitude to the range of  values for a measurement, the 
10th (perc10) and 90th (perc90) percentile for each measurement were 
calculated. The amplitude was subsequently normalized as:
(5)
A threshold for the seasonality was determined by visually inspecting the 
histogram of  Anorm (Figure S2F). Most amplitudes fall within a range of  
about 0 to 0.14. The cut-off  threshold was placed at the first peak in the 
histogram after this range, at a value of  0.1601.
Non-linear seasonality analysis
To verify if  the seasonality results were independent of  the type of  test 
used, a non-linear curve-fitting approach was also performed using the ‘nls’ 
function from R package ‘stats’ with algorithm ‘port’. Briefly, a non-linear 
least-square regression model was fitted to cytokine response and circulating 
mediator data as a function of  time of  sampling, according to the following 
formula:
y ~ Amplitude * cos(2 * π * (t - Phase)/366) + linearIncrease * t + y0 (6)
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where
• ‘y’ was the measured intensity value
• ‘t’ was the number of  days since 1st of  January 2013
• ‘Phase’ was the day of  the year at which the intensity peaked
• ‘linearIncrease’ was the linear increase in intensity over time
• and ‘y0’ was the intercept (estimated average intensity on 1
st of  January 
2013)
Vitamin D analysis
To check if  vitamin D levels held any predictive power beyond their periodic 
signal, the levels were separated into a periodic signal and residuals. The 
periodic signal with 7 degrees of  freedom was fitted using the “smooth.
spline” function part of  the “stats” package in R. The residuals were 
calculated by substracting the periodic signal from the vitamin D levels.
 Next, a rank-based regression model was fitted using Rfit (similar to 
before): This provides p-values for the significance of  both the periodic and 
the residual signal.
RNA expression analysis
Sequencing reads were mapped to the human genome using STAR (version 
2.3.0) (Dobin et al., 2013). The aligner was provided with a file containing 
junctions from Ensembl GRCh37.75. Htseq-count of  the Python package 
HTSeq (version 0.5.4p3) was used (The HTSeq package, http://www-huber.
embl.de/users/anders/HTSeq/doc/overview.html) to quantify the read 
counts per gene based on annotation version GRCh37.75, using the default 
union-counting mode. Reads Per Kilobase of  transcript per Million mapped 
reads (RPKM) values were then calculated to quantify gene expression 
levels.
 (7)
RNA seasonality analysis
Seasonality analysis on the mRNA data was applied to a select subset of  
genes of  interest to retain as much statistical power as possible. Two subsets 
were created: one first set of  the four cytokines/molecules showing a clear 
pattern of  seasonality at the protein expression level: TNFα, IL-1b, IL-6 
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and AAT; secondly, a set of  genes that encode for receptors of  the microbial 
ligands and the signaling molecules inducing cytokines, assembled based on 
expert knowledge integrated with information obtained from various public 
resources, such as HGNC (http://www.genenames.org), KEGG Pathways 
and GO (PRRs, adaptor molecules, transcription factors). These lists are 
provided in Table S5 and Table S6, respectively.
 The RNA seasonality analysis was performed in a similar fashion to the 
linear seasonality analysis described previously. Formula (1) was applied, 
except for the removal of  the “vitD”-term, since our previous analysis 
showed that vitamin D had no residual influence on seasonal cytokine 
responses and might interfere with the seasonal (sine and cosine) terms.
Combining the rank based regression and seasonality analysis
P-values for all measured parameters for the factors “age”, “gender”, “BMI”, 
“smoking”, “vitD” and “oralContraceptive” obtained using “Rfit” were 
merged with the p-values for the “seasonality” term obtained with the ‘lm’ 
function. Multiple testing correction as described in the section “Multiple 
Testing Correction” was performed over all these p-values simultaneously.
Hormone correlation analysis
For those cytokines found to be affected by gender, the influence of  hormones 
on this effect was evaluated. The (rank-based) Spearman correlation was 
calculated between hormone levels and cytokines, and all p-values were 
corrected for multiple testing (see section “Multiple testing correction).
Multiple-testing correction
Multiple-testing correction was applied using the Benjamini-Hochberg 
FDR correction (Benjamini and Hochberg, 1995) over the three large scale 
analyses separately: the correlation between circulating cytokines, the main 
regression analysis (factors with circulating cytokines/circulating mediators 
and cytokines after stimulation) and the hormone correlation analysis.
IL-6 validation cohort analysis
A similar model as used in our main cohort was applied to our validation 
cohort using Rfit. We assessed the influence of  age and gender on circulating 
IL-6 concentrations using the formula:
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showed that vitamin D had no residual influence on seasonal cytokine 
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Combining the rank based regression and seasonality analysis
P-values for all measured parameters for the factors “age”, “gender”, “BMI”, 
“smoking”, “vitD” and “oralContraceptive” obtained using “Rfit” were 
merged with the p-values for the “seasonality” term obtained with the ‘lm’ 
function. Multiple testing correction as described in the section “Multiple 
Testing Correction” was performed over all these p-values simultaneously.
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For those cytokines found to be affected by gender, the influence of  hormones 
on this effect was evaluated. The (rank-based) Spearman correlation was 
calculated between hormone levels and cytokines, and all p-values were 
corrected for multiple testing (see section “Multiple testing correction).
Multiple-testing correction
Multiple-testing correction was applied using the Benjamini-Hochberg 
FDR correction (Benjamini and Hochberg, 1995) over the three large scale 
analyses separately: the correlation between circulating cytokines, the main 
regression analysis (factors with circulating cytokines/circulating mediators 
and cytokines after stimulation) and the hormone correlation analysis.
IL-6 validation cohort analysis
A similar model as used in our main cohort was applied to our validation 
cohort using Rfit. We assessed the influence of  age and gender on circulating 
IL-6 concentrations using the formula:
(8)
Data and software availability
All data used in this project have been meticulously catalogued and archived 
at BBMRI-NL data infrastructure at https://bbmri.nl/molgenis/500FG 
aiming for maximum reuse following the FAIR principles, i.e., Findability, 
Accessibility, Interoperability and Reusability (Wilkinson et al., 2016). 
The central data stewardship and access has been implemented using 
MOLGENIS open source platform for scientific data (Swertz et al., 2010) 
that enables flexible data upload, management and querying, including 
sufficiently rich metadata and interfaces for machine processing and custom 
(R statistics) visualization for human processing (see http://molgenis.
org). Also summaries of  the study have been submitted to BBMRI central 
catalogues https://catalogue.bbmri.nl (Netherlands) and http://bbmri-eric.
eu/bbmri-eric-directory (EU). 
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Supplemental Tables
Table S1 Stimulation scheme for the in vitro cytokine production assays, Related to 
Figure 1, Figure 2 and Figure 4.
Whole Blood stimulation experiment (48 hours of stimulation)
Stimulus Final concentration Strain/Manufacture
RPMI (1640 Dutch 
Modified)
- Life Technologies
LPS 100ng/ml E.coli/Sigma
PHA 10 µg/mL Sigma
C. albicans yeast 1x10^6/mL UC820
Staphylococcus aureus 1x10^6/mL ATCC29213
PBMC stimulation experiment (24 hours of stimulation)
Stimulus Final concentration Strain/Manufacture
LPS 1 and 100ng/ml E.coli/Sigma
Pam3Cys 10 µg/mL EMC microcollections
RPMI + Serum 10% human serum Life Technologies
Poly I:C 100 µg/mL Sas Invivogen
CpG (ODN M362) 10 µg/mL Sas Invivogen
Influenza+serum 1.25x10^6PFU/mL H1N1 / In house
MSU 300 µg/mL Sigma, Merck
MSU + C16 300 µg/mL + 100 uM Sigma, Merck
E.Coli 1x10^6/mL ATCC 35218 / In house
RPMI - Life Technologies
B.burgdorferi 1x10^6/mL ATCC 35210
Borrelia mix 1x10^6/mL B.burgdorferi ATCC 35210, B.afzelii 
ATCC51567 , B.garinii ATCC51383
C. albicans yeast 1x10^6/mL UC820/ In house
C. albicans yeast  hyphae 1x10^6/mL UC820 /In house
A.fumigatus conidia + serum 1x10^7/ml/10% V05-27 clinical isolate
Mycobacterium tuberculosis 1 µg/mL H37Rv/ In house
Coxiella burnetii + serum 1x10^6/mL Strain nine mile, RSA493
Staphylococcus aureus 1x10^6/mL ATCC29213/ In house
Cryptococcus gattii + serum 1x10^7/mL A1M-R265, AFLP type 6/ Clinical Isolate
Bacteroides fragilis 1x10^6/mL ATCC 25285 / In house
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PBMC stimulation experiment (7 days of stimulation)
Stimulus Final concentration Strain/Manufacture
RPMI + Serum 10% Life Technologies
B.burgdorferi 1x10^6/mL ATCC 35210
Borrelia mix 1x10^6/mL B.burgdorferi ATCC 35210, B.afzelii 
ATCC51567 , B.garinii ATCC51383
C. albicans yeast 1x10^6/mL UC820/ In house
C. albicans yeast hyphae 1x10^6/mL UC820 /In house
A.fumigatus conidia 1x10^7/mL V05-27 clinical isolate
Mycobacterium tuberculosis 1 µg/mL H37Rv/ In house
Staphylococcus aureus 1x10^6/mL ATCC29213/ In house
Cryptococcus gattii 1x10^7/mL A1M-R265, AFLP type 6/ Clinical Isolate
Bacteroides fragilis 1x10^6/mL ATCC 25285 / In house
Macrophage stimulation (24 hours of stimulation)
Stimulus Final concentration Strain/Manufacture
RPMI  - Life Technologies
LPS 100 ng/mL E.coli/Sigma
C. albicans yeast 1x10^6/mL UC820/ In house
A.fumigatus conidia 1x10^7/mL V05-27 clinical isolate
Mycobacterium tuberculosis 1 µg/mL H37Rv/ In house
Salmonella typhimurium 1x10^7/mL Phage type 510/In house
RPMI + Serum 10% Life Technologies
Table S1 Continued
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Table S2 Characteristics of  the 500FG cohort as part of  the Human Functional 
Genomics Project (HFGP), Related to Figure 1 and Figure 2. Slight differences between 
the percentages in Table S2 and Figure 2 are caused by extra exclusion criteria (see 
Experimental procedures) implemented in calculating the percentages in Figure 1. 
Gender (% of whole cohort) Male 237 (44,5)
Female 296 (55,5)
Mean Age (years) (SD) Mean 28,5 (13,9)
Mean body mass index (SD) 22,7 (2,9)
Presence of allergy (% of whole cohort) No 394 (75,6)
Yes 127 (24,3)
Medicine usage (% of whole cohort) No 432 (81,9)
Yes 95 (18,0)
Usage of pill as birth control (% of women) Yes 155 (53,0)
No 137 (46,9)
Smoking behavior (% of whole cohort) Present 70 (13,3)
Past 83 (15,8)
Never 330 (63,0)
Passive 41 (7,8)
Table S5 First set of  genes tested for seasonal patterns, Related to Figure 5 and Figure 6. 
The columns that might not be evident are as follows: “FDR” is the Benjamini-Hochberg 
False Discovery Rate and “peakMonth” indicates the month at which the seasonal 
response is at its highest. 
Ensemble Id pVals FDR peakMonth geneName
ENSG00000232810 0.004051187 0.016204747 Jul TNF
ENSG00000125538 0.434778091 0.65254259 Aug IL1B
ENSG00000136244 0.489406942 0.65254259 Jun IL6
ENSG00000197249 0.990451058 0.990451058 Jan SERPINA1/AAT
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Abstract 
Vulvovaginal candididasis (VVC) is a frequent disease affecting more 
than 75% of  all women at least once in their lifetime. Up to 8% of  them 
suffer from recurrent vulvovaginal candidiasis (RVVC) characterized by at 
least three episodes each year. Several risk factors such as antibiotic use, 
diabetes or pregnancy are known, but the vast majority of  women with 
RVVC develop the infection without having any risk factor, implying that a 
genetic component most likely plays an important role in the susceptibility 
to RVVC. This review summarizes the immunogenetic alterations that lead 
to an increased susceptibility to vaginal infections with Candida albicans. 
Different mutations and polymorphisms in innate immune genes alter the 
mucosal immune response against fungi, and are likely to have an important 
role in susceptibility to RVVC. A better understanding of  the genetic and 
immunological mechanisms leading to RVVC is important for both the 
understanding of  the pathophysiology of  the disease, as well as for the 
design of  novel therapeutic strategies.
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Introduction
The vaginal mucosa is inhabited by both fungal and bacterial microorganisms, 
which normally coexist with the host in a tightly regulated and commensal 
manner. Nevertheless, under certain circumstances, the passive coexistence 
between particular microorganisms and the host can turn into a pathologic 
state, followed by symptomatic disease. The immune system plays a dual 
role in this process, as it limits the microbial burden at different body sites 
on one hand, and it regulates tolerance to commensal microorganisms on 
the other hand. Both processes have beneficial effects for the host [1].
 Candida albicans is by far the most abundant fungal microorganism in 
the vaginal microbiome, making up about 85-95% of  the total fungal load 
[2, 3]. As a consequence, this dimorphic fungus is the main opportunistic 
pathogen found in patients with vulvovaginal candidiasis (VVC), a fungal 
infection affecting more than 75% of  all childbearing women at least once 
in their lifetime [4-6]. VVC not only causes significant costs for the health 
system and the society, but also dramatically worsens the quality of  life 
of  affected women [2, 7]. Moreover, a significant percentage of  women 
of  approximately 5-8% experience recurrent episodes of  VVC (RVVC). 
This distressing condition is characterized by at least 3 episodes of  VVC 
per year [5, 6]. Different predisposing risk factors have been reported to be 
responsible to increase the susceptibility to (R)VVC, among which diabetes, 
oral contraceptives , pregnancy, steroid and immunosuppressive therapy, as 
well as HIV, are the most common ones [2, 3, 8-11]. However, research 
on cohorts with different ethnical background revealed that there is most 
likely also a genetic component that contributes to the onset of  RVVC. This 
argument is strengthened by the fact that most tested women having RVVC 
are not enervated by one of  the afore mentioned risk factors [12]. 
 In this review we will summarize the different genetic changes that 
contribute to an altered innate immune defense against C. albicans and 
therefore contribute to the susceptibility of  recurrent vaginal infections with 
this fungus. 
Candida interaction with the mucosal epithelium
Epithelial cells (EC) at the level of  the vaginal mucosa form the first barrier 
against C. albicans. Not surprisingly, it has been shown that these cells express 
different pattern recognition receptors (PRRs) as dectin-1 and several of  the 
Toll-like receptors (TLRs). ECs actively play a role in the fungal immune 
response by initiating the secretion of  pro-inflammatory cytokines such 
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as TNF-α and IL-1α, or chemokines [13-15]. Released cytokines will 
subsequently recruit and activate various immune cells including neutrophils 
that may have both protective and deleterious effects. In humans, in limited 
studies,  it has been shown that high mucosal loads of  Candida can lead 
to an overwhelming harmful innate immune response, with a loss of  local 
tolerance [6]. The release of  “danger” molecules by the mucosal ECs, such 
as S100 alarmins, in response to Candida potentially could lead to massive 
PMN recruitment and symptoms of  inflammation [16].
 Naglik et al. described a model in which C. albicans is recognized by ECs, 
but only cell wall moieties from the invading hyphal form of  C. albicans are 
able to induce full activation and cytokine secretion [17]. In vitro experiments 
have additionally shown that ECs are able to inhibit the growth of  C. albicans 
[18-20]. This antifungal activity of  vaginal ECs against C. albicans is based on 
simple EC-Candida interaction without the involvement of  soluble factors. 
Accordingly, this defensive anti-Candida effect is supposed to be critically 
reduced in patients with RVVC, leading to uncontrolled outgrowth of  this 
fungus [18, 21]. 
Anti-fungal defense against Candida albicans
Besides the fact that mucosal anti-fungal activity has been partially attributed 
to vaginal ECs, an important role for components of  the innate immune 
system has also been reported. Two different types of  innate immune cell 
receptors, namely Toll like receptors (TLRs) and lectin-like receptors (LR), 
play a major role in the recognition of  Candida cell wall components [22, 
23]. Engagement of  these receptors by their ligands, such as N- and- O- 
linked-mannans or β-glucans, leads to the production of  cytokines, which in 
turn recruit and activate other immune cells. Beside the various cell surface 
receptors, the complement system forms another strong defense mechanism 
against pathogenic invaders. Mannose binding lectin (MBL) plays an 
important role in this context as it recognizes mannose residues present on 
the fungal cell wall, which subsequently leads to complement activation and 
microbial killing or opsonisation of  the pathogen [24]. Alterations in these 
mechanisms can lead to defective mucosal defense mechanisms and harmful 
imbalances in both pro- as well as anti-inflammatory cytokine responses 
against C. albicans.
Genetic susceptibility to RVVC
Although some antifungal properties have been attributed to vaginal 
epithelial cells, very little is known about genetic alterations within these 
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Figure 1. Interaction of  C. albicans with the vaginal epithelium and innate immune 
cells. EC: Endothelial cell, TLR: Toll like receptor, MR: mannose receptor, PMN: 
Polymorphonuclear leukocytes, MΦ: Macrophage.
Tabel 1. Genetic factors increasing the susceptibility to RVVC.
Protein Gene Alterations Location Effect
Dectin-1 CLEC7A Y238X Exon 6 Premature Stop codon, 
structural effects, Expression 
and β-glucan recognition 
decreased
NLRP3 NLRP3/
CIAS1
Length 
polymorphism 
with different 
genotypes
Intron 4 Decreased IL-1β production and 
processing
MBL MBL2 ARG52CYS Exon 1 Decreased expression and vaginal 
levels of MBL
IL-4 IL-4 C589T Promotor 
region
Increased expression of IL-4, 
decreased NO secretion
Lewis
Phenotype
FUT3,FUT2 Le(a+b-) or 
Le(a-b-), non-
secretor phenotype
not known
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cells concerning the susceptibility to recurrent vulvovaginal infections. The 
first study assessing the association of  host factors with susceptibility to 
RVVC dates from Sobel and coworkers in 1997, who showed that there was 
no difference in the AB0 phenotype between RVVC patients and controls, 
while there was a difference between these two groups regarding the Lewis 
phenotype. Patients from the RVVC group were more likely to have the 
nonsecretor phenotype (Le(a+b-) or Le(a-b-)) rather than the secretor 
phenotype (Le(a-b+) [25].  
 ECs express various surface recognition receptors that are able to respond 
to C. albicans components followed by cytokine secretion and immune cell 
activation and differentiation [17]. Different polymorphisms have been 
found for those receptors, but a direct link between ECs and RVVC still 
remains to be tested in the future [26, 27]. In addition, ECs have been shown 
to participate in growth inhibition of  Candida. This antifungal activity was 
decreased in patients suffering from RVVC, even when patients did not fall 
under any of  the known predisposing factors [18, 19]. This observation may 
point towards a genetic component altering EC-dependent anti-Candida 
activity, but future experiments have to confirm these observations. On the 
other hand, much more is known about the genetics of  specific components 
of  the innate immune system. Various monogenetic as well as polygenetic 
alterations have been reported so far, all of  which affect different areas of  
the innate antifungal defense. Figure 1 shows the interactions of  Candida 
with the vaginal epithelium and innate immune system, while Table 1 shows 
the alterations within these components.
Dectin-1 and CARD9
The cell wall of  C. albicans contains mainly polysaccharides, with β-glucans, 
mannans and chitin being the most prominent. Beta-glucans are recognized 
by the C-type lectin receptor dectin-1 which is expressed by myeloid and 
epithelial cells [13, 28, 29]. Dectin-1 synergizes with TLR2 and TLR4 for 
the induction of  cytokine production, but also induces IL-17, IL-10 and IL-1 
independently of  these TLRs [30]. Binding of  dectin-1 to β-glucans leads to 
the activation of  a Src-Syk-CARD9 dependent pathway ultimately leading 
to the activation of  NFкB and the transcription of  important antifungal 
cytokines as IL-1β, IL-6, and IL-23 [31]. 
 Non-synonymous mutations have been identified affecting either dectin-1 
itself  or the adaptor molecule CARD9 downstream of  the receptor [26, 
31, 32]. An early stop codon mutation in exon 6 at position 236 of  the 
dectin-1 gene (TYR238X) leads to a truncated carbohydrate recognition 
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domain lacking the last ten aminoacids [33]. As a consequence, β-glucan 
recognition as well as surface expression is severely impaired. An impaired 
C. albicans recognition and cytokine response, especially IL-17 and IL-6, 
are the consequences of  this mutation [26-28]. A family of  patients with 
three siblings homozygous for the mutation has been identified, with two of  
them suffering from RVVC [26, 33]. In addition, mucosal colonization with 
Candida has been shown to be increased in heterozygous patients bearing 
this mutation [33]. Individuals homozygous for a nonsense mutation in 
exon 6 of  the CARD9 gene (GLN295X) also display an impaired antifungal 
host response and severe invasive fungal infections, although no RVVC has 
been reported in this family [31]. This impaired response is characterized 
by decreased levels of  IL-2, IL-6, IL-10, and TNFα, as well as a reduction 
of  Th17 cells [34, 35]. Besides the involvement of  CARD9 in dectin-1 
signaling, this adapter protein also participates in the signaling of  dectin-2 
and macrophage-inducible C-type lectin (MINCLE) both of  which are 
known to recognize mannans from Candida, and this explains the broad 
spectrum of  fungal infections in these patients [28].
NLRP3
The production and release of  the proinflammatory cytokines IL-1β and 
IL-18 is accomplished by the processing of  inactive precursors of  these 
two cytokines. The processing step is mediated by specialized cytoplasmic 
structures named inflammasomes. NACHT-LRR-PYD-containing protein 
(NLRP3) and apoptosis-associated speck-like protein (ASC) assemble into 
a protein platform to recruit and activate caspase-1, allowing the processing 
of  pro-IL-1β and pro-IL-18 into their bioactive forms [36, 37]. A length 
polymorphisms in intron 4 of  the NLRP3 (CIAS1) gene has been found. 
Due to the nature of  this length polymorphism, different genotypes arise, 
from which the 12/12 genotype is reported to have the highest NLRP3 
production. Accordingly, this genotype was more frequent in a control group 
(N=182) compared to a group of  VVC patients (N=143). The 7/7 genotype 
on the other hand was higher in the VVC group and was associated with 
reduced NLRP3 production and therefore diminished IL-1β processing. 
Further subdivision of  the VVC group into patients with RVVC and sporadic 
disease showed similar results, with the 7,7 genotype being increasingly 
present in the RVVC group compared to the sporadic and control groups 
[37, 38]. Nevertheless, more studies regarding this and other inflammasome 
components have to be performed to link various genetic alterations in the 
inflammasome components to the susceptibility to (R)VVC.
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Mannose-binding-Lectin (MBL) 
The best studied gene polymorphisms related to the susceptibility to (R)
VVC are SNPs in the MBL2 gene. This gene encodes for MBL, which plays 
an important role in the innate anti- Candida immune response. Mainly 
produced in the liver, this circulating and opsonic C-type lectin is able to 
recognize and bind mannose and N-acetyl-glucosamine residues present on 
the surface of  microorganisms in general, and Candida in particular [39-42]. 
By binding to these residues, MBL activates the complement system, which 
ultimately results in the opsonization of  the microorganism and activation 
of  the cytokine response through release of  C5a anaphylatoxin [41, 43]. 
Due to the thick cell wall, it is believed that the terminal membrane attack 
complex of  the complement system does not have a role in the direct killing 
of  Candida. 
 Although MBL levels can differ between individuals, three polymorphisms 
have been identified that affect circulating MBL levels. These three SNPs, 
known as ARG52CYS, GLY54ASP and GLY57GLU, are all located in exon 
1 of  the MBL2 gene and are differently distributed in populations of  various 
ethnic origins [43, 44]. Studies in Latvian, Brazilian, Chinese and Belgium 
patients and controls showed a direct negative correlation between severely 
decreased vaginal MBL levels and the prevalence of  RVVC [39, 45-48]. In 
addition to that, Donders and co-workers suggested that RVVC patients 
that carry at least one of  the risk alleles in codon 54 are more likely to 
respond to treatment with fluconazole [45]. However, not all studies were 
able to validate this association, with Milanese and colleagues reporting 
no correlation between MBL2 GLY54ASP genotypes and susceptibility to 
RVVC [44].
 Although it has been shown that the GLY57GLU SNP is exclusively 
present in African populations, whereas the ARG52CYS SNP is present at 
low frequencies in both European and African individuals, future studies 
should assess whether this differential distribution may be associated with a 
different prevalence of  RVVC in these populations [47].   
Nitric oxide (NO) and Interleukin-4 (IL-4)
During the response against Candida, innate immune cells secrete mediators 
that have direct anti-Candida effects. Once activated by interferon-γ or TNF-α, 
macrophages secrete nitric oxide which is known to have cytotoxic effects 
for microorganisms [49]. IL-4, an anti-inflammatory cytokine secreted by 
activated Th-2 cells, is known to inhibit the NO production and secretion by 
macrophages [50]. A SNP in the IL-4 gene leads to elevated IL-4 production 
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and therefore a decrease in NO production. This polymorphism affects the 
promoter region of  the IL-4 gene by a C to T transmission (C589T). Babula 
et al. showed that around 60.5% of  the study control subjects compared 
to 7.1% of  the RVVC patients were homozygous for the normal C allele 
(P< .0001). On the other hand, 76.2% (RVVC) versus 23.3% (controls) 
were homozygous for the T risk allele (P< .0001) [51]. In their study, they 
postulate that homozygosity for the risk allele was associated with a two-
fold increase of  vaginal IL-4, coupled to a three-fold decrease of  vaginal 
NO. Additionally to that, patients being homozygous for the risk allele had 
also severely reduced levels of  MBL (by a 2-fold factor) [51]. In future, it 
remains to be clarified whether the IL-4 polymorphism or an additional 
polymorphism in the MBL2 gene are responsible for these findings.
Genotype of  vaginal C. albicans species
Recently, Fan and coworkers revealed a relationship between different 
vaginal Candida genotypes and the severity of  VVC. By comparing a highly 
polymorphic microsatellite locus (CAI) within Candida strains found in VVC 
patients with varying severity of  the infection, they were able to show that 
some specific genotypes were more virulent than others [52, 53]. Although 
in a lesser extent, they were also able to confirm this for a relatively small 
group of  RVVC patients [54]. These results indicate that the genetic makeup 
from both the host and the pathogen may play an important role in the 
susceptibility and severity of  (R)VVC. Future studies are warranted to 
assess the interaction between host and fungus genomes, and the complex 
ecological and evolutionary interactions that may lead to the potential 
association of  certain Candida strains with the genetic make-up of  the host.
Future directions 
Although some predisposing environmental factors and behavioral patterns 
increase the susceptibility to fungal infections, the vast majority of  women 
suffering from recurrent vulvovaginal infections do not display any of  these 
factors. Therefore, genetic components are most likely to play an important 
part in susceptibility to RVVC. Several polymorphisms in IL-4, NALP3 and 
MBL have been described to be associated with an increased risk for RVVC 
[37, 39, 51], but it is expected that they represent only the tip of  the iceberg. 
The genetic studies comparing healthy individuals and RVVC patient 
cohorts reveal both a better understanding of  the genetic variations that 
contribute to susceptibility to mucosal fungal infections, as well as revealing 
the pathophysiological mechanisms important for mucosal anti-Candida 
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defense. To name only one example, defects in NLRP3, more frequently 
found in RVVC patients compared to controls, identifies the inflammasome 
as a crucial component for mucosal antifungal host defense. 
 Therefore, genetic association studies in bigger cohorts of  RVVC patients, 
with different ethnic background, are warranted in order to obtain a better 
overview of  the genetic susceptibility to the disease. Both hypothesis-driven 
studies on genes known to be involved in mucosal antifungal defense and 
discovery-driven studies by genome-wide association studies (GWAS) may 
give important insight in the genetic landscape of  the disease. This may 
finally lead to a better understanding of  the pathogenesis and the design of  
novel therapies.
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Abstract
Candida albicans is part of  the normal commensal microbiota of  mucosal 
surfaces in a large percentage of  the human population. However, 
perturbations of  the host’s immune response or bacterial microbiota have 
been shown to predispose to the development of  opportunistic Candida 
infections. It was recently discovered that a defect in the chemokine receptor 
CX3CR1 increases susceptibility of  mice and humans to systemic candidiasis. 
However, whether CX3CR1 confers protection against mucosal C. albicans 
infection has not been investigated. Using two different mouse models, we 
found that Cx3cr1 is dispensable for the induction of  IL-17A, IL-22 and 
IL-23 in the tongue after infection, as well as for the clearance of  mucosal 
candidiasis from the tongue or lower gastrointestinal (GI) tract colonization. 
Furthermore, the dysfunctional human CX3CR1 allele CX3CR1-M280 was not 
associated with development of  recurrent vulvovaginal candidiasis (RVVC) 
in women. Taken together, these data indicate that CX3CR1 is not essential 
for protection of  the host against mucosal candidiasis, underscoring the 
dependence on different mammalian immune factors for control of  mucosal 
versus systemic Candida infections.
165
6
Introduction
Candida albicans is a normal constituent of  the human mucosal microbial 
ecology. However, inherited and acquired immunodeficiency syndromes and 
iatrogenic factors, such as catheter and antibiotic use, result in perturbations 
in the local mucosal immune environment and predispose patients to 
development of  opportunistic mucosal Candida infections and systemic 
candidiasis due to translocation of  yeast from mucosal surfaces into the 
systemic circulation [1, 2]. The most common forms of  mucosal candidiasis 
are oropharyngeal candidiasis (OPC) and vulvovaginal candidiasis (VVC), 
while infections of  the skin and nails occur less often [3]. Although human 
mucosal candidiasis is not life-threatening, it has a substantial global 
disease burden. For example, the majority of  HIV-infected patients will 
develop oral mucosal candidiasis [4], and approximately 75% of  healthy 
reproductive-age women will develop at least one episode of  VVC during 
their lifetime. Furthermore, about 50% of  these women will develop at least 
one episode of  recurrent infection, and in 5-10% of  them, recurrent VVC 
(RVVC), defined as ≥3 episodes of  infection per year, will occur [5]. The 
substantial incidence and morbidity of  mucosal candidiasis, the significant 
cost associated with it (i.e., the estimated annual cost of  VVC exceeds 2 
billion dollars in the US alone) [6], and the emerging resistance of  Candida 
spp. to available antifungal agents that limits therapeutic options [7] highlight 
the importance for a better understanding of  the cellular and molecular 
immune factors that mediate effective anti-Candida host defense at the 
mucosa and systemically, with an aim to develop immune-based strategies 
for risk stratification, prognostication and/or treatment of  affected patients.
 The chemokine receptor CX3CR1 binds specifically to its sole ligand, 
CX3CL1 (fractalkine), and is expressed by hematopoietic (i.e., mononuclear 
phagocytes and subsets of  NK and T cells) and non-hematopoietic (i.e., 
epithelial and endothelial) cells, where it mediates cell adhesion, proliferation, 
differentiation, recruitment, survival, and effector functions [8, 9]. We have 
previously shown that Cx3cr1 is critical for host survival and control of  
proliferation of  C. albicans in the kidneys of  mice, by promoting resident 
kidney macrophage survival, accumulation in tissue, and contact with and 
killing of  C. albicans in vivo. In agreement with the mouse data, the mutant 
human CX3CR1-M280 allele was shown to be an independent risk factor for 
the development of  candidemia and disseminated candidiasis in two different 
cohorts of  patients from the US and Europe [10]. However, whether this 
receptor plays a role in mucosal host defense against Candida is unknown. 
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In recent years, it has become evident that IL-23-dependent IL-17 and IL-
22 signaling is critical for protection against mucosal candidiasis in mice 
and humans [11-17]. Of  interest, Cx3cr1 has previously been shown to 
promote IL-23-dependent IL-22 production and mucosal immune responses 
in the context of  bacterial GI infection and intestinal inflammation [18, 19]. 
Similarly, it has also been found that Cx3cr1 modulates IL-17 responses, 
both at the mucosal level in the setting of  intestinal inflammation [20], and 
systemically in models of  experimental autoimmune encephalomyelitis and 
collagen-induced arthritis [21, 22]. Therefore, the aim of  this study was to 
determine whether a deficiency in CX3CR1 impairs the production of  IL-
17A, IL-22, and IL-23, while enhancing susceptibility of  mice or humans to 
mucosal Candida infections. Interestingly, Cx3cr1-deficient mice did not have 
impaired expression of  IL-17A, IL-22, or IL-23 in the context of  mucosal 
candidiasis. Also, unlike systemic candidiasis, Cx3cr1-deficient mice did not 
exhibit an impaired ability to control C. albicans infection in the oral cavity 
or yeast colonization of  the lower GI tract. Furthermore, the dysfunctional 
human CX3CR1-M280 allele was not associated with development of  RVVC 
in a cohort of  113 affected patients. Therefore, CX3CR1 protects the host 
specifically during systemic but not mucosal C. albicans challenge.
Materials and Methods
Mice
Age and sex-matched Cx3cr1-/- mice and C57Bl/6 controls were obtained 
from Taconic Farms. The Cx3cr1-/- mice were developed and backcrossed to 
the C57Bl/6 background as described previously [23]. All mice were used 
between 7 and 14 weeks of  age, and were housed under specific-pathogen-free 
conditions. All experiments were conducted in accordance with guidelines 
set forth by the Guide for the Care and Use of  Laboratory Animals under a 
protocol approved by the Animal Care and Use Committee of  the NIAID 
in an Association for Assessment and Accreditation of  Laboratory Animal 
Care-accredited animal facility.
Fungal strains
The C. albicans strain SC5314, recovered from a patient with systemic 
candidiasis, was used for the majority of  the experiments performed. In some 
experiments of  oropharyngeal candidiasis (OPC), other strains of  C. albicans 
were used. The oropharyngeal clinical strain 529L has been described before 
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[24]. The strains Y42 and Y72 are clinical isolates recovered from patients 
at the NIH with chronic mucocutaneous candidiasis due to autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), while 
they had active oral C. albicans infection. The organisms were grown in yeast 
extract, peptone, and dextrose (YPD) media that contained penicillin and 
streptomycin (Mediatech, Inc.) in a shaking incubator set at 30°C.
Mouse model of OPC
To induce OPC in mice, sublingual infections were performed as previously 
described [25]. Briefly, mice were sedated with ketamine and xylazine, and 
a cotton swab (Puritan Medical Products) saturated in media containing 1 
x 107 C. albicans/mL was placed securely under the tongue for 90 minutes, 
using subsequent doses of  anesthesia to keep animals sedated for the entirety 
of  the infection. No corticosteroid or other immunomodulatory treatment 
was administered to mice prior to oral C. albicans infection.
Mouse model of GI Candida colonization
The GI tract of  mice was colonized with C. albicans as previously described 
[26]. Briefly, in order to eradicate the endogenous microbial flora in the 
mouse gut, streptomycin (2 mg/mL) (Research Products International 
Corp.), penicillin G(1500 U/mL) (Research Products International Corp.), 
and fluconazole (0.25 mg/mL) (Roxanne Laboratories) were added to the 
drinking water for 3 days, after which the drinking water was replaced with 
water containing streptomycin and penicillin G at the same concentration 
for 2 more days. Following antibiotic/antifungal treatment, the mice were 
given water containing 1 x 107 C. albicans/mL, streptomycin (2 mg/mL), 
and penicillin G (1500 U/mL) for the next 5 days. After five days of  C. 
albicans administration, the stool was collected from the mice, weighed, 
homogenized in 1 mL of  PBS, and quantitatively cultured to determine 
the fungal load. Following stool harvesting, mice were observed for 4 
weeks for signs of  development of  systemic candidiasis caused by GI tract 
translocation.
Determination of gene expression via real-time quantitative 
PCR
Cx3cr1+/+ and Cx3cr1-/- mice were sublingually infected with C. albicans and 
euthanized 1 day post-infection (p.i.). Tongues were harvested, and mRNA 
was extracted using Trizol (Invitrogen) and the RNeasy kit (Qiagen), 
according to the manufacturer’s instructions. To convert mRNA to cDNA, 
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the qScript cDNA Supermix kt (Quanta BioSciences) was used. Quantitative 
PCR was then performed with Taqman detection (PerfeCTa qPCR FastMix 
ROX; Quanta BioSciences), using the 7500 Real-Time PCR system (Applied 
Biosystems) and pre-designed primer/probe mixes for GAPDH (Applied 
Biosystems or Integrated DNA Technologies), IL-17A (Integrated DNA 
Technologies), IL-22, or IL-23p19 (Invitrogen). All qPCR assays were 
performed in duplicate and normalized to GAPDH transcript levels using 
the DDCT method. 
Determination of cytokine and chemokine protein 
concentrations
Cx3cr1+/+ and Cx3cr1-/- mice were sublingually infected with C. albicans 
SC5314 as described above and tongues were harvested at day 1 post-
infection. Tongues were homogenized with an Omni Tissue Homogenizer 
(Omni International) in PBS with 0.5% Tween-20 (Sigma-Aldrich) and a 
protease inhibitor cocktail (Roche Applied Science). The homogenate was 
then centrifuged at 16,168 g for 10 minutes at 4°C, supernatants filtered 
through a 22mm filter (EMD Millipore), and frozen at 80°C until use. 
Cytokine and chemokine protein concentrations were determined using 
a multiplex bead array assay. Antibodies and cytokine standards were 
purchased from R&D Systems or Peprotech as antibody pairs. Individual 
luminex bead sets were coupled to capture antibodies for each cytokine or 
chemokine measured as previously described [27]. As recommended by the 
manufacturer, biotinylated antibodies were used at twice the recommended 
concentration for ELISA, and all procedures were performed in PBS with 
1% normal mouse serum (Gibco BRL), 1% normal goat serum (Gibco BRL), 
and 20mM Tris-HCl (pH 7.4). 1200 beads were used for each cytokine 
or chemokine per sample. The plates were read on a Luminex MAGPIX 
platform, and at least 50 beads collected for each set of  beads per sample. 
The median fluorescence intensity for each bead was determined for analysis 
with the Milliplex software using a 5P regression algorithm.
Quantification of colony forming units (CFUs)
In order to assess fungal load, the tongues or stool of  mice were harvested, 
weighed, and homogenized with the Omni Tissue Homogenizer. The 
homogenate was then serially diluted or plated undiluted on YPD agar 
plates containing penicillin and streptomycin. After incubation at 37°C for 
24-48 hours, fungal colonies were counted, and the data were expressed 
as CFUs/gram of  tissue. To lower the limit of  fungal burden detection in 
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tongues during infection with SC5314, the entire tissue homogenate was 
plated onto three plates. If  no colonies were counted from the entire tongue 
homogenate, then a value of  0 was assigned.
Histology
Tongues were harvested at days 3 or 5 post-sublingual infection, fixed in 
10% formalin, and embedded in paraffin. Longitudinal sections of  the 
tongue were prepared for Hematoxylin and Eosin (H&E) or Periodic acid-
Schiff  (PAS) staining (Histoserve, Inc.). Sections were then viewed under a 
microscope and representative pictures were taken.
Association of CX3CR1 genotype with susceptibility to 
RVVC
 Microbiologically validated RVVC patients with at least 3 episodes of  VVC 
per year were recruited at Radboud University Medical Centre (Nijmegen, 
The Netherlands) and Wayne State University School of  Medicine (Detriot, 
MI, USA). Patient inclusion took place between 2010 and 2011. Patients gave written 
informed consent, and the study was approved by the Institutional Review 
Boards of  both medical centers. Healthy, asymptomatic controls were also 
recruited and gave written informed consent. Both RVVC and control groups 
had a West-European genetic ancestry. For both cohorts, venous blood from 
EDTA tube was collected and genomic DNA was isolated using the Qiagen 
isolation kit following the manufacturer’s standard protocol.
CX3CR1-M280 genotyping
To determine whether individuals carried the CX3CR1-M280 mutant 
allele, a PCR reaction was performed on DNA that had been isolated 
from whole blood as previously described (10), using the following 
primers (15 pmoles): 5′-AGAATCATCCAGACGCTGTTTTCC-3′ and 
5′-CACAGGACAGCCAGGCATTTCC-3′. The PCR reaction also included 
the following components: 2.0 mM MgCl2, 175 mM each of  dNTP, 1.5 U Taq 
polymerase, and 1X buffer (Life Technologies). To amplify the product, the 
following protocol was used: a single cycle of  95°C for 3 minutes, followed 
by 35 cycles of  95°C, 69°C, and 72°C at 30 seconds each, and a single cycle 
of  72°C for 10 minutes. The resulting product is 311 bp in length. In order to 
type the alleles at codon 280, the resulting PCR product was digested with 
1.5 U of  Bst4Cl (New England Biolabs) via an overnight incubation at 65°C. 
The digestion results in two fragments (107 bp and 204 bp in length) when 
a C is present at nucleotide 839 of  the open reading frame, while an uncut 
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product remains when this C is mutated to a T. Therefore, individuals with 
the “wild-type” allele will have two bands on the gel, those heterozygous 
for the M280 mutation will have three bands, and those homozygous for 
the M280 mutation will only have one band. Genotyping was determined 
by electrophoresis using a 2% agarose gel staining with Gelstar (FMC 
Bioproducts).
Statistics
To determine whether values reached statistical significance for the mouse 
experiments, multiple t-tests using the Holm-Sidak method, unpaired 
t-tests, or Mann-Whitney tests were performed, where appropriate. For the 
comparison of  the frequency of  the CX3CR1 genotypes from human samples, 
a c2 test was performed. All statistical analyses were performed using Prism 
6 software (GraphPad), and data were presented as the mean +/- SEM. In 
all cases, a p-value of  less than 0.05 was considered significant.
Results
Cx3cr1 is not required for the induction of IL-23, IL-22, or 
IL-17A or control of oral C. albicans infection in mice
To determine the importance of  Cx3cr1 on C. albicans clearance from the 
oral mucosa, a mouse model of  OPC was used as previously described 
[25]. To determine whether a deficiency in Cx3cr1 impacts the IL-23/IL-
22/IL-17 axis during mucosal fungal infection, real-time quantitative PCR 
was performed on tongue homogenates from Cx3cr1+/+ and Cx3cr1-/- mice. 
Consistent with previous reports, uninfected mice had very little, if  any, IL-
17A mRNA expression in their tongues [17, 28]. Similarly, steady-state IL-
22 mRNA levels were low or undetectable, whereas modest constitutive IL-
23p19 expression was equally detected in both Cx3cr1+/+ and Cx3cr1-/- mice 
(data not shown). Importantly, upon infection, IL-17A and IL-22 were highly 
induced, and IL-23p19 was also significantly induced (~3-fold), though 
to a lesser extent than IL-17A and IL-22, as compared with tongues from 
uninfected Cx3cr1+/+ and Cx3cr1-/- mice. However, there was no difference in 
the relative mRNA levels of  IL-23p19 (Fig. 1A), IL-22 (Fig. 1B), or IL-17A 
(Fig. 1C) at day 1 p.i. between the two groups, highlighting the Cx3cr1-
independent regulation of  IL-23/IL-22/IL-17A signaling in the tongue 
during C. albicans infection. Consonant with the mRNA data, there was no 
difference between Cx3cr1+/+ and Cx3cr1-/- mice in protein concentrations of  
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Figure 1. Cx3cr1 is not required for the induction of IL-23p19, IL-22, or IL-17A in the 
tongue or control of oral C. albicans infection.
Cx3cr1+/+ and Cx3cr1-/- mice were infected sublingually with Candida albicans strain 
SC5314. One day p.i., the mRNA levels of  IL-23p19 (A), IL-22 (B), and IL-17A (C), 
relative to GAPDH, were determined from tongue homogenates. Protein concentrations 
of  IL-22 (D) and IL-17A (E) in tongue homogenates at day 1 p.i. were also determined. 
(F) Tongue fungal burden after infection. (G) Percent weight change p.i. relative to mouse 
weight before infection. (H) Representative H&E and PAS images of  infected tongues 
(magnifications x100 and x400, respectively). Arrows indicate areas of  neutrophilic 
abscesses containing degraded fungal elements. Data in panels A to E were analyzed 
using Mann-Whitney tests or unpaired t tests, where appropriate, while data in panel G 
were analyzed using multiple t tests by the Holm-Sidak method. The data in panels A to 
E are combined from two independent experiments (n=6 mice/group). The data in panel 
G are combined from 2 to 4 independent experiments (n = 8 to 16 mice/group). The 
data in panel H are representative images from 2 independent experiments. **, data are 
significantly different at a P value of  <0.01. ns, not significant.
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IL-22 or IL-17A in the tongue at day 1 p.i. (Fig. 1D and 1E and Table 1). 
In agreement with the lack of  difference in IL-23p19, IL-22, and IL-17A 
induction, which is indispensable for mucosal anti-Candida host defense 
[11-17], we found no statistically significant difference between Cx3cr1+/+ 
and Cx3cr1-/- mice in their ability to clear C. albicans from the tongue at days 
1, 3, and 5 p.i. (Fig. 1F). Importantly, both groups of  mice controlled the 
infection rapidly, as very few CFUs could be recovered from the tongue at 
either day 3 or 5 p.i., despite a similarly high fungal load observed at day 1 
p.i. In agreement with the fungal burden data, Cx3cr1+/+ and Cx3cr1-/- mice 
developed similar weight loss at day 1 after infection, a surrogate marker 
of  disease severity (Fig. 1G). The recovery of  weight loss by day 5 p.i. was 
also similar between Cx3cr1+/+ and Cx3cr1-/- mice, despite a slight delay in 
weight gain seen in Cx3cr1-deficient mice (Fig. 1G). At the histological 
level, H&E staining did not reveal any differences between Cx3cr1+/+ or 
Cx3cr1-/- mice in the overall architectural integrity of  the tongue epithelium 
nor in the inflammatory cell infiltrate of  the tongue (Fig. 1H, left panel). 
Furthermore, PAS staining showed that both Cx3cr1+/+ and Cx3cr1-/- mice 
formed neutrophilic abscesses in the tongue at day 3 p.i., which contained 
degraded hyphal elements, while no C. albicans abscesses were found at day 
5 p.i. (Fig. 1H, right panel), confirming the microbiological data that the 
vast majority of  C. albicans had been cleared by day 5 p.i. (Fig 1F). Finally, 
to further understand the role of  Cx3cr1 on the production of  inflammatory 
mediators in the tongue after infection, protein concentrations for 9 
cytokines and 9 chemokines were determined in tongue homogenates at day 
1 p.i. with C. albicans. There were no significant differences in the protein 
concentrations of  these cytokine and chemokines (Table 1), highlighting 
the lack of  dependence on Cx3cr1 for the generation of  an inflammatory 
response in the tongue during C. albicans infection. These results collectively 
indicate that Cx3cr1 is not essential for the control of  oral C. albicans 
infection. 
 To verify the strain-independence of  our findings and to extend our analysis 
using C. albicans strains recovered from patients with mucosal candidiasis, 
three clinical oropharyngeal isolates from patients with OPC were used to 
sublingually infect Cx3cr1+/+ and Cx3cr1-/- mice. C. albicans strain 529L has 
been shown to colonize the oral mucosa of  mice for extended periods of  
time [24]. Using this isolate, no differences were observed between Cx3cr1+/+ 
and Cx3cr1-/- mice in the tongue fungal load at days 1, 3, or 5 p.i. (Fig. 2A).
Interestingly, compared to infection with strain SC5314, there was lesser 
induction of  IL-23p19, IL-22, and IL-17A at day 1 p.i., as compared with 
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Table 1. Production of  inflammatory mediators after oral C. albicans infections does not 
depend on Cx3cr1.
Cytokine or chemokine Cx3cr1 +/+ mice Cx3cr1 -/- mice P value
Concn (pg/g of tongue) in a:
IL-1b 13,183 ± 2,279 9,106 ± 1,765 0.1797
IL-2 446,4 ± 66,23 417,5 ± 49,95 0.7352
IL-4 2,680 ± 138,9 2,711 ± 174,6 0.8918
IL-6 22,695 ± 2,667 23,947 ± 3,888 0.7960
IL-10 2,511 ± 239,8 2,151 ± 222,7 0.2975
IL-12p70 33,945 ± 8,534 19,851 ± 6,782 0.2251
IL-15 2,089 ± 193,5 1,909 ± 183,7 0.5163
IL-17a 422,2 ± 28,23 356,5 ± 39,25 0.2045
IL-22 1,050 ± 266,5 844,1 ± 235,5 0.7879
Ccl2 46,214 ± 5,721 37,332 ± 11.366 0.5011
Ccl3 1,042 ± 219,9 666 ± 216,8 0.2509
Ccl4 983,9 ± 278,9 615,1 ± 234,1 0.2381
Ccl5 240,4 ± 24,92 328,3 ± 62,87 0.2381
Ccl7 5,375 ± 754 4,826 ± 1,518 0.7528
Ccl20 7,477 ± 2,206 6,995 ± 3,357 0.5714
Cxcl1 5,325 ± 725,3 4,719 ± 1,497 0.7231
Cxcl2 11,298 ± 1,327 7,420 ± 2,454 0.1947
Cxcl12 35,654 ± 3,609 33,012 ± 2,223 0.5470
a Concentrations were determined at day 1 postinfection. Data are mean values ± SEMs and 
are combined from two independent experiments with 6 mice/group. 
Figure 2. Cx3cr1 is not necessary for the control of C. albicans oral infection caused by 
clinical oropharyngeal isolates.
Cx3cr1+/+ and Cx3cr1-/- mice were infected sublingually with C. albicans strains 529L, 
Y42, and Y72. Tongue fungal burden was determined on days 1, 3, and 5 p.i. for strain 
529L (A) or day 5 p.i. for strains Y42 (B) and Y72 (C). These data were analyzed using 
Mann-Whitney tests. The data are combined from 2 independent experiments (n = 4 to 
7 mice/group).
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uninfected tongues (data not shown). However, consistent with our findings 
with SC5314, (Fig. 1A-C) there was no dependence on Cx3cr1 for induction 
of  these cytokines in the tongues of  mice post-529L infection (data not 
shown). Moreover, in agreement with our findings with strains SC5314 and 
529L, Cx3cr1+/+ and Cx3cr1-/- mice also exhibited equivalent fungal burden in 
the tongue following infection with both Y42 (Fig. 2B) and Y72 (Fig. 2C) 
strains, which were recovered from patients with APECED and OPC. These 
data collectively indicate that Cx3cr1 is dispensable for fungal clearance 
from the tongue regardless of  the strain of  C. albicans used.
Cx3cr1 is dispensable for the control of C. albicans colonization 
from the lower GI tract
To further explore the importance of  Cx3cr1 on the clearance of  C. albicans 
from mucosal surfaces, a mouse model of  GI tract colonization was 
utilized as previously described (see Fig. 3A for experimental setup) [26]. 
In agreement with the results obtained with the OPC model of  infection, 
there was no difference in the amount of  C. albicans recovered from stool 
of  Cx3cr1+/+ and Cx3cr1-/- mice (Fig. 3B). In addition, neither Cx3cr1+/+ nor 
Cx3cr1-/- mice developed systemic candidiasis due to translocation of  C. 
albicans from the GI tract into the systemic circulation (data not shown). 
These data indicate that Cx3cr1 is not necessary for the local control of  
Candida colonization and translocation in the GI tract.
CX3CR1 deficiency does not predispose women to develop 
RVVC
 Finally, the impact of  CX3CR1 deficiency on control of  mucosal candidiasis 
was studied in humans using a cohort of  women who developed RVVC 
and control women without mucosal candidiasis. As described previously, 
the mutant CX3CR1-M280 allele leads to defective fractalkine binding and 
downstream CX3CR1 signaling and is a risk factor for the development 
of  systemic candidiasis (10). However, whether the CX3CR1-M280 allele is 
associated with development of  human mucosal Candida infection has not 
been addressed. As shown in Fig. 4, the frequencies of  women carrying 
the mutant CX3CR1-M280 allele versus the WT CX3CR1 genotype among 
control and RVVC individuals was similar, indicating that genetic variation 
at CX3CR1 is not a risk factor for development of  persistent mucosal 
candidiasis in humans.
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Figure 3. Cx3cr1 is dispensable for control of lower GI tract colonization by C. albicans. 
Cx3cr1+/+ and Cx3cr1-/- mice were given antibiotics in their drinking water for 5 days prior 
to replacement with drinking water containing 1x107 C. albicans organisms/ml (strain 
SC5314) until day 10 after initiation of  antibiotic treatment (A). At day 10, stools were 
collected from the mice, weighed, homogenized, and plated to determine fungal load (B). 
These data were analyzed using a Mann-Whitney test. The data are combined from 2 
independent experiments (n = 10 mice/group).
Figure 4. The dysfunctional CX3CR1 allele CX3CR1-M280 is not associated with 
development of recurrent vulvovaginal candidiasis.
Patients with recurrent vulvovaginal candidiasis (RVVC) and healthy controls were 
genotyped for the presence of  theCX3CR1-M280 allele, and the frequencies of  the genotype 
in the two cohorts were compared. The data are presented as such where T/T corresponds 
to individuals homozygous for the wild-type allele, T/M corresponds to heterozygous 
individuals, and M/M corresponds to individuals homozygous for the mutant allele. The 
data were analyzed using X2 test, with no significant differences observed.
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Discussion
In the present study, we show that the chemokine receptor Cx3cr1 is 
dispensable for host defense against C. albicans at the mucosa in mice and 
humans. Specifically, we show that, in contrast to the Cx3cr1-dependent 
IL-23 and IL-22 induction during mucosal bacterial infection [18], Cx3cr1+/+ 
and Cx3cr1-/- mice exhibit similar expression of  IL-23 and IL-22 from tongue 
homogenates during OPC. In addition, we found no Cx3cr1-dependent 
regulation of  IL-17A during oral fungal infection, which is in contrast to 
what has been observed in the context of  inflammatory colitis, collagen-
induced arthritis, and experimental autoimmune encephalomyelitis [20-22]. 
Furthermore, the ability to control C. albicans in the oral cavity and the 
lower GI tract is not impaired in Cx3cr1-/- mice, and Cx3cr1-deficient mice 
colonized with C. albicans in their GI tract do not spontaneously develop 
GI-derived systemic candidiasis. In addition, the dysfunctional human 
CX3CR1-M280 mutation is not associated with development of  RVVC 
in women. These findings contrast the previously reported crucial role 
of  Cx3cr1 in protection against systemic candidiasis in mice and against 
candidemia in humans [10]. Taken together, these data further highlight 
the divergent mammalian immune factors that are required for control of  
mucosal versus systemic Candida infections. 
 In accordance with this observation, patients with oral or vaginal 
candidiasis do not spontaneously develop systemic candidiasis as a result of  
their mucosal infection [29]. Indeed, by studying perturbations in cellular 
and molecular immune factors in human populations, there is a segregation 
of  factors necessary for control of  systemic versus mucosal candidiasis. 
Specifically, it would appear that the adaptive immune response is most 
important for the development of  effective host defense against mucosal 
infection, as patients with HIV and idiopathic CD4 lymphocytopenia are 
prone to mucocutaneous candidiasis, but not systemic candidiasis [4, 30]. 
Furthermore, patients with either mutations in various components of  
the IL-17 pathway (i.e., IL-17RA, IL-17F, ACT1 (14, 31)) or with inherited 
immunodeficiencies that result in impaired IL-17 signaling (i.e., mutations 
in STAT1, STAT3, STK4, DOCK8, AIRE, DECTIN-1 [11]) are susceptible 
to mucosal, but not systemic candidiasis. In stark contrast, patients 
with inherited or acquired neutropenia, chronic granulomatous disease, 
and complete myeloperoxidase deficiency have increased likelihood of  
developing systemic, but not mucosal Candida infections [11, 32-34], 
indicating a stronger requirement for innate immune cell mechanisms for 
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the protection against systemic infection. The only immune factor known 
to date to confer heightened susceptibility to both mucosal and systemic 
candidiasis in humans is CARD9, attesting to the central positioning of  
this adaptor protein downstream of  several C-type lectin receptors [29, 35]. 
However, the mechanisms by which CARD9 promotes effective mucosal 
and systemic anti-Candida effects in humans remain elusive.
 In the mouse models of  infection, there is evidence to suggest that a 
certain cellular or molecular immune factor may be protective for both 
systemic and mucosal Candida infections. For instance, neutrophils [28, 36], 
and cytokines such as IL-17, TNF-a, and IL-6 [37-39] are indispensable for 
host defense against both systemic and mucosal mouse Candida infections. 
Nonetheless, the mechanisms involved in mucosal versus systemic anti-
Candida immune protection by a given immune factor (e.g., IL-17) can be 
very distinct [12, 40]. Our study indicates that Cx3cr1 does not mediate 
protective IL-23–dependent mucosal immune responses against C. albicans 
in mice and humans, despite its indispensable role in phagocyte-mediated 
protection during systemic candidiasis [10]. Our data also underscore 
the divergent dependence on Cx3cr1 for induction of  IL-22 and IL-17A-
mediated mucosal immune responses during mucosal bacterial versus fungal 
infection [18].
 In mice and humans, there are two distinct subsets of  monocytes/
macrophages based on expression of  CX3CR1 and CCR2. CX3CR1 expression 
characterizes resident monocytes/macrophages with “patrolling” immune 
functions, whereas CCR2+ cells are “inflammatory” and are recruited to 
tissues in high numbers after infection [41]. Recent studies have highlighted 
the important role of  CCR2+ mononuclear phagocytes in mediating innate 
and adaptive antifungal immune responses during systemic and respiratory 
fungal disease, including systemic candidiasis [42-46]. Therefore, future 
studies should examine the role of  CCR2+ “inflammatory” mononuclear 
phagocytes during mucosal Candida infection.
 Although recent advances have been made in understanding immune 
responses against Candida and other fungal pathogens, there is still much to 
be learned. For example, mortality from systemic candidiasis still remains 
unacceptably high (~40%) despite antifungal use [47]. Furthermore, mucosal 
Candida infections, including RVVC and chronic mucocutaneous candidiasis 
lead to significant morbidity and hospital costs [48]. In addition, because life-
threatening systemic candidiasis originates from translocation of  Candida 
from the mucosal surfaces into the bloodstream, better understanding of  
the immune factors that control Candida at the mucosa will be important 
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to devise preventive strategies against systemic infection. The fact that 
effective treatment approaches are still needed for candidiasis to improve 
patient outcomes underscores the importance of  continued research in the 
area of  mucosal and systemic fungal immunity.
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Abstract
Objective: Vaginal infections with Candida spp. frequently occur in women 
of  childbearing age. A small proportion of  these women experience 
recurrent vulvovaginal candidosis (RVVC), which is characterized by at 
least three episodes of  infection in one year. In addition to known risk 
factors such as antibiotics, diabetes or pregnancy, host genetic variation and 
inflammatory pathways such as the IL-1β/Th17 axis have been reported to 
play a substantial role in the pathogenesis of  RVVC. 
Study design: In this study, we assessed a VNTR polymorphism in the 
NLRP3 gene that encodes a component of  the inflammasome, processing 
the proinflammatory cytokines IL-1β and IL-18.
Results: A total of  270 RVVC patients and 583 healthy controls were analyzed 
and increased diseases susceptibility was associated with the presence of  
the 12/9 genotype. Furthermore, functional studies demonstrate that IL-1β 
production at the vaginal surface is higher in RVVC patients bearing the 
12/9 genotype compared to controls, whereas IL-1Ra levels were decreased 
and IL-18 levels remained unchanged. 
Conclusion: These findings suggest that IL-1ß-mediated hyperinflammation 
conveyed by the NLRP3 gene plays a causal role in the pathogenesis of  RVVC 
and may identify this pathway as a potential therapeutic target in the disease.
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Introduction
Vulvovaginal candidosis is one of  the most frequent infections in women. 
Candida spp. in general and Candida albicans in particular are the main cause 
of  this infection. Although not life-threatening, vulvovaginal candidosis 
leads to severe discomfort, manifested by itching, soreness, rash and 
vaginal discharge [1]. Antifungal medication leads to improvement of  
the health status in these women, but a small portion of  women continue 
to experience recurrent vaginal infections with the fungus, a condition 
described as recurrent vulvovaginal candidosis (RVVC). Up to 6-8% of  all 
women are known to suffer from RVVC, defined by at least three periods 
of  vaginal Candida infection per year [2-4]. Although glucocorticosteroid 
use, immunosuppressive and antibiotic therapy, or pregnancy are known 
risk factors for RVVC, most patients lack any of  these risk factors.
 This led to extensive research to identify the (multi)-genic components 
predisposing to RVVC susceptibility. Several variants in genes known to 
be important in the innate host defense have been found to be associated 
with RVVC susceptibility [5-10]. A whole range of  genetic variations in the 
NLRP3 gene have previously been shown to be associated with inflammatory 
diseases [11-13]. NLRP3 is part of  a multicomplex cytoplasmic protein 
platform called inflammasome, which allows the activation of  caspase-1. In 
turn, caspase-1 cleaves the inactive precursors of  interleukin-1 beta (IL-1β) 
and IL-18 into the biologically active cytokines. A variable number tandem 
repeat (VNTR) in intron 4 (rs74163773) of  the NLRP3 gene has previously 
been shown to be associated with essential hypertension, as well as (self  
reported history of) vaginal C. albicans infections, and a reduction of  IL-1β 
levels in patients suffering from vulvar vestibulitis syndrome [14, 15]. The 
present study aims to assess the role of  the VNTR in NLRP3 in patients 
suffering from RVVC, as well as to investigate the functional consequences 
of  this sequence variant on the specific host defense against C. albicans at the 
vaginal surface.
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Materials and Methods
Patients were recruited at the S. Maria della Misericordia Medical 
Center (Perugia, Italy), Wayne State University School of  Medicine 
(Detroit, MI, USA), Radboud University Medical Center (Nijmegen, The 
Netherlands), and Hôpital Necker (Paris, France). Patients were enrolled 
during episodes of  acute vaginitis or, if  asymptomatic, while receiving 
maintenance fluconazole therapy. Inclusion criteria for the study were: 
otherwise healthy women of  at least 18 years old, diagnosed with at least 
three microbiologically documented episodes of  VVC within one year, all 
caused by C. albicans. Exclusion criteria were use of  any immunosuppressive 
therapy (including steroids), diabetes, pregnancy, or HIV infection. EDTA 
venous blood was collected after obtaining written informed consent. The 
study was approved by the Institutional Review Boards of  each of  the study 
centers, and enrollment took place between January 2009 until December 
2013. All patients and controls were of  self-reported Western-European 
genetic background. To confirm the genetic homogeneity between samples 
we performed multidimensional scaling (MDS) analysis based on 550.000 
SNPs and excluded outliers. 
Genotyping
Genomic DNA was isolated from ETDA venous blood using the Gentra Pure 
Gene Blood kit following the manufacturer’s standard protocol (Quiagen, 
Venlo, The Netherlands). To amplify the 42bp variable nucleotide tandem repeat 
(rs74163773) in the intron 4 of  the NLRP3 gene, we used conventional PCR 
with a primer pair already described by Omi et al. [16]. The resulting amplicons 
were subsequently loaded on a 3% agarose gel to perform electrophoresis. In 
our setup, we found 5 different alleles, namely 6,7,9,12 and 13 forming the 
following 8 genotypes: 12/13 , 12/12 , 12/9, 12/7, 12/6, 9/9, 7/9, 7/7. The 12 
allele was reported to consist of  720bp while the 9, 7 and 6 allele consist of  594, 
510 and 468 bp, respectively [16]. In addition to this, we observed an additional 
allele just 42bp above the 720bp 12 allele, named allele 13 (762bp), in line with 
Omi et al. [15]. Differences between patients and controls in each of  the two 
cohorts were determined using the X2 statistical analysis.
Cytokine measurement in vaginal fluids
Cervicovaginal samples were collected as described earlier by Snowhite et 
al.[17]. In brief, samples were obtained from all participants during episodes 
of  vaginosis by instilling 3 ml of  sterile saline into the posterior vagina, 
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mixing the saline with secretions and withdrawing the solution with 10ml 
plastic syringe. No needles or flushes were used. All vaginal washes were 
centrifuged at 12,000 ×g for 10 min to separate the mucus from the PBS 
wash solution shortly after collection, and pellet fractions were immediately 
frozen at -80ºC. Cytokine levels in the lavage fluids were determined by 
ELISA (R&D Systems). Data were normalized to total protein levels for 
each sample using the Bio-Rad Protein Assay (Bio-Rad, Milan, Italy) and 
expressed as log10 pg cytokine/µg total protein).
Results
In our experimental setup, the 42bp variable number tandem repeat 
(rs74163773) within intron 4 of  the NLRP3 gene has 8 genotypes derived 
from 5 different alleles. The genotypes appear in different bands on an 
agarose gel, as shown in Figure 1. The 12/12 genotype was the most 
prevalent in both control and patient groups, while the 12/7, and 12/9 
and 7/7 genotypes were less prevalent. The 12/13, 12/6, 7/9 as well as 
9/9 genotypes were less abundant, together accounting for around 15% of  
the genotypes present. Except for the 12/9 genotype, we observed minor 
differences comparing the different genotypes between controls and patients. 
Nevertheless, significant differences were seen when we compared the 12/9 
genotype between patients and controls (p-value 0.02) (Table 1). 
 To investigate the local immune response at the mucosal surface, we 
measured inflammasome-dependent cytokine concentrations in vaginal 
fluids from either controls or patients suffering from RVVC. In the analysis, 
we concentrated on the 12/12 wild-type genotype and the 12/9 genotype 
that was found to be associated with RVVC. IL-1β levels were higher in the 
vaginal fluid of  RVVC patients compared to healthy controls. In addition, 
the 12/9 genotype led to even higher IL-1β concentrations compared to the 
12/12 genotype. On the other hand, IL-1Ra levels were lower in patients for 
both genotypes compared to controls, while those with the 12/9 genotype 
had lower concentrations than the patients with 12/12 genotype. Differences 
in IL-18 levels did not reveal significant differences between patients and 
controls, or between the RVVC patients with different genotypes (Figure 2).
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Figure 1. Example of  different genotypes of  the NLRP3 VNTR polymorphism on a 3% 
agarose gel. Allele 13: 762bp, allele 12: 720bp, allele 9: 594bp, allele 7: 510bp and allele 
6: 468bp, M= 100bp Marker.
Table 1. Genotype distribution of  the NLRP3 genotypes for the VNTR in intron 4.
 Controls RVVC patients  
NLRP3 genotype n % N % p value
12-12 308 52,83 134 49,63 0,43
12-13 9 1,54 7 2,59 0,44
12-7 134 22,98 62 22,96 1,00
12-9 52 8,92 39 14,44 0,02
12-6 3 0,51 2 0,74 1,00
7-7 45 7,72 11 4,07 0,06
7-9 22 3,77 11 4,07 0,98
9-9 10 1,72 4 1,48 1,00
Total 583  270   
Comment
A small study has reported a specific genotype distribution of a VNTR in the 
NLRP3 gene in patients with vaginal candidosis [14, 16]. If confirmed, this 
finding would have important consequences for our understanding of RVVC, as 
it would identify cytokines of IL-1β family as a potential therapeutic target in the 
disease. Moreover, a crucial aspect that needed to be elucidated was whether the 
189
7
risk allele was associated with a higher or lower cytokine production capacity at 
the level of vaginal mucosa. In the present study, we report that the 12/9 genotype 
of the rs74163773 VNTR in NLRP3 was associated with recurrent vulvovaginal 
infections with C. albicans. Moreover, we report differential production of the 
inflammasome-associated cytokines between patients and controls, with the 
patients bearing the risk allele displaying the highest concentration of IL-1b in 
the vaginal fluid. 
Figure 2. Log10 cytokines (IL-1β, IL-1Ra and IL-18 in pg cytokine/µg total protein) in 
vaginal fluid from RVVC patients and controls. A) IL-1ββ levels between healthy controls 
(red) and RVVC patients (blue) bearing either the 12/12 or the 12/9 genotype. B) IL-1Ra 
levels, C) IL-18 levels. Data was analyzed using the Mann-Whitney U test and *indicates 
significance of  P≤0.05,**P≤0.01, ***P≤0.001.
The NLRP3 polymorphism rs74163773 results in 11 genotypes derived from 
5 different alleles. In our setup, we found only eight of  the 11 genotypes, 
which might be the result of  the low prevalence of  the other three genotypes 
within the Caucasian population [15]. A previous study found allele 7 of  
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the NLRP3 gene to be associated with an increased frequency of  RVVC [14]. 
We were not able to validate this association, however we observed that the 
12/9 genotype is significantly associated with an increased susceptibility 
to RVVC. Both studies argue thus that genetic variation in NLRP3 may 
influence the occurrence of  vulvo-vaginal candidosis, but larger future 
studies are needed to validate this and discern the exact genotypes involved.
In the vaginal fluid, IL-1β cytokine concentrations were higher in RVVC 
patients compared to controls. Furthermore, carriage of the 12/9 genotype led 
to an even higher IL-1β concentration in the vaginal fluid. In line with this, 
we found an inverse correlation between IL-1β and IL-1Ra concentrations, 
with IL-1Ra levels lower in patient samples and even further decreased in 
patients carrying the 12/9 genotype. An increase in IL-1β levels accompanied 
by a decreased IL-1Ra concentration in patients bearing the 12/9 genotype may 
lead to a hyperinflammatory state at the vaginal surface [18]. This is in line 
with the concept that RVVC is likely due to an inappropriate immunological 
reaction to Candida growth and colonization, rather than an immune defect 
resulting in fungal overgrowth. There are several important recent findings that 
strengthen this conclusion, and propose that the inflammasome/IL-1b pathway 
as an important mediator for the inflammatory reaction:
i. The yeast-to-hyphae germination has been recently shown to be 
an important component of  VVC pathogenesis [19], and earlier 
studies demonstrated that inflammasome/IL-1β activation is a 
main component of  the hyphae-specific immune response [20].
ii. a recent transcriptome study of  murine vaginal candidosis has 
identified the NLRP3 inflammasome of  a strong feature of  the 
Candida-induced transcription profile in the vagina [21].
iii. the vaginal fluid showed continuous increases in neutrophils 
and IL-1β of  vaginally-infected mice during the late phases of  
infection, despite a stable fungal load [19].
In the present study, we present strong evidence that a similar over-activation of 
the inflammasome and IL-1b (but not IL-18) production apparently is present 
in patients with RVVC, and genetic variation in the NLRP3 inflammasome gene 
has an important impact on this mechanism.
 In conclusion, this study reveals new insights into genetic susceptibility 
factors that contribute to the development of  RVVC. Defects in the 
inflammasome component NLRP3 are involved in disease development and 
progression, most likely by influencing Candida-induced cytokines towards 
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a hyperinflammatory state. It is important to emphasize that RVVC is a 
multifactorial disease, in which not only genetics and the innate immune 
system but also the local microbiome, metabolome as well as external factors 
likely play a substantial role. However, understanding genetic and local 
defects may increase our knowledge of  the exact pathological mechanisms 
and contributes to the development of  a better diagnosis and novel therapies. 
In this respect, agents targeting IL-1ββ overproduction may prove useful in 
the management of  RVVC.
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Abstract
Candida vaginitis is a frequent clinical diagnosis, with up to 8% of  women 
experiencing recurrent vulvo-vaginal candidiasis (RVVC) characterized by 
at least 3 episodes per year. Although several clinical risk factors for RVVC 
have been identified, most women with RVVC lack them, suggesting an 
important role for genetic risk factors. Through integration of  a genomic 
approach with immunological studies in two independent cohorts of  RVVC 
patients and two cohorts of  healthy individuals, we identified several 
important cellular processes and novel gene candidates that contribute to 
the pathogenesis of  RVVC. Cellular morphogenesis and metabolism, as well 
as cell adhesion, are the pathways affected most strongly at a genetic level in 
RVVC patients. In addition, we identified SIGLEC15 as novel candidate gene 
involved in RVVC susceptibility, with the risk allele leading to an increased 
inflammatory response upon C. albicans stimulation of  immune cells. The 
role of  SIGLEC15 in the pathogenesis of  vaginal candidiasis was validated 
in in vitro studies and in vivo experimental vaginal candidiasis models. 
Identification of  these novel pathways and cellular processes contributes to 
a better understanding of  RVVC and opens new therapeutic avenues. 
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Introduction
The dimorphic fungus Candida can cause both systemic and mucosal 
infections in humans. Although Candida is a commensal in the majority 
of  the healthy population, dysregulation or defects in the host defense 
mechanisms can lead to infections by Candida species[1, 2]. Systemic 
Candida infections occur almost exclusively in immunocompromised hosts 
and are characterized by sepsis and deep tissue invasion[3]. Treatment 
remains difficult despite recent improvements in antifungal therapies[4]. A 
novel systems genomics approach to understand the cytokine architecture 
against fungal pathogens in general and in systemic Candida infections in 
particular is described in a second accompanying manuscript (Jaeger et al.). 
Here, novel gene candidates as well as pathways have been identified that 
are most likely dysregulated in patients compared to controls. Non-invasive 
mucosal infections (oral, skin, vagina) are more prevalent, probably due to 
the presence of  Candida spp. within the microbiome of  healthy individuals. 
Although these infections rarely pose a life-threatening risk for the patients, 
superficial candidiasis represents a high burden of  morbidity and has a 
strong impact on the quality of  life. 
 Most women suffer at least once in their lifetime from vulvovaginal 
candidiasis (VVC), a vaginal infection with C. albicans[5-7]. An estimated 
proportion of  up to 3-8% of  these women will experience recurrent episodes 
of  VVC, characterized by at least 3 episodes of  VVC per year [5, 7-12]. 
While antifungal medication serves as adequate remedy for single episodes 
of  vaginal infection, the long-term treatment for women with RVVC is 
challenging and often unsuccessful [13]. Several risk factors that increase 
susceptibility to RVVC have been reported and include diabetes mellitus, 
prolonged use of  antibiotics, and oral contraceptives [10, 14-16]. However, 
the majority of  women with RVVC do not have any of  these known risk 
factors. Several studies attempted to link specific Candida strains to disease 
incidence and severity, but no conclusive arguments for an association 
with RVVC have been provided [17, 18]. This led us to hypothesise that the 
genetic background of  the host is an important risk factor to be considered 
in RVVC pathophysiology.
 A limited number of  studies have studied a small series of  genetic 
polymorphisms in different pathways that contribute to susceptibility to 
RVVC [19-26]. However, these studies were based on a few previously 
identified genes, while no comprehensive assessment of  the host genetic 
component in RVVC has so far been performed. In the present study, we 
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applied a comprehensive genomic approach, to assess both rare and common 
genetic variants that affect susceptibility to RVVC. A combination of  whole 
exome sequencing (WES) and genome-wide association analysis (GWAS) 
of  two independent cohorts of  RVVC patient cohorts and two cohorts of  
healthy controls was performed to identify pathways and gene clusters 
that may influence the hosts susceptibility to the disease. Furthermore, 
functional human in vitro and experimental (murine) in vivo infections were 
used to validate some of  the identified novel target genes. 
Results
Patient cohorts
Two different cohorts of  RVVC patients were recruited for the Whole Exome 
Sequencing (WES) study. The first cohort consisted of  75 RVVC patients of  
Northern European genetic background (NEC). A cohort of  98 sequenced 
healthy NEC individuals served as control population. The second cohort 
consisted of  85 patients with RVVC with Southern European genetic 
background (SEC), while the control population consisted of  77 healthy 
SEC individuals. Eight samples did not pass quality controls as they had 
either very uncommon frequencies of  variants compared to their reference 
population [27] or both low median coverage together with an exceptionally 
high number of  variants (see also method section). In total 170 NEC (75 
case and 95 control) and 157 SEC (80 case and 77 control) samples were 
included in the analysis. In addition, isolated PBMCs of  two independent 
cohorts of  73 and 50 healthy control individuals of  Northern European 
genetic background were subject to an in vitro C. albicans stimulation test 
of  cytokine production capacity. The schematic overview for this study is 
shown in Figure 1.
Whole exome sequencing and analysis
The alignment of  the WES reads covered an average of  85.6% and 84.1% 
of  the target regions with more than 20x, in NEC and SEC respectively. 
Variant calling identified 224,127 (NEC) and 312,018 (SEC) variant loci, 
for a total of  8,385,054 (NEC) and 9,745,235 (SEC) alleles. Subsequently, 
a per-variant filtering was performed to remove variants with low quality 
and low coverage (<20x). The study-set of  good quality variants consisted 
of  109,014 (NEC) and 187,115 (SEC) loci, with 3,678,608 (NEC) and 
5,862,276 (SEC) alleles.
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Common SNP (cSNP) were defined as variants with a MAF greater than 
5% and that were in Hardy-Weinberg equilibrium. A total of  2,979,231 
alleles for 28,328 cSNPs (NEC) and 4,693,252 alleles for 45,819 cSNPs 
(SEC) were found. Of  them, 1,471 NEC cSNP (involving 1,026 genes) and 
2,152 SEC cSNPs (involving 1,370 genes) were significantly associated with 
RVVC by means of  the Fisher-test nominal p-values (Supplementary Figure 
1). Two-hundred-one genes contained RVVC-cSNP (RcSNP) in both cohorts 
and 11 had the exact same allele associated with increase of  RVVC risk 
(Supplementary Table S1. The overlap of  201 genes between the 1026 
RcSNPs genes in the NEC and 1370 RcSNPs genes in SEC is very unlikely 
to occur by chance, according to a hypergeometric test performed (p<10-9, 
Figure 2A). The functional characterization of  the overlapping genes 
resulted in a strong enrichment (FDR<0.05) for GO annotations regarding 
cell-adhesion and membrane protein functions (Figure 2B and 
Supplementary Table S2), hence suggesting that these functions may be 
some of  the underlying biological mechanisms that drive the disease 
association in both cohorts. 
Whole	Exome	
Sequencing
North	European	
Cases	(N=75)	NEC
North	European	
Controls	(N=98)
Cytokine	response	after	
Candida exposure	
(N=73)
Genes	with	candida	
QTL	(cQTL)
South	European	
Controls	(N=77)
South	European	
Cases	(N=85)	SEC
Genes	associated	to	
RVVC	(Burden)	
(Exome)	SNPs	
associated	to	RVVC
Identification	of	novel	genes	and	pathways	in	
RVVC	pathogenesis
Validation	stimulation	
experiments	(N=50)
Figure 1. Schematic overview of  the study
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Functional Rare Variants (FRV) were defined as those with a minor allele 
frequency (MAF) lower than 5% and with a potential functional effect because 
of  their predicted impact on protein function, high evolutionary conserved 
nucleotide (phyloP>2) and population frequencies lower than 1%. In total, we 
identified 46,949 FRV in 11,585 different genes (Supplementary Table S3. A 
set of  39 genes had FRVs in multiple cases of  both cohorts and none present in 
control individuals (Table 1). Those genes can be considered as candidate genes 
for highly-penetrant mutations that predispose to RVVC. After performing a 
burden test, no gene reached FDR-corrected significance for an enrichment of  
rare variants in both cohorts (Supplementary Table S4). 
Candida-stimulated cytokine release (QTL)
In the following analysis, we aimed to identify common SNPs (cSNPs) that 
influence the capacity of  peripheral blood mononuclear cells (PBMCs) to 
produce cytokines in response to stimulation with C. albicans. Because of  their 
ability to alter a quantitative measure, we defined these cSNP as cytokine-
QTL (cQTL). PBMCs of  73 NEC controls were sampled and exposed to 
either C. albicans yeast or hyphae for 24 hours and subsequently cytokines 
were measured. We selected the 52,811 SNPs (in 10,938 different genes) 
that were associated with a cytokine alteration after C. albicans stimulation 
according to a nominally significant Mann-Whitney test. A relevant number 
of  genes (n=1810) harboured both cQTL and RcSNP (hypergeometric 
test panel B, p<10-16, Figure 2C). Notably, most of  RcSNP associated 
in both cohorts were also cQTL. The overlap between both groups was 
still significant after comparing cQTL of  NEC-RcSNP and SEC-RcSNP 
separately, thus, avoiding the potential bias due to sequencing artefacts 
of  only a few NEC controls. These results suggest a link between the host 
genetic makeup with regard to cytokine release in response to C. albicans 
stimulation and potential RVVC risk. The GO functional characterization 
of  these genes is shown in Figure 2D and Supplementary Table S5.
Identification of SIGLEC15 as susceptibility factor in RVVC
By overlapping SNPs and corresponding genes of  both the disease 
association data as well as the altered cytokine data after C. albicans 
stimulation, we obtained a signal in both datasets that derived from a 
polymorphism in the SIGLEC15 gene (rs2919643). In order to identify the 
functional consequence of  this polymorphism influencing RVVC 
susceptibility, we assessed the cytokine production capacity after specific 
stimulation with C. albicans in cells isolated from individuals carrying 
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Table 1. Genes with Functional Rare Variants (FRV) only present in cases: Genes with at least 
2 FRV only present in cases (both NEC and SEC). 
GENE P-value (FRV Burden Test) FRV in NEC FRV in SEC All FRV
IGFN1 0.002 3 5 8
ATP6AP1L 0.005 4 3 7
ADAMTS20 0.005 3 4 7
SALL1 0.011 4 2 6
YTHDC2 0.011 3 3 6
MMEL1 0.011 2 4 6
MAN2A2 0.011 2 4 6
EVC2 0.011 2 4 6
PKP3 0.011 2 4 6
SMG8 0.023 3 2 5
SLC45A1 0.023 3 2 5
SCAF8 0.023 3 2 5
OR10G3 0.023 3 2 5
SLC5A11 0.023 3 2 5
HSD17B4 0.023 3 2 5
CCKAR 0.023 3 2 5
OR4C16 0.023 2 3 5
PRPF40B 0.023 2 3 5
NFKB1 0.023 2 3 5
ABHD1 0.023 2 3 5
RASAL2 0.023 2 3 5
DACH2 0.023 2 3 5
AREL1 0.048 2 2 4
LANCL1 0.048 2 2 4
CHAMP1 0.048 2 2 4
AMPH 0.048 2 2 4
HACL1 0.048 2 2 4
FRK 0.048 2 2 4
CLCN6 0.048 2 2 4
PPEF2 0.048 2 2 4
RFT1 0.048 2 2 4
BBS5 0.048 2 2 4
SYNPO2 0.048 2 2 4
CYP4V2 0.048 2 2 4
CCDC90B 0.048 2 2 4
CLIP2 0.048 2 2 4
ABCG4 0.048 2 2 4
KIAA1407 0.048 2 2 4
DSG2 0.048 2 2 4
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different allele. Interestingly, the monocyte-derived cytokine production of  
IL-6, TNFa, IL-1b and IL-23 were unaffected by the risk variant, whereas 
the T-cell cytokines IL-17A and IL-22 were increased in individuals carrying 
the disease-associated C-allele (Figure 3A). Further validation of  these 
findings in a second dataset in an independent cohort of  50 healthy 
individuals revealed the same trend for stimulation with both C. albicans 
yeast as well as hyphae (Supplementary Figure S2). Importantly, we did not 
observe the same difference when cells were stimulated with Staphylococcus 
aureus, arguing for the specificity of  this effect (Supplementary Figure S3). 
The direct fungal killing capacity by PBMCs was not influenced by the 
different genotypes whereas individuals carrying the C allele produced more 
reactive oxygen species (ROS) after C. albicans stimulation (Figure 3B). 
Sialic acid-binding immunoglobulin-like lectins (SIGLECs) are cellular 
receptors for sialic acid, making them interesting candidates as pattern 
recognition receptors: therefore, we aimed to validate their role in the 
pathogenesis of  Candida vaginitis.
B) D)
RcSNPs cQTLNECSEC
10261370 201
Genes	containing	common	SNPs	(cSNP)	associated	with	RVVC
P-value=4*10-9
A)
441 80401810
P-value=4*10-16
C)
0 1 2 3 4 5 6 7 8
Formation	of	translation	preinitiation	complex	
Formation	of	cytoplasmic	translation	initiation	complex	
Mitochondrial	electron	transport,	cytochrome	c	to	oxygen	
Fructose	6-phosphate	metabolic	process	
Cytokinesis	
5-phosphoribose	1-diphosphate	biosynthetic	process	
Biological	adhesion	
Cell	adhesion
Cell-cell	adhesion	
Homophilic	cell	adhesion
-10LOG	P-value
GO-term	Characterization	of	201	overlapping	Genes
0 1 2 3 4 5 6 7 8
Mitochondrial	genome	maintenance
Single	strand	break	repair
Regulation	of	mitotic	recombination
Mitotic	spindle	elongation
Regulation	of	DNA	recombination
Reproduction
Biological	adhesion
Cell	adhesion
Cell-cell	adhesion	via	plasma-membrane	adhesion	molecules
Homophilic	cell	adhesion	via	plasma	membrane	adhesion	molecules
-10LOG	P-value
GO-term	Characterization	of	1810	overlapping	Genes
Figure 2. A) Analysis of  RcSNPs in both RVVC cohorts: Overlap between SEC and NEC 
with RcSNPs and GO-term characterization of  the 201 overlapping genes between SEC 
and NEC.B) Analysis of  cSNPs and RcSNPs in both cohorts: Overlap between cQTL and 
RcSNPs in SEC and NEC and GO-term characterization of  the 1810 overlapping genes.
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In order to investigate the potential of  C. albicans to affect SIGLEC15 
expression of, PBMCs were stimulated for 4 hours with the fungus. An 
increase of  SIGLEC15 expression (~5.5x upregulation) was consistently 
observed although it was variable between the different donors (Figure 3C). 
Interestingly, when looking at different primary cell types we found the 
highest expression of  SIGLEC15 in PBMCs and neutrophils compared to 
CD4+ or CD14+ cell. Moreover, SIGLEC15 expression was moderately high 
in a vaginal epithelial cell line and inducible after stimulation with different 
C. albicans morphotypes (Supplementary Figure S4). Given the finding 
that SIGLEC15 most likely plays a role in the immune response against C. 
albicans, we were interested in the potential of  C. albicans to induce other 
SIGLEC family members. In an extensive RNAseq approach in PBMCs 
we identified the SIGLEC15 gene as one of  the strongest induced SIGLEC-
family member after C. albicans stimulation. Both 4 and 24 hour post- 
stimulation with C. albicans time points showed significant upregulation of  
SIGLEC15, although, after multiple testing correction, only the 24 hour post 
stimulation remained significant (Figure 3C).
 In additional experiments, we aimed to specifically silence SIGLEC15 
in human primary macrophages to subsequently stimulate the cells with 
C. albicans. SIGLEC15 silenced cells consistently showed reduced levels of  
IL-6 and TNFa after 24 hours in 3 independent experiments. Interestingly, 
levels of  PGE2 were slightly increased in SIGLEC15 siRNA silenced cells 
compared to control siRNA treated cells (Figure 3D). Gene silencing in 
primary cells is challenging due to reduced cell viability and low silencing 
efficiency. Figure 3D shows the siRNA silencing efficiency in our 
experiments.
 In order to investigate the interaction of  SIGLEC15 with C. albicans 
we performed binding assays using flow cytometry. Heat killed C. albicans 
yeast was incubated with recombinant SIGLEC15, SIGLEC7 or remained 
untreated. Following the incubation period the samples were incubated 
with a secondary antibody labelled with Alexa 647. A strong increase in the 
fluorescent signal in the recSIGLEC15 treated conditions (red histogram) 
confirming the binding of  the protein to C. albicans (Figure 3E). Treating 
C. albicans with the secondary antibody alone also led to an increase in 
the signal due to some non-specific binding of  the antibody to C. albicans 
(green histogram) compared to the untreated condition (blue histogram). 
Within this setup, we used an antibody against b-glucan as positive control 
(Figure 3F) as b-glucans are present in the cell wall of  C. albicans and get 
strongly exposed after heat killing due to structural changes of  the cell 
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wall. Interestingly, performing the same experiments with a recombinant 
protein against SIGLEC7 did not result in an increased fluorescence signal 
underlining the specificity of  SIGLEC15 to bind to C. albicans (Figure 3G). 
In addition to C. albicans we tested recombinant SIGLEC15for its binding 
capacity to C. glabrata and C. tropicalis. Similar to C. albicans, SIGLEC15 
showed a strong binding to both strains (Supplementary Figure S5).
 The SIGLEC (sialic acid-binding immunoglobulin-like lectin) family 
plays an important role in the immune system as they can regulate immune 
cell function [28]. Members of  the SIGLEC family, including SIGLEC15, 
bind sialic acid sugars that frequently terminate glycan structures on 
the cell surface of  different pathogens, and modulate immune cell 
activation[29],[30]. Interestingly, sialic acids have also been identified on 
the surface of  C. albicans [31]. In order to test whether the immune response 
against Candida is modulated by the presence or absence of  sialic acids on the 
surface of  the fungus, we pre-treated C. albicans with neuraminidase which 
is known to cleave sialic acid residues from glycans. C. albicans-induced 
reactive oxygen species were highly increased when the yeast was pre-
treated with neuraminidase compared to the control situation (Figure 4A 
and C). When Aspergillus fumigatus conidia were treated with neuraminidase, 
no difference between treatment and control treatment was observed 
(Figure 4B and C), underlining the importance of  sialic acids in the host 
response specifically against C. albicans. Regarding the potential to induce 
more ROS, we stimulated PBMCs with either neuraminidase treated or 
untreated C. albicans. Again, minor differences between the treated and 
untreated C. albicans was observed after 24 hours whereas significant 
differences were observed for the T cell derived cytokines IL-17A and INFγ 
after 7 days of  stimulation (Figure 4D).
 Taken together these results suggest that SIGLEC15 is a novel receptor in 
the immune response against C. albicans and patients with the risk genotype 
display an altered cytokine profile in response to stimulation with C. albicans.
 In order to investigate the involvement of  Siglec15 in the mucosal in vivo 
immune response against C. albicans, C57BL/6 mice were intravaginally 
infected with C. albicans. Expression of  Siglec15 significantly increased 
during the infection and peaked at day 3 post infection (Figure 5A and B). 
Mice treated with siRNA directed against Siglec15 showed significantly 
higher fungal burdens compared to mice treated with non-targeting siRNA 
(Figure 5C). In line with this, the numbers of  PMNs were strongly increased 
in Siglec15 siRNA treated mice during the infection, underlining the 
observation that Siglec15 plays in important role in the immune response 
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Figure 4. A-C) Reactive oxygen species in PBMCs induced by (A) C. albicans (1x106/
ml) and (B) A. fumigatus (1x107/ml) either untreated or treated with neuraminidase. 
Measurements (ROS induction, (RLU/sec) were taken within 1 hour in intervals of  
2.23 minutes. (C) Area under the curve (AUC) of  both experiments. Data is represented 
as mean ±SEM where *p<0.05, **p<0.01 and ***p<0.001. (D) Cytokine induction by 
PBMCs after 24 hours or 7 days stimulation with C. albicans treated or untreated with 
neuraminidase.
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against C. albicans (Figure 5D and E). To strengthen these findings, we 
measured IL-1b and IL-1Ra levels in vaginal fluids of  mice treated with 
Siglec15 targeting siRNA or control siRNA. IL-1b levels were significantly 
increased in Siglec15 siRNA treated mice, while IL-1Ra levels were decreased 
from day 7 to day14 post infection (Figure 5F). Consistent with the 
pathogenic role of  NLRP3 in RVVC, a protein involved in the maturation 
of  pro-IL-1b to mature and bioactive IL-1b, mRNA levels of  Nlrp3 were 
highly decreased in Siglec15 siRNA treated mice, while levels of  Nlrc4 
mRNA were significantly decreased throughout the infection (Figure 5G). 
Cytokine levels of  IL-6 and IL-10 were reduced in Siglec15 siRNA treated 
mice compared to control treated mice, while cytokine levels of  IL17A and 
IL-22 were significantly increased on day 14 post infection (Figure 5H). 
 IL-17A and IL-22 produced at the vaginal mucosal surface is not solely 
produced by classical T cells but also by γd T-cells as well ILC3 cells. To 
address this, we performed flow cytometry from cells of  naïve or infected 
vaginal tissue after 7 days of  infection. The percentage of  positive cells per 
condition is shown in Supplementary Figure S6.
Figure 5. SIGLEC15 activity in vaginal candidiasis. C. albicans blastospores from 
early–stationary-phase cultures (i.e., 18 h of  culture at 36°C in Sabouraud-dextrose agar 
with chloramphenicol plates, BD Diagnostics) were resuspended in sterile PBS. For 
the infection, C57BL/6 mice (n = 6) were intravaginally inoculated with 5 x 106/20 μL 
PBS. (A) Immunohistochemistry staining (scale bars, 200 µm) of  vaginal sections with 
antibodies to SIGLEC15 (Abcam, Cat.# ab198684). Sections were stained with the relevant 
primary antibody overnight at 4°C followed by secondary biotinylated anti-rabbit antibody 
(Cytodiagnostics, Cat.# AC-5-01-05). The VECTASTAIN® ABC kit (Cat.# PK-4000) was 
used for the secondary antibody detection. Images were acquired with a 40× objective and 
the analySIS image processing software. (B) Siglec15 gene expression (Real-Time RT-PCR). 
(C-F) Infected mice were intravaginally treated with unmodified siRNA against murine 
SIGLEC15 (10μg/kg) or equivalent doses of  nonspecific control siRNA (scrambled) duplex 
in a volume of  20 μL of  duplex buffer. Intravaginal siRNA was given once the day before 
infection and every 2 days after the infection until the sacrifice (at 3, 7 and 14 dpi). Mice were 
assessed for (C) vaginal fungal burden (Log10 CFU/100µL VF ± SD), (D) PMN recruitment 
in vaginal fluids (VF) (identified by nuclear morphology and enumerated per field at × 100 
magnification), and (E) vaginal pathology (periodic acid-Schiff-staining of  sections. Scale 
bars, 200 µm), (F) IL-1β/IL-1Ra levels (pg/mg, cytokine/total proteins for each sample) 
in VF. (G) Nlrp3, Nlrc4 gene expression on ex vivo vaginas by Real-Time RT-PCR and (H) 
IL-6, IL-17A, IL-22 and IL-10 levels (pg/mg, cytokine/total proteins for each sample) in 
VF. Data are presented as mean ± SD for all bar graphs. *P<0.05, **P<0.001, ***P<0.001, 
****P<0.0001, (B) Naïve vs Infected mice at different dpi One-way ANOVA, Bonferroni 
post, (C-D, F-G) Scrambled vs SIGLEC15 infected mice at different dpi Two-way ANOVA, 
Bonferroni post test.
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Discussion
The present study is the first comprehensive genome-wide investigation 
on the role of  genetic variation for the susceptibility to RVVC. Pathway 
analysis of  both rare and common genetic variants in the exome has identified 
several major biological processes that are likely dysregulated in patients with 
RVVC. Amongst these, cell morphogenesis, cell adhesion, as well as cellular 
metabolism showed the strongest association with disease susceptibility. In 
addition, a complementary approach using genetic and functional immune 
data identified a number of  susceptibility genes in immune system as well: 
one of  them is SIGLEC15, a novel recognition receptor for C. albicans. Both, 
in vitro and in vivo validation studies support an important role of  SIGLEC15 
for RVVC: in addition, these studies strongly suggest that immune hyper-
responsiveness of  individuals bearing the risk genetic variants is responsible 
for the clinical symptoms, as previously supported by earlier studies[6, 32-34].
 A limitation of  the present study is the relatively small sample size of  
the cohorts. One reason for this was the very strict inclusion criteria for 
RVVC in our study: only patients with both clinical and microbiologically 
confirmed candidiasis were included in the study, and not solely based 
on clinical criteria. Although this reduced the number of  patients in the 
cohorts, we believe that this approach has improved the chance of  positive 
findings by limiting the ‘background noise’ in the genetic signal. We have 
also employed additional approaches to compensate for the small cohorts: 
in the two independent patient cohorts we employed several independent 
types of  analyses to asses both rare and common polymorphisms, and we 
also combined these data with functional assessment of  immune function 
in a third cohort of  individuals. Finally, we applied extensive functional 
validation in human primary cells and murine experimental studies to 
confirm the important role of  SIGLEC15 as a novel receptor in the host 
defense against C. albicans. 
 The Siglec family of  receptors recognizes sialylated structures [28, 35], 
and this is presumably the ligand recognized in the fungal cell wall as well. 
In fact, sialic acids have been earlier identified on the surface of  C. albicans, 
and treatment of  the fungus with neuraminidase that cleaves sialic acid from 
glycans changed the induction of  inflammatory mediators. SIGLEC15 has 
been shown to be present on several immune cells, such as macrophages 
and dendritic cells [36]. Interestingly, SIGLEC15 has also been shown to be 
constitutively expressed in osteoclasts and mice lacking this receptor are 
prone to develop osteopetrosis due to imbalances in osteoclast differentiation 
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processes [37, 38]. The polymorphism identified in this study (rs2919643) is 
located on position 273 within the SIGLEC15 gene and leads to a missense 
mutation from phenylalanine to leucine (F273L): a change from a large 
aromatic amino acid into a medium size hydrophobic amino acid is likely to 
lead to structural consequences. Interestingly, a lysine residue is located at 
amino acid positon 274 within the transmembrane domain, which is critical 
for signal transduction through the DAP12-Syk pathway [39]. The amino acid 
change might influence signalling upon ligand binding to SIGLEC15, and 
this needs to be investigated in future studies. The functional consequence of  
the risk allele in this polymorphism is hyper-production of  the Th17 cytokines 
IL-17A and IL-22: through increased neutrophil recruitment and release 
of  inflammatory mediators, this contributes to the pathophysiology of  the 
disease. Indeed, the current concept supported by a wealth of  experimental 
studies is that hyper-inflammation, rather than immunodeficiency, is the 
basis of  the pathological effects of  RVVC [6],[40, 41],[32, 33].
 In addition to the novel immunological genes and pathways identified 
here, a clear conclusion of  the combined analyses of  the rare and common 
genetic variants is that not only immune-related mechanisms, but also 
biological processes related to cell morphology and adhesion are important 
for RVVC susceptibility. Adhesion and colonization of  epithelium by 
Candida is well known to be important for mucosal infections [42], and the 
specific genes and pathways that influence RVVC pathophysiology need to 
be further studied in the future. Furthermore, one of  the most interesting 
observations was the impact of  genetic variants in genes involved in fatty 
acid oxidation for the susceptibility to RVVC. Cellular metabolism has 
been recently identified to be one of  the main processes that determine 
the function of  immune cells, with glycolysis being strongly up-regulated 
during induction of  inflammation, while fatty acid oxidation is crucial 
for the maintenance of  the balance between inflammatory and regulatory 
T-cells [43]. Fatty acid oxidation is crucial for the function of  regulatory 
T-cells [44] and for induction of  long-term CD8 memory [45], mechanisms 
that may have important roles in maintaining a balanced mucosal 
antifungal response. A thorough investigation of  the impact of  potential 
dysregulation in immune cell metabolism in RVVC patients is warranted. 
In a complementary manuscript investigating invasive fungal infections we 
identified genes that are associated with Candidemia on one hand and on 
the other hand alter the cytokine production after in vitro Candida stimulation 
in a genotype dependent manner. Interestingly, these genes overrepresent 
pathways belonging to lipid and lipoprotein metabolism.
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In conclusion, combining genomic data with functional immune 
measurements provided a systems-based approach that allowed us to identify 
important pathophysiological pathways and novel therapeutic targets in 
patients with RVVC. Validating these findings in additional independent 
studies and approaching these targets for therapy are needed to fulfil the 
need for novel diagnostic and therapeutic methods in RVVC.
Material and Methods
Patient and control cohort 
The inclusion of  the North European RVVC cohort took place from January 
2009 until December 2013 at the Radboud University Medical Center 
(Nijmegen, Netherlands) and Wayne State University School of  Medicine 
(Detroit, USA). The South European RVVC cohort was recruited at the 
Santa Maria della Misericordia Medical Centre (Perugia, Italy) and was 
approved by the institutional review boards of  all centres. The cohorts were 
described earlier [33]. All patients gave written informed consent and the 
study was in accordance to the declaration of  Helsinki. 
 Patients were diagnosed with at least three documented episodes of  
VVC in a year that were microbiologically confirmed to be caused by 
C. albicans. Recruitment took place during episodes of  acute vaginitis or, if  
asymptomatic, while receiving maintenance fluconazole therapy. Enrolment 
for the control cohort took place at the Radboud University Medical Center. 
All controls were from European origin asymptomatic and without a history 
of  Candida infections. All subjects gave written informed consent. 
DNA Isolation
DNA was isolated from ETDA venous blood using the Gentra Pure Gene 
Blood kit following the manufactures standard protocol (Qiagen, Venlo, 
The Netherlands). 
Whole Exome sequencing
Whole Exome Sequencing was carried out at the Beijing Genome Institute 
for both, the NEC and SEC cohort. Two different enrichment kits were used 
during the enrichment step: Agilent SureSelect version 2 for NEC and version 
4 for the SEC. The genomic DNA samples were randomly fragmented by 
Covaris and adapters were ligated to both ends of  the resulting fragments. 
The adapter-ligated templates were purified by the Agencourt AMPure 
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SPRI beads and fragments with an insert size of  about 176bp were excised. 
Extracted DNA was amplified, purified, and hybridized to the SureSelect 
Biotinylated RNA Library (BAITS) for enrichment. The enriched libraries 
were loaded on Hiseq2000 platform for the high-throughput sequencing. 
Raw image files were processed by Illumina base-calling Software 1.7 for 
base-calling with default parameters and the sequences of  each individual 
were generated as 90bp pair-end reads. 
Bioinformatics 
The sequence reads were aligned to the human genome (hg19) using BWA 
(0.7.0) [46]. Potential PCR duplicates were removed using Picard version 
1.84 [http://picard.sourceforge.net] and reads were local-realigned using the 
GATK “IndelRealigner” tool. The base quality was re-calibrated using the 
GATK “BaseRecalibration”. Both single nucleotide variants and small insertion 
deletions were called using the GATK “UnifiedGenotyper” on the 4 samples 
simultaneously [47]. All steps were performed in accordance with the GATK 
version 2.4.9 “Best Practices” (http://www.broadinstitute.org/gatk/pdfdocs/
GATK_GuideBook_2.4-9.pdf) [48, 49]. We filtered out all variants with a 
‘quality-by-depth’ lower than 60 and with less than 20X coverage. 
 Variants were annotated using a custom-made pipeline described earlier 
[50]. Annotations include RefSeq gene annotation, amino acid consequences, 
variants and frequencies from dbSNP135, variants and frequencies from the 
RadboudUMC Human Genetics database, and disease information from 
OMIM and HGMD [51]. 
 Samples were considered failed if  there was an indication of  unreliable 
sequencing. To this aim, we filtered out samples with genotypes that were very 
different from those of  their reference populations, under the assumption that 
a very high degree of  variability was more likely attributable to artefacts than 
to true variants [27]. Additionally, samples with a non-normal coverage and 
number of  called variants were removed. To calculate the coverage and the 
number of  variants, we used in-house scripts and bedtools version 2.17.0 [52].
 Variants were not considered in further analyses if  they were either marked 
as failed by the variant calling software (GATK), had quality lower than 50, a 
coverage depth larger than 200x or lower than 20x or a variant-call that failed 
in more than 20 samples (either reference or alternative). 
 The subset of  Functional Rare Variant (FRV) were selected for the higher 
probability to have a high-penetrant and direct effect on RVVC risk (Rare-
Variant Common-Phenotype Hypothesis). FDR were those predicted to affect 
the predicted protein sequence, were rare with the study sample (MAF<5%) 
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and in any of  the available population databases (MAF<1%) and had to 
map in evolutionary conserved nucleotides (phyloP >2). A second subset of  
Common SNP (cSNP) were selected because of  their potential combined and 
low-penetrance effect (Common-Variant Common-Phenotype Hypothesis). 
These variants had to be biallelic, frequent among the study-sample (MAF of  
≥ 5%) and in agreement with Hardy-Weinberg equilibrium. 
Statistical analysis
The cSNP analyses were performed using the fisher-test function implemented 
in PLINK software (ver 1.07) to detect cSNPs with imbalanced number 
of  alleles between cases and controls in the NEC and SEC separately. 
Subsequently, the overlap between the cSNPs and genes between the two 
cohorts were performed and the statistical significance was calculated. The 
rare-variant analysis focused on the genes enriched by FRV in cases and 
being absent in controls. Ideally, candidate genes had multiple FRV present 
in cases in both cohort and none in any control. We explored also a statistical 
association test for rare variant, by recursively performing the Fisher test for 
every gene by counting the FRVs between cases and controls and either 
within or without the gene. In theory, FRVs might act as protecting factor by 
inactivating genes in controls, however, we only considered the very more 
likely mechanism of  gene inactivation in cases as predisposing factors. 
 The Cytokine-QTL analysis was performed by calculating the difference 
of  pre- and post-stimulation levels of  cytokines using the Mann–Whitney U 
test. All sample-stimulation pairs that were positive for the negative RPMI 
stimulation were removed from the analysis. The cytokines used for the 
cQTL analysis were: TNFα, IL-1β, IL-6 (all after 24 hours) IL-17A, IL-22 
and IFN-γ (after 7days). 
 The functional characterization of  gene-sets was performed with the 
TopGO package (R code which can be downloaded from Bioconductor 
(https://www.bioconductor.org/pack ages/GEM/)). In every analysis, the 
reference set contained all genes with at least one variant in the corresponding 
cohort. To calculate the statistical significance between gene-sets overlaps 
was calculated with the hypergeometric test implemented in the R function 
(“phyper”). All statistical analysis, when not differently specified, were 
performed with R version 3.2.5. When specified the multiple-test correction 
was performed by the calculation of  False Discovery Rate (FDR).
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Power analysis
A power analysis was performed to estimate the smallest effect size detectable 
by statistical tests within this study. A power of  80% and a baseline alpha of  
0.05 were considered. Alpha values were further corrected for the number of  
variants with the Bonferroni method. The statistical power of  the common 
variant analysis was estimated with the procedure described by Purcell et 
al. [53], whereas the one of  rare variants was performed with the standard 
procedure for repetitions of  2-by-2 fisher tests. The power analysis was 
corrected with the Bonferroni method. The two common-SNPs analyses 
were performed with allelic association tests on 28,328 (NEC) and 45,819 
(SEC) variants, resulting in corrected alpha values of  1.7x10-6 (NEC) and 
1.1x10-6 (SEC). With sample sizes of  170 (NEC, 75 cases and 95 controls) and 
157 (SEC, 80 cases and 77 controls), it is most likely to detect the minimum 
relative risks of  2.5 (NEC) and 2.65 (SEC). The rare-variants burden test 
was performed on 48,308 variants, resulting in a corrected alpha value of  
4x10-6, that, with the sample sizes of  327 (150 cases and 172 controls) is 
likely to detect the minimum relative risks of  about 10 (2% versus 20%).
Isolation and stimulation of PBMCs
73 healthy controls participated in an in vitro-stimulation assay. From these 
volunteers EDTA venous blood was collected to subsequently isolate PBMCs 
by Ficoll-Paque density centrifugation as described earlier [54]. 5x105 
PBMCs were plated in 96 wells round bottom plates to subsequently get 
stimulated for either 24 hours or 7 days with RPMI (control, unstimulated), 
C. albicans yeast 1x106/ml, or C. albicans hyphae 1x106/mL (both UC820, 
heat killed).
Preparation of Candida albicans
The C. albicans strain ATCC MYA-3573, UC820 was used for the in vitro 
experiments in this study. To generate hyphae, live yeast forms of  C. albicans 
were grown for 24 hours at 37°C in RPMI 1640 (Gibco-BRL, Grand Island, 
NY), adjusted to pH 6.4 by using hydrochloric acid. After 24 hours, more 
than 95% of  the yeast cells were grown to hyphae, which were checked by 
microscope. Hyphae were subsequently heat killed for 45 min at 98°C and 
resuspended in RPMI 1640 to a hyphal inoculum size that originated from 
1x106/mL yeast cells (referred to as 1x106/mL hyphae).
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Cytokine measurement
After stimulation for either 24 hours or 7 days the cell culture supernatants 
were collected and TNFα, IL-1β, IL-17A, IL-22, IL-23, IL-1RA, PGE2 
(R&D Systems, Abingdon, UK) and IL-6 and IFN-γ (Sanquin Research, 
Amsterdam, Netherlands) as well as IL-23 (eBioscience) cytokines 
concentrations were measured using enzyme-linked immunosorbent assay 
following the protocols of  the manufactures. 
Fungal killing assays
Human PBMCs from 33 healthy volunteers were plated in 96 flat bottom 
plates (5x105 cells per well). 1x106/mL live Candida was added for 24 hours. 
Following incubation, the well contents were serial diluted in sterile water 
and plated on Sabouraud agar for counting of  colony forming units (CFUs) 
after 24 hours of  incubation. 
RNAseq
1x107 PBMCs were stimulated in 6 well plates with 1x106/mL C. albicans 
(UC820, heat killed), or were left unstimulated for 4 hour or 24 hours at 
37°C with 5% CO2. After incubation, the supernatant was removed and the 
cells were lysed and RNA was isolated using the mirVANA RNA isolation 
kit (Applied Biosystems), before RNA sequencing was performed. 
Human SIGLEC15 siRNA experiments
PBCMS derived from healthy volunteers (3 independent experiments with at 
least 2 donors) have been isolated as described before [54]. For macrophage 
differentiation 10% serum in the presence of  5ng/mL was added for 6 days 
and refreshed on day 4. Afterwards adherent cells were counted and 1,5x105 
serum derived macrophages were plated into 96wells flat bottom plates. After 2 
hours of  adherence these cells were subsequently transfected with either 25nM 
SIGLEC15 siRNA (L-023427-02-0005) (on target) or scrambled (non target) 
control siRNA (D-001810-10-05) (Smartpool, Thermo Scientific, Waltham, 
USA) for 48 hours at 37ºC. After centrifugation, the supernatant was discarded 
and the pellet was resuspended in 200µl of  stimuli containing either C. albicans 
yeast 106/mL (UC820, heat killed) or RPMI 1640 for 24 hours. Subsequently 
the supernatants were collected for cytokine analysis using enzyme-linked 
immunosorbent assay for IL-6 and TNFα (ELISA) (Sanquin Research, 
Amsterdam, Netherlands and R&D Systems, Abingdon, UK). Silencing 
efficiency was testes using qPCR and the following primer pairs:
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Gene Sequences
SIGLEC15 Sense Ü CGCGGATCGTCAACATCTC
αSense Ü GTTCGGCGGTCACTAGGTG
GAPDH Sense Ü AGGGGAGATTCAGTGTGGTG
αSense Ü CGACCACTTTGTCAAGCTCA
Neuraminidase treatment of C. albicans
108/mL C. albicans yeast (UC820, heat killed) were either treated with 0.5 
U/mL neuraminidase derived from Clostridium perfringens (Sigma-Aldrich 
(St. Louis, Missouri, USA) or with a 25mM KCl solution (untreated) for 30 
minutes at 37°C (pH=5) in the presence of  polymyxin B. After two washing 
steps with PBS Candida was counted and 106/mL yeast per mL were 
subsequently used for cell stimulation experiments as well as ROS assays.
Measurement of the oxidative burst (ROS)
The induction of  reactive oxygen species (ROS) was measured by oxidation 
of  luminol (5-amino-2,3, dihydro-1,4-phtalazinedione). 5x105 PBMCs 
(Figure 3B) or 1x105 macrophages (Figure 3E-G) of  healthy volunteers 
were resuspended in HBSS and put in dark 96 wells plates. Cells were 
exposed to 1x106/mL C. albicans yeast (UC820, heat killed) or A. fumigatus 
conidia (1x107/ml, heat killed) together with 20µl of  1mM luminol (final 
concentration 50mM). Chemiluminescence was measured in BioTek Synergy 
HTreader at 37°C for 1 hour with intervals of  2.23 minutes. The relative 
luminescence units per second (RLU/sec) within the area under the curve 
(AUC) were plotted against time and analysed by using Graphpad Prism 
v5.0. p<0.05 = *, p<0.01 = ** and p<0.001 = ***.
Flow cytometry
To test the direct interaction of  SIGLEC15 to C. albicans, 1mg/mL 
recombinant SIGLEC15-Fc (R&D Systems) or recombinant SIGLEC7-Fc 
(R&D Systems) was incubated with different Candida strains (C. albicans, 
C. glabrata and C. tropicalis) for 2 hours at 37°C. Afterwards the samples 
were washed twice with PBS (1% BSA) to be subsequently been stained 
for 20 minutes with the secondary antibody (Goat anti-Human IgG (H+L), 
Alexa 647), (Thermo Fisher). After two additional washing steps samples 
were measured on the CytoFLEX flow cytometer (Beckman Coulter). 
Data were analysed using the Kaluza Analysis software version 1.5a. In 
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addition to SIGLEC15, a mouse antibody directed against b-glucan (1mg/
mL) (Biosupplies, Bundoora, VIC, Australia) was used as positive control 
(secondary antibody mIgG-PE (BD Bioscience). 
Mice
Female C57BL/6, 8–10 weeks of  age, were purchased from Charles River 
(Calco, Italy) and then, bred under specific pathogen-free conditions at 
the Animal Facility of  the University of  Perugia, Perugia, Italy. Murine 
experiments were performed according to the Italian Approved Animal 
Welfare Authorization 360/2015-PR and Legislative decree 26/2014 
regarding the animal license obtained by the Italian Ministry of  Health 
lasting for five years (2015-2020). All efforts were made to minimize 
suffering. 
Fungal strains and vaginal infection
In VVC model, mice were injected subcutaneously with 100μL of  1g/
mL β-estradiol 17–valerate (Sigma Chemical Co.) dissolved in sesame oil 
(Sigma-Aldrich) 48 h before vaginal infection. Estrogen administration 
continued weekly until completion of  the study to maintain pseudoestrus. 
The estrogen-treated mice were inoculated intravaginally with 20 μL of  a 
phosphate-buffered saline (PBS) suspension of  5 x 106 viable C. albicans 
yeast from early–stationary-phase cultures. The time course of  infection 
was monitored in individual mice by culturing 100 μL of  serially diluted 
(1:10) vaginal lavages on Sabouraud-dextrose agar with chloramphenicol 
plates. Vaginal lavages were conducted using 100 μL of  sterile PBS. CFUs 
were enumerated after incubation at 37°C for 24 h and expressed as log10 
CFU/100 μL of  lavage fluid. In addition, mice were assessed for PMN 
recruitment in vaginal fluids by cytospin preparations of  the lavage fluids, 
which were stained with May-Grünwald-Giemsa and observed with a BX51 
microscope equipped with a high-resolution DP71 camera (Olympus).
siRNA design and delivery 
Predesigned siRNA against murine SIGLEC15 (MMC.RNAI.N001101038.1) 
were purchased from Integrated DNA Technologies (IDT) (TEMA Ricerca, 
Italy). Each mouse was intravaginally treated with unmodified siRNA 
(10 μg/kg) or equivalent doses of  nonspecific control siRNA duplex in a 
volume of  20 μL of  duplex buffer (IDT, TEMA ricerca). Intravaginal siRNA 
was given once the day before infection and every 2 days after the infection 
until the sacrifice (at 3, 7 and 14 dpi). 
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Control of  SIGLEC15 silencing was performed by Real-Time RT-PCR and 
electrophoretic separation of  amplified fragments. Amplification efficiencies 
were validated and normalized against β-actin (Supplementary Figure S7).
Histological analysis and immunohistochemical staining
The vagina was removed and fixed in 10% phosphate-buffered formalin, 
embedded in paraffin and sectioned. For the histological analysis tissue 
were stained with periodic acid-Schiff  reagent and observed using a BX51 
microscope equipped with a high-resolution DP71 camera (Olympus).
 For immunohistochemistry, the sections were stained with the primary 
polyclonal anti-Siglec15 antibody (Abcam, Cat.# ab198684) overnight at 4°C 
followed by secondary biotinylated anti-rabbit antibody (Cytodiagnostics, 
Cat.# AC-5-01-05). The VECTASTAIN® ABC kit (Cat.# PK-4000) was 
used for the secondary antibody detection. Tissues were counterstained 
with hematoxylin and the images were acquired with a 40× objective and 
the analySIS image processing software (Olympus).
Mouse ELISA and real-time PCR
The level of  murine cytokines in the VF were determined by Kit ELISA 
(eBioscience and R&D System). The detection limits of  the assays were 
< 8 pg/mL for IL-1β, <156 pg/mL for IL-1Ra, < 10 pg/mL for IL-22 and 
IL-17A, < 3 pg/mL for IL-10 and < 4 pg/mL for IL-6. Data were normalized 
to total protein levels for each sample as determined using the Bio-Rad 
Protein assay (Life Science, Bio-Rad Laboratories S.r.l. Milan Italy) and 
results represent mean cytokine levels (± s.e.m.) from samples pooled from 
three similar experiments (n = 6 total samples per group). 
 Real-time PCR was performed using the iCycler iQ detection system (Bio-
Rad) and iTaq™ Universal SYBR® Green Supermix (Biorad). Vaginal tissues 
were lysed and total RNA was extracted using RNeasy Mini Kit (QIAGEN, 
Milan, Italy). Isolated RNA was reverse transcribed with Sensiscript 
Reverse Transcriptase (QIAGEN) according to the manufacturer’s protocol. 
Amplification efficiency was validated and normalized against β-actin.
 The thermal profile for Real-time PCR was at 95°C for 3 min, followed by 
40 cycles of  denaturation for 30 s at 95°C and an annealing/extension step 
of  30 sec at 60°C. Each data point was examined for integrity by analysis 
of  the amplification plot. The mRNA-normalized data were expressed as 
relative mRNA in naїve vs. infected or silenced and infected mice.
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Gene Sequences
β-actin Sense Ü AGCCATGTACGTAGCCATCC
αSense Ü CTCTCAGCTGTGGTGGTGAA
Nlrc4 Sense Ü TCACCACGGATGACGAACAG
αSense Ü GTCAATCAGACCACCTGGCA
Nlrp3 SenseÜ ATGCTGCTTCGACATCTCCT
aSenseÜ GTTTCTGGAGGTTGCAGAGC
Siglec15 Sense ÜCTACTTCTGCCGCGTGGAGT
αSense ÜAGCACCGAGATGTTGACGAT
Cell isolation and flow cytometry
Vaginas from infected mice were finely minced, digested in 450U/mL 
Collagenase VIII (Sigma-Aldrich) for 1 hour and meshed through a 70-μm 
cell strainer. This step was repeated 3 times. Purification of  lineage positive 
and lineage negative cells was performed by magnetic depletion (Miltenyi 
Biotec). Flow cytometry on enriched Lin+ and Lin- cells was performed 
with a combination of  the following fluorescence-conjugated mAbs (all 
from Miltenyi Biotec unless specified otherwise): APC-conjugated anti-
CD4 (GK1.5) and anti-CD117 (3C11); FITC-conjugated anti-TCR γδ 
(eBioscience, B1.1). Lin+ cells were negative for CD117 staining and Lin- 
cells were negative for CD4 and TCR γδ staining (data not shown). For 
intracellular staining, phorbol 12-myristate 13-acetate (PMA)/ionomycin-
stimulated cells were added of  brefeldin, and then permeabilized with the 
CytoFix/CytoPerm kit (BD Biosciences) for intra-cytoplasmic detection of  
IL-17A (PE-conjugated anti-IL17A, eBioscience, eBio17B7) and IL-22 (PE-
conjugated anti-IL22, eBioscience, 1H8PWSR). Cells were analysed with a 
BD LSRFortessa flow cytometer equipped with BD FACSDiva 7.0 software.
Statistical analysis
Analysis of  variance (ANOVA) with Bonferroni’s adjustment were used to 
determine statistical significance. The data reported are either from three 
independent experiments. The in vivo groups consisted of  6 mice/group. 
Data were analyzed by GraphPad Prism version 4.03 program (GraphPad 
Software). Data are presented as mean + SD for all bar graphs. *P<0.05, 
**P<0.001, ***P<0.001, ****P<0.0001. Naïve vs Infected mice at different 
dpi One-way ANOVA, Bonferroni post. Scrambled vs Silenced infected 
mice at different dpi Two-way ANOVA, Bonferroni post test.
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Supplementary Figure 1. Manhattan plot form both RVVC cohorts (A) North European 
cohort (NEC) and (B) South European cohort (SEC). 
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Supplementary Figure 2. Cytokine production capacity in PBMCs stimulated with heat 
killed C. albicans for 24 hours (IL-1b, IL-6 and TNFa)  or 7 days (IL-17A, IL-22 and 
IFN-γ). Individuals have been stratified regarding their genotype for the genetic variant 
rs2919643 in SIGLEC15.
Supplementary Figure 3. Cytokine production capacity (in PBMCs stimulated with heat 
killed S. aureus (1x106/ml) for 24 hours (IL-1b, IL-6 and TNFa) or 7 days (IL-17A, IL-22 
and  IFN-γ). Individuals have been stratified regarding their genotype for the genetic 
variant rs2919643 in SIGLEC15.
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Supplementary Figure 4. (A) Relative SIGLEC15 expression in different primary cell 
types as well as the vaginal cell line VK2/E6E7. (B) RPMI normalized gene expression 
of  SIGLEC15 in the vaginal cell line VK2/E6E7 after stimulation with different C. albicans 
morphotypes for 24 hours.
Supplementary Figure 5. Binding of  recombinant SIGLEC15 to C. glabrata (A) and 
C. tropicalis (B). Blue: C. albicans alone; Green: C. albicans and the secondary antibody; 
red: C. albicans, recombinant SIGLEC15 and the secondary antibody.
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Supplementary Figure 6. Flow cytometry of  cells derived from C. albicans infected (dpi7) 
or naive mouse vaginas. IL-17A as well as IL-22 were measured in CD4+, TCR-γd+ or 
CD117+ cells.
Supplementary Figure 7. Silencing efficiency control for the mouse siRNA experiments. 
Efficiency was tested using Real-Time RT-PCR and electrophoretic separation of  
amplified fragments. Efficiencies were normalized against b-actin.
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Abstract
Background: The induction of  host defense against Candida species is 
initiated by recognition of  the fungi by pattern recognition receptors and 
activation of  downstream pathways that produce inflammatory mediators 
essential for infection clearance. 
Methods: In this study, we present complementary evidence based on 
transcriptome analysis, genetics, and immunological studies in knockout 
mice and humans, that the cytosolic RIG-I-like receptor MDA5 (IFIHI) has 
an important role in the host defense against C. albicans.
Results: Firstly, IFIH1 expression in macrophages is specifically induced 
by invasive C. albicans hyphae, and patients suffering from chronic 
mucocutaneous candidiasis (CMC) express lower levels of  MDA5 than 
healthy controls. Secondly, there is a strong association between missense 
variants in the IFIH1 gene (rs1990760 and rs3747517) and susceptibility to 
systemic Candida infections. Thirdly, cells from Mda5 knockout mice and 
human PBMCs with different IFIH1 genotypes display an altered cytokine 
response to C. albicans. These data strongly suggest that MDA5 is involved 
in immune responses to Candida infection. 
Conclusions: As a receptor for viral RNA, MDA5 until now has been linked 
to antiviral host defense, but these novel studies show unexpected effects in 
antifungal immunity as well. Future studies are warranted to explore the 
potential of  MDA5 as novel target for immunotherapeutic strategies.
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Introduction
Candida species are one of  the most common human fungal pathogens. 
Oropharyngeal and vaginal Candida infections are often diagnosed in the 
population, while systemic candidiasis is the fourth most common form of  
bloodstream infections in the US with mortality rates reaching up to 40% 
[1-4]. In addition to the known risk factors (immunosuppressive medication, 
parenteral nutrition, prolonged intensive care hospitalization, etc.), recent 
studies have described several genetic risk factors that contribute to the cause 
and severity of  systemic candidiasis [5, 6]. Several monogenic disorders 
that result in primary immunodeficiencies increase the susceptibility to 
Candida infection, as demonstrated for mutations in CARD9 and STAT1 [7-
9]. Common genetic variants, for example in pattern recognition receptors 
(e.g. Dectin-1 and TLR1) and interleukins (e.g. IL-4, IL-10 and IL-12B), also 
increase the risk of  infection by affecting Candida recognition and cytokine 
signaling [6, 10]. 
 However, more insight is needed to identify host defense pathways that 
are suitable targets for novel immunotherapeutic approaches. Recently, we 
described that the type I interferon (IFN) pathway plays a central role in host 
defense against C. albicans [11]. In the present work, we demonstrate that 
MDA5 (IFIHI), a RIG-I-like receptor, until now described as a receptor of  
viral RNA that induces a signaling pathway leading to the production of  type I 
interferons, is directly involved in the inflammatory response against Candida 
infections in humans. To this end, we present complementary evidence based 
on transcriptome analysis, genetics, and functional immunological studies in 
knockout mice and in healthy humans, as well as in patients suffering from 
systemic candidiasis or chronic mucocutaneous candidiasis (CMC). This is 
the first time that a receptor of  the RIG-I-like helicase family has been shown 
to be involved in the antifungal immune response.
Materials and Methods
Transcriptome analysis of Candida-stimulated macrophages
CD14+ monocytes derived from healthy volunteers were differentiated 
into macrophages using M-CSF for 7 days. Macrophages (2x105/well) were 
stimulated for 4 or 24h with either culture medium, a wild-type C. albicans 
strain (UC820) or a HGC1 null mutant strain. This mutant is unable to 
form hyphae and is therefore locked in a yeast form, although this form 
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does not correspond to wild-type yeast cells as the mutant expresses several 
filament-specific genes [12]. As yeast-hyphal transition is considered an 
invasive trait of  Candida albicans, gene expression induced by either the 
wild-type (hyphae) or HGC1 null (yeast) strains was profiled and compared 
to unstimulated macrophages, as described previously [11]. We identified 
genes that showed significant differential expression in at least one of  the 
conditions after Benjamini-Hochberg correction (P < 0.05 and > 2-fold 
change in expression). From this set, we selected the 62 genes that are 
exclusively induced after stimulation with wild-type C. albicans for 24h.
Candidemia and control cohorts
In this study we included 227 unrelated adult Caucasian candidemia patients 
(described in detail in [6]). Patient enrollment took place after confirmation 
of  at least one positive blood culture for a Candida species. The control 
cohort of  176 Caucasians consists of  non-infected (candidiasis free) matched 
patients from the same medical centres as the patient cohort. Controls were 
recruited consecutively from the same hospital wards as infected patients 
during the study period, with a similar balance of  medical, surgical, and 
oncology patients in case and control groups. Review boards of  the involved 
medical centres approved the study and patients were enrolled after giving 
written informed consent (Supplementary Methods).
Genotyping and genetic analyses
Cases and controls in the candidemia cohort were genotyped on the Illumina 
Immunochip SNP array platform, which contains ~200,000 SNPs focused 
on genomic regions known to be involved in immune-mediated diseases 
[13]. After application of  quality control filters, we tested 843 SNPs in the 
FAP-IFIH1-GCA-KCNH7 LD region for candidemia case-control association. 
This 405 kb LD region (hg18 coordinates: chr2 162,720 kb – 163125 kb) was 
defined based on the LD patterns in the larger genomic region (Figure S1). 
See Supplementary Methods for detailed information.
Expression analysis of PBMCs
To assess the expression levels of  genes in the FAP-IFIH1-GCA-KCNH7 
LD region, blood was collected from healthy volunteers. Peripheral blood 
mononuclear cells (PBMCs, 5×105/well) were stimulated with either 
culture medium, 1 × 106/ml heat killed Borrelia burgdorferi [14], 1×106/ml 
heat killed Candida albicans (UC820) [15], 10 ng/ml Escherichia coli-derived 
lipopolysaccharide (LPS), or 1×107/ml sonicated Mycobacterium tuberculosis 
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(MTB) (Hv37Rv) for either 4 or 24h. Gene expression was profiled using 
Illumina Human HT-12 expression BeadChip [11]. Additionally, gene 
expression was assessed in PBMCs from two patients suffering from chronic 
mucocutaneous candidiasis (CMC) due to STAT1 mutations (Arg274Trp) 
[8]. Cells were stimulated with C. albicans for 4h and gene expression was 
measured by RNA sequencing as described elsewhere [11].
PBMC stimulations experiments
5×105 isolated PBMCs per well were stimulated with either heat killed 
C. albicans yeast or hyphae (UC820, 1×106/ml) for 24h (IL-10) or 7 days (IL-
17 and IFN-γ). Additionally, PBMCs were stimulated with Mycobacterium 
tuberculosis (MTB) (1µg/µl) for 24h. Supernatants were collected and 
measured for IL-10 and IFN-γ (Sanquin, Amsterdam, The Netherlands), 
and IL-17 cytokines (R&D Systems, Abingdon, UK). We excluded samples 
that showed a positive RPMI (control condition with contamination) or 
errors in the experimental readout.
Mda5 knockout mice studies 
Mda5−/− mice on C57BL/6J background have been backcrossed at least 
ten times and were kindly provided by dr. M. Colonna. Splenocytes were 
isolated from wild-type and Mda5−/− mice and stimulated with RPMI, Poly 
I:C, and heat-killed C. albicans yeasts or hyphae for 24h. Cytokines were 
measured in supernatants by ELISA. For qPCR, splenocytes from both 
Mda5 knockout mice and B6 control mice were stimulated for 24h with 
heat-killed C. albicans hyphae. RNA was isolated according to the TRIzol® 
isolation protocol (Life Technologies).
Results
Candida germination induces expression of RLR pathway 
components in macrophages
Candida albicans is a dimorphic fungus that exists either in a colonizing 
yeast form, or as an invasive filamentous form (hyphae). To identify the 
specific transcription profile induced by fungal germination into hyphae, we 
profiled the transcriptome of  macrophages stimulated with either wild-type 
(which develop hyphae) and HGC1 null strains of  C. albicans (which have a 
yeast-locked phenotype, though are different from wild-type) [12]. 62 genes 
exhibited significant differential expression specifically in macrophages 
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Figure 1. Transcriptional changes in macrophages stimulated with Candida albicans. 
(A) The heatmap shows differential gene expression after 4h or 24h stimulation of  
human macrophages with yeast-locked HGC1 null Candida albicans (which are unable 
to form hyphae, but are known to express several hyphal proteins), or wild-type invasive 
Candida albicans (that can form hyphae), compared to expression levels in unstimulated 
macrophages (control). 62 genes exhibited a significant change in expression level 
(Benjamini-Hochberg-corrected P < 0.05 and > 2-fold change in expression) specifically 
after 24h stimulation with wild-type Candida, during which germination into hyphae takes 
place. Signal-to-noise ratio scaled to the maximum absolute deviation is shown for each 
probe corresponding to the 62 differentially expressed genes. (B) Candida albicans hyphae-
induced genes, IFIH1, TRIM25, ISG15 and IL8 (indicated in red), are components of  
the RIG-I-like receptor (RLR) signaling pathway. These genes represent both the MDA5 
(IFIH1) and RIG-I (ISG15 and TRIM25) branches, as well as inflammatory cytokines that 
are produced by activation of  the pathway (IL8). Figure based on the KEGG map of  the 
RLR pathway [47].
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stimulated with Candida hyphae for 24h (required for hyphal formation), 
but not for 4h (Benjamini-Hochberg-corrected P < 0.05 and > 2-fold change 
in expression compared to unstimulated macrophages, Figure 1A). Many 
of  these genes are involved in interferon (IFN) signaling, consistent with 
a previous study [11]. Interestingly, four of  the genes induced by Candida 
hyphae stimulation (IFIH1, ISG15, IL8, and TRIM25) are components of  
the RIG-I-like receptor (RLR) signaling pathway, significantly more than 
expected for a random set of  genes (P = 4.3 × 10-3, 11.5-fold enrichment, 
Table 1).
 RIG-I-like receptors are well-known intracellular receptors of  viral RNA 
leading to the production of  type I IFNs and proinflammatory cytokines 
[16]. IFIH1, with its protein product known as MDA5, is the receptor of  one 
branch of  the RLR pathway (Figure 1B). ISG15 and TRIM25 are involved 
in the RIG-I branch. Thus, the invasive form of  Candida induces expression 
of  components of  two branches of  the virus-recognition RLR pathway in 
macrophages.
Table 1. KEGG pathway enrichment for genes that are specifically induced in 
macrophages stimulated with wild-type Candida for 24 hours.
KEGG 
identifier
Pathway P value Fold 
enrichment
Genes
hsa04622 RIG-I-like receptor signaling pathway 4.3 × 10-3 11.5 IFIH1, ISG15, IL8, 
TRIM25
hsa04060 Cytokine-cytokine receptor 
interaction
6.6 × 10-3 4.7 OSM, TNFSF13B, 
IL8, CXCR4, 
CCL3L1, CCL5
hsa04612 Antigen processing and presentation 6.6 × 10-3 9.8 TAP2, TAP1, 
HSPA6, HSPA1B
hsa04062 Chemokine signaling pathway 1.1 × 10-2 5.4 IL8, CXCR4, 
CCL3L1, CCL5, 
STAT1
hsa04621 NOD-like receptor signaling 
pathway
3.4 × 10-2 9.8 IL8, RIPK2, CCL5
hsa05120 Epithelial cell signaling in 
Helicobacter pylori infection
4.0 × 10-2 9.0 IL8, HBEGF, 
CCL5
Enrichment for KEGG pathway components [47] was determined using the functional 
annotation tool of  the DAVID suite [50]. Background: all human genes.
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Genetic variation linked to IFIH1 modulates susceptibility to 
candidemia
To validate a role for components of  the RLR pathway in invasive Candida 
infection, we investigated whether genetic variation linked to IFIH1, ISG15, 
IL8, or TRIM25 correlates with susceptibility to candidemia in patients. 
Analysis of  64 SNPs associated with IFIH1 revealed strong associations 
(Figure 2A and Table 2). The IFIH1 locus is present in a 405 kb region on 
chromosome 2 with low recombination rates (Figure 2A) and accompanying 
strong linkage disequilibrium (LD) in both the candidemia cohort and the 
HapMap CEU population (Figures 2B and S1) [17-19]. Besides IFIH1, the 
LD region contains the genes FAP, GCA, and part of  KCNH7. 15 of  the 64 
SNPs in the FAP-IFIH1-GCA-KCNH7 LD region differ significantly between 
cases and controls (Benjamini-Hochberg-corrected genotypic P < 0.05, 
Table S1). The significant SNPs are distributed mainly across the central 
part of  the LD region (Figure 2A) and the association does not extend 
beyond the LD region (Figure S2).
 An intergenic SNP between GCA and KCNH7 shows the strongest 
association with candidemia (rs984971, genotypic P = 2.2 × 10-5, allelic 
P = 2.2 × 10-4, odds of  disease 0.43 – 0.77, Table 2). Although the 
Immunochip covers missense coding variants in all four genes, only IFIH1 
harbors significant missense SNPs (rs1990760 – Ala946Thr, and rs3747517 
– His843Arg, which are also in strong LD with each other; HapMap CEU: 
D’ = 1, r2 = 0.42 – candidemia cohort: D’ = 1, r2 = 0.55). Furthermore, 
rs1990760 and rs3747517 are quantitative trait loci (QTLs) to IFIH1 
expression, with the candidemia risk alleles correlating with higher IFIH1 
expression in PBMCs [18, 20]. These results suggest that IFIH1 is involved 
in candidemia.
IFIH1 is strongly upregulated upon Candida stimulation of 
PBMCs, while FAP, GCA, and KCNH7 are not
To provide additional evidence regarding which genes in the FAP-IFIH1-
GCA-KCNH7 LD region are important for the host response to Candida, 
we assessed gene expression in PBMCs from healthy volunteers after 
stimulation with various microbes. Stimulation with C. albicans resulted 
in a strong increase of  IFIH1 expression (P = 1.5 × 10-15 at 4h and 
P = 1.9 × 10-12 at 24h, Welch-corrected t-tests, Figure 3A). Of  the other LD 
region genes, only GCA was also weakly induced by C. albicans. In addition, 
we compared the expression patterns of  IFIH1 in healthy individuals with 
two patients suffering from chronic mucocutaneous candidiasis (CMC) 
239
9
Table 2. Selection of SNPs in the FAP-IFIH1-GCA-KCNH7 LD region that are 
significantly associated with susceptibility to candidemia
 SNP Immunochip Closest 
gene(s)
Alleles 
(dbSNP)
Functional class 
(AA change)
BH-corrected 
genotypic  
P value
rs984971 imm_2_162932767 GCA | KCNH7 A/G intergenic 6.9 × 10-4
Genotypes GG GA AA
Controls 25 (14.2%) 103 (58.5%) 48 (27.3%) P = 2.2 × 10-5
Cases 25 (11.0%) 89 (39.2%) 113 (49.8%)
Alleles G A*
Controls 153 (43.5%) 199 (56.5%) P = 2.2 × 10-4
OR, G vs. A = 0.57 (0.43 – 0.77)Cases 139 (30.6%) 315 (69.4%)
rs1990760 imm_2_162832297 IFIH1 C/T missense 
(Ala946Thr)
3.0 × 10-3
Genotypes CC CT TT
Controls 31 (17.6%) 99 (56.3%) 46 (26.1%) P = 1.9 × 10-4
Cases 37 (16.3%) 87 (38.3%) 103 (45.4%)
Alleles C T*
Controls 161 (45.7%) 191 (54.3%) P = 3.7 × 10-3
OR, C vs. T = 0.65 (0.49 – 0.87)Cases 161 (35.5%) 293 (64.5%)
rs3747517 imm_2_162837070 IFIH1 T/C (A/G) missense 
(His843Arg)
8.7 × 10-3
Genotypes TT TC CC
Controls 12 (6.8%) 88 (50.0%) 76 (43.2%) P = 1.4 × 10-3
Cases 20 (8.8%) 73 (32.2%) 134 (59.0%)
Alleles T C*
Controls 112 (31.8%) 240 (68.2%) P = 3.3 × 10-2
OR, T vs. C = 0.71 (0.52 – 0.97)Cases 113 (24.9%) 341 (75.1%)
Genotypic and allelic associations were assessed using the Fisher’s exact test. P values 
are shown next to the corresponding contingency tables. Odds ratios (OR, with 95% 
confidence intervals) are reported for the allelic association tests and represent the 
odds of  disease for individuals carrying the non-risk allele versus the risk allele. Risk 
alleles are denoted by an asterisk. BH-corrected genotypic P value: Benjamini-Hochberg 
correction of  the genotypic association test P values for testing multiple SNPs (64 in 
total). Immunochip: the identifier of  the SNP on the Immunochip SNP array. Alleles: the 
alleles measured with the Immunochip, and the complementary alleles reported by dbSNP 
(build 138), if  they are different. The table shows the top SNP in the LD region, along 
with the only two significant missense SNPs. All SNPs tested are in Hardy–Weinberg 
equilibrium in the controls (P > 1 × 10-3). See Table S1 for the full list of  significant SNPs.
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Figure 2. (A) Regional association plot and (B) linkage disequilibrium (LD) map for the FAP-
IFIH1-GCA-KCNH7 LD region on chromosome 2. (A) 64 SNPs with MAF > 5% in 403 Caucasian 
individuals of  the candidemia cohort (cases and controls together) were assessed for genotypic 
association with candidemia. The resulting -log10(genotypic P values) (left y-axis) are plotted as a 
function of  genomic coordinates (hg18, x-axis). The blue diamond highlights the most significant 
SNP with its P value (rs984971). rs1990760 and rs3747517 are the only two significant missense 
SNPs; both are in the coding region of  IFIH1. Recombination rates, estimated from the CEU, YRI 
and JPT+CHB HapMap populations (HapMap 2, Release 22) [48], are plotted to reflect the local 
LD structure (right y-axis, cyan line). SNPs are colored according to the degree of  LD with the most 
significant SNP, rs984971 (R-squared, calculated across the controls in the candidemia cohort; from 
strong to weak LD - red: r2≥0.8; orange: 0.5≤r2<0.8; yellow: 0.2≤ r2<0.5; white: r2<0.2). Genes 
with their direction of  transcription are shown at the bottom; KCNH7 is only partly in this region. (B) 
LD patterns across the 405 kb FAP-IFIH1-GCA-KCNH7 LD region are calculated based on genotypes 
of  control individuals in the candidemia cohort, measured using the Immunochip SNP array. The 
intersections of  the diagonals between pairs of  SNPs are colored according to the degree of  LD, 
which is calculated as D’ and LOD: SNPs with D’ values between 0 and 1 and with LOD ≥ 2 are 
colored from white to red. Haplotype blocks (triangles with bold black borders) are regions where 
at least 95% of  SNPs are in strong LD, defined by high D’ values [49]. Chromosome 2 coordinates 
(hg18) and Entrez genes are shown at the top. Orange boxes around SNP identifiers indicate the top 
SNP and two IFIH1 missense SNPs significantly associated with susceptibility to candidemia (see 
Table 2). The corresponding R-squared LD map for the candidemia cohort is depicted in Figure 
S1D. See Figures S1A-C for R-squared and D’/LOD LD maps calculated based on the HapMap 
CEU population.
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A
B
Figure 3. Transcriptional response of genes in the FAP-IFIH1-GCA-KCNH7 LD region 
to various microbial stimuli. (A) Peripheral blood mononuclear cells (PBMCs) from 
healthy volunteers (minimum n=23) were stimulated for either 4 or 24 hours with 
Borrelia burgdorferi, Candida albicans, Escherichia coli-derived lipopolysaccharide (LPS), or 
Mycobacterium tuberculosis (MTB). Gene expression (Mean ± SD) was measured using 
microarrays and normalized to the control RPMI condition (untreated). P values (Welch-
corrected t-test) compared expression distributions of  individual stimuli to their respective 
untreated controls and were Bonferroni-corrected for testing 32 hypotheses (four stimuli 
across four genes at two time points). Asterisks represent all significant comparisons at 
α < 0.05. (B) Gene expression (Mean ± SD) in PBMCs of  healthy controls (n=3) and 
patients suffering from chronic mucocutaneous candidiasis (CMC) (n=2) were stimulated 
with C. albicans for 4 hours. P values were calculated using the Welch-corrected t-test.
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due to a deleterious STAT1 mutation [8]. CMC patient cells expressed 
significantly lower levels of  IFIH1 after stimulation with C. albicans than 
cells from healthy individuals (P = 0.04, Welch-corrected t-test, Figure 3B), 
while of  the other genes only GCA also displayed minor differences 
(P = 0.05). Together, the observations in healthy individuals and CMC 
patients indicate that expression of  IFIH1, and not expression of  the other 
genes in the LD region, is specifically induced by stimulation with C. albicans.
Genetic variants in IFIH1 are associated with an altered 
cytokine profile in response to Candida
To investigate the functional consequences of  genetic variants associated 
with IFIH1 that predispose individuals to candidemia (Table 2), we 
correlated the genotypes of  the SNPs with in vitro cytokines levels upon 
Candida stimulation. A trend was observed towards an increased capacity 
to release the proinflammatory cytokines IFN-γ and IL-17 in cells isolated 
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Figure 4. IFIH1 missense SNP genotypes correlate with Candida-induced cytokine levels. 
PBMCs from healthy volunteers with different genotypes for (A) rs1990760 (candidemia risk 
allele T) and (B) rs3747517 (candidemia risk allele C) were stimulated in vitro with either C. 
albicans yeast or hyphae. Cytokine levels (scatterplots with mean indicated) were measured after 
24 hours (IL-10) or 7 days (IL-17 and IFN-γ) by enzyme linked immunosorbent assay (ELISA). 
P values were calculated using the Mann-Whitney U test comparing cytokine levels of  the two 
homozygous genotypes.
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from individuals homozygous for the risk allele for both IFIH1 missense 
polymorphisms (TT for rs1990760; CC for rs3747517) (Figure 4). 
In contrast, levels of  the anti-inflammatory IL-10 tended to be lower in 
individuals carrying the risk allele. The top intergenic SNP associated 
with candidemia (rs984971) did not reveal the same trends (Figure S3). 
Furthermore, stimulation with other microbial stimuli did not reveal clear 
correlations between cytokine levels and IFIH1 missense SNP genotypes 
(Figure S4), suggesting specificity for Candida. Thus, genetic variation in 
IFIH1 may influence anti-Candida cytokine profiles in vitro.
Missense SNPs could affect MDA5 protein function
We next sought to gain insight into the possible consequences of  having 
alternative alleles at the IFIH1 missense SNPs on MDA5 protein function. 
In silico analysis shows that residue 946 (rs1990760, Ala946Thr) is part 
of  an intrinsically disordered loop [21]. The equivalent loop is rigid in 
RIG-I, and this differential flexibility contributes to the different RNA 
binding preferences between MDA5 and RIG-I [22]. The human MDA5 
crystal structure has an arginine at position 843 (rs3747517, His843Arg), 
which interacts with the negatively charged RNA backbone (Figure S5). 
Histidine would weaken this electrostatic interaction because it is less often 
positively charged at physiological pH than arginine. Furthermore, position 
843 is close to the interface likely involved in interactions between MDA5 
monomers (Figure S5) [22]. The formation of  MDA5 filaments along the 
RNA is critical for downstream activation of  MAVS [23] and mutation of  
nearby residues 841 and 842 disrupts signaling [22]. Thus, the Ala946Thr and 
His843Arg substitutions could alter dsRNA binding selectivity and affinity, 
and the latter might also affect signaling activity. 
Mda5 knockout mice have reduced cytokine production in 
response to C. albicans
To provide an additional argument for the role of  MDA5 in the anti-Candida 
response, we stimulated splenocytes from Mda5 knockout and B6 control 
mice with C. albicans yeasts or hyphae. Mda5-deficient cells showed a defective 
production of  interferon β induced by Candida (Figure 5). Similarly, the 
IL-6 and IL-10 cytokine responses were lower in cells from Mda5 knockout 
mice. These differences were more pronounced in stimulations with hyphae 
compared to the yeast form (Figure S6).
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Figure 5. Relative gene expression (mean ± SEM) of  mouse interferon β (mIFN-β) in 
splenocytes isolated from control B6 control mice (C57BL/6J) and Mda5 knockout mice, 
upon stimulation with C. albicans hyphae (106/ml) (n=5/group). The P value was not 
significant at α < 0.05 (calculated using the Welch-corrected t-test).
Discussion
In the present study we propose that the pattern recognition receptor 
MDA5, which belongs to the RIG-I-like receptor (RLR) family and plays 
an important role in antiviral immunity by recognizing of  viral RNA [16], 
is also involved in antifungal host defense. MDA5 modulates cytokine 
production induced in human leukocytes by C. albicans, while genetic 
variants in the IFIH1 gene that encodes MDA5 influence susceptibility to 
disseminated candidiasis. Based on these data and the known role of  MDA5 
in interferon production, it is most likely that this effect is mediated through 
induction of  type I interferons (IFN). 
 C. albicans is a dimorphic fungus, and germination from yeasts to hyphae 
is a central process for the invasion of  tissues. Surprisingly, transcriptome 
analysis aiming to identify the immunological programs induced in human 
macrophages specifically by Candida germination into hyphae identified the 
MDA5/RIG-I signaling pathway as one of  the top targets. The hypothesis 
that MDA5 is important for host defense against Candida was strengthened 
by the observation that MDA5 induction is defective in cells isolated from 
patients suffering from chronic mucocutaneous candidiasis. Furthermore, 
assessment of  genetic variation predisposing to candidemia in a patient 
cohort revealed a strong association between the disease and the genomic 
region that contains IFIH1. While genetic variation in IFIH1 has previously 
been shown to influence susceptibility to several autoimmune diseases such 
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as type I diabetes, Graves’ disease, and multiple sclerosis [18-20, 24-29], this 
is the first report of  polymorphisms in IFIH1 linked to a fungal infection. 
These data are in line with recent studies showing that polymorphisms in 
other pattern recognition receptors such as TLRs [6, 30-32], or components 
of  the IFN pathway such as STAT1 or IRF1 [11], also influence susceptibility 
to systemic fungal infections.
 It is important to point out that the candidemia-associated LD region 
contains several genes: FAP (fibroblast activation protein), IFIH1 (interferon 
induced with helicase C domain 1), GCA (grancalcin) and KCNH7 (potassium 
voltage-gated channel subfamily H member 7). IFIH1 and grancalcin were 
the strongest candidates for causing the susceptibility to candidemia as 
these genes have known functions in immunity. Grancalcin is abundant 
in macrophages and neutrophils [33], and is thought to mediate leukocyte 
adhesion and migration [34]. Gene expression analysis confirmed IFIH1 
was strongly induced in PBMCs stimulated with Candida and GCA to 
lesser extent, while the other genes did not show any expression changes. 
IFIH1 and GCA are divergently transcribed neighboring genes with ~25kb 
separating their transcription start sites. As such neighboring genes tend 
to be co-expressed [35, 36], the moderate upregulation of  GCA in response 
to Candida stimulation could be a by-effect of  the strong induction of  IFIH1, 
although the genes are still relatively far apart. Importantly, grancalcin-
deficient (Gca−/−) mice are not more susceptible to candidiasis than wild-
type mice [37], which strongly argues against an important role for GCA 
in the immune response against C. albicans. Therefore, we concluded that 
genetic variants acting at IFIH1 are the most likely cause of  the association 
of  the FAP-IFIH1-GCA-KCNH7 LD region with candidemia.
 The candidemia risk alleles of  the IFIH1-linked SNPs identified in our study 
have previously been shown to lead to higher expression of  IFIH1 in PBMCs 
[18, 20]. Furthermore, our protein structure analysis indicates a possibly 
stronger RNA binding by MDA5 through Arg843, which is encoded by the 
risk allele C of  rs3747517. To gain insight into the downstream immunological 
effects of  IFIH1 variants, we measured cytokine levels produced by PBMCs 
with different genotypes for the two IFIH1 missense SNPs (rs1990760 and 
rs3747517). These data indicate that cells from individuals bearing the 
candidemia risk alleles produce more proinflammatory cytokines (IFN-γ and 
IL-17) and less anti-inflammatory IL-10 in response to C. albicans yeast and 
hyphal forms than cells bearing the protective alleles.
 These observations bring into discussion the nature of the involvement of 
MDA5 in the host defense against Candida. MDA5 activates the RLR pathway 
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leading to the production of type I interferons during viral infections [38]. A 
similar biological activity during Candida stimulation was shown by our data 
from Mda5 knockout mouse splenocytes, which displayed a decreased capacity 
to induce IFN-b. A role for type I IFNs in antifungal immunity has been 
recently proposed [11], and MDA5 is likely the receptor that is at least partially 
responsible for the type I IFN induction during C. albicans infection.
 Mutations leading to inherently increased expression or activity of  
MDA5 are likely to increase IFN production [39] Aberrant production of  
type I IFNs in turn can cause imbalances in the immune response that are 
reflected in our observed alterations in the levels of  other cytokines. The 
apparent deleterious effect of  MDA5 hyperactivity on the anti-Candida host 
defense is consistent with observations that type I IFNs could be harmful for 
this response: mice defective in type I interferon receptors (Ifnar1−/− mice) 
are actually more resistant to systemic Candida infections [40]. This is also 
in line with our findings that PBMCs with the candidemia risk genotype in 
IFIH1 tend to release more inflammatory cytokines. The hypothesis that 
MDA5 has a negative effect on the anti-Candida immune response has been 
proven by a very recent elegant study demonstrating that Mda5−/− mice 
are more resistant to disseminated candidiasis (Malireddi and Kanneganti, 
personal communication).
 It is currently unclear which ligands cause activation of  MDA5 in Candida 
infection. Candida is mainly recognized by cell surface pattern recognition 
receptors such as TLRs and C-type lectin receptors (CLRs), after which the 
fungus is internalized and subsequently digested in the phagolysosome [41, 
42]. It is conceivable that, during this process, Candida-derived structures 
may leak from these organelles and enter the cytoplasm, a process earlier 
described for the recognition of  mycobacterial peptidoglycans by the 
cytoplasmic receptor NOD2 [43-45]. Interestingly, a recent study has 
suggested that NOD2 is also important for the recognition of  Candida chitin 
[46]. Nevertheless, there is currently no experimental evidence to support 
that either the wild-type form or a variant form of  MDA5 has other ligands 
than the described RNAs.
 In conclusion, this study demonstrates that the viral receptor MDA5 
has an important role in modulating innate immune responses against the 
fungal pathogen C. albicans. Future research should shed light on the exact 
mechanisms through which MDA5 participates in the defense against the 
fungus. Nevertheless, the possible deleterious effects of  MDA5-dependent 
stimulation during systemic candidiasis shown by our data suggest its 
potential usefulness as a novel therapeutic target.
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Figure S1. Linkage disequilibrium (LD) maps of the FAP-IFIH1-GCA-KCNH7 LD region on 
chromosome 2. (A) 1.5 Mb region centered on the FAP-IFIH1-GCA-KCNH7 LD region. (B) 
525 kb region centered on the FAP-IFIH1-GCA-KCNH7 LD region (which is shaded in green 
in panel A). (C-D) The 405 kb FAP-IFIH1-GCA-KCNH7 LD region itself  (which is shaded 
in purple in panel A, and marked by purple dashed lines in panel B). (A-C) LD patterns are 
calculated based on 293 (panel A), 59 (B), and 31 (C) common SNPs (minor allele frequency, 
MAF > 5%) genotyped in 117 individuals from the CEU population (Utah Residents (CEPH) 
with Northern and Western European ancestry) in HapMap 3, release 2 [1]. (D) LD patterns 
are calculated based on genotypes of  control individuals in the candidemia cohort for 64 SNPs 
with MAF > 5% (cases and controls together), measured using the Immunochip SNP array. 
The intersections of  the diagonals between pairs of  SNPs (if  separated by less than 500 kb) are 
colored according to the degree of  LD. The middle part of  each panel shows R-squared (r2; 
correlation coefficient between genotypes): r2 = 0 (no correlation) is in white, r2 = 1 (complete 
correlation) is in black, and r2 values between 0 and 1 are in increasing intensities of  gray. 
The bottom part of  each panel shows D’ and LOD: SNPs with D’ values between 0 and 1 
and with LOD ≥ 2 are colored from white to red (D’ = 1 suggest that no recombination has 
occurred between two SNPs, thus indicating complete LD; logarithm of  odds (LOD) scores ≥ 
2 suggest that two markers are inherited together). Haplotype blocks (triangles with bold black 
borders) are regions where at least 95% of  SNPs are in strong LD, defined by high D’ values 
[2]. Chromosome 2 coordinates (hg18) and Entrez genes in these genomic regions are shown in 
the top part of  each panel. Orange boxes around SNP identifiers indicate the top SNP and two 
IFIH1 missense SNPs significantly associated with susceptibility to candidemia (see Table 2 in 
the main text). Figures created using Haploview version 4.2 [3].
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Figure S2. Regional association plot for the 10 Mb region around the FAP-IFIH1-
GCA-KCNH7 LD region on chromosome 2. 203 SNPs in this region with MAF > 5% 
in 403 Caucasian individuals of  the candidemia cohort (cases and controls together) 
were assessed for genotypic association with candidemia. The resulting -log10(genotypic 
P values) (left y-axis) are plotted as a function of  genomic coordinates (hg18, x-axis). 
The blue diamond highlights the most significant SNP with its P value (rs984971). 
Recombination rates, estimated from the CEU, YRI and JPT+CHB HapMap populations 
(HapMap 2, Release 22 [4]), are plotted to reflect the local LD structure around the 
associated SNPs (right y-axis, cyan line). SNPs are colored according to the degree of  LD 
with the most significant SNP, rs984971 (R-squared, calculated across the controls in the 
candidemia cohort; from strong to weak LD - red: r2≥0.8; orange: 0.5≤r2<0.8; yellow: 
0.2≤ r2<0.5; white: r2<0.2). Genes with their direction of  transcription are shown at 
the bottom. Figure created using code adapted from http://www.broadinstitute.org/
diabetes/scandinavs/figures.html. The association with candidemia in this genomic 
region is limited to the FAP-IFIH1-GCA-KCNH7 LD region (marked by purple dashed 
lines), although not all regions are as densely genotyped by the Immunochip array.
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Figure S3. Genotypes of the intergenic SNP rs984971 do not show the same Candida-
induced cytokine level trends as the missense SNPs rs1990760 and rs3747517. PBMCs 
from healthy volunteers with different genotypes for rs984971 (candidemia risk allele A) 
were stimulated in vitro with either C. albicans yeast or hyphae. Cytokine levels (scatterplots 
with mean indicated) were measured after 24 hours (IL-10) or 7 days (IL-17 and IFN-γ) 
by enzyme linked immunosorbent assay (ELISA). P values were calculated using the 
Mann-Whitney U test comparing cytokine levels of  the two homozygous genotypes.
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Figure S4. IFIH1 missense SNP genotypes do not correlate with MTB-induced cytokine 
levels. PBMCs from healthy volunteers with different genotypes for rs1990760 and rs3747517 
were stimulated in vitro with Mycobacterium tuberculosis. Cytokine levels (scatterplots with 
mean indicated) were measured after 24 hours (IL-10) or 7 days (IL-17 and IFN-γ) by enzyme 
linked immunosorbent assay (ELISA). P values were calculated using the Mann-Whitney U 
test comparing cytokine levels of  the two homozygous genotypes.
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Figure S5. rs3747517 (His843Arg) could affect RNA binding and MDA5 filament 
formation. Arginine 843 (R843, red) is depicted in the crystal structure of  MDA5 
Δ2CARD (gray) bound to dsRNA (blue) (PDB 4GL2) [5]. R843 is adjacent to the 
negatively charged RNA backbone and close to the likely protein-protein interaction 
interface (green dashed line) involved in MDA5 oligomerization. Molecular graphics 
created with YASARA (www.yasara.org).
 Residue 946 (rs1990760, Ala946Thr)  is part of  an intrinsically disordered loop [6] in 
the C-terminal domain (CTD) of  MDA5. The equivalent loop is rigid in RIG-I, and this 
differential flexibility contributes to the different RNA binding preferences: displacement 
of  the loop upon dsRNA binding allows MDA5 to recognizes long dsRNA, while the 
loop in RIG-I specifically caps shorter dsRNA [5].
 MDA5 arose from a duplication of  the MDA5/LGP2 gene in the ancestor of  jawed 
vertebrates [7]  Analysis of  MDA5 orthologs in 59 jawed vertebrates reveals that both 
amino acids of  rs1990760 (Ala946Thr) are common (alanine: 36/59=61%, threonine: 
10/59=17%), while for rs3747517 (His843Arg) the type sequence of  human is the only 
sequence that encodes a histidine (similar data in [8]). The occurrence of  alternative 
alleles at both SNPs suggests that both lead to a functional protein, although there may 
be functional differences.
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Figure S6. Mean (±SEM) in vitro cytokine response of mouse splenocytes after 
stimulation with different stimuli. Splenocytes from B6 control mice and Mda5 
knockout mice were stimulated for 24 hours. (A) mIL-6 levels (B) mIL-10 levels.
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Supplementary Methods
Ethics statement
PBMCs were isolated from blood of  healthy volunteers after obtaining 
written informed consent. Candidemia patients were enrolled after giving 
written informed consent at the Duke University Hospital (DUMC, Durham, 
North Carolina, USA) as well as the Radboud University Medical Centre 
(Radboudumc, Nijmegen, The Netherlands). The study was approved by 
the Institutional Review Boards of  both medical centres, the Institutional 
Review Board of  Duke University (CR4_Pro00006427) in North Carolina 
(USA) and the ‘Commissie Mensgebonden Onderzoek Arnhem-Nijmegen’ 
(2001/198) in Nijmegen (The Netherlands). The study was performed in 
accordance with the international guidelines of  the declaration of  Helsinki 
(year 2000) of  the World Medical Association adopted by the World Medical 
Assembly. Enrollment took place between January 2003 and January 2009. 
Mice studies were reviewed and approved by the internal animal care 
committee of  the University Hospital Bonn and were performed according 
to national and European regulations.
Genotyping and quality control (extended)
DNA was isolated from whole blood using the Gentra Pure Gene Blood 
kit (Qiagen, Venlo, The Netherlands), according to the protocol of  the 
manufacturer. Only samples with a SNP call rate above 90% were included. 
We applied quality control filters to exclude SNPs with: (i) a genotype 
call rate of  less than 90%, (ii) strong deviation from Hardy-Weinberg 
equilibrium in control samples (Hardy-Weinberg exact test P ≤ 1 × 10-3), 
and (iii) significant differences in missingness between cases and controls 
(Fisher’s exact P < 1 × 10-2). As our cohort does not have the power to detect 
associations with rare variants, we only included SNPs with a minor allele 
frequency (MAF) of  greater than 5% in cases and controls together.
Genetic analyses (extended)
Linkage disequilibrium (LD) measures were calculated using Haploview 
version 4.2 [3] for both the candidemia cohort (LD patterns are based on 
genotypes of  control individuals only) and common SNPs (MAF > 5%) in 
the CEU population (Utah Residents (CEPH) with Northern and Western 
European ancestry) in HapMap 3, release 2 [1]. The 405 kb FAP-IFIH1-
GCA-KCNH7 LD region on chromosome 2 (hg18 coordinates: 162,720 kb 
– 163125 kb) was defined based on the LD patterns in the larger genomic 
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region (Figure S1). It includes the complete FAP gene and part of  the 
KCNH7 gene.
Associations between SNPs and susceptibility to candidemia were assessed 
using both genotypic and allelic tests. Genotypic association was calculated 
using the Fisher’s exact test, asking whether candidemia cases and controls 
have significantly different genotype count distributions (H0: genotype 
counts are the same). We corrected for testing multiple SNPs using the 
Benjamini-Hochberg procedure. Similarly, allelic association was calculated 
using the Fisher’s exact test, asking whether candidemia cases and controls 
have significantly different allele count distributions (H0: allele counts are 
the same). Odds ratios (OR, with 95% confidence intervals) are reported for 
the allelic association tests and represent the odds of  disease for individuals 
carrying the non-risk allele versus the risk allele. Quality filtering and genetic 
analyses were performed using PLINK v1.07 [9] and custom R scripts. 
Regional association plots were created using code adapted from http://
www.broadinstitute.org/diabetes/scandinavs/figures.html.
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Abstract
Infections with Candida albicans are still a major problem in immunocompromised 
and hospitalized patients leading to a large number of death and costs for health 
care systems worldwide. Extensive genetic and population wide studies have 
identified important components in Candida host response pathways that are 
dysregulated that are responsible for disease susceptibility. By performing 
experiments with primary human cells in vitro as well as murine in vivo 
experiments, we here for the first time, identified interleukin (IL)-32 as a novel 
mediator in the host response against C. albicans. A intronic polymorphism in 
the IL-32 gene strongly influences C. albicans induced IFN-γ production in 
human PBMCs in vitro. Moreover, addition of recombinant human IL-32γ led 
to increased concentrations of this cytokine as well as an increase in C. albicans 
phagocytosis whereas other IL-32 isoforms did not. In a large cohort of patients 
suffering from Candidemia, the TT genotype of the described genetic variant 
led to strongly diminished serum levels of IFN-γ whereas other cytokines 
remained unaffected. Finally, we show that C. albicans infected human IL-
32γ transgenic mice show an improved 14-day survival compared to wild type 
mice. These novel insights may help to improve existing therapies and will 
eventually lead to benefits for (immunocompromised) patients suffering from 
Candida infections. 
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Introduction
Fungal infections in general and infections with C. albicans in particular cause 
a high mortality and morbidity worldwide. Although Candida species normally 
co-exist at mucosal surfaces and the skin without causing damage to the host, 
imbalances of the this tightly regulated homeostasis can turn commensalism into a 
pathological state leading to severe infections [1]. 
 Especially in immunocompromised and hospitalized patients C. albicans can 
invade tissue barriers, enter the bloodstream and cause invasive infections often 
leading to life threatening infections followed by organ failure and eventually 
death. Numerous human and murine in vitro and in vivo studies in the last decade 
have led to a broad and comprehensive understanding in the immune mechanisms 
and pathways involved in the defensive response against C. albicans [2]. 
Furthermore, extensive genetic studies identified novel genes and mechanism that 
are dysregulated in the C. albicans immune response by comparing healthy controls 
and patient samples [3, 4]. Especially, the initiated cytokine response downstream 
of the Candida recognition receptors is crucial to control the infection. Pro- as well 
as anti-inflammatory cytokines regulate and attract immune cells to eventually clear 
the infection. 
 This study investigates the role of IL-32 in the immune response against 
C. albicans. IL-32, formerly known as NK4, is a pro-inflammatory cytokine with 
variable functions and sites of expression. The latter is the reason why IL-32 is 
associated with different diseases such as rheumatoid arthritis, Crohn’s disease and 
even cancer for example. Associations of IL-32 with viral, parasitic, and bacterial 
infections have been reported, however a role of IL-32 in fungal infections remains 
to be investigated [5-7]. 
 The main function of IL-32 is supposed to regulate and induce other 
inflammatory chemokines and cytokines such as IL-1b, IL-6, MIP-2, and TNFa 
making it a potential candidate to be involved in C. albicans induced immune 
responses [8]. Through alternative splicing, IL-32 has several different isoforms 
and IL-32γ and IL-32b have been reported to be the most active ones [9]. 
IL-32 overexpression showed that next to biological activity, IL-32b and IL-32γ 
are both associated with cell death after 24, 48 and 72 hours of overexpression 
whereas the IL32a isoform does not seem to influence cell death in vitro [10].
 By using different isoforms of IL-32 we investigated the role of this mediator 
on the cytokine production capacity of human PBMC challenged with C. albicans 
in vitro. Furthermore, we assessed the role of an IL-32 gene polymorphism in 
patients suffering of Candidemia and healthy controls. Finally, for the first 
time, in vivo murine studies with human IL-32tg mice allowed us to directly 
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investigate, the role of IL-32 in a systemic Candida infection model. Novel 
insights in the biology of IL-32 in the immune response against Candida may lead 
to improvement of existing therapies and even development of novel strategies. 
Material and Methods
In vitro PBMC experiments
Healthy donors who participated in this study were part of the Human Functional 
genomics Project (500FG) [11]. PBMC stimulation are described elsewhere 
[13]. In brief, PBMC stimulations with C. albicans yeast (1x106/mL) or hyphae 
(1x105/mL) were performed with 5x105 cells/well in round-bottom 96-wells 
plates (Greiner) for either 24 hours or 7days in the presence of 10% human 
pool serum at 37°C and 5% CO2. In addition, we tested whether recombinant 
IL-32γ as well as IL-32a or IL-32b (all R&D) influenced the cytokine production 
capacity of PBMCs after 7 days of stimulation with either Candida yeast or 
hyphae in two different concentrations. 
 Whole blood experiments were performed using 100μl of heparin blood in a 48 
wells plate to subsequently stimulate with 400ul stimulus (final volume 500ul) 
for 48 hours at 37°C and 5% CO2. After the stimulation period supernatants 
were analyzed using ELISA.
Generation of fungal C. albicans yeast and hyphae
C. albicans strain ATCC MYA-3573, UC820 was used throughout this study. 
To generate hyphae, live yeast forms of  Candida were grown for 24 hours at 
37°C in RPMI 1640 (Gibco-BRL, Grand Island, NY), adjusted to pH 6.4 by 
using hydrochloric acid. After 24 hours, more than 95% of  yeast were grown 
to hyphae, which were checked by microscope. Hyphae were heat killed for 
45 min at 98°C and resuspended in RPMI 1640 to a hyphal inoculum size 
that originated from 106/mL yeast (referred to as 1x106/mL hyphae).
ELISA analysis
After 24 hours IL-6 as well as TNFα (PeliKine Compact or R&D Systems) were 
measured. Supernatants of the 7 days stimulation assays were used to measure 
IFN-γ and IL-17 (PeliKine Compact or R&D Systems). For the whole blood 
samples IFN-γ levels were determined (PeliKine Compact or R&D Systems). 
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Phagocytosis assays
Macs isolated CD14+ monocytes were plated in 96 flat bottom plates at 1x105/
well. Cells were allowed to phagocytose 1x106/mL heat inactivated FITC labeled 
Candida for 2h in the presence or absence of IL-32a, IL-32γ (both 100ng) or 
RPMI. Subsequently the fluorescence signal of extracellular non-phagocytosed 
Candida was quenched using trypan blue, as previously described [14]. The 
monocytes that phagocytosed one or more Candida yeast were enumerated by 
their positivity for the FITC signal and could be divided into three populations 
FITC negative (monocytes that did not engulf Candida), FITC+ low (monocytes 
that engulfed 1 yeast) and FITC+ high (monocytes that engulfed more than 1 yeast).
Candida growth assays
To determine the effect of the IL-32 isoforms on Candida growth 200ul of 
RPMI with 1x106/mL live C. albicans was added into flat bottom 96 wells plate. 
Afterwards 100ng/mL of either IL-32a, IL-32b, IL-32γ as well as BSA was 
added to the wells. Subsequently the plate was put in an optical density reader 
(BioTek, Synergy HT) at 37oC for 24 hours. Optical density was measured every 
10 minutes during 20 hours. In a second set of experiments C. albicans was pre-
incubated in 10mM Sodium phosphate buffer (PH 7) for 4 hours prior to the 
incubation period for 20 hours. Multiple replicates of the OD600 were plotted 
against the time for every condition in at least 3 independent experiments. 
 To test the direct effect of the IL-32 isoforms on Candida killing, 1x106/mL 
C. albicans was incubated at 37oC for 6 and 24 (not shown) hours with either 
IL-32a, IL-32b, IL-32γ or BSA in RPMI or 10mM Sodium phosphate buffer 
(PH 7) (Supplementary Figure 2). After the incubation period serial dilutions 
in sterile water were made and 100 ml was plated onto fresh Sabouraud plates. 
After 24 hours of incubation at 37oC CFUs were counted.
 In a third series of experiments 200ml of 1x107/mL live C. albicans was plated 
on Sabouraud plates. Subsequently 50ml of 400ng/mL of the IL-32 isoform or 
RPMI with BSA was added as droplets to the plates and incubated for 24 hours 
at 37oC. 
Candida survival experiments in mice
IL-32γ-tg mice were generated as described earlier [15]. IL-32γ-tg (N=30) 
and wild type control C57BL/6 mice (N=30) between 6 and 8 weeks old were 
intravenously infected with freshly cultured Candida albicans (5x107) UC820 
in the tail vein in a volume of 200μL. Survival was monitored over a period 
of 14 days. All animal experiments were in accordance with the guidelines 
of and legislation of ethics of the Brazilian Society of Science in Laboratory 
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Animals (SBCAL) and National Council of Control of Animal Experimentation 
(CONCEA). Project approved by the Institutional Ethics Committee (CEUA/
PRPI/UFG, protocol 042/16,).
Genetic assessment of IL-32 polymorphisms
DNA from 327 patients and 147 cohort matched controls isolated from 
freshly drawn venous blood using the Gentra Pure Blood Kit (Qiagen, Venlo, 
The Netherlands). DNA was subsequently genotyped using the Illumina 
custom-designed high-density genotyping array described earlier [16, 17]. 
In addition to the patient cohort, 55 healthy volunteers were isolated and 
genotypes using the same method.
Functional assessment of a polymorphism in IL-32γ 
Based on the genotyping data of the IL-32γ polymorphism (rs1555001) cytokine 
responses after Candida stimulation (yeast and hyphae) of healthy volunteers 
were divided. Statistics have been performed by using the Mann-Whitney U 
test between the different genotype groups in GraphPad Prism 4.03 software 
(GraphPad Software).
 In addition, serum levels of Candidemia patients have been determined 
during the course of the infection. Serum cytokine levels of IFN-γ, IL-6 and 
IL-8 have been pooled: 0-5 days, 5-10 days and 10-15 days after administration 
to the hospital. Next to the serum cytokine levels of the Candidemia patients, 
90day survival was recorded and analyzed in the different genotype groups for 
rs1555001 in IL-32γ.
IL-32 gene expression and Protein detection
Stimulated PBMCs in 96 wells plate were centrifuged and TriZol 
reagent was added to cell cell pellet. Subsequently, RNA was isolated as 
described before [10]. From RNA cDNA was made using the iScript kit 
(Bio-Rad). Primerpairs for the IL-32 isoforms as well as whole IL-32 are 
described elsewhere [18] and were produced by Biolegio (Nijmegen, The 
Netherlands). A StepOnePlus qPCR system (Applied Biosystems) was used 
to analyze relative mRNA expression using beta-actin as housekeeping gene. 
Intracellular IL-32 protein was detected using a commercially available 
ELISA kit from R&D (DY3040-05). Prior to measurement PBMC cell 
pellets were lysed using 0.1% Triton X-100 in PBS.
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In silico analysis of rs1555001 in IL-32
The in silico analysis was done with the Human Splicing Finder software 
[19]i.The following sequences were analysed in the Human Splicing Finder 
software (www.umd.be/HSF3/4DATION); 
The intronic and exonic regions were manually depicted and the exonic 
regions are displayed in capital characters. The rs1555001 variant is displayed 
in bold and underlined. The software predicts a new silencer motif  (marked) 
with a value of  67.87 on a 0-100 scale in the A allele sequence but is not 
present in the T allele sequence. 
Results
Association of a single nucleotide polymorphism in IL-32 
with Candida induced cytokines
In order to investigate the role of IL-32 in the immune response against C. 
albicans we were first interested in the question if there are genetic variants 
in the IL32 gene that influence the cytokine production capacity of PBMCs 
after exposure to C. albicans. A specific polymorphism in IL-32γ (rs1555001) 
showed significant differences in the cytokine production capacity from healthy 
volunteers after C. albicans challenge. IFN-γ levels, and to a lesser extend 
levels of IL-17, were increased for individuals with the AA genotype compared 
to either the TT or AT genotype (Figure 1A). In a validation cohort of well 
described healthy volunteers [11], we were able to confirm an increase of 
cytokine production capacity linked to the AA genotype in PBMCs although it 
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was less pronounced than we observed in the initial cohort (Supplementary 
figure S1A and S1B). Interestingly, levels of TNFa and IL-6 showed 
no genotype dependent differences, suggesting that IL-32 modulates 
specifically the T-cell mediated C. albicans responses (Figure 1B). Along 
with genotype dependent cytokines induced by C. albicans we investigated 
whether the Candida killing capacity as well as the Candida induced 
ROS production by PBMCs was affected by the different genotypes. No 
significant genotype dependent differences regarding killing capacity and 
ROS production was observed (Figure 1C). 
Influence of recombinant IL-32γ on cytokine production 
capacity
Since a polymorphism in IL-32γ modulates the C. albicans induced T cell 
derived cytokines in human PBMCs we were interested whether recombinant 
human IL-32γ was able to influence C. albicans induced cytokines in vitro 
as well. 
 To investigate this, we stimulated PBMCs from healthy volunteers with 
C. albicans yeast or hyphae for 7 days. After 7 days of incubation, PBMCs 
stimulated with C. albicans hyphae in the presence of IL-32γ produced 
significantly more IL-17 and IFN-γ than PBMCs stimulated with C. albicans 
hyphae alone (Figure 2A). Interestingly, this effect was not seen in PBMCs 
stimulated with yeast (1x104 and 1x106 (data not shown)) suggesting a hyphae 
specific mechanism (Figure 2B).
Influence of IL-32 isoforms on Candida phagocytosis and 
cytokine induction 
IL-32 can be expressed as different isoforms with varying biological 
activity [9]. Although IL-32γ is known to be the most active one, we were 
interested whether other IL-32 isoforms such as IL-32a and IL-32b, had 
comparable effects on C. albicans induced cytokines. Interestingly, we did 
not observe differences in  IFN-γ and IL-17 levels when either IL-32a or 
IL-32b were used as co-stimulation with C. albicans hyphae, suggestion a 
IL-32γ specific effect (Figure 2C). Beside its effect on cytokine induction 
after C. albicans stimulation we were interested if different IL-32 isoforms 
influence the capacity of primary human monocytes to phagocytize 
Candida in vitro. IL-32γ treated monocytes were more capable in taking up 
FITC labeled C. albicans compared to control or IL-32a treated monocytes 
(Figure 2D).
269
10
TT AT AA
0
2×106
4×106
6×106
8×106
1×107
Luminescence
Genotype IL-32
R
LU
/S
ec
TT AT AA
0
50
100
150
Genotype IL-32
%
 k
ill
in
g
Candida killingC)IFN-γ
TT AT AA
0
1000
2000
3000
Genotype rs1555001
IF
N
-γ
 (p
g/
m
L,
 M
ea
n 
(+
/- 
SE
M
) *
*ns
IFN-γ
TT AT AA
0
1000
2000
3000
Genotype rs1555001
IF
N
-γ
 (p
g/
m
L,
 M
ea
n 
(+
/- 
SE
M
) *
*ns
IL-17
TT AT AA
0
1000
2000
3000
Genotype rs1555001
IL
-1
7 
(p
g/
m
L)
, M
ea
n 
(+
/- 
SE
M
)
ns ns
ns
IL-17
TT AT AA
0
1000
2000
3000
Genotype rs1555001
IL
-1
7 
(p
g/
m
L)
, M
ea
n 
(+
/- 
SE
M
)
ns ns
ns
TNFα
TT AT AA
0
5000
10000
15000
20000
25000
30000
Genotype rs1555001
TN
Fα
 (p
g/
m
L)
, M
ea
n 
(+
/- 
SE
M
)
ns ns
ns
TNFα
TT AT AA
0
5000
10000
15000
20000
25000
30000
Genotype rs1555001
TN
Fα
 (p
g/
m
L)
,M
ea
n 
(+
/- 
SE
M
)
ns ns
ns
IL-6
TT AT AA
0
5000
10000
15000
20000
25000
Genotype rs1555001
IL
-6
 (p
g/
m
L)
, M
ea
n 
(+
/- 
SE
M
)
ns ns
ns
IL-6
TT AT AA
0
5000
10000
Genotype rs1555001
IL
-6
 (p
g/
m
l),
 M
ea
n 
(+
/- 
SE
M
)
ns ns
ns
A) B)
Yeast Hyphae Yeast Hyphae
Figure 1: C. albicans stimulation of PBMCs from healthy donors with different genotypes for 
rs1555001 in the intronic region of the IL-32 gene: Cytokine levels of (A)  IFN-γ and IL-17 as 
well as (B) TNFa and IL-6 were measured after PBMC stimulation for either 7days ( IFN-γ 
and IL-17) or 24 hours (IL-6 and TNFa) with either C. albicans yeast or hyphae. Cytokine 
levels were stratified for the different genotypes for rs1555001 in the IL-32 gene. Data was 
analyzed using the Mann-Whitney U test and *indicates significance of P≤0.05, **P≤0.01, 
***P≤0.001. (C) C. albicans induced ROS (RLU/sec) induction in PBMCs as well as 
C. albicans killing capacity (%) in different genotypes of the IL-32 genetic variant. 
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IL-32 secretion and expression after Candida stimulation
To confirm that IL-32 is indeed induced after C. albicans stimulation we 
performed intracellular IL-32 protein measurements in primary human 
PBMCs. Furthermore, RNA expression experiments were performed in order 
to investigate the capacity of Candida to induce IL-32 gene expression. 
Intracellular IL-32 was significantly increased in PBMCs stimulated for either 
24 hours or 7 days with both Candida yeast or hyphae compared to the control 
stimulation (Figure 3A and 3B). As the ELISA detects whole IL-32 protein it was 
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Figure 2: Cytokine production capacity of PBMCs stimulated with C. albicans for 7days in 
presence of recombinant IL-32γ: A) IL-17 and  IFN-γ levels after 7 days of PBMCs of healthy 
donors (N=6) stimulated with C. albicans yeast (A) 104/mL as well as (B) Candida hyphae 
(105/mL) in the presence and absence of IL-32γ. Data was analyzed using the Mann-Whitney 
U test and *indicates significance of P≤0.05, **P≤0.01, ***P≤0.001. (C) PBMC stimulation 
for 7 days with C. albicans hyphae in the presence of recombinant IL-32a, IL-32 b and IL-
32γ. (D) Percentage of FITC positive monocytes after in vitro C. albicans stimulation in the 
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difficult to distinguish between the different isoforms that get expressed after 
the stimulation period. Therefore, qPCR was performed on PBMCs at the two 
different time points. After 24 hours whole IL-32 as well as all three isoforms 
(IL-32a,b,γ) were elevated compared to the control stimulation although no 
statistical significance could be reached (Figure 3A). However, after 7 days of 
stimulation we observed a significant increase for whole IL-32 as well as IL-
32a and IL-32b after Candida stimulation. In contrast to that, expression levels 
of IL-32γ were completely lost in the stimulated conditions compared to the 
control condition (Figure 3B).
Evaluation of a direct antimicrobial effect of IL-32 isoforms 
on Candida growth 
IL-32 contains a RGD motif and previous research has points towards the 
possibility of Candida having a receptor that is able to bind RGD motifs. In this 
line, we decided to investigate the direct effects of IL-32 on Candida without 
the involvement of immune cells. 
 Candida was pretreated with either IL-32a, IL-32b, IL-32γ or BSA as protein 
control and growth was monitored as well as the amount of colony forming 
units (CFU) after 24 hours.
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Figure 3: (A+B) Intracellular IL-32 protein after stimulation for 24 hours and 7 days in 
PBMCs and whole IL-32 as well as IL-32 isoform gene expression in PBMCs for both time 
points (Candida yeast and hyphae (both 1x106)). Experiment have been performed at least 3 
times in at least 2 donors per experiment. Data was tested using the Wilcoxon signed-rank test 
and *indicates significance of P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001.
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 Neither IL-32γ nor IL-32a or IL-32b did impact C. albicans CFUs after 
incubation for 24 hours (Figure 4A). In line, no inhibition of growth was 
observed when droplets of the IL-32 isoforms were added to a dense layer of C. 
albicans on Sabouraud plates (Figure 4B). 
 In line, direct growth of C. albicans was not influenced by IL-32 isoforms 
compared to the control condition in both RPMI (Figure 4C) or 10mM Sodium 
Phosphate buffer (Ph7) (Supplementary Figure 2), underlining its direct role in 
immune modulation within the anti-Candida response.
IL-32γ genetic variant associates with low serum  IFN-γ levels 
in Candidemia patients
Due to its potential function in the immune response against C. albicans 
in general and systemic infections in particular, we investigated the role of 
rs1555001 in a cohort of Candidemia patients and matched controls. Here, we 
compared patients and controls regarding their genotype distribution for variant 
rs1555001 in the promotor region of the IL-32 gene. No significant difference 
between controls and patients in genotype distribution was observed, excluding 
this variant as a direct susceptibility factor for Candidemia (Figure 5A). 
 Next, we were interested whether different genotypes of rs1555001 
influence circulating serum cytokine concentrations in patients suffering from 
Candidemia. For this, we grouped Candidemia patients according to their day 
of administration to the hospital into three separate groups (0-5 days, 5-10 days 
and 10-15 days after administration). 
 Investigating the circulating concentrations of  IFN-γ, IL-6 and IL-8 we 
observed that Candidemia patients with the AA or AT genotype, who had 
normal cytokine concentrations, patients with the TT genotype showed strongly 
diminished concentrations of  IFN-γ. Interestingly, concentrations of IL-6 and 
IL-8 were unaffected, again pointing towards a specific effect on T-cell derived 
cytokines (Figure 5B). 
 Interestingly, when looking at clinical follow up data in these patients we 
observed that the AA genotype was significantly more often present in the 90-
day survivor group compared to the non-survivor group (Figure 5C). 
Predicted functional consequences in different rs1555001 
genotypes
Because the genetic variant in the intronic region of IL-32 (rs1555001) seems 
to influence cytokines in vitro as well as in vivo, we were interested in the 
functional consequences that this variant may have on either expression or 
activity of IL-32γ.The variant is located in an intronic region between the first 
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Figure 4: (A) C. albicans growth in the presence of 
IL-32a or IL-32γ for 16 hours. (B) C. albicans colony 
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exon which encodes for the first part of the coding sequence (CDS) of IL-32 
and the second exon, as depicted in supplementary Figure 3A [12]. The second 
exon can be spliced, leading to smaller IL-32 isoforms such as IL-32a or IL-
32b. However, when splicing is prevented, the second exon can be extended and 
the IL-32γ specific exon can be included and therefore only the most bioactive 
isoform IL32γ is produced. Prediction of intronic splicing factors predicts that 
the A allele genotype harbor a Sironi silencer motif “ACAGAGTG” whereas this 
is not predicted in a sequence bearing the T allele (Supplementary Figure 3B).
IL-32γ transgenic mice displayed reduced mortality during a 
systemic C. albicans infection
Due to the findings described above, we were interested whether mice 
challenged with a lethal dose of C. albicans would benefit from the presence of 
IL-32γ during a systemic infection. To answer this question, IL-32γ transgenic 
mice (IL-32tg) were intravenously infected with 5x107 live C. albicans yeast 
and survival was monitored during 14 days of infection. After 14 days of 
infection 26% of the wild type mice were alive, while 50% of the IL-32tg mice 
were alive, again indicating a protective role of IL-32γ in the immune response 
against C. albicans (Figure 6). 
Discussion
The present study investigates the role of IL-32 in the host immune response 
against Candida albicans. Human as well as murine experiments identified the 
IL-32 isoform IL-32γ as a novel component in the anti-Candida immune response. 
Especially  IFN-γ levels in in vitro as well as in Candidemia patient samples in 
vivo were affected by IL-32γ, which might be an important aspect in developing 
novel and beneficial therapies for patients suffering from Candidemia. 
  IFN-γ has been repeatedly shown to be crucial in invasive and systemic 
Candida infections. In this context  IFN-γ together with TNFa are supposed to be 
responsible for the recruitment and activation of neutrophils and phagocytes at the 
site of infected organs [20-22]. At the same time  IFN-γ immunotherapy has been 
shown to be beneficial in patients with different invasive fungal infections among 
which Candidemia [23, 24]. IL-32γ may influence levels of  IFN-γ and therefore 
play a role in the immune response against C. albicans. Interestingly, next to its 
potential role in fungal immunology, IL-32 is associated with other infections such 
as MTB, HIV and Leishmania. Here, IL-32 has mainly the role in controlling 
microbes by regulating ROS and acts as an antimicrobial peptide [7] .
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It still remains to be investigated which extra and intracellular receptor on 
(innate) immune cells is responsible for IL-32 binding or in which way IL-32 
is able to interact with immune cells. Recent studies speculate about the of 
the integrin aVb3 as a potential extracellular receptor for IL-32 [25]. In fact, 
this integrin is present on different immune cells as monocytes, macrophages, 
T cells and endothelial cells [26]. In the same study, focal adhesion kinase 
(FAK) is pinpointed as a potential intracellular receptor for several IL-32 
isoforms which is able to initiate IL-32 downstream effects such the activation 
of different caspases or the production of cytokines such as TNFa or IL-1b for 
example. Interestingly, the Candida specific effects of IL-32 were only found 
when looking at the IL-32γ isoform and no other IL-32 family members such 
as IL-32a or IL-32b. In fact, it has been shown that  IFN-γ is a potent inducer 
of IL-32γ expression which might point towards a positive feedback loop after 
recognition of Candida by antigen presenting cells and the activation of  IFN-γ 
producing cells. At the same time IL-32γ has been to shown to increase Th1 and 
Th17 responses [27]. 
 IL-32 can be detected after stimulation with both Candida morphotypes 
on both, protein levels as well as on mRNA level at different time points. 
Interestingly, after 7 days of stimulation mRNA levels of specifically IL-32γ 
were significantly decreased compared to the control condition. An explanation 
for the low levels could be the fact that IL-32γ gets spliced into the smaller 
isoforms, usually IL-32b, after stimulation [18]. 
 The in silico model predicts a Sironi silencer motif “ACAGAGTG” in the A 
allele and not in the T allele. Although prediction of splicing motifs in intronic 
regions is difficult and most software programs predict motifs in exonic 
regions, the Human Splicing Finder software predicted the silencer motif in 
the A allele genotype while taking into account intronic and exonic regions 
during the prediction. The A allele that harbors a silencing motif, might prevent 
splicing of the IL-32γ specific part of exon 2 as the rs1555001 variant is only 
23 nucleotides apart from exon 2. As a consequence, this leads to higher levels 
of intracellular IL-32γ, which in turn might lead to higher levels of  IFN-γ. 
Future experiments using splice inhibitors in PBMCs from different genotypes 
should shed more lite on the exact mechanisms underlying this phenotype [10]. 
No direct effect of IL-32γ of one of the other IL-32 isoforms has been observed 
regarding potential growth inhibition or direct Candida killing. Interestingly, 
IL-32 has been reported to contain a RGD – (Arg-Gly-Asp) motif [26] and at 
the same time several studies report the ability of C. albicans to bind RGD- 
containing peptides [28]Georgia 31207.</auth-address><titles><title>Arg-
Gly-Asp (RGD. It remains to be investigated if IL-32 can directly bind to 
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C. albicans and alter intracellular processes that change the properties of C. 
albicans other than growth. 
 As IL-32γ increases the production of  IFN-γ in vitro (see figure 2A), patients 
suffering from invasive fungal infection might benefit from the administration 
of IL-32γ. Furthermore, stratification of high risk patients for Candida 
infections regarding their genotype for rs1555001 might help to improve and 
adjust existing therapies that are currently applied. Although more research is 
needed to decipher the exact mechanisms by which IL-32γ is modulating the 
immune response against Candida, these new insights might form the basis for 
novel approaches in anti-Candida immunotherapy.
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Supplementary Figure 1: Genotype dependent production of  IFN-γ after stimulation with 
C. albicans yeast (A) and C. albicans hyphae (B) for 24 hours. 
Supplementary Figure 2: Growth of C. albicans in the presence of different IL-32 isoforms 
in 10mM Sodium phosphate buffer (Ph7) for 20 hours.
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Supplementary Figure 3: (A) Genomic location of rs1555001 within the IL-32 gene. 
(B) Schematic comparison between the different IL-32 isotypes and predicted functional 
consequences for rs1555001 [12].
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Abstract
Cytokines play a critical role in anti-fungal host defense, but a comprehensive 
approach to understanding the genetic architecture of  cytokine responses 
against fungi and their role in fungal disease susceptibility is still lacking. To 
address this knowledge gap, we assessed the cytokine production capacity 
in different cellular systems following stimulation with three different 
opportunistic fungal pathogens: Candida albicans, Aspergillus fumigatus and 
Cryptococcus neoformans. The inter-individual variation pattern in cytokine 
production was specific for each fungal stimulus, but was similar between 
C. albicans yeast and hyphae. Using genome-wide genetic analysis we 
identified a novel significant locus that regulates IL-17A production upon 
stimulation with C. albicans hyphae and 10 shared significant loci in response 
to both C. albicans morphotypes, including the TLR2 gene that regulates 
cytokine production. We observed enrichment of  common genetic loci that 
regulate T-cell-derived cytokine levels in response to both C. albicans and C. 
neoformans, and identified seven significant genetic loci including the well-
known chronic mucocutaneous candidiasis susceptibility gene, TRAF3IP2. 
To explain susceptibility to disseminated fungal infections, we performed 
the first candidemia genome-wide association study and identified genes 
at 21 independent cytokine QTLs important for susceptibility to infection. 
These loci were enriched for the lipid metabolism functional pathway. Our 
data suggest that genetic loci that affect cytokine responses to stimulation 
with fungi can partly explain an individual’s fungal disease susceptibility. 
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Introduction
Invasive fungal infections are an increasingly significant cause of  sepsis 
in critically ill and immunocompromised patients and are associated 
with high morbidity and mortality. The majority of  fungal-related deaths 
are caused by fungal species belonging to the Cryptococcus, Candida and 
Aspergillus species1. The opportunistic fungus Candida albicans is the most 
predominant infectious agent causing invasive fungal infections. The 
dimorphic yeast C. albicans causes approximately 250,000 new infections on 
a yearly basis, leading to more than 50,000 deaths2. While Candida spp. co-
exists as commensal in the human gastrointestinal tract and other mucous 
membranes, Candida can invade tissue and eventually blood circulation 
when epithelial barrier function is impaired and/or the host immune system 
is compromised, leading to systemic infections. From the bloodstream, 
Candida can disseminate to vital organs, leading to organ failure. 
 Both innate and adaptive immune mechanisms are crucial for an effective 
host defense against fungi. The innate immune system represents the first 
line defense by recognition of  the pathogen, followed by phagocytosis and/
or killing. Subsequently, innate immune cells contribute to the activation 
of  adaptive immune response through antigen presentation and secretion 
of  pro-inflammatory cytokines3,4. Cytokines in particular play a critical 
role during anti-Candida host immune defense, and recombinant cytokines 
have been proposed as adjunctive therapy in systemic Candida infection5,6. 
Administration of  recombinant interferon (IFN)-γ also improved immune 
responses in patients with severe fungal infections7,8.
 In previous studies from the Human Functional Genomics Project 
(HFGP) consortium, we assessed the impact of  genetic polymorphisms on 
cytokine production capacity in response to several pathogens, including 
fungi, in 500 healthy volunteers9. However, it remains unknown to what 
extent genetic variants, that determine cytokine variability in response to 
different fungal species can also affect susceptibility to systemic fungal 
infections such as candidemia. It is also unclear whether cytokine production 
in response to the different morphotypes of  C. albicans (hyphae and yeast) 
and to other fungal species such as Aspergillus fumigatus and Cryptocossus 
neoformans is regulated by genetic variants that are shared or unique for 
specific opportunistic fungal pathogens. 
 In the present study, we use a functional genomics approach that integrates 
genomics, transcriptomics and immunological methods to understand the 
architecture of  anti-fungal immune responses against opportunistic systemic 
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Figure 1. Study overview. We collected blood samples from 500 healthy individuals in the 500FG 
cohort, isolated their DNA and genotyped it using the HumanCoreExome SNP Chip. Imputation 
increased the genotype information to approximately 8 million SNPs. Blood was also used to perform 
a series of  stimulation experiments with three different fungal species (C. albicans, A. fumigatus and C. 
neoformans) to profile the cytokines released in serum. Using the genotype information and cytokine 
measurements, we mapped fungal-response cQTLs and ran meta-analysis to further investigate the 
genetics of  both C. albicans morphotypes (yeast and hyphae) and of  A. fumigatus and C. neoformans.
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fungal infections (Fig. 1). In an accompanying manuscript, we present the 
use of  a same approach to identify genetic factors and biological pathways 
that are dysregulated in a prevalent opportunistic mucosal infection, known 
as recurrent vulvovaginal Candidiasis (RVVC). For RVVC, we validated an 
interesting novel gene candidate that is involved in Candida host response 
using both in vitro and in vivo human and mouse systems. Here, we 
perform the first genome-wide association study (GWAS) of  candidemia 
on the largest candidemia cohort published to date. This allows us to 
investigate whether the genetic variants that determine cytokine variation 
are also associated with susceptibility to candidemia. We also examine 
cytokine variation in the context of  in vitro C. albicans yeast and hyphae 
stimulation and compare these cytokine responses to those induced by 
A. fumigatus and C. neoformans. Our work highlights the importance of  
genetic variation for cytokine production in the human response to the 
two different C. albicans morphologies and to other opportunistic fungal 
pathogens. Identifying shared genetic loci of  common systemic fungal 
infections can help us understand susceptibility mechanisms for different 
systemic fungal infections, an understanding that can aid in the design of  
novel diagnostic and therapeutic approaches.
Results
Variations in cytokine immune response to opportunistic 
fungal pathogens in humans
Unsupervised clustering of  the levels of  monocyte-derived cytokines (IL-
1b, IL-6 and TNFα) and T-cell-derived cytokines ( IFN-γ, IL-17A and 
IL-22) upon stimulation with C. albicans yeast and hyphae in whole blood 
(WB), peripheral blood mononuclear cells (PBMCs) and monocyte-derived 
macrophages indicated that there is a clear distinction between WB, PBMCs 
and macrophage-derived cytokines (Fig. 2a). Clustering also revealed a 
separation between monocyte-derived and T-cell-derived cytokine responses 
within the PBMC fraction, although the production of  cytokines induced by 
C. albicans was generally strongly correlated. 
 To assess the correlation between cytokine responses induced by 
C. albicans and the responses induced by A. fumigatus and C. neoformans, 
we compared cytokine responses induced by the two latter fungi to 
C. albicans-induced responses. Clustering was mainly dependent on specific 
fungal species rather than between different cytokines, and we observed 
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distinct clusters for C. albicans, A. fumigatus and C. neoformans (Fig. 2b). At 
the level of  host anti-fungal response, this observation further substantiates 
the concept that immune responses are organized to respond specifically 
to defined pathogens rather than to respond uniformly to any infection 
with the production of  the same cytokines9. Interestingly, we observed a 
stronger positive correlation between cytokines induced by A. fumigatus 
and C. albicans compared to those induced by C. neoformans (Fig. 2b). In 
contrast, only the T-cell-derived cytokines induced by C. neoformans were 
more similar to the T-cell-derived cytokine responses induced by C. albicans 
yeast (Fig. 2b). Of  note, the distinct cluster between monocyte-derived and 
T-cell-derived cytokines was weaker for C. neoformans-induced cytokine 
responses compared to the C. albicans-induced responses (Fig. 2b).
Genetic variation has a role in heterogeneity of anti-Candida 
cytokine responses 
We observed a significant variation in cytokine levels upon stimulation with 
C. albicans yeast and hyphae in all our stimulation systems compared to that 
seen in the cell culture medium used as a control (Supplementary Fig. 1). We 
have previously shown that non-genetic host factors such as age and gender 
affect cytokine responses to fungal stimulation11, while cell counts had only 
a minor effect9. Additionally, we identified three genome-wide significant 
SNPs (cytokine QTLs) that affect C. albicans-yeast-induced cytokines 
and two genome-wide significant SNPs that affect C. neoformans-induced 
cytokines9. To investigate whether the same genetic variants determine the 
cytokine responses of  C. albicans yeast and hyphae, we mapped C. albicans-
hyphae-response cQTLs by correcting for age, gender and cell counts using 
genome-wide genotypes from the 500FG cohort. This identified a novel 
genome-wide significant cQTL (P < 5 x 10-8) at chromosome 16p12.2 
(Fig. 3a). This top associated cQTL, rs13333993, was associated with IL-
17A levels induced by C. albicans hyphae (Fig. 3b), and this SNP is located 
in close proximity to the HS3ST2 gene that codes for the heparan sulfate 
glucosamine 3-O-sulfotransferase 2 protein (Fig. 3c).
 Clustering analysis revealed a strong positive correlation between cytokine 
responses induced by both morphotypes of  C. albicans, which suggests 
that the cytokine responses to each of  these morphotypes are regulated 
by similar factors. To explore the extent to which the same genetic factors 
control cytokine responses induced by both morphotypes, and in the same 
allelic direction, we performed meta-analysis between independent cQTLs 
(P < 1.0 x 10-4) of  C. albicans yeast and hyphae. Meta-analysis of  cQTLs 
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Figure 2. Results from unsupervised hierarchical clustering (a) of  cytokine responses 
in macrophages, PBMCs and WB induced by C. albicans yeast and hyphae and (b) of  
the cytokine responses induced by C. albicans, A. fumigatus and C. neoformans in PBMCs. 
Clustering was performed using Spearman’s correlation as the measure of  similarity. Red 
indicates strong positive correlation. Blue indicates strong negative correlation. In (a), 
cluster 1 depicts the positive correlation of  IL-6 and TNFα derived by macrophages upon 
stimulation with C. albicans yeast. Clusters 2 and 4 show that there is a clear distinction 
between the monocyte-derived cytokines (IL-6, TNFα and IL-1b ) and the T-cell-derived 
cytokines (IL-17A,  IFN-γ and IL-22) upon stimulation with C. albicans yeast and hyphae. 
Cluster 3 depicts the positive correlation of  monocyte-derived cytokines and the T-cell-
derived cytokine  IFN-γ upon stimulation with C. albicans yeast in WB. In (b), cluster 1 
depicts the positive correlation between monocyte-induced cytokines on stimulation of  
PBMCs with C. albicans yeast and hyphae and with A. fumigatus (IL-6 and TNFα). Cluster 
2 depicts the positive correlation between monocyte- and T–cell-derived cytokines on 
stimulation of  PBMCs with C. neoformans. Cluster 3 depicts the positive correlation among 
cytokines derived from T-helper cells on stimulation of  PBMCs with both C. albicans yeast 
and hyphae and with A. fumigatus (IL-22 and  IFN-γ). macroPG: macrophages, PBMC: 
Peripheral blood mononuclear cells, WB: whole blood.
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revealed 10 genome-wide significant cQTLs with the same allelic direction 
(Supplementary Fig. 2a-f). To identify specific genes from these shared loci, 
we prioritized cis genes located within a 1 Mb window from all 10 loci by 
mapping expression QTLs (eQTLs) and intersected the cis genes with C. 
albicans-induced gene expression data9,12. We prioritized 10 genes from six 
loci that affect T-cell-derived cytokines and two genes from two loci that 
affect monocyte-derived cytokines (Table 1). Among these 12 genes, the 
TLR2 locus at chromosome 4 has been extensively studied in the context of  
anti-fungal host defence10,13,14,15 and the ZC3H12C gene has been shown to 
be an important inhibitor of  vascular inflammation in endothelial cells and 
macrophage activation16,17. Of  note, the meta-analysis of  cQTLs that affect 
either T-cell-derived-cytokines or monocyte-derived cytokines show a small 
number of  shared cQTLs (Supplementary Table 1 and 2), which suggests 
that the observed correlation between cytokine variation in response to C. 
albicans yeast and hyphae is at least partly determined by genetic factors.
Correlations between T cell cytokines induced by C. albicans 
yeast and C. neoformans are partly genetically determined
Unsupervised clustering of  the cytokine responses induced by C. neoformans 
and C. albicans yeast indicated a positive correlation within the T-cell-derived 
cytokines (Fig. 1b). To investigate whether this correlation is driven by a 
genetic component, we tested if  independent C. albicans-response cQTLs 
(P < 9.99 x 10-4) could be associated with cytokine levels induced by C. 
neoformans with a nominal significance (P < 0.05). We found a significant 
enrichment of  shared cQTLs from T-cell-derived cytokines induced by C. 
albicans yeast and by C. neoformans compared to monocyte-derived cytokines 
(Fig. 4a), and this enrichment remained significant across the different 
P-value thresholds used to define cQTLs (Fig. 4a). 
 Given that T-cell-derived cytokines induced by C. albicans yeast showed 
a significant enrichment for C. neoformans-induced cQTLs, we performed a 
meta-analysis of  cQTLs (P < 0.05) that affect T-cell-derived cytokines to 
identity shared genetic loci that regulate T-cell-derived cytokines induced 
by both fungi. Our meta-analysis identified seven genome-wide significant 
loci with same allelic direction, of  which three loci were associated with 
IFNγ levels and four loci associated with IL-17A levels in response to both 
C. albicans yeast and C. neoformans (Table 1, Fig. 4b,c). All three loci that 
regulate IFNγ levels are novel. The FGF4-FGF3 locus has been reported to 
alter C. neoformans-induced IFNγ levels, but this SNP had not been identified 
as a cQTL upon C. albicans yeast stimulation of  PBMCs18. Among the 
four novel loci that alter IL-17A levels in response to both fungal species, 
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the TRAF3IP2 locus on chromosome 6 is particularly interesting because 
mutations in this gene have been shown to abolish IL-17A responses in 
chronic mucocutaneous candidiasis patients19. 
 To gain further insight into the molecular pathways that regulate T-cell-
derived cytokine responses to both fungal species, we performed pathway 
Table 1. Genome-wide significant cQTLs identified by meta-analysis of  cQTLs in 
response to C. albicans yeast and hyphae (upper panel) and to both C. albicans yeast and C. 
neoformans (lower panel) in PBMCs.
Meta-analysis of cQTLs in response to C. albicans yeast and hyphae in PBMCs
Locus Cytokine SNP Chr Base Pair P-value Gene(s)
1 IFNγ rs80215292 10 36589487 9.35 x 10-11 RNF6a
1 IL-17A rs57697772 3 69023696 1.50 x 10-9 FRMD4Bb, FAM19A1c, 
C3orf64|AC109587.2a
3 IL-17A rs7113219 11 109943972 8.78 x 10-9 ZC3H12Ca, c, RDXc
4 IL-17A rs73106632 20 18307581 3.29 x 10-8
1 IL-22 rs62576416 9 112120264 1.50 x 10-10 EPB41L4Bc, 
EPB41L4Ba
3 IL-22 rs2606322 4 154643222 1.76 x 10-8 TLR2b, c, RNF175c
1 TNFα rs3823681 7 5708660 2.40 x 10-8 FSCN1a,b,c
1 IL-6 rs7993073 13 109449510 1.99 x 10-9 TNFSF13Ba
2 IL-6 rs148896824 5 152038867 4.51 x 10-8
1 IL-1β rs11109775 12 99641804 5.24 x 10-9
Meta-analysis of cQTLs in response to both C. albicans yeast and C. neoformans in PBMCs
Locus Cytokine SNP Chr Base Pair P-value Gene(s)
1 IFNγ rs79668317 10 36598171 7.13 x 10-9
3 IFNγ rs57976825 11 131970564 1.08 x 10-8
4 IFNγ rs2344360 2 233259092 4.13 x 10-8 C2orf82c
1 IL-17A rs1587097 12 63530245 3.245 x 10-9 PPM1Hc
2 IL-17A rs77589665 6 111874433 2.45 x 10-8 TRAF3IP2c, 
SLC16A10c
3 IL-17A rs1675129 11 61893356 4.655 x 10-8 ASRGL1c, ROM1c, 
BEST1c, RAB3IL1c,
FTH1c, INCENPa, 
RAB3IL1a, FTHL16/
BEST1a
4 IL-17A rs74997115 2 11046183 4.78 x 10-8 ATP6V1C2c
a  SNPs showed an eQTL effect based on publicly available eQTL datasets in WB or 
PBMCs
b Differentially expressed genes in response to Candida stimulation for 4 hours 
c Differentially expressed genes in response to Candida stimulation for 24 hours
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enrichment analysis. For this, we prioritized the cis genes in a window of  
1 Mb around loci that were moderately associated (P < 1.0 x 10-3) and in the 
same direction as shown in our meta-analysis. Pathway enrichment analysis 
using the KEGG pathway database (Fig. 4d, Supplementary Table 3) 
identified immune pathways associated with several infectious diseases 
including African trypanosomiasis (P = 1.1 x 10-9), malaria (P = 7.83 x 10-7), 
Chagas disease (American trypanosomiasis, P = 6.1 x 10-6) and influenza 
A (P = 0.0001), as well as with the immune-mediated diseases including 
rheumatoid arthritis (P = 2.1 x 10-8) and inflammatory bowel disease 
(P = 1.15 x 10-5). These results suggest the same genes may be involved 
Figure 3. Genome-wide QTL mapping identifies a novel C. albicans hyphae response 
cQTL. (a) Manhattan plot showing the genome-wide QTL mapping results for C. 
albicans-induced IL-17A levels. Y-axis represents the –log10P values of  cQTLs. Their 
chromosomal positions are shown on the X-axis. Horizontal dashed line represents the 
genome-wide significance threshold for association (P < 5 x 10-8). (b) Box plot showing 
the association of  the genotypes of  SNP rs13333993 with IL-17A levels. (c) Regional 
association plot showing the –log10P for SNPs centered on the most strongly associated 
signal (rs13333993, purple diamond) associated with IL-17A levels upon C. albicans 
hyphae stimulation in PBMCs. 
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in regulating downstream responses to different pathogens. In addition, 
pathway enrichment analysis using the Reactome database showed 
that there is an overrepresentation of  genes involved in immune system 
(P 1.49 x 10-13), cytokine signaling in immune system (P 4.12 x 10-12), 
signaling by interleukins (P 5.2 x10-8) and neutrophil degranulation 
(1.16 x 10-7) (Fig. x, Supplementary Table x). Of  those, interferon signaling 
and, in particular type I IFN, is well–known that is involved in anti-viral and 
anti-Candida host immune defence20,21. However, mice lacking type I IFN 
signaling showed an increased clearance of  C. neoformans, suggesting that 
type I IFNs may be involved in the negative regulation of  early host defence 
to C. neoformans infection22. 
Meta-analysis identifies common cQTLs of A. fumigatus-, C. 
albicans- and C. neoformans-induced cytokines
Genome-wide cQTL mapping of  A. fumigatus-induced cytokines did not 
identify any significant cQTLs18. To test whether common genetic loci 
regulate cytokine responses to all three different species of  opportunist 
fungal pathogens, we performed a meta-analysis. There were four common 
cytokine measurements (IFNγ, IL-22, IL-6 and TNFα) available for this 
analysis. Upon mapping of  cQTLs (P < 0.05) we identified 12 independent 
genome-wide significant loci affecting cytokine production in response to 
all three fungal species (Supplementary Table 4). Prioritization of  potential 
causal genes in these loci identified well-known immune genes such as HLA-
DQA1, HLA-DRB5 and RGS18 as affecting T-cell-derived cytokines, and 
these genes are also known to play an important role in anti-fungal host 
defence23,24.  
SNPs modulating cytokine levels associate with candidemia 
susceptibility 
To investigate whether SNPs modulating cytokine levels upon C. albicans 
stimulation are also associated with candidemia susceptibility – which would 
demonstrate the importance of  inherited cytokine production capacity for 
susceptibility to infection – we performed the first GWAS of  candidemia 
patients and controls and intersected the results with those of  the cQTL 
mapping. We genotyped 178 candidemia patients and 175 disease-matched 
controls of  European ancestry on a genome-wide scale. After quality control 
filtering, 161 patients and 152 disease-matched controls for whom we had 
genotype information on 5,326,313 SNPs variants were tested for disease 
association. 
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 This GWAS identified 235 SNPs in 70 independent loci that show 
suggestive disease associations (P < 9.99 x 10-5). Among these loci, a 
SNP on chromosome 15, rs8028958, showed the strongest association 
with susceptibility to candidemia (P = 7.79 x 10-8, OR = 0.4002). We 
found 75 SNPs from 21 independent candidemia-susceptibility loci 
(Fig. 5, Supplementary Table 5) that modulate cytokine levels upon C. albicans 
stimulation in any of  the cell systems (PBMCs, WB, and macrophages). 
Twenty SNPs modulate multiple cytokines upon stimulation with both 
Figure 4. Shared genetics between C. albicans yeast and C. neoformans. (a) Barplot shows a 
significant enrichment of  shared cQTLs that affect T-cell-derived cytokines ( IFN-γ, IL-
17A and IL-22) compared to cQTLs that affect monocyte-derived cytokines at different 
P-value thresholds: P < 1 x 10-4, P < 1 x 10-5 and P < 1 x 10-6. (b) Manhattan plot of  
meta-analysis results where novel genetic loci that regulate (b)  IFN-γ and (c) IL-17A 
levels induced by both fungal species in PBMCs are highlighted. Red line represents 
the genome-wide significance level (P < 5 x 10-8). (d) Pathway enrichment analysis of  
cQTLs that regulate T-cell-derived cytokines (IFNγ, IL-77 and IL-22) induced by both 
C. albicans yeast and C. neoformans. Cis genes in a 1 Mb window were extracted from loci 
that show moderate association with the T-cell-derived cytokines (P < 1 x 10-3) upon 
stimulation with both fungal species. KEGG was used as a database resource of  the 
molecular pathways.
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Candida morphotypes (Supplementary Table 6). These observations suggest 
that susceptibility can be partly explained by defects in cytokine pathways, 
but that there are also other alternative mechanisms involved in candidemia 
susceptibility. Finally, from these loci, we extracted genes in a 500 Kb 
window upstream and downstream of  each cQTL and prioritized genes 
that could determine susceptibility by modulating cytokine levels (Table 
2). For gene prioritization, we used publicly available eQTL mapping 
datasets from blood25,26. Our prioritization identified a number of  genes, 
including ALOX15B, GGT5, HSD17B4, JMJD7-PLA2G4B, AGPAT1, TTC7B 
and ALOXE3, known to be involved in different lipid metabolism processes, 
a finding which was also confirmed by pathway enrichment analysis 
(Supplementary Table 7).
Candidemia GWAS identifies the PLA2G4B locus association 
with susceptibility
The candidemia susceptibility GWAS had revealed a strongly associated 
locus at chromosome 15 (Fig. 5), with the top associated SNP, rs8028958, 
located within the intronic region of  the SPTBN5 gene (Supplementary Fig. 
3a). Previous eQTL analysis showed that SNP rs11070352, a proxy SNP 
to rs8028958 (r2 = 0.9 and D’ = 0.99), affects the expression of  EHD4 (P 
= 7.76 x 10-27) and JMJD7-PLA2G4B (P = 2.63 x 10-18) in WB26. However, 
eQTL data from GTEx project also indicated the effect of  this SNP on 
different genes in different tissues including PLA2G4B, suggesting its strong 
regulatory function. JMJD7-PLA2G4B encodes a fusion protein known as 
JMJD7-PLA2G4B and is a paralog gene of  PLA2G4B27. In addition, we also 
observed that differential expression analysis upon C. albicans stimulation in 
PBMCs prioritized PLA2G4B as a plausible candidemia susceptibility gene 
(Supplementary Fig. 3b). 
 Given the differential expression to C. albicans response and the genetic 
association data, we performed in vitro functional experiments to validate 
the role of  PLA2G4B in anti-Candida host immune defense. To investigate 
the importance of  the PLA2G4B locus in the response against C. albicans 
and disease susceptibility, human primary monocytes were isolated and 
differentiated into macrophages or left undifferentiated. Specific PLA2G4B 
siRNA or control siRNA were used to silence the gene prior to stimulation 
with C. albicans, and cytokine production capacity was subsequently 
measured. Comparing cytokine levels of  non-targeting control siRNA with 
PLA2G4B siRNA revealed a decrease in IL-6 and TNFa production in the 
targeted group in macrophages (Supplementary Fig. 4). Targeted silencing 
of  PLA2G4B also led to a reduction of  the capacity of  primary monocytes to 
296
Figure 5. Manhattan plot of  SNPs associated with candidemia susceptibility identified 
by GWAS. Twenty-one independent cQTLs are associated with candidemia susceptibility 
(green circles). GWAS also revealed a locus strongly associated with susceptibility to 
candidemia at chromosome 15 (P = 7.972 x 10-8, OR = 0.4002). Y-axis represents –
log10P values of  SNPs. X-axis shows chromosomal positions. Blue line is the suggestive 
threshold for association (P < 9.99 x 10-5). 
Figure 6. C. albicans killing capacity of  primary 
monocytes upon targeted silencing of  the PLA2G4B 
gene. A significant reduction of  the killing capacity 
of  monocytes was observed upon siRNA silencing 
of  the PLA2G4B gene compared to control siRNA. 
CFU: colony forming units.
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kill C. albicans yeast (Fig. 6), suggesting a role for PLA2G4B in host defense 
against C. albicans. 
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Discussion 
In a given at-risk population not all patients develop infections, which indicates 
that there is a strong genetic influence on individual susceptibility to different 
infections28. Although systemic fungal infections result in high morbidity and 
mortality in developed countries, genetic association studies that identify risk 
genes for systemic fungal infections are extremely challenging because of  the 
difficulty of  enrolling large numbers of  case-matched controls. To circumvent 
these challenges, we looked to identifying genetic variants that affect human 
immune responses to common opportunistic fungal pathogens by studying 
the variability of  cytokine production, an approach that should elucidate the 
role of  these variations in explaining susceptibility to candidemia. 
 Our study revealed that the inter-individual variations in cytokine 
production were similar for C. albicans yeast and hyphae. Through genetic 
analysis we identified a significant novel genome-wide genetic locus that 
regulates IL-17A production upon stimulation with C. albicans hyphae and 
10 shared genetic loci with genome-wide significance that regulate cytokine 
production in response to both C. albicans hyphae and yeast. We also found a 
significantly higher contribution of  shared genetics in the regulation of  T-cell-
derived cytokine levels in response to both C. albicans and C. neoformans, a 
relationship that was not present in monocyte-derived cytokines. Finally, by 
integrating cQTLs with SNPs associated with candidemia-susceptibility in 
our GWAS, we identified 21 independent cQTLs important in determining 
susceptibility to candidemia. 
 To cause infection, fungi need to cross skin and/or mucosal barriers, 
penetrate and invade underlying tissues and at the same time resist 
human immune defences29. To achieve this, these fungi adapt to changing 
environments by developing different escape strategies. The human host 
responds to these strategies by organizing the host cytokine response in 
a pathogen-specific manner, which was clear in the distinct clusters of  
association we observed for the cytokine production induced by A. fumigatus, 
C. albicans or C. neoformans. It has been shown that C. albicans hyphae 
(associated with tissue invasion) have a different cell wall composition 
compared to the yeast (associated with colonization), indicating differential 
host recognition of  hyphae and yeast as well as explaining differences in 
the virulence of  these two morphological forms30,31. Interestingly, the high 
correlation between hyphae- and yeast-induced cytokine responses suggests 
that cytokine responses to these two morphotypes are regulated by similar 
genetic and non-genetic factors. 
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An important finding of  the present study is the identification of  novel 
genetic factors that influence C. albicans-induced cytokine production while 
also impacting susceptibility to candidemia. The strong correlation we 
observed between yeast- and hyphae-induced responses suggests that the 
pathways involved in the recognition of  the two morphotypes may converge 
on a limited number of  genes controlling induction and regulation of  
cytokine production. In line with this, we have now identified 10 cQTLs 
with genome-wide significance that strongly affect both yeast- and hyphae-
induced cytokine responses (Table 1). We also identified seven genome-
wide significant cQTLs shared between C. albicans- and C. neoformans-
induced T-cell-derived cytokines (IL-17A, IFNγ and IL-22) (Table 1), which 
indicates a core genetic regulatory module for fungal-induced lymphocyte 
stimulation. These data should be valuable for the identification of  novel 
regulatory pathways of  anti-fungal cytokine responses. 
 We also found a cQTL with genome-wide significance for C. albicans 
hyphae-induced IL-17A production. The gene located closest to this 
variant is HS3ST2, which codes for the heparan sulfate glucosamine 
3-O-sulfotransferase 2 protein. HS3ST2 is an important gene involved in 
macrophage polarization, and we have previously identified this gene as 
one of  the differentially regulated genes by the TLR locus genotype18. 
These results indicate that some of  the cQTLs influencing Candida-
induced cytokines are downstream of  TLR-signaling, which is in line with 
earlier literature demonstrating the role of  TLRs for pattern recognition 
of  C. albicans10. What remains to be investigated is the precise mechanism 
through which HS3ST2 modulates IL-17A production. Our effort to identify 
common genetic loci that regulate cytokine responses to opportunistic 
fungal pathogens also revealed important genes such as the HLA alleles in 
the MHC locus and the TRAF3IP2 locus on chromosome 6. The human 
MHC region has been identified as a hotspot for determining susceptibility 
to many bacterial and viral infectious diseases32, but whether HLA alleles 
also affect susceptibility to fungal diseases still needs to be investigated. 
 One of  the most important aspects of  our study was our demonstration 
in an unbiased manner of  the strong impact of  cQTLs on susceptibility 
to candidemia. As shown in Fig. 5 (and in more detail in Supplementary 
Table 5), there is a strong overrepresentation of  cQTLs within gene 
polymorphisms that modulate susceptibility to candidemia. Among these 
polymorphisms, 20 SNPs modulate cytokines in response to both C. albicans 
morphotypes (Supplementary Table 6). The variants that affect T-cell-
derived and monocyte-derived cytokines are found to be associated with 
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candidemia, and these genes are enriched for those involved in lipid and 
lipoprotein metabolism processes (Supplementary Table 7). Many metabolic 
changes including lipid synthesis are shown to be important in regulating 
cytokine secretion to coordinate immune response33–35. In mouse studies, 
hyper-lipoproteinemia increased the susceptibility to systemic candidiasis 
due to an increased fungal outgrowth in their organs36, while a beneficial 
effect was seen in rats infected with gram-negative bacteria37. These data 
were in agreement with human studies where infusion of  lipoproteins 
enhances the growth of  C. albicans in the plasma of  volunteers38. Although 
the lipid profiles differ between humans and mice, both studies suggest 
that hyperlipidemia have deleterious effects by enhancing the growth of  
C. albicans in both species. Therefore, it needs to be tested whether the 
candidemia-associated SNPs that we have identified in this study influence 
cytokine levels through affecting lipids and lipoprotein levels. Nevertheless, 
our data demonstrate the power of  a systems-based approach for identifying 
the most important host defense mechanisms against specific infections. 
For instance, we also identified novel genes and pathways involved in the 
pathogenesis of  RVVC by using a same approach (which is described in an 
additional manuscript). For RVVC, pathways and genes belonging to cell 
adhesion were strongly overrepresented by genetic variants in the patient 
cohort compared to controls. Overall, our studies on candidemia and RVVC 
suggest that different genetic factors and molecular pathways are involved in 
determining susceptibility to both fungal infections. Of  note, several previous 
studies observed that patients carrying mutations in certain immune genes, 
such as IL-17F, IL17RA, DECTIN1, STAT1 or STAT3 suffer from mucosal 
candidiasis but not invasive candidiasis10. This indicates that different 
genetic factors determine immune responses against systemic and mucosal 
fungal infections, which, in turn, may determine disease susceptibility. 
 Finally, we have also identified a novel genome-wide genetic association 
of  candidemia with polymorphisms in PLA2G4B, a gene encoding the 
cytosolic phospholipase A2 protein that selectively hydrolyses phospholipids 
to release lysophospholipids and fatty acids. In addition, a recent study 
provided insights into the oncogenic control of  this fusion gene in head 
and neck squamous cell carcinoma proliferation and survival27,39. However, 
the role of  PLA2G4B has never been studied in the context of  infectious 
diseases. Interestingly, specific down-regulation of  PLA2G4B by siRNA 
resulted in the impairment of  the candidacidal properties of  macrophages, 
confirming its importance in the host response against C. albicans. 
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In conclusion, our study provides an important resource for understanding 
genetic factors determining cytokine production induced by opportunistic 
fungal pathogens and susceptibility to candidemia. The novel approach 
we have taken demonstrates the strength of  a systems genomics approach 
to identifying novel risk genes and pathways for fungal infections. In the 
future, systematic integration of  such datasets may also be useful for other 
infectious diseases and could ultimately lead to the development of  novel 
therapies and treatment strategies that target these genes and pathways.
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Methods
Study populations
Population-based cohorts. To understand the variation in cytokine production 
in humans in response to C. albicans in vitro, we used two independent 
population-based cohorts, 500FG and 200FG, composed of  healthy 
individuals of  Western European ancestry from the Human Functional 
Genomics Project (HFGP, see www.humanfunctionalgenomics.org). The 
500FG cohort is composed of  534 well-characterized healthy individuals, 
237 males and 296 females all between 18 and 75 years old. The 200FG 
cohort is composed ~200 healthy individuals from the Netherlands, is 
77% male and 23% female9 and has an age range from 23 to 73 years old. 
The HFGP study was approved by the Ethical Committee of  Radboud 
University Nijmegen, the Netherlands (no. 42561.091.12). Experiments 
were conducted according to the principles expressed in the Declaration 
of  Helsinki and venous blood samples were drawn after written informed 
consent was obtained. 
Candidemia cohort. To identify genetic variants associated with candidemia 
susceptibility, we performed the first GWAS analysis of  a well-described 
candidemia cohort with corresponding disease-matched controls. In total, 
178 candidemia cases and 175 disease-matched controls of  European 
ancestry were tested for disease association. The demographic and clinical 
characteristics of  the candidemia cohort have been described previously40. 
Disease-matched controls were recruited from the same hospital wards as 
candidemia cases so that co-morbidities and clinical risk factors for infection 
were similar. Both candidemia cases and disease-matched controls were 
enrolled after informed written consent was given at the Duke University 
Hospital (DUMC, Durham, North Carolina, USA). The study was approved 
by the institutional review boards at the Duke University Hospital.
PBMC collection and stimulation experiments
Venous blood from the cubital vein of  healthy volunteers was drawn in 
EDTA tubes after obtaining written informed consent. PBMC isolation 
was performed as previously described41. In short, the PBMC fraction was 
obtained using density centrifugation in Ficoll-Paque (Pharmacia Biotech). 
Cells were then washed twice in PBS and re-suspended in RPMI 1640 
medium supplemented with gentamicin 10 mg/mL, L-glutamine 10 mM and 
pyruvate 10 mM. PBMCs were counted and re-suspended in a concentration 
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of  5 x 106 cells/mL. 5 x 105 PBMCs were added in 100 μL to round-bottom 
96-well plates (Greiner) and incubated with 100 μL of  stimulus (RPMI, heat 
killed Candida albicans yeast 1 x 106/mL or Candida albicans hyphae 1 x 105/
mL). After 24 hours or 7 days in the presence of  10% human serum, the 
supernatants were collected and stored at −20°C. Cytokines were measured 
using different ELISA assays.
Macrophage differentiation and stimulation
After PBMC isolation, purification of  monocytes was performed by hyper-
osmotic Percoll density gradient centrifugation. Remaining cells were washed 
once with PBS and subsequently added to Petri dishes containing RPMI 1640 
medium supplemented with 10% human serum and 5 ng/mL GM-CSF. The 
medium was refreshed after 3 days. After 6 days, differentiated monocytes 
were de-attached, counted, and subsequently used to seed 1.5 x 105 cells in 
a 96-well flat bottom plate (Greiner). After 24 hours of  attachment, 25 nM 
of  either non-targeting siRNA control pool (D-001810-10-05) or PLA2G4B 
(L-187552-01-0005) targeting siRNA (Smartpool, Thermo Scientific) were 
added for 24 hours. After the transfection period, cells were stimulated 
for 24 hours with 1 x 106/mL Candida yeast. After the stimulation period, 
supernatants were collected and stored at −20°C. Cytokines were measured 
using different ELISA assays.
Whole-blood stimulation experiments
100 µL of  fresh heparin blood was added to a 48-well plate and then 
stimulated with 400 µL stimulus (either RPMI or C. albicans 1x106/mL) for 
48 hr at 37°C and 5%CO
2
. Supernatants were collected and stored at –200C 
until used for ELISA. 
Cytokine measurements
Frozen supernatants from PBMCs, macrophages, monocytes and WB 
stimulation experiments were measured for IL-1b, IL-6, TNFa, IL-22, IL-
17A, and  IFN-γ using commercial available ELISA kits (PeliKine Compact 
or R&D Systems). All ELISAs were carried out according to manufacturer 
protocol. Data were analyzed using GraphPad prism v5.0. Data are shown 
as means ± SEM. P < 0.05 = *, P < 0.01 = ** and P < 0.001 = ***.
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Variance analysis and cytokine clustering
We first log-transformed raw cytokine levels and filtered out cytokine 
measurements showing little/no variation across individuals as previously 
described18. We used Levene’s test to check the equality of  variance of  
cytokine levels before and after stimulation. We performed unsupervised 
hierarchical clustering using Spearman’s correlation as the measure of  
similarity. All statistical analyses regarding the cytokine data were performed 
in R (https://www.R-project.org/).
Monocyte fungal killing assays
For the monocyte siRNA experiments, 1.5 x 105 cells were directly seeded 
into 96-well flat bottom plates. After 24 hours of  siRNA treatment, 
1 x 106/mL live C. albicans yeast was added for 24h of  incubation at 37°C. 
Following incubation, well contents were serial diluted in sterile water and 
plated on Sabouraud agar for counting of  colony forming units. Data was 
stratified regarding genotypes for SNP rs8028958 in PLA2G4B. Data from 
3 experiment with at least 2 donors per experiment was pooled and data 
was analyzed using Graphpad Prism v5.0. P < 0.05 = *, P < 0.01 = ** and 
P < 0.001 = ***.
Genotyping, quality control and imputation of the 500FG 
cohort
DNA obtained from the 500FG cohort was genotyped using the commercially 
available Illumina HumanOmniExpressExome-8 v1.0 SNP chip. Genotype 
calling was performed using Opticall 0.7.0 using default settings42. We applied 
quality control per sample to exclude samples with a call rate ≤ 0.99 and quality 
control per SNP to exclude variants with a Hardy-Weinberg equilibrium ≤ 
0.0001, a call rate ≤ 0.99 and a minor allele frequency (MAF) ≤ 0.001. We 
identified 17 ethnic outliers by merging multi-dimensional scaling plots of  
samples with 1000 Genomes data, and these outliers were excluded from 
further analysis18. The quality control filters resulted in a dataset of  483 samples 
containing genotype information on 518,980 variants for further imputation. 
Imputation has been described previously using the reference Genome of  the 
Netherlands (GoNL, Genome of  the Netherlands Consortium, 2014) dataset 
as a reference panel9,43. We selected SNPs that showed an INFO score ≥ 0.8 
upon imputation for further cytokine QTL mapping. 
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Genotyping, quality control and imputation of the candidemia 
cohort
Isolated DNA obtained from case and control samples was genotyped 
using the commercially available SNP chips, HumanCoreExome-12 v1.0 
and HumanCoreExome-24 v1.0 BeadChip from Illumina (https://www.
illumina.com). Genotype calling was performed using Optical 0.7.0 using 
the default settings42. Strands of  variants were aligned and identified against 
the 1000 Genome reference panel using Genotype Harmonizer. We then 
imputed the samples on the Michigan imputation server using the human 
reference consortium as a reference panel, and we filtered variants with an 
R2 of  0.3 for imputation quality44. After excluding imputed variants with a 
MAF < 0.10 and variants within the HLA region, we applied quality control 
per sample and removed 15 individuals (5 cases and 10 controls) due to 
excess/reduced heterozygosity and cryptic relatedness. Next, we applied 
SNP quality control filters to exclude SNPs with a MAF of  < 0.05 and a 
Hardy-Weinberg equilibrium of  P < 1 x 10-06 in control samples only. We also 
identified 25 ethnic outliers (12 cases and 13 controls) by multidimensional 
scaling analysis (performed in PLINK on the N x N matrix of  genome-wide 
IBS pairwise distance) of  candidemia patients and disease-matched controls 
for the two first principle components (Supplementary Fig. 5). The quantile-
quantile plot that shows the distribution of  the observed –log10 for the 
whole-genome SNPs against the theoretical distribution of  expected –log10 
indicated no or little evidence of  population stratification (Supplementary 
Fig. 5b). The genomic inflation factor based on median chisq was equal 
to 1 ( λ = 1). Quality control filters resulted in a dataset of  161 cases and 
152 disease-matched control samples containing genotype information on 
5,326,313 SNP variants for further testing for association with candidemia 
susceptibility. 
Cytokine QTL mapping
We selected 442 individuals from 500FG for whom both genotype and 
cytokine data were available. We obtained cell count data measured by 
FACS for total lymphocytes, T cells, B cells, monocytes and NK-cells from 
487 individuals from the 500FG cohort. For cytokine QTL mapping, we 
used 409 samples with genotype, cytokine and cell-count data. Of  these, 17 
samples were excluded due to genetic differences. To correct the cytokine 
distributions for QTL mapping, we used a linear model adjusting for age, 
gender and cell-count. Raw cytokine levels were first log-transformed and the 
correlation between cytokine production and genotype was tested by linear 
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regression model with age and gender as co-variables using the R-package 
Matrix-eQTL. We considered P < 5 x 10-8 to be the threshold for significant 
cQTLs. C. albicans response QTLs (P < 0.05) were intersected with SNPs 
associated with susceptibility to candidemia showing a P-value between 
9.99 x 10-5 and 5 x 10-8 to identify cQTLs associated with susceptibility.
 Finally, we used METAL (http://www.sph.umich.edu/csg/abecasis/
metal/) for performing meta-analysis of  cQTLs to identify novel loci 
associated with our traits of  interest45.
Pathway enrichment analysis
We performed gene over-representation analysis using ConsensusPathDB-
human database (CPDB; http://cpdb.molgen.mpg.de/). The analysis was 
done using the default settings, where pre-defined lists of  functionally 
associated genes (pathways, Gene Ontology categories and neighborhood-
based entity sets) are tested for over-representation in a user-specified list 
based on the hypergeometric test. For each of  the predefined sets, a P-value 
was calculated according to the hypergeometric test based on the number of  
physical entities present in both the pre-defined set and the user-specified list 
of  physical entities. P-values were corrected for multiple testing using the 
false discovery rate method and are available as q-values. For this analysis, 
linkage disequilibrium (LD) SNP pruning of  cQTLs using genotypes 
extracted from the 500FG cohort was performed based on pairwise genotypic 
correlation using PLINK 1.90 (https://www.cog-genomics.org/plink2), 
with one of  a pair of  SNPs removed if  LD was > 0.2. Next we extracted 
SNPs with the same allelic direction as shown in our meta-analysis results, 
and genes in a window of  ±500 kb from the independent loci were extracted 
and filtered using differential gene expression data of  PBMCs in response 
to C. albicans for 4 and 24 hours. Once this had all been done, we finally ran 
the over-representation analysis.
Genome-wide case-control association analysis
The associations between the GWAS-identified variants and candidemia 
susceptibility were tested by Fisher’s exact test using PLINK 1.9 (www.cog-
genomics.org/plink/1.9/)46. The genomic inflation factor (λ = 1) indicated 
that there was no population stratification effect (Supplementary Figure 5). 
We considered SNPs with a P-value between 9.99 x 10-5 and 5 x 10-8 as 
showing a suggestive association with candidemia susceptibility. 
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Supplementary Figures
Supplementary Figure 1. Increased cytokine variation upon stimulation with C. 
albicans yeast and hyphae in PBMCs, WB and monocyte-derived macrophages. Y-axis 
depicts the log2 transformed cytokine levels. X-axis shows stimulation used: C. albicans 
hyphae, C. albicans yeast or the RPMI 1640 medium (with or without serum) used as 
control. Colors in legend indicate the three different cell systems used. Gray: peripheral 
blood mononuclear cells (PBMCs). Red: whole blood (WB). Blue: monocyte-derived 
macrophages (macroPG).
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Supplementary Figure 2. Manhattan plots of  meta-analysis results showing the genome-
wide significant SNPs that affect (a)  IFN-γ, (b) IL-17A, (c) IL-22, (d) TNFα, (e) IL-6 and 
(f) IL1-β levels upon stimulation with both C. albicans yeast and hyphae are highlighted. 
Y-axis represents –log10P values of  SNPs. X-axis shows chromosomal positions. Red line 
is genome-wide significance level (P < 5 x 10-8).
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Supplementary Figure 3. Differential expression analysis upon C. albicans stimulation 
prioritized PLA2G4B as a plausible candidemia susceptibility gene. (a) Regional 
association plot for the candidemia-associated SNP, rs8028958, which mapped to the 
JMJD7-PLAS2G4B locus at chromosome 15. (B) Barplot showing the –logP values of  
differential expression of  PLA2G4B upon stimulation with C. albicans in PBMCs compared 
to the RPMI 1640 medium used as controls.
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Supplementary Figure 4. Cytokine production capacity of  (a) TNFa, (b) IL-
1β, (c) IL-6 and (d) IL-1RA upon specific PLA2G4B siRNA, or control siRNA 
of  C. albicans stimulated macrophages.
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Supplementary Figure 5. (a) Multidimensional scaling (MDS) analysis 
(performed in PLINK, on the N x N matrix of  genome-wide IBS pairwise 
distance) of  candidemia patients and disease-matched controls for the 
two first principle components. Each dot represents an individual. Green: 
patients. Yellow: controls. (b) Quantile-Quantile plot of  association P-values 
for all SNPs on the genome-wide genotyping array (Black dots). The genetic 
inflation factor λ for all SNPs was 1, indicating no population stratification.
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Summary and Conclusion
Chapter 12
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The immune system discriminates between self  and foreign antigens to 
initiate an immune response when necessary. In addition, it plays an even 
more complex role by allowing commensal bacteria, fungi and viruses 
to colonize the human body and skin, but at the same time balances this 
co-existence to avoid overgrowth and host invasion. The importance of  
coordination between immune system and colonizing microorganisms 
in determining health or infection becomes clear in patients that are 
strongly immunocompromised or patients with a disrupted microflora. 
Immunocompromised patients are on high risk for infections due to the lack 
of  effectiveness of  the immune system to clear invading pathogens. At the 
same time the absence or presence of  specific colonizing microorganisms has 
been shown to have direct effects on the immune system, ultimately leading 
to specific pathologies as for example seen in patients with inflammatory 
bowel diseases [1].
 The function of  the immune system and the complex interplay of  its 
different components is strongly influenced by variation in the DNA of  the 
individual. Subtle differences in the genetic code can lead to changes or even 
loss of  function of  immune components, which ultimately leads to alterations 
in how the immune system can interact with different microorganisms. 
 Huge advances regarding the identification of  these genetic polymorphisms 
have been made in the last decades. This resulted in a better understanding 
of  the mechanisms leading to disease on the one hand, and to the targeted 
development of  novel treatment strategies for several diseases on the other 
hand. In addition to the genetic makeup, non-genetic factors such as age, 
gender or lifestyle also modulate immune responses.
 In this thesis, we have identified novel immune components that are 
crucial for the host response against the fungal pathogen Candida albicans. 
Next to genetic assessment of  patient cohorts with mucosal as well as 
invasive Candida infections, a large cohort of  healthy individuals was used 
to assess genetic and non-genetic inter-individual differences influencing 
the immune response against different microorganisms. Integrating 
demographic, immunological, genetic and omics datasets ultimately leads 
to a deeper understanding of  the different factors that shape the individual 
immune response. 
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Part I of  this thesis focused on differences in the immune response in the 
healthy host. Light was shed on the genetic and non-genetic factors that 
influence the individual immune response to various pathogens and how 
they are connected to each other. Chapter 2 summarizes the current insights 
into genetic variations in pattern recognition receptors (PRR) as well as 
their functional consequences on (infectious) disease susceptibility and 
development. Currently, PRR are divided into five subclasses based on their 
structure and ligand affinity. Due to advances in technology (ea. WES and 
WGS) and growing patient cohorts, the identification of  novel variants is 
still ongoing and even structural variants such as large insertions or copy 
number variations can be traced by now. 
 To identify factors that shape the individual immune response, large 
amounts of  different immunological as well as environmental factors 
have to be taken into account. Big datasets with well-defined and deeply 
characterized individuals are needed to draw accurate conclusions. Within 
the Human Functional Genomics Project (HFGP), more than 500 healthy 
individuals with Western-European genetic background have been thoroughly 
characterized for different immunological parameters. Moreover, genetics, 
metabolomics as well as the microbiome have been determined to ultimately 
combine these datasets in systems biology approaches [2]. Chapter 3 
focused on the influence of  genetics on the inter-individual differences in 
the cytokine response to different pathogens. Novel genome-wide significant 
cQTLs have been identified that strongly influence the in vitro cytokine 
production capacity after stimulation with bacterial, viral as well as fungal 
pathogens. Pathway analysis of  the genes within the cQTLs revealed an 
overrepresentation of  pathways belonging to pattern recognition, cytokine 
and complement inhibitors and interestingly also the kallikrein system. 
Moreover, systematic analysis of  the individual cytokine responses revealed 
that the general cytokine response is built around a certain pathogen rather 
than a particular pathway that is activated independently of  the pathogen 
that is recognized. Finally, we show that the influence of  genetic variations 
in the immune response to different pathogens differs between the stimuli as 
well as the cytokine measured. Follow up studies should lead to more insights 
by integrating deeper genetic as well as transcriptional data and successively 
identify important connections between these different biological levels. 
 Although the genetic makeup plays an important part in the individual 
cytokine production capacity, non-genetic factors have been shown to 
have an essential influence as well. Numerous valuable studies have been 
performed that looked at the influence of  single parameters on the immune 
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response against individual pathogens or their influence on baseline 
immunological markers. Chapter 4 integrates different datasets from the 
HFGP to draw a comprehensive picture about common non-genetic factors 
and how they influence the cytokine response against whole microorganisms 
as well as specific (single) PRR ligands. The T cell cytokines IL-22 and 
IFN-γ significantly decreased with age whereas IL-17, together with 
monocyte derived cytokines did not show significant decline with age. 
Next to the influence of  age on the individual immune response, a clear 
gender difference was observed which likely contributes to gender specific 
differences in disease susceptibility. Moreover, a couple of  cytokines clearly 
follow a seasonal pattern, which may explain the seasonal nature of  a couple 
of  infectious diseases. Next to the in vitro cytokines, circulating cytokine 
levels did also seem to be influenced by the different seasons. From these 
we identified an important regulatory mechanism through which alpha-1-
antitrypsin (AAT) inversely correlated with IL-1b production.
In Part II of  this thesis we performed case-control genetic studies to 
identify novel components of  the anti-Candida immune response. Chapter 
5 provides an overview of  the components that have been found so far to be 
dysregulated in patients suffering from recurrent vulvovaginal candidiasis 
(RVVC). Those patients suffer from multiple episodes of  vulvovaginal 
infections per year leading to huge discomfort and high costs for health 
care systems. Normally, treatment includes azole-based antifungal therapy. 
Despite the fact that a number of  predisposing factors (e.g. pregnancy, 
diabetes, antibiotic treatment) that favor vaginal infections have been 
identified, these factors do not play a major role in the majority of  women 
with RVVC, making a genetic component most likely. The immune response 
against Candida is not yet fully understood, although the main receptors 
and pathways already have been extensively described, and it is not 
surprising that genetic variations in components of  Candida recognition 
(ea. DECTIN-1 and NLRP3) or downstream effector molecules (ea. IL-4 or 
MBL) lead to the disease phenotype [3-5]. In future, advances in techniques 
as well reductions in costs will lead to even more insights in this multi-
genetic disease and will eventually lead to novel therapies. In Chapter 6 
we assess the role of  the receptor CX3CR1 that has recently been described 
to be crucial in invasive Candida infections [6]. It has been shown that the 
chemokine receptor CX3CR1, present on various immune cells, is essential 
for the (early) immune function of  resident kidney macrophages in a mouse 
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model of  systemic candidiasis [6]. Beside this, a genetic variant in this 
surface receptor was associated with candidemia in humans [6]. Because of  
its important role in the host response against Candida in this model, as well 
as in the human invasive infections, in Chapter 6 we investigated whether 
this receptor also plays a role in RVVC. Neither immune function at the 
mucosal surface nor genetic variants in this receptor were associated with 
the pathology in RVVC or disease susceptibility, suggesting that CX3CR1 
is solely involved in invasive fungal infections. Although the results of  this 
study underline the importance of  CX3CR1 in invasive infections rather 
than mucosal infection, one has to keep in mind that the mucosal models 
(ea. oral candidiasis) used in Chapter 6 are different than in vaginal infection 
models. 
 Increasing data in the literature suggest that RVVC is not due to immune 
defects, but rather to an over-reactive immune response to colonizing 
Candida. This in turn results in excessive production of  proinflammatory 
cytokines.
 This concept is supported by recent findings that show that both an 
increase in immune cell influx (mainly PMNs) during disease, as well as 
changes of  Candida itself  due to the acidic environment, lead to a significant 
increase in the local immune response [7, 8]. 
 Chapter 7 investigates the functional consequence of  a structural genetic 
variation in the NLRP3 gene and its role in RVVC susceptibility. A variable 
number tandem repeat (VNTR) in the NLPR3 gene, which is responsible 
for the procession of  proIL-1b into its bioactive form, is dysregulated in 
patients with RVVC. As a consequence, cytokine levels of  IL-1b measured 
at the vaginal surface of  patients were highly increased compared to 
controls. Within the patient group, individuals carrying the risk genotype 
of  the NLRP3 gene had even increased levels of  IL-1b. Moreover, levels of  
IL-1Ra at the vaginal surface were inversely correlated with IL-1b levels, 
leading to a hyper-inflammatory state. Interestingly, levels of  IL-18, which 
are processed by the NLRP3 inflammasome seemed to be unchanged 
between both the control and patient groups, as well as between the different 
genotypes. The identification of  NLRP3 in the pathogenesis of  RVVC may 
serve as a target in the development of  novel treatment strategies in this 
disease. One could think of  specifically targeting components of  the IL-
1b pathway to counterbalance high levels of  IL-1b at the level of  vaginal 
mucosal surface. 
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The availability of  genetic as well as immunological data in patients and 
controls makes it possible to systematically combine different datasets to 
generate an even more accurate picture of  the exact pathogenesis in different 
(immune related) diseases. In this way, not only novel gene candidates can 
be identified but also whole pathways that are most likely be affected. 
In Chapter 8 a systems genomic approach was applied to identify novel 
components that are dysregulated in RVVC. Two different cohorts of  RVVC 
patients and matched controls were genetically assessed and compared by 
whole exome sequencing. Moreover, extensive immunological parameters 
(ea. in vitro cytokine measurements) have been determined. By integrating 
genetic data from two different RVVC cohorts with immunological assays, 
pathways of  cellular morphogenesis and metabolism, as well as cell adhesion 
processes were found to be most strongly affected in RVVC patients. A 
novel gene candidate that was associated with the disease phenotype was 
SIGLEC15. The role of  SIGLEC15 in the pathogenesis of  vaginal candidiasis 
was validated in different in-vitro studies and in-vivo experimental vaginal 
infection models. Individuals with a specific genetic variant in SIGLEC15 
showed an altered cytokine response against Candida and specific gene 
silencing of  SIGLEC15 in primary immune cells revealed a Candida specific 
reduction of  cytokine production capacity. Treatment of  Candida with 
neuraminidase, which leads to the cleavage of  sialic acids from the surface 
of  Candida, resulted in an increase of  both reactive oxygen species as well 
as proinflammatory cytokines. In a murine vaginal infection model, mice 
treated with SIGLEC15 siRNA showed significantly increased amounts of  
Candida along with an increased influx of  PMNs. Cytokine measured in at 
the vaginal surface, point towards a highly inflammatory state with IL-1b 
to be most significantly upregulated in SIGLEC15 silenced mice. Although 
strong evidence points towards a role for SIGLEC15 in the immune response 
against Candida, the exact mechanism and pathway by which this surface 
receptor is triggered by Candida need to be assessed in more detail in future. 
Moreover, the identified pathways should be examined in more detail to 
identify their role in RVVC pathogenesis. 
 In contrast to mucosal Candida infection which are normally not life 
threatening, invasive infections are characterized by high mortality, 
especially in hospitalized and immunocompromised patients [9]. When 
physical barriers are breached, Candida is able to enter the bloodstream 
where it is able to reach other organs leading to excessive outgrowth, 
organ failure and fungal sepsis. Extensive studies in the past decade have 
identified different risk factors that increase susceptibility to candidemia 
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and at the same time improved our understanding in the exact pathologic 
mechanisms underlying this disease [10-13]. In Chapter 9 a novel receptor 
for Candida recognition has been identified. This receptor, MDA5 (IFIH1), is 
until now solely known to recognize (long) double stranded RNA (dsRNA) 
derived from viruses to initiate a type I interferon response. Interestingly, 
MDA5 gets highly expressed by different immune cells after stimulation 
with Candida and patients suffering from Candidemia are predominately 
affected by a specific genetic variant in MDA5 compared to matched control 
individuals. Beside this, this genetic variant was associated with an altered 
cytokine profile in PBMCs stimulated with Candida underlining its potential 
role in the immune response against Candida. 
 In silico analysis of  this genetic variant on protein function revealed 
a possible effect on dsRNA binding selectivity as well as affinity, which 
in turn might lead to a decrease in signalling activity. Although the exact 
mechanism by which the intracellular receptor MDA5 is able to recognize 
Candida is not known yet, these new findings give conclusive evidence that 
MDA5 is involved in the host response against Candida. 
In this thesis, the identification of  novel components in the immune 
response against Candida most often arises from the (genetic) comparison 
of  diseased individuals with healthy controls. Genes with variants that are 
more often present in the disease cohort are most likely to be involved in 
either recognition, signalling or effector mechanisms with anti-Candida 
immunity. 
 However, approaches to specifically look at a chosen candidate gene, as 
done in Chapter 7, because of  its biological relevance and importance from 
literature, are possible as well. 
 In Chapter 10, genetic variants in the IL-32 gene were systematically 
assessed for their impact on Candida induced cytokine in vitro. IL-32 has 
recently been shown to be important in host defense against different 
bacterial infections, whereas little is known about its role in fungal infections 
[14]. Intronic genetic variant within the IL-32 gene led to an altered cytokine 
profile after Candida stimulation in vitro, which made this gene interesting 
for further investigation in the context of  Candida infections. IL-32 has 
different splice variants and especially IL-32γ was able to modulate Candida-
induced cytokines. Addition of  recombinant IL-32γ not only increases IL-17 
and INFγ in a dose dependent manner in human PBMCs, but also increases 
Candida phagocytosis by monocytes. 
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We did not observe a direct antifungal effect of  IL-32γ on Candida growth, 
making an effect of  IL-32γ on immune cells most likely. Looking more closely 
into the genetic variants in IL-32, despite the effects on cytokine production, 
no difference in IL32 genotype distribution was observed in patients with 
candidemia. However, strongly decreased levels of  circulating INFγ were 
associated with the variant allele, while this was not the case for IL-6 and 
IL-8. Finally, mice transgenic for human IL-32γ displayed significantly 
increased 14-day survival compared to wild-type mice in a systemic Candida 
infection model. Although the exact mechanism by which IL-32γ interacts 
with immune cells and influences Candida induced cytokines needs to be 
further investigated, this study identifies IL-32 as a new pathway involved 
in host defense against Candida infections. 
 In Chapter 11 we were interested in the shared characteristics in the 
immune response against different fungal pathogens. For this, in vitro 
immune responses against three fungal pathogens were tested in different 
cellular systems. By correlating the cytokine data, we clearly found distinct 
correlation clusters of  the different fungal pathogens, confirming the 
previous hypothesis that cytokine responses are built specifically around 
pathogens rather than immune pathways.
 Subsequently, the cytokine production capacity in a large cohort of  500 
healthy individuals was used to identify novel cQTLs. To even more clearly 
distinguish novel gene candidates, this data was intersected with mRNA 
expression data after Candida stimulation. Finally, novel gene candidates 
derived from the first GWAS in candidemia patients were further validated 
using Candida expression data as well as in vitro functional assays. This 
study identified novel gene candidates, which influence anti-Candida host 
defense and should be in the future validated in clinical settings. 
 In the second part of  this thesis, the focus was set on two different 
Candida infections, namely systemic Candida infection (candidemia) and 
recurrent mucosal vaginal Candida infections (RVVC). One has to keep in 
mind that both diseases have a polygenetic background and that there are 
most likely both genetic and non-genetic factors that contribute to the onset 
and outcome of  those infections. Thorough patient classifications as well 
as in depth characterization of  the interplay between different components 
that are dysregulated are key points in the development of  personalized 
therapies to overcome the high discomfort experienced by RVVC patients, 
and prevent mortality in invasive fungal infections. 
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Addendum
Chapter 13
328
Nederlandse samenvatting
Het immuunsysteem is in staat om tussen zelf  en niet zelf  onderscheid 
te maken en wanneer nodig een immuun response in gang te zetten. Het 
heeft verder een complexe rol bij het toestaan van commensale bacteriën, 
schimmels en virussen die het lichaam koloniseren, maar zorgt er 
tegelijkertijd voor dat deze het lichaam niet overgroeien of  binnendringen 
en vervolgens schade aan richten. Het belang van een goede balans tussen 
immune systeem en koloniserende micro-organismen wordt duidelijk bij 
patiënten die sterk immuun gecompromitteerd zijn of  patiënten die juist 
een verstoorde microflora hebben. Immuun gecompromitteerde patiënten 
hebben een sterk verhoogd risico voor infecties door een inefficiënt werkend 
immuunsysteem en de daardoor missende klaring van potentieel gevaarlijke 
micro-organismen. Tegelijkertijd is er sterke aanwijzing dat de aanwezigheid 
ofwel afwezigheid van bepaalde micro-organismen een direct effect of  het 
immuunsysteem heeft wat uiteindelijk tot specifieke ziekteverschijnselen 
kan leiden zoals gezien in patiënten met inflammatoire darmziektes (IBD). 
De functie van het immuunsysteem, en de complexe interactie van alle 
componenten hiervan, wordt sterk door variaties in de individuele DNA 
beïnvloed. Kleine verschillen in de genetische code kunnen tot veranderingen 
en zelfs totaal verlies van de functie of  een bepaald component leiden, wat 
uiteindelijk tot veranderingen in de manier hoe het immuunsysteem met 
verschilleden micro-organismen omgaat leidt. 
 In de laatste jaren is er grote vooruitgang gedaan in het identificeren van 
nieuwe genetisch polymorphismen en uiteindelijk heeft dit tot een beter 
begrip van verschillende ziektes aan de ene kant en tot ontwikkeling van 
nieuwe behandelmethodes aan de andere kant geleid. Naast de genetische 
factoren hebben niet genetische factoren zoals leeftijd, geslacht en levensstijl 
een belangrijke rol in het vormen van de immuun response.
 Binnen deze thesis hebben wij nieuwe immuun componenten die belangrijk 
zijn voor de afweer tegen de schimmel Candida albicans geïdentificeerd. 
Naast de genetische analyse tussen patiënten met mucosalen en invasieve 
schimmelinfecties met Candida hebben we ook een grote cohort van gezonde 
vrijwilligers gebruikt om zowel genetische als ook niet genetische factoren 
te bepalen die de immuun response tegen verschillende micro-organismen 
beïnvloeden. Het samenvoegen van demografische, immunologische, 
genetische en zogenoemde “omics” datasets zal uiteindelijk tot een beter 
begrip, in de verschillende factoren die de immuun responsevormen, leiden.
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Deel 1 van thesis behandelt de verschillen in de immuun response in de 
gezonde gastheer. Genetische en niet genetische factoren worden onderzocht 
en hoe deze factoren de individuele immuun response tegen verschillende 
ziekteverwekkers beïnvloeden. Hoofdstuk 2 vat de meest recente inzichten in 
de genetische variaties, in de zogenoemde Pattern recognition receptors (PRR) 
en de functionele gevolgen met betrekking tot het ontstaan en verloop van 
infectieziektes, samen. Tot op heden zijn de PRR gebaseerd op hun structuur 
en ligand affiniteit in vijf  classes opgedeeld. Grote technologische vooruitgang 
in de laatste jaren (bijvoorbeeld WES en WGS) en de beschikbaarheid van 
grotere groepen patiënten en controles heeft ertoe geleid dat steeds nieuwe 
varianten en zelfs structurele veranderingen zoals “large insertions” of  “copy 
number variations” opgespoord kunnen worden. 
 Bij het identificeren van factoren die de immuun response beïnvloeden, 
moet er op een aantal zowel immunologische als ook omgevingsfactoren 
gelet worden. Om exacte uitspraken te maken zijn er daarom grote datasets 
met zorgvuldig uitgezochte en gedefinieerde individuen nodig. Binnen het 
“Human Functional Genomics Project” (HFGP) zijn er meer dan 500 gezonde 
individuen met westerse afkomst geïncludeerd en grondig geëvalueerd voor 
verschillende immunologische parameters. Verder is er genetische en metabole 
data gegenereerd en uiteindelijk ook het microbiome bepaald om deze datasets 
in systeem biologie analyses te onderzoeken. Hoofdstuk 3 beschrijft de invloed 
van de individuele erfinformatie op de uitkomst in de cytokine response tegen 
verschillende ziekteverwekkers. Nieuwe regio’s in de erfinformatie die een sterk 
invloed op de cytokine levels na stimulatie met verschillende ziekteverwekkers 
hebben, worden geïdentificeerd. Pathway analyse van de genen die de cytokine 
levels beïnvloeden liet zien dat deze genen voornamelijk tot de families 
van pattern recognition receptoren, cytokine en complement remmers en 
onverwacht ook het kallikrein systeem behoren. Uiteindelijk konden wij laten 
zien dat de cytokine response tegen verschillende ziekteverwekkers specifiek 
tegen de ziekteverwekkers is gericht en dat er juist niet een bepaald pathway 
in gang gezet wordt onafhankelijk van de ziekteverwerker die door immuun 
cellen herkend wordt. Tot slot laten we zien dat de invloed van de genetische 
variatie op de immuun response tegen verschillende ziekteverwekkers afhangt 
van de ziekteverwekker zelf, maar ook van het onderzochte cytokine. Het 
gebruik van diepere genetische en transcriptionele data zal in vervolgstudies in 
de toekomst meer inzichten creëren en de verschillende biologische levels en 
componenten met elkaar verbinden.
 Alhoewel de individuele genetische informatie een belangrijke rol speelt 
in het cytokine productievermogen, is er sterk bewijs dat niet genetische 
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factoren ook een belangrijke rol spelen. Er zijn talrijke belangrijke studies 
die naar enkele parameters en hun invloed op baseline cytokine levels dan 
wel de productie van cytokine in vitro hebben gekeken. 
 In hoofdstuk 4 hebben we verschillende datasets van het HFGP gebruikt 
om uitspraken te maken over hoe deze niet genetische factoren die cytokine 
response tegen hele micro-organismen maar ook specifieke PRR-liganden 
beïnvloeden. De T-cel cytokine levels van IL-22 en IFN-γ zijn verlaagd 
in oudere mensen, terwijl IL-17 samen met de monocyt cytokines geen 
leeftijdseffect lieten zien. Naast de invloed van leeftijd op de cytokine 
response, hebben we een duidelijk geslachtsverschil kunnen observeren die 
wellicht (mede) verantwoordelijk kan zijn voor het verschil in vatbaarheid 
voor bepaalde ziektes. Naast deze bevindingen hebben we kunnen laten zien 
dat een aantal cytokines een duidelijk seizoensgebonden patroon laten zien 
wat wederom het seizoensgebonden optreden van bepaalde infectieziektes 
kan verklaren. Vooral een aantal circulerende cytokines in plasma lieten 
dit soort veranderingen zien. Een belangrijk mechanisme betreft Alpha-1-
antitrypsine (AAT), die omgekeerde correlatie met IL-1b liet zien. Deze 
bevindingen werden uiteindelijk met klinische data en muis studies bevestigd. 
In deel 2 van deze thesis hebben wij patiënten cohorten met gezonde 
vrijwilligers vergeleken om vervolgens nieuwe componenten te identificeren 
die belangrijk zijn in de immuun response tegen Candida. Hoofdstuk 5 
geeft een overzicht van de componenten die verstoord zijn in patiënten met 
herhaalde vaginale infectie(s) met Candida (recurrent vulvovaginal candidiasis 
RVVC). Deze patiënten lijden aan multiple vaginale Candida infecties per jaar 
wat tot enorm ongemak en hoge kosten voor verzekeringsmaatschappijen 
leidt. De normale behandeling van deze episodes houdt het toedienen van 
antischimmel (Azol) medicatie in. Ook zijn een aantal factoren bekend die 
de vaginale infectie met Candida bevorderen zoals zwangerschap, diabetes 
en het gebruik van antibiotica. Het blijkt toch zo te zijn dat de meeste 
vrouwen met RVVC niet door deze factoren beïnvloed zijn, wat een sterk 
genetisch component zeer waarschijnlijk maakt. De immuun response tegen 
Candida is nog niet volledig begrepen alhoewel de meeste receptoren en 
signaalwegen bekend zijn. Het is daarom ook niet verrassend dat genetische 
variatie in deze componenten (bijvoorbeeld DECTIN-1, NLRP3, IL-4 en 
MBL) tot een ziekte fenotype leiden. In de toekomst zullen vooruitgang 
in technieken en ook mindere kosten ervoor zorgen dat er meer inzichten 
in deze multi-genetische ziekte komen en uiteindelijk nieuwe therapieën 
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ontwikkeld kunnen worden. In hoofdstuk 6 wordt de rol van de immuun 
cel receptor CX3CR1 onderzocht. Recentelijk is gebleken dat deze receptor 
cruciaal is in invasieve infecties met Candida, voornamelijk in de macrofagen 
die in de nier zitten. Naast deze bevindingen is er een genetische variant 
in het CX3CR1 gen die verhoogd voorkomt in Candidemie patiënten en 
daardoor een gevoeligheidsfactor is voor deze ziekte. Door zijn belangrijke 
rol in deze ziekte hebben we in hoofdstuk 6 gekeken naar de rol van deze 
receptor in mucosale infecties (RVVC) met Candida. De resultaten laten zien 
dat CX3CR1 noch een rol speelt bij de mucosale immuun response noch dat 
er genetische varianten in dit gen geassocieerd zijn met RVVC en daardoor 
alleen een belangrijke rol speelt bij invasieve infecties met de schimmel. 
In dit hoofdstuk is er een oraal infectie model gebruikt om de functie van 
CX3CR1 te bepalen en het is belangrijk om in het achterhoofd te houden dat 
er significante verschillen zijn tussen het orale en vaginale infectie model.
 Op dit moment wordt in de literatuur ervan uitgegaan dat RVVC niet 
door een immuun defect ontstaat, maar juist door een te sterke reactie van 
het immuusysteem tot stand komt.
 Het immuunsysteem reageert in feite op de lokaal aanwezige Candida met 
een heel hoge productie van cytokines en andere immuun functies. Deze 
bevindingen worden met een aantal studies onderbouwd, die laten zien 
dat er een sterke immuun cel influx plaatsvindt. Verder is er gebleken dat 
Candida door het zure milieu oppervlakkige veranderingen ondergaat die 
wederom tot een verhoging van de immuun response leiden.
 Hoofdstuk 7 beschrijft de functionele gevolgen van een structurele 
verandering in het NLRP3 gen en zijn rol in de gevoeligheid voor RVVC. 
NLRP3 is verantwoordelijk voor het omzetten van pro IL-1b in zijn 
bioactieve vorm en een zogenoemde “variable tandem repeat” (VNTR) 
in het voor NLRP3coderende gen was vaker in RVVC-patiënten genetisch 
veranderd dan in gezonde controles. Als gevolg hiervan waren de levels 
van vaginaal IL-1b sterk verhoogd, vergeleken met de gezonde controles. 
Binnen de patiëntengroep hadden individuen met de risico genotypes even 
verhoogde waardes van IL-1b. Tegelijkertijd waren de levels van IL-1Ra, 
een anti inflammatoir cytokine, verlaagd, wat uiteindelijk tot een hyper-
inflammatoir milieu leidt. De levels van IL-18, welk ook door het NLRP3 
inflammasome omgezet wordt, waren onveranderd tussen patiënten en 
controles even als tussen de verschillende genotypes. De identificatie van 
NLRP3 als component in de RVVC-pathogenese zou in de toekomst als 
potentieel doelwit voor nieuwe therapieën kunnen dienen, bijvoorbeeld 
door de hoge levels van IL-1b in de vaginale mucosa te remmen. 
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De beschikbaarheid van genomische en immunologische data in patiënten 
en controles maakt het mogelijk verschillende datasets te combineren en 
daardoor een accuraat plaatje van de exacte pathologische mechanismen 
in immuun gerelateerde ziektes te creëren. Op deze manier kunnen niet 
alleen enkele nieuwe gen-kandidaten ontdekt worden maar juist ook 
hele signaalwegen die verstoord kunnen zijn. In hoofdstuk 8 hebben we 
een zogenoemde “systems genomics” approach toegepast om nieuwe 
componenten te identificeren die verstoord zijn in RVVC-patiënten. Twee 
onafhankelijke cohorten van RVVC-patiënten en controles zijn genetisch 
vergeleken via whole exome sequencing. Bovendien zijn er verschillende 
immunologische metingen gedaan zoals de in vitro cytokineproductie 
na stimulatie met Candida. Na het analyseren en samenvoegen van de 
genetische en immunologische data bleken de signaalwegen van cellulaire 
morfogenese en metabolisme, even als celadhesie, het meest aangetast te 
zijn in patiënten met RVVC. Bovendien is SIGLEC15 als een nieuw gen 
kandidaat geïdentificeerd die met de ziekte geassocieerd was.
 De rol van SIGLEC15 is vervolgens in verschillende in vitro en in vivo 
modellen gevalideerd. 
 Individuen met een specifieke genetische variant in SIGLEC15 lieten 
een sterk veranderd cytokine response zien na stimulatie met Candida en 
het specifiek uitschakelen van het SIGLEC15 gen leidde tot een verlaagde 
cytokineproductie. Het behandelen van Candida met neuraminidase liet een 
verhoogd effect zien in de cytokine en ROS-productie door immuuncellen. 
In een vaginaal infectie model in muizen resulteerde het toedienen van 
SIGLEC siRNA in een sterk verhoogde infectie met Candida, samen met het 
aantal PMNs. Tegelijkertijd waren de cytokine levels lokaal sterk verhoogd 
met IL-1b, dit als een van de meest significant stijgingen.
 Alhoewel er sterk bewijs is dat SIGLEC15 een belangrijke rol speelt 
in de immuun response tegen Candida, moet het exacte mechanisme en 
de signaalwegen die door Candida aangezet worden, in de toekomst nog 
(verder) uitgezocht worden. In tegenstelling tot mucosale infecties met 
Candida, die normaalgesproken niet levensbedreigend zijn, zijn invasieve 
infecties gekenmerkt door hoge mortaliteit, in het bijzonder bij opgenomen 
patiënten die een verzwakt immuunsysteem hebben. Zodra de fysieke 
barrières doorbroken zijn, kan Candida in de bloedbaan terecht komen en 
vervolgens in verschillende organen uitgroeien, wat tot slot tot orgaan falen 
kan leiden. Talrijke studies hebben in de laatste jaren nieuwe risicofactoren 
geïdentificeerd die de gevoeligheid voor deze invasieve infecties bevorderen 
en tegelijkertijd ons begrip voor de exacte onderliggende ziektemechanisme 
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verhoogd. In hoofdstuk 9 wordt een nieuwe receptor in de herkenning 
van Candida geïdentificeerd. Deze receptor, MDA5 (IFIH1), was tot kort 
alleen maar bekend door zijn rol in de herkenning van dubbelstrengs RNA 
van bijvoorbeeld virussen om vervolgens een type 1 interferon reponse te 
initiëren. In dit hoofdstuk laten we zien dat MDA5 ook tot hoge expressie 
komt in Candida gestimuleerde immuuncellen. Bovendien is een genetische 
variant in IFIH1 vaker aanwezig in patiënten die Candidemie hebben 
vergeleken met gezonde controles. Deze genetische variant was uiteindelijk 
ook geassocieerd met een veranderd cytokine profile. Een in silico analyse 
van deze variant voorspelde een mogelijk functioneel effect op dsRNA 
bindings capacieteit en affiniteit en daardoor ook signaleringsactiviteit. Ook 
al zijn de precieze mechanismes waardoor MDA5 en Candida met elkaar 
interageren nog niet bekend, geeft deze studie sterk bewijs dat MDA5 in de 
immuun reponse tegen Candida betrokken is. 
 Binnen deze thesis zijn meestal patiënten met gezonde controles 
vergeleken om vervolgens nieuwe gen kandidaten te identificeren. Genen 
met varianten die vaker in de patiëntengroepen voorkomen zijn vaak 
betrokken bij de herkenning, de signalering of  juist effector mechanismes 
binnen de Candida afweer. In hoofdstuk 10 hebben we specifiek naar een 
gekozen gen gekeken gebaseerd op zijn biologische relevantie. Onlangs is 
gebleken dat IL-32 een belangrijke rol speelt bij de immune afweer tegen 
verschillende bacteriën maar er is weinig bekend over de rol van IL-32 in 
de immuun reponse tegen schimmels en specifiek Candida. Een genetische 
variant in de intronische regio van IL-32 heeft als gevolg dat de cytokine 
reponse na Candida stimulatie veranderd was, alhoewel er geen directe 
associatie met een Candida gerelateerde ziekte (RVVC of  Candidemie) vast 
te stellen was. In tegenstelling tot de genetische verdeling van de variant 
binnen de patiëntencohorten, bleken de serumwaardes van IFN-γ, maar 
niet van IL-6 en IL-8, door de variant beïnvloed te worden. 
 Binnen de verschillende IL-32 isoformen is gebleken dat de IL-32γ 
isoform de biologisch meest actieve is. Het toedienen van IL-32γ aan de 
PBMC stimulatie met Candida verhoogde de T cel cytokines IL-17 en IFN-γ 
even als de fagocytose van Candida door monozyten. Omdat we geen direct 
effect van de IL-32 isoformen op Candida hebben kunnen observeren, 
is het zeer waarschijnlijk dat IL-32 immuuncellen beïnvloed. Tot slot 
hebben we kunnen laten zien dat IL-32γ transgene muizen een verbeterde 
overlevingskans hadden in een systemisch Candida model dan normale 
controle muizen. De exacte manier hoe IL-32γ de immuun reponse tegen 
Candida beïnvloed, zal in de toekomst onderzocht moeten worden. 
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In hoofdstuk 11 waren we geïnteresseerd in de gemeenschappelijke 
componenten binnen de immuun response tegen verschillende schimmels. 
Hiervoor werden drie schimmels in verschillende cellulaire systemen getest. 
Vervolgens is de cytokine respons gemeten en is er een duidelijk patroon 
per schimmel gevonden. Deze bevindingen bevestigen eerdere resultaten 
die lieten zien dat de immuun reponse specifiek tegen een ziekteverwekker 
en niet om een algemeen signaalweg gebouwd is. Hiernaast is een grote 
cohort van meer dan 500 individuen (HGFP) gebruikt om nieuwe cQTL te 
identificeren. In een vervolgstap zijn deze cQTLs met behulp van mRNA 
expressie data na Candida stimulatie bevestigd. Uiteindelijk is wederom de 
cohort van Candidemie patiënten en functionele in vitro assays gebruikt 
om de nieuwe gen kandidaten te valideren. In vervolgexperimenten in de 
toekomst zullen deze nieuwe kandidaatgenen in klinische setttings getest 
moeten worden.
 In het tweede deel van dit proefschrift lag de focus op twee verschillende 
infecties met Candida, namelijk systemische Candida infecties (Candidemie) 
en herhaalde vaginale infecties met Candida (RVVC). Beide ziektes hebben 
een polygenetische achtergrond en beiden hebben zeer waarschijnlijk ook een 
aantal niet genetische factoren die een grote rol spelen bij het ontwikkelen en 
het verloop van de ziekte. Grondige classificatie van patiënten en een diep 
begrip van het samenspel van de verschillende componenten die verstoord 
zijn, zullen sleutelvoorwaarden zijn om gepersonaliseerde therapieën te 
ontwikkelen om uiteindelijk het hoge ongemak en mortaliteit binnen deze 
schimmelinfectie te voorkomen. 
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Deutsche Zusammenfassung und Schlussfolgerung
Das humane Immmunsystem unterscheidet zwischen eigenen und fremden 
Antigenen, um eine Immunantwort einzuleiten, wenn dies nötig ist. Zusätzlich 
spielt das Immunsystem eine komplexe Rolle, indem es kommensale 
Bakterien, Pilze oder auch Viren toleriert, damit diese Körper und Haut 
besiedeln, und gleichzeitig ausgleichend dafür sorgt, dass sie sich nicht 
übermäßig vermehren, oder invasiv wachsen und somit Schaden anrichten. 
Die Bedeutung der Koordination des Immunsystems und kolonisierender 
Mikroorganismen bei der Unterscheidung von Gesundheit oder Krankheit 
wird in Patienten deutlich, die zum einen stark immunkomprommitiert 
(abwehrgeschwächt) sind, zum Beispiel durch Chemotherapie, oder zum 
anderen, deren Mikroflora (IBD) stark gestört ist. Immungeschwächte 
Patienten haben ein großes Infektionsrisiko, weil ihre Immunabwehr die 
Angreifer (Pathogene) nicht effektiv bekämpfen kann. Gleichzeitig wurde 
in mehreren Studien gezeigt, dass die Abwesenheit oder Anwesenheit von 
bestimmten besiedelnden Bakterien einen direkten negativen Effekt auf  das 
Immunsystem hat, was bei letzterem zu bestimmten Krankheitsbilder führen 
kann, wie zum Beispiel bei Patienten mit entzündlichen (chronischen) 
Darmerkrankungen. 
 Die Funktionalität des Immunsystems, sowie das komplexe 
Zusammenspiel zwischen den einzelnen Komponenten dieses Systems, 
wird stark durch die Variabilität in der DNS jedes einzelnen Menschen 
beeinflusst. Kleinste Unterschiede im genetischen Code der DNS können 
zu Veränderungen oder sogar zu einem Verlust der Funktion der einzelnen 
Komponenten führen, was schlussendlich zu Veränderungen in der 
Interaktion des Immunsystems mit verschiedenen, potentiell gefährlichen, 
eindringenden Mikroorganismen führt.
 In den letzten Jahrzehnten wurden erhebliche Fortschritte in der 
Identifizierung neuer genetischer Varianten erzielt. Dieses hat zu einem 
zu einem verbesserten Verständnis der exakten Mechanismen bei der 
Entstehung von Infektionskrankheiten, und zum anderen zur gezielten 
Entwicklung von neuen Behandlungsstrategien dieser Krankheiten geführt. 
Neben den genetischen Faktoren beeinflussen nicht-genetische Faktoren 
wie das Alter, Geschlecht, aber auch der Lebensstil die Immunantwort 
gegen verschiedene Mikroorganismen. 
 In der vorliegenden Doktorarbeit wurden neue Komponenten der 
humanen Immunantwort gegen verschiedenen Schimmelinfektionen mit 
Candida albicans identifiziert. Neben verschiedenen Patientengruppen mit 
337
13
mucosalen/oberflächlichen sowie invasiven (Schimmel-) Infektionen wurde 
eine große Gruppe von gesunden freiwilligen Individuen verwendet, um 
individuelle genetische, wie auch nicht-genetische Unterschiede in der 
Immunantwort gegen verschiedene Mikroorganismen zu identifizieren. 
Das Verknüpfung verschiedener Teilbereiche wie demografische Daten, 
genetische Informationen, sowie verschiedene Omics- Daten führen 
schlussendlich zu einem tieferen Verständnis der Faktoren, die prägend für 
die individuelle Immunantwort sind. 
Teil 1 dieser Arbeit befasst sich mit den Unterschieden der Immunantwort 
bei gesunden Individuen. Es wurden genetische, wie auch nicht-genetische 
Faktoren wurden untersucht, und deren Einfluss auf  individuelle 
Immunantwort gegen verschiedene Krankheitserrege, sowie die Vernetzung 
dieser Faktoren. 
 Das zweite Kapitel (Chapter 2) dieser Arbeit fasst die heutigen 
Erkenntnisse der genetischen Variationen in den sogenannten ‘Pattern 
Recognition Receptores ´(PRR)` zusammen, und welche funktionellen 
Auswirkungen diese Veränderungen in Bezug auf  die Anfälligkeit und 
Entwicklung von (Infektions-) Krankheiten haben. Diese PRRs sind, 
basierend auf  ihrer Struktur und ihrer Ligandenaffinität, in fünf  funktionelle 
Klassen eingeteilt. Durch den enormen Fortschritt in Technologien, wie 
Whole Exome Sequencing (WES) und Whole Genome Sequencing (WGS), 
sowie immer wachsender und besser charakterisierter Patientencohorten, 
ist die Identifizierung von neuen genetischen Varianten noch lange nicht 
abgeschlossen, es können nun sogar auch strukturelle Varianten wie „Large 
Insertions“ oder „Copy Number Variations“ identifiziert werden. 
 Um Faktoren, welche die Immunantwort beeinflussen, zu identifizieren, 
sind viele immunparameter als auch diverse Umwelteinflüsse zu 
berücksichtigen. Große Datensets mit sorgfältig charakterisierten Patienten 
sind notwendig, um akkurate Schlüsse ziehen zu können. Im „Human 
Functional Genomics Project (HGFP)“ wurden mehr als 500 gesunde 
freiwillige Testpersonen mit westeuropäischem genetischen Hintergrund 
eingeschlossen und intensiv auf  verschiedene immunologische Parameter 
getestet. Zusätzlich wurden genetische Informationen, sowie das Metabolom 
und das Mikrobiom erfasst, um diese verschiedenen Datasets in „Systems 
Biology“ - Analysen zu kombinieren. 
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Das dritte Kapitel (Chapter 3) befasst sich mit dem Einfluss der Genetik auf  
die interindividuellen Unterschiede in der Zytokinantwort auf  verschiedene 
Pathogene. Neue, genomweit signifikante cytokine quantitive trait loci 
(cQTLs) wurden identifiziert, die einen starken Einfluss auf  die in-vitro 
Zytokinproduktion nach Stimulation mit verschieden bakteriellen, viralen und 
fungalen Pathogenen haben. Pathway Analysen zeigten eine Überrepräsentation 
von Pathways für Pattern-Recognition, Zytokinproduktion, Komplement-
Hemmung und interessanterweise auch des Kallikrein Systems. Ausserdem 
zeigte die systematische Analyse der individuellen Zytokinantworten, dass 
die generelle Zytokinantwort eher auf  einem bestimmten Pathogen basiert 
als auf  einem bestimmten Pathway, der unabhängig vom erkannten Pathogen 
aktiviert wird. Der Einfluss von genetischen Varianten der Immunantwort auf  
verschiedene Pathogene ist zum einen Stimulus spezifisch, und hängt zum 
anderen auch von dem gemessenen Zytokin ab. Weiterführende Studien werden 
durch Integration von komplexeren genetischen, wie auch transkriptionellen 
Datensets und nachfolgender Verbindung zwischen diesen biologischen 
Ebenen tiefere Einsichten und Zusammenhänge in diesem Feld liefern. 
 Neben der individuellen genetischen Information der DNS, die einen 
großen Einfluss auf  die Zytokinproduktion hat, sind auch nicht-genetische 
Faktoren von großer Wichtigkeit. Zahlreiche Studien in den letzten Jahren 
haben einzelne Umwelteinflüsse oder demografische Daten mit verschiedenen 
Immunparametern korreliert. 
 Im vierten Kapitel (Chapter 4) dieser Arbeit wurden verschiedene Datasets 
des HFGP einbezogen, um umfassende Aussagen über die nicht-genetischen 
Faktoren und deren Einfluss auf  die Immunantwort zu treffen. Die T- Zell 
Zytokine IL-22 und IFN-γ sanken deutlich mit dem Alter, wohingegen das T- 
Zell Zytokin IL-17 sowie die durch Monozyten produzierten Zytokine IL-6, 
TNFa und IL-1b mit fortschreitendem Alter keinen deutlichen Abfall zeigten. 
Neben den Einflüssen des Alters auf  die individuelle Immunabwehr wurden 
auch deutliche Geschlechterunterschiede in Bezug auf  die Immunabwehr 
gefunden, die wahrscheinlich das geschlechtsspezifisch erhöhte Risiko 
bestimmter Infektionskrankheiten erklären können. Zusätzlich zeigten wir, 
dass einige Zytokine einem deutlichen saisonalen Muster folgen, was wiederum 
das vermehrte Auftreten bestimmter Infektionskrankheiten zu verschiedenen 
Jahreszeiten erklärt. Im Gegensatz zu den in-vitro Zytokinen scheinen die 
(baseline) zirkulierenden Zytokine im Blutplasma saisonal beeinflusst zu sein. 
Es wurde wichtiger Regulationsmechanismus identifiziert, bei dem das „Acute 
Phase Protein“ alpha-1-antitrypsin (AAT) invers mit der Produktion von 
IL-1b korreliert. 
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In weiteren Validierungsstudien wurden diese Befunde durch die 
Untersuchung von (humanen) klinischen Daten sowie Experimenten in 
Mäusen bestätigt.
Im zweiten Teil (Part II) dieser Arbeit habe ich einige Case-Control Studien 
durchgeführt, um neue Komponenten der Anti-Candida-Immunantwort zu 
identifizieren. 
 Das fünfte Kapitel (Chapter 5) fasst die einzelnen Komponenten 
zusammen, die bisher in der Pathogenese von Recurrent Vulvovaginal 
Candidiasis (RVVC) entdeckt wurden. RVVC Patienten leiden pro Jahr an 
mehreren Episoden von vaginalen Infektionen mit dem Schimmelpilz C. 
albicans, was für die Patienten nicht nur enormen Dyskomfort bedeutet, 
sondern auch einen großen Kostenpunkt für das Gesundheitssystem 
darstellt. Für die Behandlung dieser Infektionen werden normalerweise Azol-
Medikamenten verwendet. Trotz der bisher beschriebenen prädisponierenden 
Risikofaktoren, die vaginale Infektionen begünstigen, wie zum Beispiel 
Schwangerschaft, Diabetes oder die (übermäßige) Einnahme von Antibiotika, 
spielen diese Faktoren bei der Mehrheit der Frauen mit RVVC keine große 
Rolle, was drauf  hinweist, dass ein großer Teil dieser Infektionen durch den 
genetischen Hintergrund der Patienten verursacht wird. Die Immunantwort 
gegen Candida ist immer noch nicht vollständig entschlüsselt, dennoch sind 
die Hauptrezeptoren, wie auch deren Signalwege, beschrieben. Es ist daher 
nicht überraschend, dass genetische Abweichungen in Komponenten der 
Candida-Erkennung (DECTIN-1 und NLRP3) oder Effektor-Molekülen (IL-
4 und MBL) zu diesem Krankheitsbild führen. In der nahen Zukunft werden 
technische Fortschritte, als auch Kostenreduktionen der anzuwendenden 
Methoden zu neuen Erkenntnissen in dieser multigenetischen Krankheit 
führen, was letztendlich in neue Therapien resultieren wird. 
 Im sechsten Kapitel (Chapter 6) dieser Arbeit wurde die Rolle des 
Chemokine Rezeptors CX3CR1 untersucht. In einer früheren Studie 
wurde dieser Chemokine Rezeptor als äußerst wichtig in invasiven 
Schimmelinfektionen beschrieben. CX3CR1 befindet sich auf  verschiedenen 
Immunzellen und wurde kürzlich im Mausmodell für systemische 
Candidiasis (Kandidose) als essentiell für die (frühe) Immunfunktion 
von (Maus-) Makrophagen in der Niere beschrieben. Zusätzlich wurde in 
diesem Oberflächenrezeptor eine genetische Variante identifiziert, die beim 
Menschen mit einem erhöhten Risiko bei der Entstehung von invasiven 
Schimmelinfektionen assoziiert ist. Aufgrund seiner wichtigen Rolle bei 
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invasiven Schimmelinfektionen in Mäusen wie auch bei Menschen, wurde 
in Kapitel 6 untersucht, ob dieser Rezeptor auch bei der Entstehung oder 
dem Verlauf  von RVVC eine Rolle spielt. In unseren Untersuchungen haben 
wir gezeigt, dass weder die mucosale Immunantwort, noch genetische 
Varianten in diesem Rezeptor mit der Pathologie in der RVVC oder der 
Krankheitsanfälligkeit assoziiert waren, was nahelegt, dass CX3CR1 
ausschließlich bei an invasiven Pilzinfektionen beteiligt ist. Obwohl durch 
diese Daten die Wichtigkeit von CX3CR1 bei invasiven (Schimmel-) 
Infektionen belegt wird, sollte trotzdem auch bedacht werden, dass das 
experimentelle Setup (Orale Kandidose) in dieser Studie dem Setup in 
vaginalem Milieu und Gewebe nur wenig gleicht. 
 Eine wachsende Zahl von Artikeln und Studien weisen darauf  hin, dass 
RVVC nicht durch Defekte im der Immunabwehr, sondern in einer zu 
heftigen Reaktion des Immunsystem gegen die Kolonisierung von Candida 
hervorgerufen wird. Dabei werden übermäßig viele pro-inflammatorische 
Zytokine produziert, die ihrerseits mehr Immunzellen rekrutieren.
 Dieses Konzept wird durch verschiedene Forschungsergebnisse bestätigt, 
die zeigen, dass während der Erkrankung zum einen eine stark erhöhte 
Anzahl von Immunzellen (hauptsächlich PMNs) lokal gefunden wurden, 
und sich zum anderen Candida selbst durch das säuerliche Milieu äußerlich 
verändert, was wiederum zu einer deutlichen Steigerung der lokalen 
Immunantwort führt. 
 Im siebten Kapitel (Chapter 7) wurden die funktionellen Konsequenzen 
einer strukturellen genetischen Veränderung im NLRP3 Gen und deren 
Zusammenhang in der Anfälligkeit für RVVC untersucht. Ein „Variable 
Number Tandem Repeat“ (VNTR) im NLRP3 Gen, das für die Verarbeitung 
von pro-IL-1b zu bioaktiven Il-1b verantwortlich ist, zeigte sich deutlich 
geschädigt in RVVC Patienten. Dadurch ist die Konzentration von diesem 
Zytokin im vaginalen Gewebe in Patienten verglichen mit dem gesunder 
Personen deutlich erhöht. Innerhalb der Patientengruppe hatten Personen 
mit dem Risikogenotyp NLRP3 die höchsten Level von IL-1b. Darüber 
hinaus waren die Konzentrationen von IL-1Ra an der Vaginaloberfläche 
invers mit den Konzentrationen von IL-1b korreliert, was schlussendlich 
zu einem hyperinflammatorischen Milieu führt. Interessanterweise 
waren die Konzentrationen des Zytokins IL-18, das auch vom NLRP3 
Inflammasom verarbeitet wird, bei beiden Gruppen als auch für die 
verschiedenen Genotypen unverändert. Diese Erkenntnisse rund um das 
NLRP3 Inflammasom in der Pathogenese von RVVC könnten in Zukunft 
ein wichtiger Bestandteill bei der Behandlung der Krankheit sein. So 
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könnte man zum Beispiel spezifisch die hohen lokalen Level von IL-1b 
blocken und somit der verstärkten Immunantwort der Vaginalschleimhaut 
entgegenwirken. 
 Die genetischen sowie immunologischen Daten in Patienten und Kontrollen 
ermöglicht die systematische Kombination verschiedener Datensätze, um 
somit noch genauere Erkenntnisse und Schlussfolgerungen bezüglich der 
Pathogenese verschiedener Iimmun-) Krankheiten zu ziehen. Somit können 
nicht nur neue Gen-Kandidaten identifiziert werden, sondern auch ganze 
Pathways, die bei der Krankheit betroffen sind.
 Im achten Kapitel (Chapter 8) dieser Arbeit wurde eine solche 
systemgenetische Methode angewandt, um neue Komponenten zu identifizieren, 
die in RVVC dysreguliert sind. Zwei unterschiedliche Gruppen von RVVC 
Patienten sowie Kontrollen wurden anhand von Exom-sequenzierung 
genetisch verglichen. Zudem wurden umfangreiche immunologische Parameter 
ermittelt (z. B. in-vitro Zytokinmessungen) und mit den genetischen Daten 
kombiniert. Die Pathways der Zell-Morphogenese und des Zell-Metabolismus 
sowie die Zell-Adhäsion waren in RVVC Patienten am stärksten betroffen. 
Ein neu identifiziertes, mit dem Krankheitsphänotyp RVVC assoziiertes Gen, 
ist SIGLEC15. Dessen Rolle wurde in der RVVC Pathogenese daraufhin in 
verschiedenen in-vitro Studien, sowie in experimentellen in vivo Modellen zu 
vaginalen Infektionen validiert. Individuen mit einer bestimmten genetischen 
Variante im SIGLEC15 Gen zeigten eine deutlich veränderte Zytokinantwort 
verglichen mit Individuen anderer Genotypen. Ein spezifisches „silencing“ 
von SIGLEC15 in den primären Immunzellen führte zu einer reduzierten 
Candida spezifischen Immunantwort. Die Behandlung von Candida mit 
Neuraminidase bewirkte die Abspaltung aller Sialicylsäuren auf  der Oberfläche 
von Candida. Die anschließende Stimulation von Immunzellen mit dieser 
behandelten Candida führte schlussendlich zu einem Anstieg von „Reactive 
Oxygen Species” sowie proinflammatorischer Zytokinen. In einem vaginalen 
Infektionsmodel wurden in Mäusen SIGLEC15 „gesilenced”, was zu einem 
signifikanten Anstieg von Candida und Immunzellen im vaginalen Gewebe 
bewirkte. Hiermit einhergehend waren die Konzentration von Zytokinen in 
diesem Gewebe (SIGLEC15 silenced vs. Control silenced) deutlich erhöht. 
Trotz deutlicher Hinweise auf  eine signifikante Rolle von SIGLEC15 in der 
Anti-Candida Immunantwort, müssen zukünftige Experimente darauf  abzielen, 
die exakten Mechanismen in denen Candida mit diesem Rezeptor interagiert, 
noch genauer zu entschlüsseln, um ihre Rolle bei der RVVC-Pathogenese zu 
identifizieren. Zusätzlich sollten in weiteren Experimenten die identifizierten 
Pathways in Bezug auf  RVVC validiert werden. 
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Im Gegensatz zu oberflächigen mucosalen Pilzinfektionen, die normalerweise 
nicht lebensgefährlich sind, kennzeichnen sich invasive Infektionen durch 
hohe Mortalität. Dies trifft besonders auf  hospitalisierte Patienten zu und 
solche, die durch verschiedene Behandlungen eine geschwächte (Immun-) 
Abwehr haben. Sobald die physischen Barrieren, beispielsweise der Haut, 
durchbrochen sind, kann Candida in die Blutbahn gelangen und sich in 
anderen Organen verbreiten, was wiederum dann zu einem unkontrollierten 
Wachstum des Pilzes führen und schlussendlich zum Organversagen und 
Sepsis führen kann. Umfangreiche Studien haben in den letzten Jahren 
verschiedene Faktoren identifiziert, die für eine erhöhte Anfälligkeit für 
diese Pilzinfektionen verantwortlich sind, und gleichzeitig unser Wissen 
über die exakten pathologischen Mechanismen dieser Krankheit erweitert. 
 Das neunte Kapitel (Chapter 9) dieser Arbeit beschreibt die Identifizierung 
eines potentiell neuen Rezeptors für die Erkennung von Candida. Dieser 
Rezeptor, MDA5 (IFIH1), war bisher nur als für die Erkennung der langen 
Doppelstrang-RNA (dsRNA) von Viren verantwortlich bekannt, auf  die 
er eine Typ I-Interferon Antwort initiierte. Interessanterweise, stieg die 
Expression von MDA5 stark an, nachdem verschiedene Immunzellen 
mit Candida stimuliert wurden. Zudem kommt, verglichen mit gesunden 
Kontrollen, eine bestimmte genetische Variante in MDA5 verstärkt in 
Patienten mit Kandidose vor. Wir konnten zeigen, dass genau diese 
genetische Variante die spezifische Zytokinantwort in PBMCs nach Candida 
Stimulation beeinflusst, was ihre potentielle Rolle in der Immunantwort 
gegen Candida unterstreicht. Eine weitere in silico Analyse dieser genetische 
Variante in Bezug auf  die Proteinstruktur und Funktion wies einen 
möglichen Effekt auf  die dsRNA- Bindungs Selektivität und Affinität 
auf, was wiederum zu einer Abnahme der Signalaktivität führen könnte. 
Obwohl die exakten Mechanismen durch die MDA5 Candida erkennt, noch 
nicht vollständig bekannt sind, liefern diese neuen Erkenntnisse schlüssige 
Beweise dafür, dass MDA5 an der Immunantwort gegen Candida beteiligt 
ist. 
 In dieser Arbeit wurden für die Identifizierung neuer Komponenten der 
Candida Immunantwort oft Patienten und gesunde Kontrollen genetisch 
verglichen. 
 Gene mit Varianten, die häufiger in der Krankheitskohorte vorhanden 
sind, sind höchstwahrscheinlich an entweder Erkennungs-, Signalisierungs- 
oder Effektormechanismen in der Anti-Candida-Immunität beteiligt.
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Neben dieser Methode können aber auch, wie in Kapitel 7 geschehen, in der 
Literatur beschriebene, aufgrund ihrer biologischen Relevanz ausgewählte 
Kandidaten-Gene untersucht werden. 
 Im zehnten Kapitel (Chapter 10) wurden genetische Varianten des IL-
32 Gens systematisch in-vitro auf  ihre Rolle in der Candida Immunantwort 
getestet. Kürzlich wurde IL-32 als wichtiges Molekül in der Immunantwort 
gegen bakterielle Infektionen identifiziert, wohingegen wenig über 
seine Rolle bei Pilzinfektionen bekannt ist. Wir haben eine intronische 
genetische Variante im IL-32 Gen identifiziert, die zu einem veränderten 
Zytokinprofil nach Candida Stimulation führte, was dieses Gen für weitere 
Untersuchungen im Zusammenhang mit Candida-Infektionen interessant 
machte. Das IL-32 Gen hat verschiedene Splicevarianten, wobei besonders 
die IL-32γ Variante Candida-induzierte Zytokine modulieren konnte. Die 
Zugabe dieser speziellen Variante von Immunzellen sorgte dosisabhängig 
für erhöhte Level von IL-17 und INFγ in humanen Monozyten sowie für 
vermehrte Phagozytose von Candida durch Monozyten.
 Es wurde kein direkter Effekt von IL32γ auf  den Pilz festgestellt, was 
den modulierenden Effekt dieses Moleküls auf  Immunzellen unterstreicht. 
Obwohl kein direkter Effekt von genetischen IL-32g Varianten auf  das 
Risiko von Candidemie festgestellt wurde, fanden wir, dass die IFN-γ 
Serumkonzentration von Candida-Patienten mit einem bestimmtem IL-32γ 
Genotyp assoziiert war, während dies bei IL-6 und IL-8 nicht der Fall war. 
Schließlich konnten wir in einem Mausmodell zeigen, dass Mäuse, die IL-32g 
besitzen, eine deutlich bessere 14-Tage-Überlebenschance haben als Mäuse, 
die dieses nicht besitzen. Obwohl der genaue Mechanismus, durch den IL-
32 mit Immunzellen interagiert und Candida-induzierte Zytokine beeinflusst, 
noch weiter untersucht werden muss, identifiziert diese Studie IL-32 als einen 
neuen Weg, der an der Abwehr des Wirtes gegen Candida-Infektionen beteiligt 
ist. 
 Der Schwerpunkt im elften Kapitel (Chapter 11) lag in der Frage, 
inwieweit sich die Immunantwort gegen verschiedene Pilze ähnelt. Zu diesem 
Zweck wurde die Immunantwort auf  drei Pilze in-vitro in verschiedenen 
zellulären Systemen getestet und verglichen. Durch die Korrelation der 
Zytokindaten fanden wir eindeutig verschiedene Korrelationscluster der 
verschiedenen Pilzpathogene, was unsere frühere Annahme bestätigt, dass 
die Immunantwort eher gegen bestimmte Pathogene aufgebaut ist als auf  
Pathways, die unabhängig vom Pathogen sind. Im Weiteren wurden mit 
Hilfe einer Gruppe von 500 gesunden Kontrollen (HGFP, 500FG) neue 
cQTLs identifiziert. Um diese Daten zu stärken, wurden die solidesten 
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„Hits“ mit Hilfe von mRNA Expressions- Daten überkreuzt und validiert. 
Diese Studie identifizierte zahlreiche neue Gen-Kandidaten in der 
Immunantwort gegen Candida, die unter Verwendung von Candida- 
Expressionsdaten und in in-vitro funktionellen Assays validiert wurden. 
Die Studie identifizierte neue Gen-Kandidaten, welche die Anti-Candida-
Abwehr beeinflussen und zukünftig in klinischen Settings validiert werden 
sollten.
 Im zweiten Teil dieser Arbeit wurde der Fokus auf  zwei unterschiedliche 
Candida Infektionen gelegt, nämlich der systemischen Candida-Infektion 
(Kandidose) sowie der rezidivierenden mukosalen vaginalen Candida-
Infektionen (RVVC). Für beide Krankheitsbilder gilt, dass sie einen 
polygenetischen Hintergrund haben, und dass sowohl genetische wie auch 
nicht-genetische Faktoren bei der Entstehung und dem Verlauf  der Krankheit 
eine Rolle spielen. Eine gründliche Patientenklassifizierung sowie intensive 
Charakterisierung dieser Patienten und fehlregulierter Komponenten 
sind ausschlaggebend für die Entwicklung neuartiger und personalisierter 
Therapien zur Überwindung des großen Leidensdrucks in RVVC-Patienten 
sowie zur Prävention der Mortalität bei invasiven Pilzinfektionen.
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